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This thesis is aimed at gaining insight into the genetic underpinnings and underlying 
biological mechanisms of the highly heritable disorder Attention-Deficit/Hyperactivity 
Disorder (ADHD). The first part of this thesis focuses on the investigation of genetic risk 
factors for ADHD and related phenotypes employing established and novel molecular 
genetics approaches. The second part describes different strategies to map the pathways 
from gene to disorder at different levels of complexity and explores a diverse suite of 
model systems. In the following sections, a brief summary is presented about the clinical 
manifestation of ADHD, recent advances in the search for genetic risk factors associated 
with the disorder, and different methods for mapping the mechanisms underlying these 
risk genes, especially brain imaging genetics and the use of animal models. Subsequently, 
the aims of this thesis and an outline of the chapters are presented.
Attention-Deficit/Hyperactivity Disorder (ADHD)
ADHD is a common neurodevelopmental disorder (Faraone et al., 2015b). The world-wide 
prevalence has been estimated at 5% in children and at 2.5-4.9% in adults (Polanczyk 
and Rohde, 2007; Simon et al., 2009). ADHD is characterized by age-inappropriate levels 
of inattention and/or hyperactivity and impulsivity (Frances, 2000), but the clinical 
phenotype is heterogeneous (American Psychiatric Association, 2013; Frances, 2000) (Box 1). 
Approximately 55-75% of patients still carry the diagnosis in adulthood or remit only partially 
and display several impairments still in adulthood (Faraone et al., 2006). Severity level and 
presentation of ADHD symptoms can change during the lifespan; adults usually display 
less symptoms of hyperactivity and impulsivity (Buitelaar et al., 2011; Haavik et al., 2010).
ADHD is clinically diagnosed using structured interviews according to the Diagnostic 
and Statistical Manual of Mental Disorders (DSM; (American Psychiatric Association, 2013)) 
or the International Classification of Diseases (ICD; (World Health, 1992)). The current DSM-5 
diagnostic criteria were published in 2013 and for a clinical diagnosis, symptoms must have 
emerged before the age of twelve years and have persisted for at least six months (Box 1). 
Generally, the symptoms must manifest “to a degree that is inconsistent with developmental 
level and that negatively impacts directly on social and academic/occupational activities” 
(American Psychiatric Association, 2013). For a clinical diagnosis of adult ADHD, the cutoff 
is at five symptoms which is based on literature (Kessler et al., 2010; Kooij et al., 2005) and 
scientific consensus.
Box 1. DSM-5 Diagnostic criteria for ADHD
A. A persistent pattern of inattention and/or hyperactivity that interferes with functioning or 
development, as characterized by (1) and/or (2):
1. Inattention: Six (or more) of the following symptoms have persisted for at least 6 months to a degree 
that is inconsistent with developmental level and that negatively impacts directly on social and 
academic/occupational activities:
 Note: The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or a 
failure to understand tasks or instructions. For older adolescents and adults (age 17 and older), at least 
five symptoms are required.
a. Often fails to give close attention to details or makes careless mistakes in schoolwork, at work, or 
during other activities (e.g., overlooks or misses details, work is inaccurate).
b. Often has difficulty sustaining attention in tasks or play activities (e.g., has difficulty remaining focused 
during lectures, conversations, or lengthy reading).
c. Often does not seem to listen when spoken to directly (e.g., mind seems elsewhere, even in the 
absence of any obvious distraction).
d. Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the 
workplace (e.g., starts tasks but quickly loses focus and is easily sidetracked).
e. Often has difficulty organizing tasks and activities (e.g., difficulty managing sequential tasks; difficulty 
keeping materials and belongings in order; messy, disorganized work; has poor time management; 
fails to meet deadlines).
f. Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (e.g., 
schoolwork or homework; for older adolescents and adults, preparing reports, completing forms, 
reviewing lengthy papers).
g. Often loses things necessary for tasks or activities (e.g., school materials, pencils, books, tools, wallets, 
keys, paperwork, eyeglasses, mobile telephones).
h. Is often easily distracted by extraneous stimuli (for older adolescents and adults, may include 
unrelated thoughts).
i. Is often forgetful in daily activities (e.g., doing chores, running errands; for older adolescents and 
adults, returning calls, paying bills, keeping appointments).
2. Hyperactivity and impulsivity: Six or more of the following symptoms have persisted for at least 6 
months to a degree that is inconsistent with developmental level and that negatively impacts directly 
on social and academic/occupational activities:
 Note: The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or a 
failure to understand tasks or instructions. For older adolescents and adults (age 17 and older), at least 
five symptoms are required.
a. Often fidgets with or taps hands or feet or squirms seat.
b. Often leaves seat in situations when remaining seated is expected (e.g., leaves his or her place in the 
classroom, in the office or other workplace, or in other situations that require remaining in place).
c. Often runs about or climbs in situations where it is inappropriate. (Note: In adolescents or adults, 
may be limited to feeling restless.)
d. Often unable to play or engage in leisure activities quietly.
e. Is often “on the go”, acting as if “driven by a motor” (e.g., is unable to be or uncomfortable being still 
for extended time, as in restaurants, meetings; may be experiences by others as being restless or 
difficult to keep up with).
f. Often talks excessively.
g. Often blurts out an answer before a question has been completed (e.g., complements people’s 
sentences; cannot wait for turn in conversation).
h. Often has difficulty waiting his or her turn (e.g., while waiting in line).
i. Often interrupts or intrudes others (e.g., butts into conversations, games, or activities; may start 
using other people’s things without asking or receiving permission; for adolescents and adults, may 
intrude into or take over what others are doing).
1
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Box 1. Continued.
In addition, the following conditions must be met:
B. Several inattentive or hyperactive-impulsive symptoms were present prior to age 12 years.
C. Several inattentive or hyperactive-impulsive symptoms are present in two or more settings (e.g., at 
home, school, or works; with friends or relatives; in other activities).
D. There is clear evidence that the symptoms interfere with, or reduce the quality of social, academic, 
or occupational functioning.
E. The symptoms do not occur exclusively during the course of schizophrenia or another psychotic 
disorder and are not better explained by another mental disorder (e.g., mood disorder, anxiety 
disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal).
Specify whether:
Predominantly inattentive presentation: If Criterion A1 (inattention) is met but Criterion A2 
(hyperactivity-impulsivity) is not met for the past 6 months.
Predominantly hyperactive-impulsive presentation: If Criterion A2 (hyperactivity-impulsivity) is met 
and Criterion A1 (inattention) is not met for the past 6 months.
Combined presentation: If both Criterion A1 (inattention) and Criterion A2 (hyperactivity-impulsivity) 
are met for the past 6 months.
Specify if:
In partial remission: When full criteria were previously met, fewer than the full criteria have been met for 
the past 6 months, and the symptoms still result in impairment in social, academic, or occupational 
functioning.
Specify current severity:
Mild: Few, if any symptoms in excess of those required to make the diagnosis are present, and symptoms 
results in no more than minor impairments in social or occupational functioning.
Moderate: Symptoms or functional impairments between “mild” and “severe” are present.
Severe: Many symptoms in excess of those required to make the diagnosis, or several symptoms that 
are particularly severe, are present, or the symptoms result in marked impairment in social or 
occupational functioning.
Changes in DSM-5 compared to DSM-IV-TR
− Age at diagnosis: For many years, the diagnostic criteria for ADHD stated that it was children who were 
diagnosed with the disorder. This meant for older adolescents and adults with impairing symptoms 
of the disorder that they could not officially be diagnosed with ADHD. The DSM-5 has changed this; 
older adolescents and adults can now be officially diagnosed with the disorder. The diagnostic criteria 
mention and give examples of how the disorder appears in older adolescents and adults.
− In diagnosing ADHD in adults, clinicians now can look back to middle childhood (age 12 years) when 
evaluating the onset of symptoms, but do not have to go back all the way to early childhood (age 7 
years).
− In the previous edition, DSM-IV-TR, the three types of ADHD were referred to as “subtypes”. This 
has changed; subtypes are now referred to as “presentations”. Furthermore, a person can change 
“presentations” during lifetime.
− Severity is now specified as mild, moderate, or severe ADHD. This is based on the impairment.
− A person can now be diagnosed with both ADHD and autism spectrum disorder.
− In making the diagnosis, children still should have six or more symptoms of the disorder. In older 
teens and adults the DSM-5 states they should have at least five symptoms.
As apprarent from Box 1, the DSM-5 recognizes three presentations: predominantly 
inattentive, predominantly hyperactive-impulsive, and combined. These diverse 
presentations can changes over time (Nigg et al., 2010) and even within such presentations 
patients greatly differ in symptom profiles (Faraone et al., 2015a). Thus, ADHD patients 
show large variation in symptom profiles, impairments, neuropsychological alterations 
and their underlying causes (Sonuga-Barke and Taylor, 2015). Heterogeneity in the clinical 
presentation of ADHD is also apparent from a diverse spectrum of psychiatric comorbidities; 
both frequently seen in children (Biederman and Faraone, 2005; Gillberg et al., 2004; Lycett 
et al., 2015; Rappley, 2005; Reinhardt and Reinhardt, 2013) and in adults (McGough et al., 
2005; Miller et al., 2007; Ollendick et al., 2008; Sobanski et al., 2007; Wilens et al., 2009). This 
indicates that psychiatric comorbidities are an important factor for impairment, severity, and 
persistence of ADHD symptoms (Biederman et al., 2011; Lara et al., 2009). The most frequent 
comorbidities seen in ADHD are substance use disorders, anxiety and mood disorders, 
oppositional, defiant and conduct disorder, and autism spectrum disorder (Anckarsater et 
al., 2006; Wilens et al., 2009). Additionally, compared to the general population, ADHD is a 
common comorbid disorder in children with intellectual disability (ID) (Maulik and Harbour, 
2010; Vorstman and Ophoff, 2013), and the risk of ID increases with increasing severity of 
ADHD (Voigt et al., 2006). Studies of children with mild ID have identified co-morbid ADHD 
in 8-39% of the cases (Baker et al., 2010; Dekker and Koot, 2003; Emerson, 2003).
Genetic architecture of ADHD
While ADHD is diagnosed at the behavioral level, it is a neurobiological disorder that is 
most likely caused by a complex interplay between genetic and environmental risk factors. 
It has been hypothesized that these risk factors affect the structure and function of brain 
networks and thereby ultimately lead to ADHD symptoms, neurocognitive deficits, and 
various functional impairments (Faraone et al., 2015a). The etiology of ADHD is strongly 
influenced by genetic factors, as demonstrated by twin and adoption studies (Burt, 2009; 
Faraone and Mick, 2010; Kotte et al., 2013; Thapar et al., 2013). ADHD heritability estimates 
range between 70 and 90% (Faraone and Mick, 2010; Larsson et al., 2013). Despite this high 
heritability, gene identification has been challenging (Franke et al., 2009; Glahn et al., 2007). 
One reason for this is the complex, polygenic background of ADHD. This means that multiple 
genetic variants, each of them with small effects, contribute to the etiology of the disorder 
in most patients. Although a substantial part of the ADHD etiology is due to genetic factors, 
many environmental risk factors and potentially also gene-environment interactions are 
associated with an increased risk for the disorder (Banerjee et al., 2007; Han et al., 2015).
Many different molecular genetics studies have been undertaken in order to study the 
genetic background of ADHD. Basically, the different methods used in this can be divided 
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into hypothesis-driven and hypothesis-generating approaches. As ADHD has a high 
prevalence in the population, the search for genetic factors started with common genetic 
variants, which are relatively frequent in the general population (>1%) and generally have 
small effect sizes (Li et al., 2014; Neale et al., 2010b) (Figure 1).
Figure 1. Relationship between allele frequency and effect size in ADHD. Common genetic variants explain 
approximately 40% of the heritability of ADHD, but compared with rarer variants, individual common 
variants have much smaller effects on the risk of the disorder. All chapters of this thesis investigated the role 
of common variants in ADHD. In addition, in chapter 3, 5, and 6, the contribution of rare and low frequency 
variants in ADHD was examined. SNPs = single nucleotide polymorphisms. The figure was adapted from 
(Faraone et al., 2015a).
Initially, only candidate gene-based association studies were performed. Although those 
were individually underpowered, meta-analyses identified several significant associations 
(Faraone et al., 2005; Gizer et al., 2009; Li et al., 2006) (reviewed elsewhere (Banaschewski 
et al., 2010; Faraone and Mick, 2010; Franke et al., 2012; Hawi et al., 2015; Li et al., 2014)), and 
most of the associated genes belong to monoaminergic neurotransmission systems and/
or are neurite outgrowth genes.
Family-based approaches, i.e. genetic linkage analysis, provided a first possibility to 
carry out hypothesis-generating studies. In linkage studies, genetic variants across the 
entire genome are measured and tested for the odds of being shared between affected 
family members compared to the odds of not being shared. However, gene identification 
through linkage is limited (Banaschewski et al., 2010) to genetic variants with bigger effect 
sizes (Figure 1). A meta-analysis of seven linkage studies identified a locus on chromosome 
16, encompassing the CDH13 gene (Zhou et al., 2008), a gene that has also been found in 
the top-ranks of several genome-wide association studies (GWASs) (Lasky-Su et al., 2008; 
Neale et al., 2010a). Other successful linkage analysis results include the LPHN3 gene on 
chromosome 4 (Arcos-Burgos et al., 2010), which was subsequently confirmed through 
association testing (Ribases et al., 2011).
The most frequently used hypothesis-generating approach is the GWAS, which 
investigates millions of common genetic markers (across the genome), so called single 
nucleotide polymorphisms (SNPs; Figure 1). Given the individual small effects of these 
genetic markers, those studies require large sample sizes (Holland et al., 2016; Smoller et al., 
2018). With the recent success of international consortia, the first genome-wide significant 
hits for clinical ADHD are now becoming available (Demontis et al., 2017). Despite this 
success, the overall SNP-based heritability (h2) has been estimated to be approximately 
22% only, which means that most of the heritability is still unexplained. These estimates 
are lower than those derived from twin studies, in part because the SNP-based heritability 
only includes effects due to common variants.
Genetic studies of ADHD are usually carried out using the clinical diagnosis (i.e. case v. 
control) as primary outcome. This has been complemented and expanded by performing 
studies of quantitative measures of (childhood) ADHD symptoms in the population (e.g. 
EAGLE consortium (Middeldorp et al., 2016)). Both phenotypes, clinical ADHD and ADHD 
symptoms, show a strong genetic correlation, suggesting genetic overlap (Demontis et al., 
2017). Most of the previously mentioned studies focused on childhood samples. A GWAS of 
persistent ADHD is currently in preparation (Ribases et al., 2017) and seems to show a very 
high genetic correlation with childhood ADHD, but the estimated SNP-based heritability is 
lower (h2~16%) (Ribases et al., 2017). This suggests that also other types of genetic variation, 
and/or gene-gene and gene-environment interactions contribute to the persistence of 
ADHD. Recent studies show that ADHD is also genetically correlated with other psychiatric 
disorders (e.g., major depressive disorder), but also with more general anthropomorphic 
traits (e.g., body mass index) (Demontis et al., 2017). With methodological advances and 
novel statistical genetics approaches to assess genetic correlations by using GWAS summary 
statistics, the genetic overlap between disorders and traits is now extensively studied (Bulik-
Sullivan et al., 2015a; Bulik-Sullivan et al., 2015b).
Following the promising findings in other psychiatric disorders (Cruceanu et al., 2013; 
Cukier et al., 2014; Kerner et al., 2013; Purcell et al., 2014), studies of rare genetic variants 
1
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have also been performed for ADHD. Several studies were successful in identifying genetic 
variants related to the disorder (Elia et al., 2010; Lesch et al., 2011; Ramos-Quiroga et al., 2014; 
Williams et al., 2012; Williams et al., 2010; Yang et al., 2013). Genome-wide analysis of (rare) 
copy number variants (CNVs) showed an enrichment of rare CNVs in patients with ADHD 
(Williams et al., 2010), and implicated the genes CHRNA7 and NPY in ADHD etiology (Lesch 
et al., 2011; Williams et al., 2012), as well as genes encoding glutamate receptors (Akutagava-
Martins et al., 2014; Elia et al., 2012), and regions on 15q11-15q13 (Valbonesi et al., 2015) and 
16p13.11 (Williams et al., 2010). A recent re-analysis of available CNV data revealed 26 novel 
ADHD genes that were observed across a set of complementary approaches (Harich et 
al., submitted). Subsequent bioinformatic analysis implicated several biological processes 
affected in ADHD, including cell–cell junctions in the blood–brain barrier, transcriptional 
regulation, apoptosis, regulation of synaptic vesicles, and ion channel activity (Harich et al., 
submitted; Thapar et al., 2015). The picture emerging from those initial studies is that the 
contribution of rare genetic variants to ADHD etiology is highly heterogeneous, similar to 
the common variant contribution. Whole-exome sequencing (WES) and whole-genome 
sequencing (WGS) are now being increasingly used, allowing the identification of rare 
single nucleotide variants and small insertions/deletions contributing to ADHD etiology. 
As apparent from Figure 1, it is hypothesized that those rare variants have larger individual 
effect sizes. A first study indeed found enrichment of rare variants in a predefined set of 51 
candidate genes in adult patients with persistent ADHD (Demontis et al., 2016). Additional 
candidate gene-based studies support the role of (de novo) rare variants in ADHD (Hawi et 
al., 2017; Kim et al., 2017).
Genetic factors associated with ADHD are widely spread across the genome, but they 
tend to be enriched within specific functional categories (Demontis et al., 2017; Thapar et 
al., 2015). Various approaches have been successful detecting ADHD-related gene clusters 
within various functional networks and biological processes that have been shown to 
be involved in the etiology of the disorder. GWAS association signals converged on the 
directed neurite outgrowth network, for example (Poelmans et al., 2011). Additionally, 
enrichment analyses showed that most significantly enriched function for ADHD-GWAS 
association signals were related to nervous system development, neuron projection 
morphogenesis, cell–cell communication, glutamatergic synapse/receptor signalling, and 
multicellular organismal development (Hawi et al., 2015; Yang et al., 2013). These findings 
were substantiated by a study that used two GWAS data sets to identify pathways associated 
with ADHD by applying six pathway analysis methods (Mooney et al., 2016).
Mapping mechanisms underlying ADHD risk genes
The effects of ADHD genetic risk factors on behavior are likely to be mediated through effects 
on cell biology and brain system development and functioning. This section emphasizes the 
importance of using complementary methods for the evaluation of mechanisms underlying 
ADHD risk genes. It also highlights two main approaches which are applied throughout the 
different chapters of this thesis.
Brain imaging genetics
ADHD is a disorder of the brain (Hoogman et al., 2017) and several aspects of brain 
development, structure, function, and connectivity have been found altered in ADHD 
(Cortese et al., 2013; Cortese et al., 2012; Greven et al., 2015; Mostert et al., 2016; Onnink et al., 
2015; Shaw et al., 2007; Shaw et al., 2012; van Ewijk et al., 2012). The different neuroimaging 
techniques used and the main findings for ADHD are described in more detail in chapter 
8. Briefly, structural magnetic resonance imaging (sMRI) has pointed to total brain volume 
and total grey matter reductions of up to 3-5% in patients with ADHD compared to controls 
(Castellanos et al., 2002; Greven et al., 2015; Valera et al., 2007). A recent meta-analysis 
revealed that, on average, patients with ADHD have a smaller intracranial volume (ICV) 
and smaller volumes of subcortical regions, such as the nucleus accumbens, amygdala, 
caudate nucleus, putamen, pallidum, thalamus, and of the hippocampus (Hoogman et al., 
2017). Next to volumetric differences observed in grey matter, white matter structure has 
also been found to be altered in ADHD, leading to a potential disorganization of the brain’s 
connectivity. Most consistently, studies reported white matter anomalies in the corpus 
callosum in childhood ADHD (van Ewijk et al., 2014) and adult ADHD (Dramsdahl et al., 2012; 
Onnink et al., 2015). A method to investigate potential changes in brain activity is functional 
magnetic resonance imaging (fMRI). Generally, dysregulation of structure and function of the 
fronto-subcortical-cerebellar pathways that control attention, response to reward, salience 
thresholds, inhibitory control, and motor behavior are among most consistently observed 
(del Campo et al., 2012; Gallo and Posner, 2016; Rommelse et al., 2011), and task-based 
functional MRI studies in ADHD have largely focused on these neurocognitive functions/
domains (Cortese et al., 2012; Hart et al., 2012; Hart et al., 2013; Plichta and Scheres, 2014). 
Such brain phenotypes are often moderately to highly heritable. Twin studies showed that 
genetic effects varied regionally within the brain, with high heritability estimates (h2) for 
frontal lobe volumes (ranging from 0.9 to 0.95) and for region-based cortical surface areas 
(ranging from 0.48 to 0.77), and moderate estimates for e.g. the hippocampus (h2-range = 
0.4–0.69) (Peper et al., 2007).
The brain phenotypes differing between patients and controls have been considered 
as intermediate phenotypes for the disorder, and investigating the genetic influences on 
these brain measures has been offered as a way for capturing underlying liability for ADHD 
1
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(Dresler et al., 2014; Durston, 2010; Wu et al., 2014). Such ‘imaging genetics’ approaches may 
provide more insight into the underlying biological mechanisms of genetic risk factors in 
ADHD. The main findings are reviewed in chapter 7 and chapter 8. Basically, most studies 
focused on genotypic effects of single genetic variants of dopamine-related genes, such 
as DAT1 and DRD4. Additionally, the majority of studies investigated the genotypic effects 
on structural MRI measures. So far, the reports have been inconsistent, making their results 
inconclusive. Next to the limited samples sizes, the current literature suffers from lack of 
homogeneity/comparability of study designs and analysis methodologies.
Animal models
Imaging genetics analyses of the human brain provide information on the effect of ADHD 
risk genes/variants on in vivo brain structure, activity, and connectivity, but other, more 
fine-grained levels of investigation are needed to understand the underlying biological 
mechanisms. In this thesis, small animal models, such as mice and Drosophila melanogaster, 
are used in order to shed light on the mechanisms underlying the effects of ADHD genes 
on behavior (and a proxy for disease) at additional levels of complexity.
The main advantages of using animal models are that they can be genetically modified 
to enable determination of causality, they have a natural complexity of the nervous system, 
and allow a tight control of environmental influences, such as diet and drug delivery (Lange 
et al., 2012; van der Voet et al., 2016).
In ADHD research, most knock-out and transgenic mouse models thus far have targeted 
dopaminergic genes. These mutant models provide an excellent opportunity to evaluate the 
contribution of dopamine-related processes to (ADHD) brain pathophysiology, to analyze 
the neuronal circuits and molecular mechanisms involved in the action of ADHD medication, 
and to test novel treatments for ADHD (for review see (Leo and Gainetdinov, 2013)). Early 
mouse studies were used to validate the involvement of candidate genes from association 
studies in ADHD, e.g. by showing ADHD-like behavioral phenotypes in Dat1 knock-out mice 
and the Snap25-mutated coloboma (Giros et al., 1996; Heyser et al., 1995).
The main advantages of the fruit fly (Drosophila melanogaster) compared to rodent 
models are that this model is relatively inexpensive, has a wide range of genomic tools 
readily available, and is highly suitable for fast, high-throughput studies of (candidate) 
genes. The combination of those characteristics with the availability of valid and quantifiable 
phenotypic readouts for ADHD-relevant traits makes this animal model a potent addition 
to non-invasive studies in humans. In the fruit fly, manipulation of the orthologues of the 
dopamine-related genes DAT1 and LPHN3 caused characteristic darkness-dependent 
increased locomotor activity, an ADHD-like behavior (van der Voet et al., 2016). Also in these 
models, ADHD medication was able to reverse the behavioral phenotype (van der Voet et 
al., 2016).
Aim and structure of this thesis
The overall aim of the studies described in this thesis was to improve our understanding of 
the genetic underpinnings of ADHD and to map the biological pathways and mechanisms 
from gene to disorder, by using brain imaging genetics approaches and animal model 
systems.
The thesis is divided into two parts, according to two main research questions:
• Part 1 “Approaches for gene identification”, tries to answer the question which 
molecular genetics mechanisms are underlying ADHD etiology employing a diverse set 
of established and innovative approaches.
• Part 2 ”Mapping of mechanisms from gene to disorder”, describes different 
approaches, such as the use of brain imaging genetics and animal models, to characterize 
and understand functional role of the genetic effects involved in ADHD.
Part 1. Approaches for gene identification (Chapter 2-6)
As the search for genetic risk factors for ADHD has proven to be difficult, the aim of the 
first part of this thesis was to work on established and novel study designs that could help 
with identifying or rejecting involvement of genetic mechanisms underlying ADHD risk. In 
order to capture the entire spectrum of genetic variations, both common genetic variants 
and rare (private) mutations were investigated. Instead of focusing on the clinical diagnosis 
only, we also used quantitative ADHD scores as research outcomes and employed a lifespan 
view on the disorder. Depending on the specific research question we asked, versatile 
analytical methodologies were applied, ranging from the hypothesis-driven, meta-analytic 
investigation of single genetic variants to genome-wide, hypothesis-generating work.
In chapter 2, we studied the association of the childhood ADHD-associated variable 
number tandem repeat (VNTR) polymorphism upstream of gene encoding the dopamine D5 
receptor, DRD5, with persistent ADHD. We compiled data from six sites of the International 
Multicentre persistent ADHD CollaboraTion (IMpACT) and investigated the largest sample to 
date. We tested the association of common DRD5 alleles with categorical ADHD status (case/
control) and with inattentive and hyperactive/impulsive symptom counts. In chapter 3, we 
also investigated common genetic variants, but now applying a hypothesis-free approach. 
Here, we report results of a genome-wide association meta-analysis on self-reported adult 
ADHD symptoms of nine adult population-based and case-only cohorts with subsequent 
rare variant analysis, and validation of findings in childhood population samples and 
mouse models. In chapter 4, we aimed to identify novel ADHD genes by studying the 
genetic overlap between ID and ADHD. This was motivated by the fact that ADHD and ID 
often occur comorbid and that shared molecular genetic influences (mainly based on rare 
CNVs) have been suggested. We thus investigated, whether genes known to carry rare 
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mutations in ID contribute to ADHD risk through common variants. Validation and functional 
characterization of two candidates was performed using Drosophila melanogaster. In the 
next two chapters, we focused on less frequent genetic variation. In chapter 5, we used 
a multi-step approach to identify and validate a novel ADHD risk gene. In a single family, 
severely affected by ADHD and comorbid disorders, we applied microarray analysis to detect 
rare structural genetic variants co-segregating with ADHD. One gene was taken forward for 
functional validation using Drosophila melanogaster as a biological model system. In chapter 
6, we explored, whether combining linkage analysis and WES in large multi-generational 
pedigrees with association testing in an independent adult ADHD exome-chip study is a 
viable approach to gene-finding in (persistent) ADHD.
Part 2. Mapping of mechanisms from gene to disorder (Chapter 7-10)
In addition to the mechanistic work that made part of chapters 3 and 4, the second part 
of the thesis focuses on diverse approaches that can help to shed light on the different 
pathways involved in ADHD etiology. In chapter 7, we reviewed the imaging genetics 
literature on three neurodevelopmental disorders, which often co-occur (ID, ASD, and 
ADHD), attempting to understand the genetic mechanisms underlying individual disorders 
and their clinical overlap. For ADHD and ASD, genes showing replicated associations through 
common genetic variants with either disorders were selected. For ID, which is mainly caused 
by rare variants, we included genes for relatively frequent forms of ID occurring comorbid 
with ADHD or ASD. We reviewed case-control studies and studies of risk variants in healthy 
individuals. In chapter 8, we performed a systematic review of brain imaging genetics 
studies involving 62 ADHD candidate genes in childhood and adult ADHD cohorts. Beyond 
reviewing brain imaging genetics studies, we also discussed the need for complementary 
approaches at multiple levels of biological complexity and emphasized the importance of 
combining and integrating findings across levels for a better understanding of biological 
pathways from gene to disease. In chapter 9, we aimed at replicating the association of 
GIT1 with ADHD and investigated its role in cognitive and brain phenotypes. Furthermore, 
functionality of a single genetic variant as an expression quantitative trait locus (eQTL) for 
GIT1 was assessed in human blood samples. Using Drosophila melanogaster as a biological 
model system, we manipulated Git expression according to the outcome of the blood gene 
expression analysis and studied the effect of Git knockdown on neuronal morphology 
and locomotor activity. Our findings suggested that genetic risk for ADHD is mediated by 
alteration in structure and function of diverse brain networks. In chapter 10, we tested 
one aspect of this hypothesis. We investigated the genetic overlap between ADHD and 
(subcortical) brain volumes, both at the level of common variant genetic architecture as well 
as on the level of single variants. For this, we used the largest publicly available genome-
wide genetic association data sets on ADHD risk and (subcortical) brain volumes.
Study cohorts and consortia
IMpACT
The International Multicentre persistent ADHD CollaboraTion (IMpACT; www.
impactadhdgenomics.com) is a consortium of clinical and basic researchers from several 
European countries (The Netherlands, Germany, Spain, Norway, The United Kingdom, 
Sweden), the United States of America, and Brazil. The mission of IMpACT is to perform 
and promote high quality research in ADHD across the lifespan (Franke and Reif, 2013). This 
research is aimed at identifying novel genetic variants for adult ADHD and at understanding 
the mechanisms underlying the effect of these genetic variants on disease risk. IMpACT 
members share data on their samples as well as biological material, which has resulted in 
the formation of the largest database for persistent ADHD research. In this thesis, different 
types of data from IMpACT were used (Table 1).
PGC ADHD Working Group
The ADHD Workgroup was formed in 1998. This workgroup focuses on the study of ADHD 
and associated features in children and adults. In 2007, it joined the Psychiatric Genomics 
Consortium (PGC; http://www.med.unc.edu/pgc/pgc-workgroups). Current goals are to 
increase the number of ADHD samples with genome-wide association data and to extend the 
work into genome/exome sequencing. In this thesis, GWAS meta-analysis summary statistics of 
the PGC ADHD samples, sometimes in combination with data from iPSYCH, was used (Table 1).
iPSYCH
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH; http://ipsych.
au.dk/; (Pedersen et al., 2017)) ADHD sample is a nationwide population-based case-cohort 
sample selected from a baseline birth cohort comprising all singletons born in Denmark 
between May 1, 1981, and December 31, 2005, who were residents in Denmark on their first 
birthday and who have a known mother. Cases were diagnosed by psychiatrists at psychiatric 
hospitals (in- or out-patient clinics) according to ICD10 (F90.0), identified using the Danish 
Psychiatric Central Research Register (DPCRR). Controls were randomly selected from the same 
nationwide birth cohort and not diagnosed with ADHD (F90.0) or moderate-severe mental 
retardation (F71-F79). In this thesis, GWAS meta-analysis summary statistics of the iPSYCH ADHD 
sample was either used individually, or in combination with the PGC ADHD data (Table 1).
SAGA
The Study of ADHD trait Genetics in Adults (SAGA) consortium aims to identify ADHD risk 
genes by investigating the association between common genetic variants and adult ADHD 
symptom scores. The SAGA consortium carried out a GWAS meta-analysis in nine adult 
population-based and case-only cohorts of European Caucasian origin (age 18 years or 
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older) for whom adult ADHD symptom scores were available: six population-based cohorts, 
including one genetic isolate, two clinical ADHD samples, and one clinical cohort ascertained 
for depressive and anxiety disorders (Table 1).
EAGLE
The EArly Genetics and Lifecourse Epidemiology Consortium (EAGLE) is a consortium 
of pregnancy and birth cohorts that aims to collaborate to investigate the genetic basis 
of phenotypes related to physical and mental health from antenatal and early life to 
adolescence (https://www.wikigenes.org/e/art/e/348.html). In this thesis, summary 
statistic data of the EAGLE GWAS meta-analysis on childhood ADHD symptoms was used 
(Middeldorp et al., 2016) (Table 1).
BIG
The Brain Imaging Genetics (BIG) study was set up in 2007 by the Human Genetics 
department of the Radboud university medical center and the Donders Centre for Cognitive 
Neuroimaging of the Radboud University (www.cognomics.nl/big). In 2010, the Max Planck 
Institute for Psycholinguistics in Nijmegen also joined. BIG aims to identify the genetic 
factors influencing behavior, cognition, and brain structure and function in health and 
disease in individuals from the general population. The BIG database consists of brain 
imaging data, genetic data, and results of cognitive tasks and questionnaires of healthy 
adults subjects recruited in the Nijmegen area (Table 1).
ENIGMA
The Enhancing NeuroImaging Genetics through Meta Analysis (ENIGMA) network brings 
together researchers in imaging genomics to investigate brain structure, function, and 
disease, based on brain imaging and genetic data (http://enigma.ini.usc.edu/). ENIGMA 
combines numerous studies, including studies with a case-control design, which performed 
neuroimaging in a range of neuropsychiatric or neurodegenerative diseases, as well as 
studies of healthy/general populations. In this thesis, summary statistic data of the ENIGMA 
GWAS meta-analysis on subcortical volumes and intracranial volume was used (Adams et 
al., 2016; Hibar et al., 2017; Hibar et al., 2015) (Table 1).
CHARGE
The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE, http://www.
chargeconsortium.com/) (Psaty et al., 2009) consortium is a collaboration of predominantly 
population-based cohort studies that investigate the genetic and molecular underpinnings 
of age-related complex diseases, including those of the brain. In this thesis, summary statistic 
data of the CHARGE GWAS meta-analysis on hippocampal volume and intracranial volume 
was used (Adams et al., 2016; Hibar et al., 2017) (Table 1).
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Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neuropsychiatric disorder 
with a complex genetic background. DRD5, the gene encoding the dopamine receptor D5, 
was recently confirmed as a candidate gene for ADHD in children through meta-analysis. 
In this study, we aimed at studying the association of the ADHD-associated variable 
number tandem repeat (VNTR) polymorphism upstream of DRD5 with adult ADHD. We 
compiled data from six sites of the International Multicentre persistent ADHD CollaboraTion 
(IMpACT) and reached N=6,979 (3,344 cases and 3,635 healthy participants), the largest 
sample investigated so far. We tested the association of the common DRD5 alleles with 
categorically defined ADHD and with inattentive and hyperactive/impulsive symptom 
counts. Our findings provide evidence that none of the common DRD5 alleles are associated 
with ADHD risk or ADHD symptom counts in adults.
Keywords: DRD5; Attention-Deficit/Hyperactivity Disorder; candidate gene; meta-analysis
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a multifactorial neurodevelopmental 
disorder with an onset before the age of 12 years. It is characterized by hyperactivity, 
restlessness, impulsivity, and/or inattention (American Psychiatric Association, 2013). In a 
considerable number of patients, the disorder persists into adulthood, with a worldwide 
prevalence of ADHD of 1-4% in adults (Simon et al., 2009). Although ADHD is highly heritable 
in both children and adults (Faraone et al., 2005), only a few genetic risk factors have 
consistently been associated with ADHD risk, and most variants investigated are related 
to genes in the dopaminergic and serotonergic neurotransmission systems (Gizer et al., 
2009). The dopamine receptor D5 (DRD5) gene is one of these; a variable number of tandem 
repeat polymorphism (VNTR) with a highly polymorphic dinucleotide repeat located 18.5 
kb upstream in the 5’ region of the gene produces multiple alleles, of which two have 
been associated with ADHD. The association was first described in 1999 (Daly et al., 1999); 
since then, several studies investigated the effect of the DRD5 VNTR on ADHD. A previous 
meta-analysis, including 12 studies (approximately 2,350 childhood cases and their parents), 
showed that the 148-bp allele is associated with increased ADHD risk, and that the 136-bp 
confers reduced ADHD risk (n=4 studies) (Wu et al., 2012). Mixed results for the role of the 
DRD5 VNTR in persistent ADHD have been reported previously (Carpentier et al., 2013; 
Johansson et al., 2008; Langley et al., 2009; Squassina et al., 2008). To clarify the association 
of the DRD5 VNTR with ADHD in adulthood, we performed a meta-analysis of case-control 
cohorts from six sites (Brazil, Germany, The Netherlands, Norway, Spain, and USA; n=6,979) 
of the International Multicentre persistent ADHD CollaboraTion (IMpACT, (Franke and Reif, 
2013)). We tested the association of the DRD5 148-bp and 136-bp alleles with categorically 
defined ADHD and also with inattentive and hyperactive/impulsive symptom counts, 
separately. Subsequently, we performed exploratory analyses investigating the effects of 
ten additional, frequent DRD5 alleles.
Experimental Procedures
Subjects
Within the IMpACT consortium, all patients were evaluated by experienced psychiatrists and 
diagnosed with persistent ADHD according to DSM-IV (Diagnostic and Statistical Manual for 
Mental Disorders) criteria. Ratings of ADHD symptom counts were retrieved from clinical 
interviews, except for the Dutch and Norwegian cohorts, where symptom counts were 
derived from self-report questionnaires (see (Franke et al., 2010) for detailed information 
on diagnostic assessments). Participants were invited to provide whole blood or saliva 
samples for genotyping. Studies were approved by ethics committees of the participating 
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institutions, and written informed consent was obtained from all patients and controls 
prior to the study.
Genetic data
Genotyping of the DRD5 (upstream VNTR) was performed in all six above-mentioned 
IMpACT cohorts by Fragment Length Analysis. The PCR reaction was performed on 
30 ng genomic DNA using 0.33 μM 5’-fluorescently labeled (FAM, VIC, PET, or NED) 
forward primer (5’-GCTCATGAGAAGAATGGAGTG-3’) and reverse primer with PIG tail 
(5’-CGTGTATGATCCCTGCAG-3’) and 1x AmpliTaq Gold® 360 Master Mix (Applied Biosystems, 
Nieuwerkerk a/d Ijssel, The Netherlands). The cycling conditions for the polymerase chain 
reaction initiated with 10 min at 95°C, followed by 35 cycles of 30 sec at 95°C, 30 sec at 
the optimized annealing temperature (58°C), and 1 min at 72°C, then followed by a final 
step of 7 min at 72°C. The product of the amplification was diluted 1:30 in H2O. 1 ul of this 
dilution, together with 9.7 µl formamide and 0.3 µl Genescan-600 LIZ Size Standard (Applied 
Biosystems) was analyzed on an automated capillary sequencer (ABI3730 genetic analyzer, 
Applied Biosystems) according to the protocol of the manufacturer. To determine the length 
of the alleles, the results were analyzed with Genemapper software version 4.0 (Applied 
Biosystems). Output of the genotyping was the actual length in base pairs per allele, which 
was re-coded into three categories, i.e. homozygous of the reference allele, heterozygous, 
or homozygous for the non-reference allele.
The frequency distribution of the DRD5 alleles (with a frequency >1%) across the different 
cohorts is shown in Figure 1. A total of 3,344 adult ADHD patients (44.4% female, average 
age = 34.9 years [range 18 – 75]) and 3,635 healthy individuals (51.7% female, average age = 
39.1 years [range 18 – 92]) were available for the study. In all cohorts, allele frequencies were 
in Hardy-Weinberg equilibrium (HWE, P>0.05); the smallest cohort (USA, n=147) showed 
non-significant deviation from HWE (P=0.021, 12 DRD5 alleles tested), which might be due 
to sampling variance in the underpowered cohort.
Statistical analyses
Output of the genotyping was the actual length in base pairs per allele, which was re-coded 
into three categories, i.e. homozygous of the reference allele, heterozygous, or homozygous 
for the non-reference allele. To prevent biases due to ethnic discrepancies, calculations 
were performed in each sample separately; subsequently, samples were subjected to meta-
analysis (see below). A trend test was used to evaluate the ADHD risk conferred by carrying 
one of the DRD5 allelic variants using logistic regression (additive model) for each individual 
IMpACT cohort. Analyses of symptom counts were performed separately for inattentive 
and hyperactive/impulsive symptoms in cases only. For this analysis, symptom count 
distributions were normalized and standardized using the Blom transformation. Impact of 
genotypes on inattentive and hyperactive/impulsive symptom scores was determined with 
linear regression using genotype dosages (additive model) as independent and the trait of 
interest as dependent variable. Age and gender were included as covariates in all analyses. 
Twelve alleles of the DRD5 VNTR were selected for analysis (Figure 1) and all data analyses 
were performed separately for each DRD5 allele using the Statistical Package for the Social 
Sciences (SPSS) version 20.0 (IBM Corp. Released 2011, IBM SPSS Statistics for Windows, 
Version 20.0 Armonk, NY: IBM Corp.).
All six cohorts were used to run a fixed effects meta-analysis model using the “rma” 
command implemented in the R package “metafor” v1.9-4 (Viechtbauer, 2010). As a measure 
for effect size either the odds ratios (ORs) or betas were calculated. Q-statistic and I2-metric 
were used to test and discard heterogeneity. When no heterogeneity was present, the 
pooled OR/beta was estimated using fixed effects model. The results of the association 
tests are indicated as pooled ORs/betas with the corresponding 95% confidence intervals 
(CIs) of the allele-induced risk of persistent ADHD or ADHD symptom counts.
Power analysis
Power analysis using the Genetic Power Calculator (GPC) (Purcell et al., 2003) and previously 
reported effect estimates showed that we had 64.1% power to detect effect sizes similar to 
the ones reported previously (OR≥1.26 for the 148-bp allele), 80% power to detect OR>1.4, 
and 100% power for effects of OR≤0.58 (for the 136-bp allele) (Wu et al., 2012). Also, our study 
had 90.1% power to detect associations explaining ≥0.5% of variance in ADHD symptom 
counts.
Figure 1: Distribution of DRD5 VNTR alleles across all IMpACT cohorts included in the study. Only alleles 
with a minor allele frequency (MAF) >1% are shown.
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Results
In total, 12 alleles of the DRD5 VNTR were selected for analysis (Figure 1). Neither the 148-bp 
childhood ADHD risk allele nor the 136-bp childhood ADHD protective allele were associated 
with ADHD risk in adults (OR=0.97, 95% CI 0.90–1.04, P=0.425 and OR=0.92, 95% CI 0.73–1.15, 
P=0.464, respectively; Figure 2A). The same was found in the analysis of the separate ADHD 
symptom domains (N≥2,415; P>0.05, Figure 2B,C). An exploratory analysis investigating 
the ten additional DRD5 alleles did not reveal any significant association with ADHD risk or 
ADHD symptom counts either (best p-value was P=0.07 for the 146-bp allele and ADHD 
risk). Overall results did not change using a random-effects model.
Discussion
While evidence for an association of DRD5 VNTR alleles with ADHD in children had been 
strengthened by meta-analysis (Wu et al., 2012), we did not find similar effects in the current 
meta-analysis of persistent ADHD in adults. These differences are consistent with twin data 
that suggest the risk alleles contributing to ADHD symptoms partly differ by age (Chang 
et al., 2013; Pingault et al., 2015). Differential association in childhood and adulthood has 
also been reported for the dopamine transporter gene (DAT1/SLC6A3) (Franke et al., 2010). 
The potential age-dependent effect of DRD5 on ADHD could be further investigated in 
longitudinal study designs. However, we cannot entirely exclude the chance of a false 
negative finding for the 148-bp allele, for which we had limited power of 64.1%. Notably, 
earlier meta-analytic studies included fewer participants than ours (e.g. the previous meta-
analysis included around 2,350 children with ADHD for analysis of the 148-bp allele, and less 
than 1,000 patients for analysis of the 136-bp allele (Wu et al., 2012)), which could explain 
the discrepancy between findings. Only three earlier studies investigating the association 
between the DRD5 VNTR and persistent ADHD have been published (Carpentier et al., 2013; 
Johansson et al., 2008; Squassina et al., 2008), and one additional study used a childhood 
cohort that was followed-up for five years (Langley et al., 2009). The results were inconsistent 
across studies, with only two studies reporting some evidence of positive association 
(Johansson et al., 2008; Langley et al., 2009); one of those two was a subsample of the 
Norwegian sample included in the current study, and the originally reported association 
was no longer present in this larger sample. In conclusion, based on the results of the current 
meta-analysis, it seems unlikely that the DRD5 VNTR contributes substantially, if at all, to 
ADHD persistence into adulthood.
Figure 2: (A) Forest plots showing the association analysis of the DRD5 148-bp and 136-bp alleles with ADHD 
risk. (B) Forest plots showing the association analysis of the DRD5 148-bp and 136-bp alleles with ADHD 
inattentive symptom counts in patients with adult ADHD. (C) Forest plots showing the association analysis 
of the DRD5 148-bp and 136-bp alleles with ADHD hyperactive/impulsive symptom counts in patients with 
adult ADHD. For each, cohort the number of cases and controls is presented in brackets.
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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is characterized by age-inappropriate levels 
of inattention and/or hyperactivity-impulsivity and persists into adulthood in a substantial 
proportion of cases. ADHD is heritable, and is thought to represent the clinical extreme of a 
continuous distribution of ADHD symptoms in the general population. We aimed to detect 
ADHD risk conferring genes leveraging the power of population studies of ADHD symptoms 
in adults. Within the SAGA (Study of ADHD trait Genetics in Adults) consortium, we estimated 
the SNP-based heritability of self-reported ADHD symptoms and carried out a genome-wide 
association meta-analysis in nine adult population-based and case-only cohorts of unrelated 
adults. A total of n=14,689 individuals were included. We found a significant SNP-based 
heritability for self-rated ADHD symptom scores of respectively 15% (n=3,656) and 30% 
(n=1,841) in the two cohorts. The top-hit of the genome-wide meta-analysis (SNP rs12661753) 
was present in the hitherto uncharacterized long non-coding RNA STXBP5-AS1 gene. This 
association was also observed in a meta-analysis of childhood ADHD symptom scores in 
eight population-based pediatric cohorts from the EAGLE ADHD consortium (n=14,776). 
Genome-wide meta-analysis of the SAGA and EAGLE data (n=29,465) increased the strength 
of the association on the STXBP5-AS1 gene. In human HEK293 cells, expression of STXBP5-AS1 
enhanced the expression of a reporter-construct of STXBP5, a gene known to be involved in 
SNARE complex formation. In mouse strains featuring different levels of impulsivity, Stxbp5-
AS1 transcript levels in the prefrontal cortex strongly correlated with motor impulsivity 
as measured in the 5-choice serial reaction time task (r2=0.55). Our results implicate the 
STXBP5-AS1 gene in ADHD symptom scores and point to vesicle transport as a biological 
mechanism involved in ADHD-related impulsivity levels.
Key words: ADHD behavior, Study of ADHD trait Genetics in Adults, STXBP5-AS1 gene, vesicle 
transport in ADHD
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder 
affecting 2–5% of children (Polanczyk and Rohde, 2007)-(Association, 1994) and adults 
(Franke et al., 2012),(Faraone et al., 2015). ADHD is characterized by age-inappropriate, 
sustained symptoms of inattention and/or hyperactivity-impulsivity. In children (Faraone 
et al., 2005) and adults (Saviouk et al., 2011), ADHD shows substantial heritability. Heritability 
estimates are largely independent of the phenotypic measurement scale (i.e., categorical or 
continuous) in children; in adults, estimates are lower when using self-report rating scales 
(Franke et al., 2012). Twin studies (Faraone et al., 2005) suggest that etiological influences 
on ADHD symptoms are distributed throughout the population, consistent with a liability 
model (Caspi et al., 2008). Inattention and hyperactivity-impulsivity symptoms can be 
reliably assessed in population-based cohorts based on rating scales (Larsson et al., 2013), 
creating the possibility to collect large samples for gene-finding studies. The genetic 
contributions to ADHD in children and adults are complex, with multiple different genetic 
variants contributing to the disorder (Faraone et al., 2015), both common and rare (Franke 
et al., 2012). Recently, 16 genome-wide associations have been established in an ADHD 
Genome-Wide Association Studies meta-analysis (GWASMA) of childhood case-control 
studies from the Psychiatric Genomics Consortium (PGC) and The Lundbeck Foundation 
Initiative for Integrative Psychiatric Research (iPSYCH)9 and population-based samples from 
the EArly Genetics and Lifecourse Epidemiology (EAGLE) consortium (Demontis et al., 2017; 
Middeldorp et al., 2016).
Here, we sought to leverage the power of population studies of ADHD symptoms in 
adults to detect disease-relevant genes. Within the SAGA (Study of ADHD trait Genetics in 
Adults) consortium, we estimated the SNP-based heritability of self-reported adult ADHD 
symptoms and subsequently carried out a GWASMA in nine cohorts of European Caucasian 
origin (n=14,689 individuals, age 18 years or older), in whom adult self-reported ADHD 
symptom scores were available. These samples included six population-based cohorts, 
two clinical ADHD samples and one clinical cohort ascertained for depressive and anxiety 
disorders (to enrich the clinical extreme of the ADHD symptom continuum). The locus with 
the strongest statistical association was followed-up in a replication analysis of quantitative 
childhood ADHD symptom scores (n=14,776) from the EAGLE consortium (Middeldorp et 
al., 2016). Genetic correlations were obtained between the PGC and the iPSYCH sample of 
children (Demontis et al., 2017) and the SAGA sample of adults. Finally, we conducted gene-
based tests for genes with SNPs showing a P value<1x10-6 in the meta-analysis, making use 
of the common SNPs from SAGA and rare variant data from the Erasmus Rucphen Family 
(ERF) study (see Table 1), one of the adult cohorts.
3
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Functional follow-up studies downstream of gene-finding in ADHD, e.g. in model systems, 
to determine the biological relevance of a genetic finding, are scarce (Klein et al., 2017). 
Core features of ADHD, inattention, hyperactivity, and impulsivity are well defined e.g. in 
mouse models (Loos et al., 2014). Here we carried out functional follow-up studies for the 
hitherto uncharacterized top-gene of the GWASMA in three mouse inbred strains with large 
differences in motor impulsivity derived from reaction time tasks, and in a human cell assay.
Methods
ADHD symptom scores and study populations
ADHD symptom scores were assessed by three instruments (see Table 1) in nine cohorts 
(for a complete description of each sample please follow the references in Table 1): the 
ADHD-index of the Conners Adult ADHD Rating Scale (Conners, 1999) (CAARS ADHD-index; 
12 items), the total scores of the DSM-IV ADHD Rating Scale (ADHD-RS) (Sandra Kooij et 
al., 2008), and the Attentional Deficit/Hyperactivity Problems subscale from the Adult Self 
Report (ASR-ADHD; 13 items) (Kessler et al., 2007). The CAARS (used in NESDA, NTR, ERF) is 
an extensively tested psychometric instrument with high internal consistency and reliability. 
Five cohorts (NeuroIMAGE, BIG, IMpACT-NL, VHIR, NBS) collected information using the 
ADHD-RS (Sandra Kooij et al., 2008), which has high validity in population-based and case 
samples. For IMpACT-NL and VHIR, only affected individuals were included. One cohort 
(TRAILS) assessed ADHD problems through the ASR-ADHD (Kessler et al., 2005; Kessler et 
al., 2007),(Achenbach, 2003) (http://www.aseba.org/).
Genetic Variant Calling and Quality Control
An overview of genome-wide single nucleotide polymorphism (SNP; for common variants) 
genotyping, quality control, and imputation is given in Supplementary Table 1. Exomes 
of 1,336 individuals from the ERF population, which is a genetically isolated population in 
the Netherlands (Aulchenko et al., 2004), were sequenced (see Supplementary Methods), 
and ADHD index data were available for 587 of these individuals. Detection of rare variants 
in the ERF study was done for those genes with SNPs with P<1x10-5 in the GWASMA, and 
variants identified in these exomes were used to estimate the contribution of rare variants 
in the genes of interest to ADHD behavior (see Supplementary Methods).
GCTA
Genome-wide Complex Trait Analysis (GCTA) (Yang et al., 2011) was used to compute the 
variance in the ADHD symptom score explained by common SNPs in the two largest cohorts 
included in the meta-analysis, the NTR and NESDA (n>1,500 unrelated subjects). A genetic 
relationship matrix (GRM) for all individuals in the dataset was estimated based on SNPs 
with high imputation quality (see Supplementary Methods). Bivariate GCTA (Yang et 
al., 2011) was additionally run on the ADHD-index of the CAARS and ASR-ADHD data also 
available in the NTR cohort, to assess the genetic correlation (rg) between the two diagnostic 
instruments.
Genome-wide association and Meta-analysis
GWAS was conducted in each cohort by linear regression under an additive model. Age 
was included as a covariate, but not gender, which was not significantly associated with 
the ADHD scores in any study. Four principal components were added to account for 
possible population stratification effects. Information on software packages is provided 
in Supplementary Table 1. In all analyses, the uncertainty of the imputed genotypes 
was taken into account. Location of SNPs reported is from the build 37 (hg19) 1000G data. 
Meta-analysis was conducted in METAL (www.sph.umich.edu/csg/abecasis/metal/index.
html) by the P-value-based method, given the intrinsic variability of the quantitative traits 
used (see Supplementary Methods). The meta-analysis was performed in the full sample 
(nine cohorts) and restricted to the population-based samples (seven cohorts; “restricted 
sample”).
Replication in the EAGLE consortium
Within EAGLE, association of ADHD-related measures was assessed in nine population-based 
childhood cohorts with genotype data imputed against the 1000 Genomes reference panel 
(Middeldorp et al., 2016). Linear regression of the phenotype on sex, age, genotype dose, 
and principal components was performed in all cohorts, followed by meta-analysis based 
on P-values in METAL. The TRAILS cohort is part of both consortia, and was excluded from 
the EAGLE consortium for replication analysis, leaving a total of 14,776 children from eight 
cohorts.
Look-up of significant GWAS loci
Evidence for an effect of the 12 independent ADHD-associated SNPs from the PGC+iPSYCH 
GWASMA on adult ADHD symptoms was studied through a look-up of results. LD-
independent loci with corresponding index-SNPs were obtained from Table 1 of Demontis 
et al (Demontis et al., 2017). If the index variant was not present in the SAGA data set, a proxy 
variant was selected using LDlink (https://analysistools.nci.nih.gov/LDlink/). The Bonferroni-
corrected significance level was set at P=0.05/12=0.00417.
Linkage disequilibrium score regression (LDSR) analysis
LDSR was used to estimate the genetic correlation between the PGC+iPSYCH sample of 
children (Demontis et al., 2017) and the SAGA sample of adults. Each dataset underwent 
additional filtering for markers overlapping with HapMap Project Phase 3 SNPs, INFO 
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score≥0.9 (where available), and MAF≥1%. Indels and strand-ambiguous SNPs were removed. 
LDSR analysis was performed using the LDSR package (https://github.com/bulik/ldsc (Bulik-
Sullivan et al., 2015), see Supplementary Methods).
Gene-wide analysis of common and rare variants
Genes containing SNPs with P-values<1x10-6 in the meta-analysis of the nine cohorts were 
selected for gene-wide tests using common and rare variants. The common variant analysis 
was performed in MAGMA (de Leeuw et al., 2015). Flanking regions of 25kb for each gene 
were included in the analyses. The rare variant analysis was performed with the Sequence 
Kernel Association Test (SKAT; only in the ERF study) library of the R-software (Wu et al., 2011).
Functional analyses
Follow-up functional analyses were performed on the locus containing the best association 
P-value. This locus contains STXBP5-AS1, representing a putative long noncoding RNA, 
predicted to be expressed in several species (Supplementary Methods; Supplementary 
Table 5 & Supplementary Fig. 2). Human STXBP5-AS1 encodes multiple splice variants, 
many of which lack a region that overlaps the STXBP5 gene. To test for regulatory effects of 
STXBP5-AS1 on the expression of STXBP5, a fluorescent reporter construct was designed to 
contain the region of antisense overlap (see Supplementary Methods).
Mouse models
RNA was derived from prefrontal cortex of adult male mice from the inbred strain C57/Bl6J 
(n=7) and recombinant inbred strains BXD29 (n=8) and BXD68 (n=7), and gene expression 
was quantitated (see Supplementary Methods). Strains were bred in the facility of the 
Neuro-Bsik consortium of the VU University (Amsterdam, The Netherlands) and used for 
behavioral analysis (Loos et al., 2014),(Spijker et al., 2004).
Results
Quantitative assessment instruments are listed in Table 1. The quantitative phenotypes 
showed a weak, negative correlation with age and no association with gender in any cohort. 
Phenotypic and genetic correlations between symptom scores assessed with the different 
instruments were substantial: in a clinical sample of 120 adults with ADHD the phenotypic 
correlation between the CAARS (Conners, 1999) (ADHD-index) and the ADHD-RS (Sandra 
Kooij et al., 2008) (total score) was high (r=0.73; P<0.01) (Sandra Kooij et al., 2008). In 380 
parents of children with ADHD, the correlation was of similar magnitude (r=0.69; P<0.001) 
(Thissen et al., 2012). We estimated the phenotypic correlation between the CAARS ADHD-
index and the ASR-ADHD (Kessler et al., 2005; Kessler et al., 2007) in the NTR (n=15,226; 
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average age 40 years, SD=16.1) to be 0.67 (P<0.0001). In younger participants in the age range 
of the TRAILS cohort (18–22 years, n=2,687), the correlation was similar (0.68, P<0.0001).
A significant SNP-based heritability was estimated for the CAARS ADHD-index in a 
subsample of each of the two largest cohorts: 30% (SE=16.7%, P=0.035) in NESDA (n=1,841 
unrelated subjects) and 15% (SE=7.8%, P=0.020) in NTR (n=3,881 unrelated participants). 
We also estimated the genetic correlation for the CAARS ADHD-index and the ASR-ADHD 
using bivariate GCTA. In all individuals from the NTR with genotype and phenotype data 
(n=6,036 related and unrelated subjects), the genetic correlation was 0.818 (SE=0.256). When 
analyzing the bivariate data in 2,921 unrelated subjects, the point estimate of the genetic 
correlation was 0.813 (SE=0.364). The significant SNP-based heritability and the considerable 
phenotypic and genetic correlations between assessment instruments support the validity 
of our meta-analysis approach of GWA results obtained across contributing data sets.
For the nine separate GWAS, the genomic control inflation factors (lambda) ranged 
between 0.996 and 1.026 (mean lambda 1.009, Supplementary Table 2). Meta-analysis 
(Supplementary Figure 1A) of the full sample revealed the lowest P-value (3.03x10-7) for 
the intronic SNP rs12661753 in STXBP5-AS1 (Supplementary Figure 3); for the meta-analysis 
of the restricted sample, P-value for this SNP was 1.48x10-6 (Supplementary Figure 1B). 
Replication was observed for rs12661753 (P=3.07x10-2) for childhood ADHD symptoms in the 
EAGLE-ADHD consortium (Middeldorp et al., 2016). The subsequent GWASMA between SAGA 
and EAGLE revealed the best association P-value=2.05x10-7 for SNP rs12664716 (n=29,465; 
Supplementary Figure 3F) located in the STXBP5-AS1 gene, and in high LD (D’=1.0, r2=0.98) 
with rs12661753 (PSAGA-EAGLE= 3.55x10
-7; Supplementary Figure 1C).
The index variant rs12661753 was not associated with ADHD risk in the recent case-
control PGC+iPSYCH GWASMA of ADHD in a sample mainly consisting of children (P=0.6316, 
n=55,374). A look-up of genome-wide significant ADHD index SNPs from this PGC+iPSYCH 
GWASMA for association in the SAGA consortium also revealed no significant associations 
with adult ADHD symptoms (Supplementary Table 6).
We estimated the genetic correlation between PGC+iPSYCH and the complete SAGA 
sample to be 0.541 (SE=0.447, P=2.26x10-1; the VHIR cohort present in both studies). We 
tested if the two rg values differed significantly from each other, which was not the case 
(X2-based test P>0.05) (Supplementary Methods).
In NTR and NESDA, a subset of participants (n=6,678) had additional phenotype data on 
hyperactivity/impulsivity and inattention symptom subscales of the CAARS available. These 
scales of each 9 items are non-overlapping with the 12 ADHD-index items. For hyperactivity/
impulsivity symptoms, the P-value for association with rs12661753 was 1.51x10-5, whereas 
for inattention it was 3.53x10-2, suggesting a stronger effect of the variant on hyperactivity/
impulsivity.
As shown in Table 2 and Supplementary Table 3, 50 common variants from 8 
independent (clumped) loci showed P-values<1x10-6. Of these, four were also amongst the 
top-associated loci from the restricted SAGA GWASMA (no patients; Supplementary Table 
4). The genes closest to these SNPs were selected for gene-wide analysis (Table 2). Analysis 
of common variants in seven genes (plus 25kb flanking regions) in the SAGA GWASMA 
showed significant association with ADHD symptoms. Two significant findings (P<0.003) 
were for long intergenic non-protein coding RNA genes (LINC01247, LINC00534), and nominal 
significant associations (P<0.05 gene-wide) were seen for STXBP5-AS1, CALB1, GNG12-AS1, 
STXBP5 (Supplementary Table 5). It is important to note that STXBP5 and STXBP5-AS1 have 
no physical separation, thus their 25kb flanking regions overlap. The rare variant analysis also 
showed nominal association for STXBP5. For four genes (GNG12-AS1, LINC01247, STXBP5-AS1, 
LINC00534), rare variants were not observed/detected ((Supplementary Table 5).
Given that the STXBP5-AS1 gene, which contains the top-hits, is hitherto uncharacterized, 
we investigated its function. STXBP5-AS1 encodes a long noncoding RNA (lncRNA). Although 
human STXBP5-AS1 does not have any orthologues listed in the UniGene database, it is 
conserved in primates and shows a modest conservation in rodents (Supplementary 
Table 7 and alignment in Supplemental Figure 2). In the hg19 genome release annotation 
STXBP5-AS1 is located next to STXBP5 in the opposite orientation, with antisense sequence 
overlap in exon 1 of STXBP5 (Figure 1A). It may be hypothesized that STXBP5-AS1 affects 
STXBP5 expression. For such natural antisense RNAs, both repression and positive effects 
on the expression of cognate genes have been described (Kimura et al., 2013; Matsui et al., 
2008). We tested this hypothesis by designing a reporter gene fusing exon 1 of STXBP5 to 
EGFP, and quantifying its expression in human HEK293 cells. Expression of the antisense 
lncRNA variant STXBP5-AS1-003 (containing the overlap with Stxbp5) caused an increase in 
the fluorescence ratio between STXBP5-EGFP and the control (Figure 1B-E).
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Figure 1. STXBP5-AS1 positively regulates the expression of its cognate mRNA. (A) Design of two reporter 
constructs. Top: Exon 1 of human STXBP5, containing the natural 5’UTR and encoding the first 50 amino 
acids, was fused in-frame to EGFP. The Stxbp5-AS1 transcript including the region showing perfect (100%) 
sequence overlap with the encoded Stxbp5 transcript is depicted schematically in blue. Bottom: To control 
for transfection efficiency and differences in cellular metabolic rates, we co-expressed a non-target mRNA 
comprised of human HPRT1 exon 1 fused to mCherry. (B) Typical examples of HEK293 cells expressing both 
constructs with or without STXBP5-AS1. (C) Quantitation of EGFP and mCherry fluorescence in presence or 
absence of AS1 (947 and 974 cells respectively). (D-E) The ratio of STXBP5-EGFP and HPRT1-mCherry was 
calculated for each cell. Data are presented as a histogram (D) or as mean±SEM (E). ***, P=6x10-51; t946=4.4412, 
Student’s t-test.
Given the in vitro effects on STXBP5-EGFP protein expression, we tested the relationship 
between gene expression of mouse Stxbp5 and/or Stxbp5-AS1 and measures of behavioral 
impulsivity. We analyzed gene expression in medial prefrontal cortex of three mouse inbred 
strains previously described to have large differences in motor impulsivity(Loos et al., 2014). 
Here, we confirmed the strain difference in motor impulsivity between the BXD68, BXD29, 
and C57BL/6J strains (F2,20=6.91, P=0.005), measured as premature responses in the 5-choice 
serial reaction time task. In addition, these strains showed differences in errors of omission 
(F2,20=5.18, P=0.015), but not attention (F2,20=0.35, P=0.771) (Figure 2A). In these mice, we 
detected expression of a mouse Stxbp5-AS1 transcript in the prefrontal cortex by real-time 
quantitative PCR, which differed across strains (F2,19=11.73; P<0.001). This transcript showed 
lowest expression in the most highly impulsive strain, BXD68 (BXD68: 4.58±0.11, C57BL/6J: 
5.25±0.14, BXD29: 5.19±0.07, PBXD68 vs C57BL/6J=0.003, t13=3.73; PBXD68 vs BXD29<0.001, t14=4.63) (Figure 
2B). Expression of Stxbp5 mRNA was not different between the three strains (BXD68: 
9.89±0.24; C57BL/6J: 9.83±0.10; BXD29: 9.99±0.23). These results suggest that the role of 
STXBP5-AS1 plays in impulsivity is not due to influencing the level of the STXBP5 transcript. 
Examining correlations between Stxbp5-AS1 transcript level and impulsivity/inattention 
measures, we found a significant correlation with motor impulsivity (r2=0.55; P=8.26x10-5, 
3
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Bonferroni-corrected P<0.0083) and a nominally significant association with attention, when 
measured as errors of omission (Guillem et al., 2011) (r2=0.1765; P=5.16x10-2), but not when 
measured as percentage correct responses (r2=0.0862; P=1.85x10-1). Expression of Stxbp5 
did not correlate with these parameters (Figure 2C).
Figure 2. Prefrontal cortex gene expression of putative mouse Stxbp5-AS1 is correlated with impulsivity. 
(A) Mouse strains BXD68 (red, n=7), C57BL/6J (black, n=8) and BXD29 (blue, n=8) were selected based on 
a difference in premature responses (motor impulsivity; BXD68 vs. BXD29, t14=3.71; C57BL/6J vs. BXD29, 
t15=2.78) and error of omissions (BXD68 vs. BXD29, t14=3.54; C57BL/6J vs. BXD29, t15=2.52), without being 
different on accuracy (Loos et al., 2014). Shown are data (mean±SEM) of the animals used for gene expression 
analysis (see b). (B) Strain mean±SEM of prefrontal cortex gene expression in BXD68 (red, n=7), C57 (black, 
n=7), and BXD29 (blue, n=8) for Stxbp5-AS1 (left) and Stxbp5 (right). Stxbp5-AS1 is differentially expressed 
between strains, with lower expression in BXD68. Yet, Stxbp5 shows no differential expression. No difference 
in variation was observed. (C) Gene expression of Stxbp5-AS1 (upper panels) in individual mice for which 
behavioral data was available (BXD68, n=6; C57BL/6J, n=7; BXD29, n=8) correlated well with premature 
responses (motor impulsivity; left), not with accuracy (attention; middle), and showed a trend towards 
correlation with errors of omissions (right; P=0.0516). Stxbp5 expression (lower panels) did not correlate 
with any of these parameters. Trend lines are given in gray. * P<0.05; ** P<0.01; ***P<0.001.
Discussion
We report a genetic variant associated with three different but correlated adult ADHD 
symptom lists in a meta-analysis of nine European adult population-based and case-only 
cohorts (n=14,689 individuals). The STXBP5-AS1 gene (best SNP P=3.02x10-7) was the most 
strongly associated locus in a meta-analysis. This association was confirmed in the EAGLE 
meta-analysis (PEAGLE=2.89x10
-2), and the top-hit from the full SAGA-EAGLE GWASMA was 
also located in the STXBP5-AS1 gene and in almost perfect LD with the original finding (SNP 
rs12664716, PSAGA-EAGLE=2.05x10
-7; n=29,465).
For the adult ADHD-index, an earlier large twin family study estimated total heritability 
at 30%, and common SNPs thus contain substantial information concerning its genetic 
variance10. SNP-based heritability analyses, which were ran prior to GWASMA, provided 
estimates of 15-30% explained variance of adult ADHD symptom scores in the general 
population. Such estimates are comparable with the estimates obtained for ADHD and 
four additional categorically defined psychiatric disorders (Cross-Disorder Group of the 
Psychiatric Genomics et al., 2013), providing rationale for a gene-finding enterprise for adult 
ADHD symptoms in the general population.
The function of the STXBP5-AS1-encoded lncRNA is currently unknown. STXBP5-AS1 
has been proposed as a prognostic biomarker for survival of cancer patients (Guo et al., 
2016), but no information is available for its role in ADHD, related traits, or other psychiatric 
diseases. It overlaps in anti-sense with STXBP5 encoding a protein involved in synaptic 
function by regulating neurotransmitter release through stimulating SNARE complex 
formation (Sakisaka et al., 2008),(Yizhar et al., 2004). This complex plays a major role in 
intracellular vesicular trafficking in eukaryotic cells and is involved in the exocytotic release 
of neurotransmitters during synaptic transmission (Antonucci et al., 2016). Genes related 
to the SNARE complex and its regulators have been investigated in ADHD (Bonvicini et al., 
2016), and current results suggest that this complex may exert distinct roles throughout 
development, with age-specific effects of its genetic variants on ADHD behavior (Cupertino 
et al., 2016). Specifically, deletions and mutations of STXBP5 occur in autism (Davis et al., 2009) 
and epilepsy (Dhillon et al., 2011). STXBP5 has a presynaptic role that negatively regulates 
neurotransmitter release by forming syntaxin-SNAP25-tomosyn complex (Sakisaka et al., 
2004). However, the postsynaptic role of STXBP5 has not been well elucidated.
Post-hoc analysis suggested that STXBP5-AS1 affects hyperactivity-impulsivity more 
strongly than inattention. The stronger link with impulsivity was corroborated in behavioral 
studies in mice. Our experiments in HEK293 cells showed that the lncRNA does not cause 
antisense inhibition of Stxbp5. The increased fluorescence of a reporter protein containing 
mouse Stxbp5 exon 1, together with unchanged Stxbp5 mRNA levels in mouse strains 
expressing different Stxbp5-AS1 levels, suggest that the lncRNA might enhance Stxbp5 
protein translation or stability. Alternatively, Stxbp5-AS1 might contribute to impulsivity by 
a Stxbp5-unrelated mechanism. In line with this idea, Stxbp5-AS1, expression (but not that 
of Stxbp5) correlated negatively with motor impulsivity in mice.
Our study should be viewed in the light of some strengths and limitations. A pro was the 
sample size that could be achieved for quantitative data available through a population-
based approach. Moreover, the functional analyses provided a very strong candidate 
associated with adult and childhood ADHD symptoms. A limitation of our study was the 
combination of three different phenotyping instruments, but given the strong phenotypic 
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and genetic correlations between the instruments, this might not have reduced power 
substantially.
The genetic correlation of PCG+iPSYCH with SAGA should be interpreted carefully 
because the standard error is high. The fact that the PCG+iPSYCH/SAGA rg (0.54), did not 
differ from the published rg estimate between the PCG+iPSYCH GWASMA and a GWAS of the 
23andMe sample (0.65, SE=0.114) (Demontis et al., 2017) is encouraging but not unexpected 
given the low power to detect a difference. The estimated genetic correlation between the 
23andMe and PGC+iPSYCH analyses was significant but lower than the genetic correlation of 
the EAGLE and PCG+iPSYCH childhood cohorts (rg=0.943, SE=0.204, P=3.65x10-6) (Demontis 
et al., 2017). The ADHD diagnosis (yes/no) in 23andMe is based on the self-reported answer 
to a single question about presence of a lifetime diagnosis of ADHD (Demontis et al., 2017) 
and we do not know if the 23andMe participants were diagnosed in childhood or as adults. 
With a further increase in GWAS sample size update rg results could suggest that there are 
different genetic correlation patterns between the association results estimated from the 
GWAS of adult (population-based) ADHD behavior and the GWAS from children, at this point 
the lack of power makes these analyses inconclusive.
Our study shows that self-reported adult ADHD symptoms measured in the general 
population have a genetic component and that performing population-based GWASMA 
of adult ADHD symptoms provides novel insights into the genetic underpinnings of 
hyperactivity/impulsivity symptoms that are a hallmark of ADHD. Our findings implicate 
synaptic function regulation through STXBP5-AS1 and potentially STXBP5 in ADHD symptom 
etiology.
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Supplementary Methods
GCTA
Genome-wide Complex Trait Analysis (GCTA; cnsgenomics.com/software/gcta/#Overview) 
was run in the two largest cohorts included in the meta-analysis, the NTR and NESDA (n=3656 
and n=1841 unrelated subjects). A genetic relationship matrix (GRM) among all individuals 
each data set was estimated, based on SNPs with high imputation quality (RSQR≥0.80). 
SNPs significantly associated (one-sided test) with genotyping platform were excluded 
with P<0.00001 threshold. In total 6,325,240 SNPs remained in the analysis. The GRM was 
subsequently used to estimate the proportion of phenotypic variance explained by additive 
genetic variance, including sex and age, and additionally four principal components (PCs) 
for population stratification as covariates to adjust for possible population stratification 
effects Bivariate GCTA was run on the ADHD-index of the CAARS and the ASR ADHD data 
in the NTR cohort, to assess their genetic correlation.
Exome sequencing
Exomes of 1,336 individuals from the ERF population were sequenced “in-house” at the 
Center for Biomics of the Cell Biology department of the Erasmus MC, The Netherlands, 
using the Agilent version V4 capture kit on an Illumina Hiseq2000 sequencer under the 
TruSeq Version 3 protocol(Amin et al., 2017). Sequence reads were aligned to the human 
genome build 19 (hg19) in the BWA (bio-bwa.sourceforge.net/) and the NARWHAL (trac.nbic.
nl/narwhal/) pipelines. The aligned reads were processed further using the IndelRealigner, 
MarkDuplicates and TableRecalibration tools from the Genome Analysis Toolkit (GATK; 
software.broadinstitute.org/gatk/) and Picard (http://picard.sourceforge.net). Genetic 
variants were called using the Unified Genotyper tool of the GATK. About 1.4 million 
Single Nucleotide Variants (SNVs) were called and, after removing the low quality variants 
(QUAL<150) out of Hardy–Weinberg equilibrium and low
call rate, we retrieved 543,954 SNVs in 1,327 individuals. The ADHD index was available 
for 587 individuals. For prediction of the functionality of the variants, annotations were 
performed in the SeattleSeq database (snp.gs.washington.edu/SeattleSeqAnnotation131). 
Detection of rare variants in the ERF study was done for those genes with SNPs with P<1x10-5 
in the GWAS meta-analysis.
Meta-analysis
Meta-analysis was conducted in METAL (www.sph.umich.edu/csg/abecasis/metal/index.
html) by the P-value-based method, given the intrinsic variability between the quantitative 
traits used (see Supplementary Methods). Poorly imputed SNPs (RSQR<0.60 or INFO<0.60) 
and SNPs with low MAF (MAF<1%) were excluded, resulting in a total number of between 
5.6 M and 13.4 M SNPs across cohorts available for meta-analysis, and only SNPs overlapping 
across all cohorts were considered. A list of independently associated SNPs and loci was 
obtained by clumping the results in PLINK 1.9 (https://www.cog-genomics.org/plink2). 
The script was downloaded from https://github.com/perslab/gwas-snps-loci, with default 
settings were used and computed first independent SNPs, that means SNPs below a 
p-value threshold of P<1x10-05 and with low linkage disequilibrium estimates (r2<0.1) to a 
more significantly associated SNP within a 500-kb window. Second, independent loci were 
computed, that is loci containing all SNPs correlated at r2>0.5 with any other associated SNP. 
Associated loci closer to 250 kb to each other were merged. Meta-analysis was performed 
including and excluding ADHD cases from the IMpACT-NL and VHIR studies.
Linkage disequilibrium score regression (LDSR) analysis
LD scores for HapMap3 SNPs, calculated based on 378 phased European-ancestry individuals 
from the 1000 Genomes Project, were used in the analyses to obtain the genetic correlations 
by a two-step procedure in LDSR analysis (https://github.com/bulik/ldsc) for the SAGA ADHD 
symptom scores and the PGC+iPSYCH meta-analysis (LD scores available on https://github.
com/bulik/ldsc). For the PGC+iPSYCH meta-analysis, only markers with an imputation 
INFO score≥0.9 were included in the analyses. Additionally, only markers overlapping with 
HapMap3 SNPs were considered and insertions, deletions and strand-ambiguous SNPs were 
removed. An unconstrained regression was run to estimate regression intercepts for each 
phenotype. Standard errors were estimated using a block jackknife procedure and used to 
calculate P-values.
Test of heterogeneity for genetic correlations
The test of the equality of the genetic correlations of 0.653 (SE=0.114; PGC+iPsych with 
23and Me) and 0.541 (SE=0.447; PGC+iPSYCH with SAGA) was conducted using the Q test of 
heterogeneity (Hedges, L. V., & Olkin, O. (1985). Statistical methods for meta-analysis. Orlando, 
FL: Academic Press). To conduct this test, we required the correlation between the estimates 
of these correlations. We denote this unknown correlation r (rho) to avoid confusion with 
the actual genetic correlations. Lacking the value of r, we carried out the Q test for a range 
of correlations (from -0.95 to +0.95). We consistently failed to reject the hypothesis that 
the correlations (0.653 and 0.541) are equal. The steps involved in this procedure were the 
following. 1) Fisher z-transformation of the correlations; 2) transformation of the standard 
errors by means the delta method; 3) the Q test for hypothetical values of r ranging from 
-0.95 to 0.95 (steps of 0.05). Regardless of the correlation, the Q statistic (centrally chi2(1) 
distributed under the null-hypothesis), was consistently insignificant (P=0.05), which allowed 
us to conclude that the correlations, .653 and .541, are equal. The Q test is usually applied 
to independent correlations (i.e., by design r=0). To check our implementation of the Q-test 
for dependent correlations, we compared it to the likelihood ratio test of the equality of 
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correlations, which can be conducted in any structural equation modeling program. The 
likelihood ratio test and the Q-test were identical.
Functional Analysis
Follow-up functional analyses were performed on the locus containing the best association 
P-value. This locus contains STXBP5-AS1, representing a putative long noncoding RNA, 
predicted to be expressed in several species. Noncoding RNAs at the STXBP5-AS1 locus 
are predicted to be expressed in Pan paniscus (see RefSeq XR_156214.1, supported by 
similarity to 11 expressed sequence tags (ESTs)), Pongo abelii (XR_152649.1, 8 ESTs), Nomascus 
leucogenys (XR_178064.1, 9 ESTs), Papio anubis (XR_160671.1, 6 ESTs), Chlorocebus sabaeus 
(LOC103240196), and Mus musculus (LOC102633974, 3 transcripts).
The 3’-splice donor site of the corresponding exon 1 (of the STXBP5-AS1 locus) is 
conserved only in man, chimpanzee, and gorilla, whereas the other exons and splice donor 
sites show conservation also in lower primates (Supplementary Table 5), and sometimes 
in rodents (Supplementary Fig. 2).
A reporter plasmid containing the region of STXBP5-AS1 and STXBP5 was constructed by 
inserting exon 1 of human STXBP5 cDNA (ENST00000367481) into pIRES-EGFP using NheI 
and BstXI. This resulted in an in-frame fusion of amino acid 1–50 with the fluorescent marker 
EGFP. A control construct was constructed by inserting exon 1 of an irrelevant housekeeping 
gene, human HPRT1 cDNA (NM_000194), into pmCherry-N1-AgeI using NheI and AgeI. 
For expression of the long noncoding RNA, a 2,519 bp cDNA encoding STXBP5-AS1-003 
(ENST00000427394) was cloned into the NheI and NotI sites of pIRES-EGFP, thereby deleting 
EGFP from the vector. All plasmids use a CMV promoter to drive eukaryotic expression. 
HEK293 cells were transfected by standard calcium phosphate precipitation. Three days 
after transfection, cells were fixed with paraformaldehyde, mounted in Mowiol and imaged 
by epifluorescence with a 40x oil immersion objective and an Orca-Flash4 digital camera 
(Hamamatsu, Japan). EGFP and mCherry fluorescence intensities were calculated for >900 
cells from 40 images and 4 coverslips per experimental condition, using ImageJ software 
(http://imagej.nih.gov/ij/index.html). To test whether the STXBP5-EGFP/HPRT1-mCherry 
fluorescence ratio differed significantly in presence or absence of STXBP5-AS1, a Student’s 
t-test was used.
Mouse models
RNA from prefrontal cortex of adult male mice from the inbred strain C57/Bl6J (The 
Jackson Laboratories; Bar Harbor, Maine, USA; n=7) and recombinant inbred strains 
BXD29 (The Jackson Laboratories; n=8) and BXD68 (Oak Ridge National Laboratory; Oak 
Ridge, Tennessee, USA; n=7), bred in the facility of the Neuro-Bsik consortium of the VU 
University (Amsterdam, Netherlands) and used for behavioral analysis(Loos et al., 2014)2, 
was extracted as previously described. Samples were DNase-I treated according to the 
manufacturer’s instructions (20 U/μg RNA; Boehringer, Germany). RNA concentration was 
determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, USA), and the integrity of RNA was checked by gel electrophoresis (1%-TBE-
agarose gel). Random-primed (25 pmol; Eurofins MWG Operon, Germany) cDNA synthesis 
was performed on individual RNA samples (starting from ~1 μg total RNA). Primers for 
PCR and real-time quantitative PCR (qPCR) were generated using Primer3.0, and were 
targeted against exon 2 and 3 of mouse Stxbp5 (5’-GCCTTTGATCCCGTTCAGAA-3’; 
5’-ACGACCAAAGAGCCTTAAAGC-3’), and for the putative mouse Stxbp5-AS against the 
conserved sequence in the mouse genome (5’-10151485GCTGGAGAAATGTCACTGGG10151504-3’; 
5’-10151446GTCAGCCTGAAACACTCTTTAGA10151424-3’), corresponding to exon 6 of human 
STXBP5-AS1 (Supplementary Fig. 2). Real-time qPCR reactions (8 μL; ABI PRISM 7700) 
were performed in 96-well format plates with transcript-specific primers (300 nM) on 
cDNA corresponding to ~20 ng RNA (Spijker et al. 2004) and SYBR Green reagents (Applied 
Biosystems, USA). Expression levels of two housekeeping genes (GAPDH, β-actin) were 
measured as reference. Amplification efficiencies of primer sets (Eurofins MWG Operon, 
Germany) were tested by qPCR. Only primers with proper amplification efficiency were 
used. Cycle threshold (Ct) values were used to calculate the relative level of gene expression, 
where Ct value is the fractional cycle number at which the fluorescent signal of a reaction 
passes the threshold (reaching intensity above background). Expression was denoted using 
normalized Ct values on a log2-scale. Let normalized Ct-values be denoted by Ctnormx 
(where x represents Stxbp5 or Stxbp5-AS expression, y represents the geometric mean of 
Ct-values of the housekeeping genes, and i represents a given sample), Ctnormxi then is 
given by Ctnormxi=Ctxi – Ctyi. As a bigger Ct-value correlates with a lower expression level, for 
practical purposes, Ctnormxi values were converted into conCtnormxi values, calculated as 
conCtnormxi=–Ctnormxi + 15. Due to this conversion, the final positive value of Ct is positively 
correlated with relative gene expression level, which makes the visualization simpler. 
Relative gene expression levels were expressed as conCtnorm-values±SEM. Thresholds 
for significance of correlation was set at a P-value of 5x10-2/6=0.0083 (correlations of 2 
transcripts were tested for three parameters).
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Supplementary Tables Supplementary Table 2. Number of SNPs tested after imputation and the lambda values per sample.
Project Name Total Number of SNPs tested Lambda
NTR 7544891 1.027
NESDA 7242045 1.020
ERF 5670464 1.000
NeuroIMAGE 13473377 0.960
BIG 13472705 0.974
NBS 8522817 1.006
TRAILS 13914043 1.009
IMpACT-NL 8969779 1.011
VHIR 13472568 0.987
Total* 2804754 ----
*Total number of SNPs overlapping across all cohorts
Supplementary Table 3. Most strongly associated SNPs (P-value<1x10-5) coming from the meta-analysis 
of nine cohorts from the SAGA consortium in physical position order (hg19).
MarkerName A1 A2 FreqA1 P-value Direction HetPVal
6:147409235 a g 0.962 3.03x10-07 -+++-++++ 1.29x10-02
6:147412691 t c 0.0367 3.45x10-07 ++--+---- 1.00x10-02
6:147414032 a g 0.0367 3.58x10-07 ++--+---- 8.68x10-03
6:147409448 c g 0.037 3.62x10-07 ++--+---- 1.36x10-02
6:147419417 t c 0.0364 3.77x10-07 ++--+---- 8.37x10-03
6:147414186 a g 0.0368 3.78x10-07 ++--+---- 8.94x10-03
6:147415636 t c 0.0369 3.93x10-07 ++--+---- 8.12x10-03
6:147416176 a t 0.9631 3.94x10-07 --++-++++ 7.86x10-03
6:147416455 t c 0.0369 3.97x10-07 ++--+---- 7.77x10-03
6:147421172 a g 0.0359 4.03x10-07 ++--+---- 8.13x10-03
22:31035876¶ t c 0.0328 7.33x10-07 --+++---- 5.50x10-01
6:147377486 t c 0.0577 8.24x10-07 -+------- 1.42x10-01
6:147383534 a g 0.942 9.90x10-07 +-+++++++ 1.60x10-01
6:147384838 t c 0.0577 1.31x10-06 -+------- 1.33x10-01
6:147385722 t c 0.0578 1.40x10-06 -+------- 1.36x10-01
6:147387912 a c 0.0575 1.42x10-06 -+------- 1.32x10-01
6:147386687 t c 0.0578 1.48x10-06 -+------- 1.26x10-01
6:147389443 c g 0.9426 1.48x10-06 +-+++++++ 1.33x10-01
6:147391455 t g 0.0574 1.58x10-06 -+------- 1.60x10-01
6:147392316 t c 0.9427 1.82x10-06 +-+++++++ 1.77x10-01
6:147391341 a g 0.0568 1.83x10-06 -+--+---- 1.21x10-01
2:6510305 t g 0.6703 2.15x10-06 +++++++++ 4.47x10-01
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Supplementary Table 3. Continued.
MarkerName A1 A2 FreqA1 P-value Direction HetPVal
2:6536733 a g 0.3469 3.41x10-06 -------+- 7.02x10-01
6:147409180 a g 0.0348 4.62x10-06 ++--+---- 1.89x10-02
6:147408046 a c 0.0348 4.66x10-06 ++--+---- 1.93x10-02
1:83491910 t c 0.5041 4.75x10-06 ---+---+- 4.27x10-01
6:147368934 t c 0.0796 5.04x10-06 -+--+---- 1.38x10-01
4:120042409 t c 0.0165 5.77x10-06 ++-+++++- 8.65x10-03
1:83493185 a t 0.5035 5.77x10-06 ---+---+- 4.32x10-01
1:83491393 c g 0.5045 6.00x10-06 ---+---+- 4.55x10-01
8:3723378 a g 0.0771 6.00x10-06 +++++++++ 9.06x10-01
2:6486352 a g 0.3345 6.24x10-06 --+------ 4.10x10-01
13:69920315 c g 0.1259 7.19x10-06 -----+-+- 2.75x10-01
6:147390776 t c 0.9385 7.23x10-06 +-+++++++ 1.09x10-01
4:120041135 a g 0.9827 7.45x10-06 --+-----+ 1.48x10-02
22:31030104 t c 0.0205 7.78x10-06 +-+------ 3.69x10-01
1:68455306 a g 0.534 7.88x10-06 --+------ 8.25x10-01
4:120042399 t g 0.9827 7.90x10-06 --+-----+ 1.51x10-02
4:120041857 a c 0.9827 8.02x10-06 --+-----+ 1.51x10-02
4:120041779 t c 0.0173 8.05x10-06 ++-+++++- 1.51x10-02
4:120041792 a t 0.9827 8.06x10-06 --+-----+ 1.51x10-02
4:120041495 a g 0.9827 8.19x10-06 --+-----+ 1.48x10-02
8:3723485 a g 0.9193 8.43x10-06 --------- 9.22x10-01
13:69938915 a g 0.1257 8.44x10-06 -----+-+- 2.27x10-01
13:69930527 t c 0.8739 8.81x10-06 +++++-+-+ 2.34x10-01
13:69909473 a t 0.8732 9.56x10-06 +++++-+-+ 4.70x10-01
8:91190297 t c 0.7029 9.61x10-06 +++++++++ 8.64x10-01
2:6485104 t c 0.334 9.79x10-06 --+------ 3.60x10-01
4:120040823 a g 0.0173 9.82x10-06 ++-+++++- 8.42x10-03
8:3726432 a t 0.9225 9.95x10-06 --------- 9.53x10-01
11:45132165 a c 0.542 1.11x10-05 ++-++++++ 3.85x10-01
11:45130956 a g 0.5418 1.13x10-05 ++-++++++ 3.64x10-01
3:71549174* c g 0.9417 1.15x10-05 --------- 8.42x10-01
6:147385308 a g 0.0796 1.17x10-05 -+--+---- 9.39x10-02
¶Cohort order: BIG, NBS, NeuroIMAGE, VHIR, ERF, NESDA, NTR, TRAILS, IMpACT-NL; Highlighted SNPs in BOLD 
we those selected by the clumping analysis; SNP in italic is the best associated SNP in the SAG-EAGLE Meta-
Analysis; ¶This marker was NOT selected for clumping analysis since there were no other SNPs in LD with it.
Supplementary Table 4. Association results for most strongly associated (clumped) SNPs (P-value<1x10-6) 
coming from the meta-analysis of seven cohorts from the SAGA consortium without including patients in 
physical position order (hg19).
SNP Name CHR POS± P-value
Tested/Non-
Tested Allele
Frequency 
Tested Allele
Gene(s) in Locus
rs1930272* 1 83491910 1.90x10-6 T/C 0.504 LOC107985037
rs13315424 3 16575568 3.37 x10-6 A/G 0.236 Upstream LINC00690
rs10027388* 4 120041135 5.22 x10-6 A/G 0.983
LOC102723967; 
LOC105377395
rs12661753* 6 147409235 1.48 x10-6 A/G 0.962 STXBP5-AS1
rs13274695* 8 3723378 8.43 x10-6 A/G 0.761
CSMD1; 
LOC105377790
rs7188379 16 5639034 9.39 x10-6 T/C 0.044 RBFOX1
rs11914089 22 31035876 5.35x10-7 T/C 0.033 SLC35E4
±position based on the GRCh37.p13 build; *SNP or gene also found in the complete analysis.
Supplementary Table 5. Gene-wide association P-values for common and rare variants present in the top 
loci from the SAGA meta-analysis of ADHD Symptom Total Score.
Gene ID
MAGMA SKAT
EntrezID Full SAGA SAGA+EAGLE ERF
P Markers P Markers P Markers
GNG12-AS1± 100289178 0.008 567 0.064 336 N/A N/A
LINC01247± 101929390 0.001 147 0.089 139 N/A N/A
STXBP5-AS1± 729178 0.002 607 0.001 526 N/A N/A
STXBP5¶ 134957 0.010 131 0.120 121 0.079 18
CSMD1 64478 0.909 8389 0.799 6816 0.250 187
CALB1 793 0.016 97 0.252 54 0.103 9
LINC00534± 100874052 0.0003 279 0.052 261 N/A N/A
Significance threshold=0.05/18 as STXBP5¶ was selected based on the physical proximity to STXBP5-AS1. 
Genes with significant (Bold) or suggestive (italic; 0.0028>P<0.05) gene-wide association p-values in either 
analysis are shown; SKAT analysis of rare variants were done in the ERF cohort only; ±GNG12-AS1, LINC01247, 
STXBP5-AS1, LINC00534 had no SNV available in the exome sequence data from ERF; N/A=Not Available.
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Supplementary Figures
Supplementary Figure 1. Manhattan (A) and QQ plot (A’)of the ADHD Symptom Total Score meta-analysis 
from the complete SAGA consortium. Manhattan (B) and QQ plot (B’) of the ADHD Symptom Total Score 
meta-analysis from the SAGA consortium without patient cohorts. Manhattan (C) and QQ plot (C’) of the 
ADHD Symptom Total Score meta-analysis from the SAGA & EAGLE consortia.
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Supplementary Figure 2. ClustalW2 alignment of primate and rodent genomic sequences sharing similarity 
with human STXBP5-AS1. Splice acceptor and (possible) donor sites are indicated in lowercase font. See 
Supplementary Table 5 for exon start/end positions and sequence accession numbers. The locations of 
mouse real-time PCR primers, as used in Figure 3, are indicated in bold. Supplementary Figure 3. Locus Zoom plots for SNPs from the SAGA Meta-analysis associated with Total 
ADHD Symptom Scores. SNP rs11209188 (A). SNP rs1930272 (B). SNP rs1564034 (C). SNP rs28734069 (D). SNP 
rs12661753 (FULL SAGA GWASMA) (E).SNP rs12661753 (SAGA-EAGLE GWASMA) (F). SNP rs13274695 (G). SNP 
rs2189255 (H). SNP rs73204517 (I).
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Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common, highly heritable 
neuropsychiatric disorder. ADHD often occurs co-morbid with Intellectual Disability (ID), 
and shared molecular genetic influences have been suggested. This study aimed to identify 
novel ADHD genes by investigating whether genes carrying rare mutations linked to ID 
contribute to ADHD risk through common genetic variants. Validation and characterization 
of candidates were performed using Drosophila melanogaster. Common genetic variants 
in a diagnostic gene panel of 396 autosomal ID genes were tested for association with 
ADHD risk, through gene-set and gene-wide analyses, using ADHD meta-analytic data of 
the Psychiatric Genomics Consortium (n=19,210) for discovery and iPSYCH ADHD data for 
replication (n=37,076). The significant genes were functionally validated and characterized 
in Drosophila by assessing locomotor activity and sleep upon knockdown of those genes in 
brain circuits. The ID gene-set was significantly associated with ADHD risk in the discovery 
and replication data-sets. The three genes most consistently associated were MEF2C, 
ST3GAL3, and TRAPPC9. Performing functional characterization of the two evolutionary 
conserved genes in Drosophila melanogaster, we found their knockdown in monoaminergic 
(dMEF2) and circadian neurons (dTRAPPC9) to result in increased locomotor activity and 
reduced sleep, concordant with the human phenotype. This study reveals that a large set 
of ID-related genes contributes to ADHD risk through effects of common alleles. Utilizing 
this continuity, we identified TRAPPC9, MEF2C, and ST3GAL3 as novel ADHD candidate genes. 
Characterization in Drosophila suggests that TRAPPC9 and MEF2C contribute to ADHD-
related behavior through distinct neuronal substrates.
Keywords: Intellectual Disability, ADHD, genetics, Drosophila melanogaster, MEF2C, TRAPPC9
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and highly heritable 
neurodevelopmental disorder (heritability 70–80%) (Faraone et al., 2015). ADHD is clinically 
characterized by two core symptom domains: inattention and hyperactivity/impulsivity, 
which can occur individually or combined (Faraone et al., 2015). The prevalence of ADHD 
is 5.3% in childhood and 2.5–4.9% in adulthood (Faraone et al., 2015). Despite the high 
heritability, identification of ADHD risk genes has been difficult, mainly due to ADHD’s 
complex genetic architecture (Faraone et al., 2015). Genetic variants that occur frequently 
in the population and have generally small individual effects on disease risk are thought to 
underlie the disorder in most patients, and first genome-wide significant findings for ADHD 
have been identified only recently (Demontis et al., 2017).
Intellectual Disability (ID) refers to a highly heterogeneous group of childhood-onset 
disorders characterized by below-average intellectual functioning (IQ<70) and significant 
limitations in adaptive functioning, which covers many everyday social and practical skills 
(van Bokhoven, 2011). ID has an estimated prevalence of 2–3% in the population; severe 
handicaps have a population-prevalence of 0.3–0.5% (Perou et al., 2013). ID is thought 
to often have monogenic origins, but many different genes and types of mutations are 
implicated (van Bokhoven, 2011). ADHD is a common comorbid disorder in children with ID 
(Baker et al., 2010). Studies of children with mild and borderline ID have identified ADHD in 
8–39% of the cases (Baker et al., 2010). A recent study using the Swedish birth registry data 
showed that nearly all of this comorbidity can be attributed to genetic factors (Faraone et 
al., 2017). Based on such phenotypic and genetic overlap, it has been hypothesized that ID 
and ADHD, and neurodevelopmental disorders more broadly, have an overlapping genetic 
etiology (Faraone et al., 2017).
Here, we evaluated the genetic overlap between ID and ADHD in an attempt to identify 
novel ADHD candidate genes. We investigated, whether genes affected by rare mutations 
in ID patients also contribute to ADHD risk through common genetic variation. For this, 
we used the latest data freeze from the Psychiatric Genomics Consortium (PGC; n=19,210) 
for discovery and the iPSYCH sample (n=37,076) for replication. To provide functional 
evidence for the newly identified ADHD candidates, we used Drosophila melanogaster. 
This model provided opportunities to characterize the neuronal circuits involved: The role 
of dopaminergic neurotransmission is well-established in ADHD (Faraone et al., 2015). In 
addition, circadian rhythm circuits have been implicated, as ADHD often goes together 
with sleep disturbances, and abnormal circadian rhythms of melatonin secretion have been 
observed in children and adult patients with ADHD (Baird et al., 2012). Moreover, disrupting 
the activity of the circadian clock gene PER1 in both mice and zebrafish revealed ADHD-like 
symptoms (Huang et al., 2015). We therefore set out to investigate potential dopaminergic 
and circadian rhythm components of the identified phenotypes in Drosophila. Dissecting 
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the role of neuronal circuits can help to pinpoint the neurotransmitter systems contributing 
to ADHD as a first step towards an individualization of treatment. Upon downregulation 
of gene expression pan-neuronally and in the individual circuits, we assessed locomotor 
activity and sleep as behavioral read-outs, which we have earlier established to be relevant 
for ADHD (van der Voet et al., 2016).
Material and methods
Ethics statement
The current study used summary statistics of GWAS meta-analyses (GWAS-MA) that had 
been approved by the local ethics committees and had the required informed consents, as 
described in the earlier publications (Demontis et al., 2017; Holmans, 2013).
Cohorts
The Psychiatric Genomics Consortium (PGC) ADHD GWAS meta-analysis (GWAS-MA) 
data, which were used at the discovery stage in this study, were available as autosome-
wide summary statistics, including single nucleotide polymorphism (SNP) data with 
corresponding P-values and odds ratios. Data were based on nine studies including 5,621 
cases and 13,589 controls. Samples were of Caucasian or Han Chinese origin and contained 
patients meeting ADHD-diagnostic criteria according to the DSM-IV (Supplementary Table 
1). Detailed procedures of DNA isolation, whole-genome genotyping, and imputation have 
been described previously (Neale et al., 2010). Shortly, genome-wide data were obtained 
from different genotyping arrays (Supplementary Table 1) and was imputed using 1000 
Genomes data as a reference panel (v3 phase1 in NCBI build 37 (hg19) coordinates) for 
autosomal SNPs. Meta-analytic data were processed through a stringent quality control 
pipeline applied at the PGC (Neale et al., 2010).
The gene-set association was replicated in an independent cohort from the Lundbeck 
Foundation Initiative for Integrative Psychiatric Research (iPSYCH) - Statens Serum Institut 
(SSI) – Broad ADHD working group (n=37,076) (Demontis et al., 2017).
A meta-analysis of the two data-sets described above (20,183 cases and 35,191 controls) 
has recently been published as part of the ADHD Working Group of the PGC and the ADHD 
iPSYCH-SSI-Broad collaboration (Demontis et al., 2017) (https://www.med.unc.edu/pgc/
results-and-downloads). This meta-analytic data-set was used by us to perform a gene-
based look-up of three genes of interest, using MAGMA software, as described below. 
Detailed quality control and imputation parameters have been described in the original 
publication (Demontis et al., 2017). In short, summary data only included markers with a 
quality (INFO score) >0.8, minor allele frequency (MAF) >0.01, and supported by an effective 
sample size greater than 70% (8,047,420 markers) (Demontis et al., 2017).
ID gene selection
For the selection of the ID gene-set, we used the publicly available ‘Intellectual Disability 
Gene Panel’ of the Radboudumc department of Human Genetics’ Genome Diagnostics 
division (downloaded from https://issuu.com/radboudumc/docs/ngs-intellectual_disability_
panel_1?e=28355229/50899368 on March 27th, 2014). This gene panel listed 490 candidate 
genes for ID (shown in Supplementary Table 2), based on findings of de novo mutations 
in patients with ID visiting the Radboudumc and collaborating institutes and on literature/
public databases. This list forms the basis for diagnostic testing using exome sequencing 
at Radboudumc.
Gene-based and gene-set analysis
Genome-wide summary statistics of ADHD (PGC and iPSYCH ADHD GWAS-MA) used as input 
for gene-based analyses. We used two software packages to test whether the ID gene-set 
was associated with ADHD risk. Firstly, the Hybrid set-based test (HYST) of the Knowledge-
based mining system for Genome-wide Genetic studies (KGG) version 3.5 software (Li et 
al., 2010) was used for association testing (Supplementary Methods). Secondly, the Multi-
marker Analysis of GenoMic Annotation (MAGMA) software version 1.02 (de Leeuw et al., 
2015) was used (Supplementary Methods). The analyses were carried out in two steps. In 
step 1, the combined effect of the SNPs in (the vicinity of) all ID genes was analyzed. Post hoc, 
in step 2, the potential effects of the individual genes were investigated, by reviewing their 
gene-based test-statistics. Genes were considered gene-wide significant if they reached 
the Bonferroni correction threshold adjusted for the number of genes tested (P<0.000128).
Functional characterization of MEF2C and TRAPPC9 in Drosophila 
melanogaster
Strains and cultivation
Drosophila orthologues were retrieved from NCBI protein DELTA-BLAST and ENSEMBL 
gene-tree (Boratyn et al., 2012; Yates et al., 2016). The Drosophila orthologues of MEF2C 
(Mef2) and TRAPPC9 (brun) were targeted for knockdown through RNA interference (RNAi) 
using the UAS-GAL4 system. Conditional knockdown was achieved using tissue-specific 
promoters driving GAL4-expression. Several neuronal populations were targeted: nSyb-
GAL4 (yw* UAS-Dcr-2 hs(X); ; nSyb-GAL4) (Dietzl et al., 2007) targets all neurons (pan-neuronal 
driver), tim-GAL4 ( ; tim-GAL4, UAS-Dcr-2/CyO; ) (Pandey et al., 2013) targets mostly circadian 
rhythm neurons, and ple-GAL4 (w*; UAS-Dcr-2; ple-GAL4) (Dietzl et al., 2007) targets tyrosine 
hydroxylase-expressing (dopaminergic) neurons. A copy of UAS-Dcr-2 was incorporated 
to improve knockdown efficiency (Dietzl et al., 2007). The driver stocks were crossed with 
UAS-RNAi lines obtained from the Vienna Drosophila Resource Center: v12482 (w1118; UAS-
dTRAPPC9RNAi; ), v15549 (w1118; ; UAS-dMef2RNAi-1), and v15550 (w1118; ; UAS-dMef2RNAi-2). Stock 
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v60000 (w1118) served as the genetic background control. All flies were maintained on 
standard corn meal food at 28oC with 60% relative humidity in 12-hour light:dark cycle.
Locomotor activity monitoring
Locomotor activity of individual 3–5 days old male flies was recorded with the Drosophila 
Activity Monitoring system (Trikinetics, Waltham, USA). The flies were collected with the aid 
of CO2 and allowed to recover for 24 hours. The activity count was recorded for four days 
at 28oC and 60% RH in 12-hour light:dark cycle, followed by two days in constant darkness. 
The activity data was collected every 30-seconds and analyzed in 1-minute bins. Activity 
and sleep were analyzed with pySolo software (Gilestro and Cirelli, 2009), defining sleep as 
≥5 minutes of inactivity. The average daily activity and sleep were then plotted in 10- and 
30-minute bins, respectively. pySolo software was modified to analyze the total activity 
and sleep between 180–540 min Zeitgeber Time (ZT) for the relative day and 900–1260 
min ZT for the relative night to capture periods of stable activity and sleep, as described 
previously (van der Voet et al., 2016). Data of individual flies from at least two independent 
experiments were pooled and t-tests were performed with Welch’s correction, when 
variances were unequal. Results were considered significant, if they reached the Bonferroni 
correction threshold adjusted for the number of drivers tested (P<0.0167). To compare 
the relative day and night activity, the delta (Δ) activity and sleep between knockdown 
and genetic background control were calculated (Δday=knockdownday–controlday and 
Δnight=knockdownnight–controlnight). All statistical analyses were performed with GraphPad 
Software (San Diego, CA).
Results
Association of ID gene-set with ADHD risk
To select candidate genes for the ID gene-set, we used the publicly available ‘Intellectual 
Disability Gene Panel’. Genes were included based on findings of de novo mutations in 
patients with ID visiting the Radboudumc and collaborating institutes and on literature/
public databases (n=490; Supplementary Table 2). The set of ID genes was tested for 
association with ADHD using two different software algorithms in a discovery-replication 
design. For discovery, we used the PGC ADHD genome-wide association study meta-analysis 
(GWAS-MA) data (n=19,210) and the KGG software; the HYST test revealed that the ID gene-
set as a whole was significantly associated with ADHD risk (PKGG=0.0001; ngenes=387). To assess 
the robustness of our findings, we tested the association of the ID gene-set with ADHD in 
the PGC data using the MAGMA software. The results also showed a significant association 
of the ID gene-set with ADHD risk in the self-contained test (Pself-contained=0.0412; ngenes=392), 
but not in the competitive test (Pcompetitive=0.9522). As an independent replication, we tested 
the gene-set association in the iPSYCH cohort (n=37,076) using MAGMA; the results robustly 
replicated the significance in the self-contained test (Pself-contained=1.2429x10
-13; ngenes=393). The 
competitive test was negative again (Pcompetitive=0.5306).
To identify the major contributors (i.e. most significantly associated individual genes) to 
the observed association for further validation, we performed individual gene-wide testing 
within the gene-set using the PGC data. The most consistent findings across algorithms 
were for the Myocyte Enhancer Factor 2C gene (MEF2C; PKGG=1.3x10
-5 and PMAGMA=1.497x10
-4; 
Fig. 1A), the Trafficking Protein Particle Complex 9 gene (TRAPPC9; PKGG=7.81x10
-7 and 
PMAGMA=0.0035; Fig. 1B), and the ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 3 gene 
(ST3GAL3; PKGG=6.18x10
-5 and PMAGMA=6.808x10
-4; Fig. 1C). Gene-based p-values for all genes 
in both KGG and MAGMA analyses can be found in Supplementary Table 3. A look-up in 
the recently published combined PGC+iPSYCH GWAS-MA (Demontis et al., 2017) revealed 
genome-wide significant results for gene-wide analysis of ST3GAL3 and MEF2C, and nominal 
significance for TRAPPC9 (PST3GAL3=4.6406x10
-13, PMEF2C=2.671x10
-10, and PTRAPPC9=0.0184).
Figure 1: Regional association plots showing association signals for ADHD in the PGC GWAS-MA (n=19,210) 
for the three most consistently associated genes, including flanking regions of 100 kb. (A) MEF2C locus with 
the top-SNP (rs190982) indicated by the purple dot. (B) TRAPPC9 locus with the top-SNP (rs7827317) indicated 
by the purple dot. (C) ST3GAL3 locus with the top-SNP (rs10789442) indicated by the purple dot. Results are 
shown as –log (p-value) for genotyped and imputed SNPs. The color of each marker reflects its LD (r2) with 
the strongest associated SNP (in purple). The recombination rate is plotted in blue. cM/Mb, centimorgan/
megabase. Chr, chromosome.
Functional validation and characterization of MEF2C and TRAPPC9 in 
Drosophila
Next, we investigated the validity of the newly identified ADHD candidate genes by mapping 
their effects on ADHD-related phenotypes in the fruit fly Drosophila melanogaster. We did 
so by investigating different neuronal circuits individually in addition to pan-neuronal 
knockdown of the genes. This allowed us to characterize the different pathways through 
which individual ADHD risk genes may act. Secondly, it may reveal phenotypes that might 
otherwise be masked by opposing actions of different neuronal circuits (Sitaraman et al., 
2015). We have earlier established Drosophila as a model for ADHD by showing that pan-
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neuronal knockdown of ADHD genes caused (dopamine-related) night-specific increased 
locomotor activity and sleep loss (van der Voet et al., 2016). Two of the three candidates 
were found conserved in Drosophila: the MEF2 gene-family homolog Mef2 (further referred 
to as dMEF2) and the TRAPPC9 homolog brun (further referred to as dTRAPPC9). ST3GAL3 is 
mainly found in vertebrates, and no known orthologue has been identified in Drosophila. We 
investigated locomotor activity and sleep after knocking down the dMEF2 and dTRAPPC9 in 
the whole nervous system, and in dopaminergic or circadian rhythm neurons, specifically. 
Conditional knockdown was achieved by driving the expression of RNA interference (RNAi) 
in the neuronal populations of interest (pan-neuronal, dopaminergic, and circadian rhythm) 
using the binary UAS/Gal4 system. Flies were monitored in 12-hour light:dark scheme, 
mimicking day and night period. We also investigated behavior in 24-hour constant darkness 
conditions, given our earlier model that the dopamine-related increased locomotor activity 
is present in the absence of light (van der Voet et al., 2016). Locomotor activity and sleep 
were quantified for relative day and relative night periods, reflecting the stable period of 
activity and sleep, as previously described (van der Voet et al., 2016).
dMEF2 knockdown gives rise to elevated night-time activity and reduced sleep
Pan-neuronal knockdown of dMEF2 expression caused no changes in activity and sleep 
during the relative day compared to the genetic background control (Fig. 2A), but 
significantly increased night activity (Pactivity=0.0059) and reduced sleep (Psleep=0.014) (Fig. 
2A). In constant darkness, the knockdown also showed significantly increased activity 
(Pactivity=0.0088) and less sleep (Psleep=0.00037) in the relative night period (Fig. 2B). The data 
from individual RNAi lines are visualized in Supplementary Figure 1. Knockdown of dMEF2 
in dopaminergic neurons recapitulated the findings from the pan-neuronal knockdown, 
and showed an even stronger effect. The knockdown showed increased night activity 
(Pactivity=1.8x10
-15) and reduced sleep (Psleep=5.1x10
-15; Fig. 2C). Activity and sleep during the 
relative day period were not different from the genetic background control (Fig. 2C). In 
constant darkness, increased activity and reduced sleep were observed in both relative 
day (Pactivity=4.5x10
-7, Psleep=2.6x10
-17) and night (Pactivity=1.6x10
-17, Psleep=9.5x10
-26; Fig. 2D). 
Knockdown in circadian rhythm neurons did not yield flies. Thus, activity and sleep were 
not monitored. Supplementary Table 4 and 5 list all tests performed and their results.
dTRAPPC9 knockdown influences activity and sleep only in neuronal subtypes
Pan-neuronal knockdown of dTRAPPC9 did not result in observable alterations in activity 
or sleep in either the 12-hour light:dark cycle (Fig. 3A) or in constant darkness (Fig. 3B). 
Specific knockdown of dTRAPPC9 in dopaminergic neurons caused significantly reduced 
activity and increased day sleep during the relative day (Pactivity =0.0022; Psleep=0.013), but 
not in the night (Fig. 3C). In constant darkness, relative night activity was increased and 
sleep was reduced (Pactivity=0.012; Psleep=0.015; Fig. 3D). In contrast, knockdown of dTRAPPC9 
in circadian rhythm neurons resulted in increased night activity and reduced night sleep 
(Pactivity=4.2x10
-5; Psleep=0.00022; Fig. 3E). In constant darkness, increased activity and reduced 
sleep were also present in the relative night (Pactivity=0.00017; Psleep=0.010; Fig. 3F). Lists of all 
tests performed and their results can be found in Supplementary Table 4 and 5.
Figure 2: Knockdown of dMEF2 in the whole nervous system, and in dopaminergic neurons specifically, 
results in higher activity and reduced sleep in the relative night. (A, B) Activity and sleep plot of pan-neuronal 
dMEF2 knockdown, (A) in 12-hour light:dark cycle and (B) in constant darkness. (A’, B’) Quantification of 
total activity and sleep during the stable period. (A”, B”) Δactivity and Δsleep: the findings for 12-hour light:dark 
cycle and for constant darkness both reveal that the difference between groups is greater in the absence 
of light. (C, D) Activity and sleep plot of dopaminergic neuron dMEF2 knockdown, (C) in 12-hour light:dark 
cycle and (D) in constant darkness. (C’, D’) Quantification of total activity and sleep during the stable period. 
(C”, D”) Δactivity and Δsleep: the findings for 12-hour light:dark cycle and for constant darkness reveal that the 
difference is greater when light is absent. For the figure, data from two dMEF2 lines with identical UAS-RNAi 
constructs were combined; the individual data are presented in Fig. S1. RD, relative day; RN, relative night. 
Error bars represent standard error of means (SEM). *P<0.0167 (Bonferroni correction threshold), **P<0.01, 
***P<0.001, ****P<0.0001, *****P<0.00001.
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Figure 3: Knockdown of dTRAPPC9 results in higher activity and reduced sleep, when induced in circadian 
rhythm neurons, but not in the whole nervous system or dopaminergic neurons. (A, B) Activity and sleep 
plot of pan-neuronal dTRAPPC9 knockdown, (A) in 12-hour light:dark cycle and (B) in constant darkness. 
(A’, B’) Quantification of total activity and sleep during the stable period. (A”, B”) Δactivity and Δsleep. (C, D) 
Activity and sleep plot of dopaminergic neuron dTRAPPC9 knockdown, (C) in 12-hour light:dark cycle and 
(D) in constant darkness. (C’, D’) Quantification of total activity and sleep during the stable period. (C”, D”) 
Δactivity and. (E, F) Activity and sleep plot of circadian rhythm neuron dTRAPPC9 knockdown, (E) in 12-hour 
light:dark cycle and (F) in constant darkness. (E’, F’) Quantification of total activity and sleep during the 
stable period. (E”, F”) Δactivity and Δsleep: the findings for 12-hour light:dark cycle and for constant darkness 
reveal that the difference is greater when light is absent. RD, relative day; RN, relative night. Error bars 
represent standard error of means (SEM). *P<0.0167 (Bonferroni correction threshold), **P<0.01, ***P<0.001, 
****P<0.0001, *****P<0.00001.
Discussion
In the current study, we used a robust discovery-replication design in the currently largest 
available, independent data sets to show that genes affected by rare genetic variation in ID 
patients also contribute to ADHD risk through common genetic variation. In the discovery 
phase, we also used different algorithms to test gene-set association to further test the 
robustness of findings. In the KGG HYST test and MAGMA, we found significance in both 
self-contained tests but not the competitive test. A non-significant competitive p-value 
in the competitive test should be interpreted as an inability to disentangle the part of the 
polygenicity attributable to the genes in the gene-set from the polygenicity “remaining” (i.e. 
not captured by the set) on the rest of the genome. In combination with a significance in the 
self-contained test, it should not be interpreted as no effect of the selected gene-set on the 
outcome. Our replication in the larger, independent data-set makes this point convincingly. 
Even more convincing is the fact that two of the three novel ADHD candidate genes that 
we identified, MEF2C and ST3GAL3, are among the genome-wide significant findings in the 
recently published ADHD GWAS-MA (Demontis et al., 2017).
Interestingly, our study design produced reproducible findings in much smaller sample 
sizes than those needed to reach genome-wide significance, which makes such overlap 
studies an attractive source of novel disease genes. While we based our selection of ID genes 
on a diagnostic gene panel, many more ID genes are currently being discovered through 
the fast advances in next generation sequencing technology; those surely leave additional 
ADHD genes to be identified.
Our interdisciplinary approach, combining highly powered statistical analyses in humans 
with functional analyses in an unconventional, validated Drosophila model for ADHD-related 
behavior (Klein et al., 2015; van der Voet et al., 2016), allowed for a direct validation and 
further characterization of neuronal substrates involved. None of our three top-genes had 
been investigated in the context of ADHD before. MEF2C encodes a member of the MADS box 
transcription factor, which binds to the conserved MADS box sequence motif (Janson et al., 
2001). MEF2C is important for normal neuronal function by regulating neuronal proliferation 
and dopaminergic neuron differentiation, survival, and synapse development (Adachi et al., 
2016; Li et al., 2008). It also plays a role in hippocampal-dependent learning and memory, 
possibly by controlling the number of excitatory synapses (Barbosa et al., 2008). While both 
haplo-insufficiency and gene-duplications of MEF2C give rise to ID in humans, most severe ID 
cases are linked to large deletions removing part or all of MEF2C and de novo point mutations 
in the gene (Rocha et al., 2016); individuals with duplications of MEF2C usually display a 
milder phenotype, with only mild cognitive impairment (Novara et al., 2013). This is why 
we chose to model reduced gene-expression in Drosophila in this study. Common variants 
(SNPs) in the MEF2C locus have previously been found associated with various cognitive, 
neuropsychiatric, and neurodegenerative phenotypes, such as intelligence (Sniekers et al., 
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2017), schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics, 2014), and 
Alzheimer’s disease (Beecham et al., 2014), indicating pleiotropic effects of this gene on a 
range of phenotypes. The findings of our study add ADHD to this list and suggest that this 
is linked to the role of MEF2C in neurotransmission mainly through dopaminergic neurons. 
However, knowing that in Drosophila dMEF2 expression is important in maintaining normal 
circadian rhythm (Blanchard et al., 2010; Sivachenko et al., 2013), we cannot yet rule out an 
additional role of this circuit in the ADHD-related behaviors as our dMEF2 knockdown did 
not yield flies.
TRAPPC9 has been implicated in NF-kB activation and is possibly involved in intracellular 
trafficking. TRAPPC9 is highly expressed in postmitotic neurons of the cerebral cortex, 
and MRI analysis of affected patients showed defects in axonal connectivity (Mochida 
et al., 2009). The Drosophila TRAPPC9 has been studied for its involvement in meiotic 
division in Drosophila male gametes (Robinett et al., 2009), but a neuronal function has 
not been described so far. TRAPPC9-associated ID is linked to loss of function of the gene 
(Marangi et al., 2013). Hyperactive behavior has so far been reported in one patient with a 
TRAPPC9 mutation (Philippe et al., 2009). Our findings indicate that TRAPPC9 plays a role in 
neurodevelopmental disorders and suggest that the gene acts by affecting brain circuits 
regulating circadian rhythm.
The third ADHD candidate, ST3GAL3, is not conserved in Drosophila, hence we were not 
able to study its contribution to ADHD-relevant behavior. The gene encodes a membrane 
protein (ST3GalIII) that adds sialic acid to the terminal site of glycolipids or glycoproteins. 
The gene is expressed in a variety of tissues including neurons (Yoo et al., 2015). In mice, 
St3gal2 and St3gal3 are responsible for nearly all the terminal sialyation of brain gangliosides 
and play an important role in cognition (Yoo et al., 2015). A role in brain development is 
also likely in humans, as the human brain is particularly enriched in sialic acid-containing 
glycolipids (i.e. gangliosides) (Wang, 2012). Gangliosides are known to modulate calcium 
homeostasis and signal transduction in neurons (Wu et al., 2001). Common genetic variants 
in ST3GAL3 have also been associated with educational attainment (Okbay et al., 2016). 
Interestingly, in a recent study of DNA-methylation, sites annotated to ST3GAL3 were found 
associated with ADHD symptom trajectories in the population (Walton et al., 2017). The use 
of alternative animal models, e.g. the zebrafish, is warranted to characterize the neuronal 
circuits underlying ST3GAL3’s effect on ADHD-related behavior further.
In summary, the genetic overlap we observed between ID and ADHD may suggest 
biological pleiotropy, in which genetic variation severity in an overlapping set of genes is 
linked to the severity of neurodevelopmental phenotypes. Functional characterization of 
neuronal substrates involved revealed that the novel ADHD candidate genes may impact 
disease etiology through different biological pathways.
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Supplementary methods
Gene-based and gene-set analysis
We extracted SNPs and association p-values from the PGC ADHD GWAS-MA for the ID 
gene-set. Since this meta-analysis only covered the autosomes, X-chromosomal genes 
were excluded, leaving 396 autosomal genes. All SNPs lying within these genes (according 
to UCSC hg19 position (Kent et al., 2002)), including flanking regions of 100 kb to capture 
regulatory regions, were extracted. In total, 308,952 SNPs with a MAF ≥0.01 and INFO-score 
≥0.8 were considered for further analysis. The gene-based and gene-set association analyses 
in the iPSYCH data were performed at secured servers in Denmark at the GenomeDK high 
performance-computing cluster (http://genome.au.dk) by the responsible researcher using 
the same protocols.
We used two software packages to test whether the ID gene-set was associated with 
ADHD risk. Firstly, the Hybrid set-based test (HYST) of the Knowledge-based mining system 
for Genome-wide Genetic studies (KGG) version 3.5 software (Li et al., 2010) was used for 
association testing. Within this software package, we chose the Hybrid set-based test (HYST) 
(Li et al., 2012) for association testing. A text file listing all 396 autosomal ID genes and a 
text file listing all SNPs that were extracted from the PGC ADHD GWAS-MA, were used as 
input for KGG. Imputed and quality-controlled genome-wide genotyping data of the Brain 
Imaging Genetics (BIG) cohort (Guadalupe et al., 2014) were used as a reference to define 
the underlying linkage disequilibrium (LD) structure. The LD upper limit was set to a r2 of 
0.8, while the lower limit was set to 0.2. Next, a gene-based association scan was run with 
HYST, based on a hybrid test of Gates and a scaled Chi-square test, in which SNPs without LD 
information were ignored. Gene-set and gene-based p-values were calculated for 388 genes, 
since eight genes could either not be annotated by the reference file (ATP1A2, ERCC2, GRIK2, 
GSS, KIAA1279, MMACHC, and TCF4) or had too few SNPs left after quality control (B4GALT7).
Secondly, the Multi-marker Analysis of GenoMic Annotation (MAGMA) software version 
1.02 (de Leeuw et al., 2015) was used. First, genome-wide SNP data from a reference panel 
(1000 Genomes, v3 phase1 (Genomes Project et al., 2010)) were annotated to NCBI Build 37.3 
gene locations using a symmetric 100 kb flanking window, and both files were downloaded 
from http://ctglab.nl/software/magma. Next, the gene annotation file was used to map 
the genome-wide SNP data to assign the SNPs to the genes and to calculate gene-based 
p-values for each cohort separately. For the gene-based analyses, single SNP p-values within 
a gene were transformed into a gene-statistic by taking the mean of the χ2-statistic among 
the SNPs in each gene. To account for LD, the 1000 Genomes Project European sample was 
used as a reference to estimate the LD between SNPs within (the vicinity of) the genes (http://
ctglab.nl/software/MAGMA/ref_data/g1000_ceu.zip). Gene-wide p-values were converted 
to z-values reflecting the strength of the association of each gene with the phenotype, with 
higher z-values corresponding to stronger associations. Subsequently, we tested, whether 
all 396 ID-related genes in the gene-set are jointly associated with each of the phenotypes, 
using an intercept-only linear regression model including a subvector corresponding to 
the genes in the gene-set. This self-contained analysis evaluated, whether the regression 
coefficient of this regression was larger than 0, testing whether the gene-set contains any 
association at all. To test if the genes in the gene-set are more strongly associated with 
each phenotype than other genes, the regression model was then expanded including 
all genes outside the gene-set. This competitive test tested, whether the association of 
a gene-set is different from association of genes outside the gene-set. To account for the 
potentially confounding factors of gene size and gene density, both gene size and gene 
density as well as their logarithms were included as covariates in the competitive gene-set 
analysis. Four genes were not included in the analyses, because they were either missing 
from the annotation file (CHKB-CPT1B and SOX2-OT) or contained too few SNPs (B4GALT7 
and RAB3GAP2).
The analyses were carried out in two steps. In step 1, the combined effect of the SNPs 
in (the vicinity of) all ID genes was analyzed. Post hoc, in step 2, the potential effects of the 
individual genes were investigated, by reviewing their gene-based test-statistics. Genes 
were considered gene-wide significant if they reached the Bonferroni correction threshold 
adjusted for the number of genes tested (P<0.000128).
URLs
https://www.med.unc.edu/pgc/results-and-downloads
http://ctglab.nl/software/MAGMA/ref_data/g1000_ceu.zip
http://locuszoom.sph.umich.edu/
https://issuu.com/radboudumc/docs/ngs-intellectual_disability_
panel_1?e=28355229/50899368
Data availability
GWAS summary statistics used in the paper are available directly from the web for ADHD 
GWAS-MA data of the PGC ADHD Working Group and the combined ADHD GWAS-MA data of 
the PGC ADHD Working Group of the PGC + ADHD iPSYCH-SSI-Broad collaboration (https://
www.med.unc.edu/pgc/results-and-downloads). The ID gene-set can be downloaded from 
https://issuu.com/radboudumc/docs/ngs-intellectual_disability_panel_1?e=28355229/ 
50899368 on March 27th, 2014. Fly strains are available in the Vienna Drosophila Resource 
Center and Bloomington Drosophila Resource Center as mentioned in the online methods, 
or upon request. All data needed to evaluate the conclusions in the paper are present in the 
paper or the supplementary materials.
4
102 103
Intellectual Disability-related genes increase ADHD risk and locomotor activity in DrosophilaChapter 4
Supplementary figures
Supplementary Figure 1: Knockdown using two dMEF2 UAS-RNAi lines in the whole nervous system and 
in the dopaminergic neurons, specifically, results in higher activity and reduced sleep in the relative night. 
(A, B) Activity and sleep plot of pan-neuronal dMEF2 knockdown, (A) in 12-hour light:dark cycle and (B) 
constant darkness. (A’, B’) Quantification of total activity and sleep during the stable period. (A”, B”) Δactivity 
and Δsleep: the findings for 12-hour light:dark cycle and for constant darkness both reveal that the difference 
between groups is greater in the absence of light, particularly for dMEF2 knockdown with RNAi 2. (C, D) 
Activity and sleep plot of dopaminergic neuron dMEF2 knockdown, (C) in 12-hour light:dark cycle and 
(D) constant darkness. (C’, D’) Quantification of total activity and sleep during the stable period. (C”, D”) 
Δactivity and Δsleep: the findings for 12-hour light:dark cycle and for constant darkness both reveal that the 
difference between groups is greater in the absence of light. RD, relative day; RN relative night. Error bars 
represent standard error of means (SEM). *P<0.0167 (Bonferroni correction threshold), **P<0.01, ***P<0.001, 
****P<0.0001, *****P<0.00001.
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Supplementary Table 2. ID gene panel listing 490 candidate genes for ID
Gene Chr Omim disease
ADAR 1 Aicardi-Goutieres syndrome 6
ADCK3 1 -
AKT3 1 Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome
ALG6 1 Congenital disorder of glycosylation type Ic
AP4B1 1 Spastic paraplegia 47 autosomal recessive
ARID1A 1 Mental retardation autosomal dominant 14
ASPM 1 Microcephaly 5 primary autosomal recessive
ATP1A2 1 Alternating hemiplegia of childhood
DARS2 1 Leukoencephalopathy with brain stem and spinal cord involvement and 
lactate elevation
DBT 1 Maple syrup urine disease type II
DHCR24 1 Desmosterolosis
DPYD 1 5-fluorouracil toxicity
FH 1 Fumarase deficiency
FUCA1 1 Fucosidosis
GALE 1 Galactose epimerase deficiency
GATAD2B 1 Mental retardation autosomal dominant 18
GJC2 1 Leukodystrophy hypomyelinating 2
GNPAT 1 Chondrodysplasia punctata rhizomelic type 2
HAX1 1 Neutropenia severe congenital 3 autosomal recessive
MMACHC 1 Methylmalonic aciduria and homocystinuria cblC type
MTR 1 Homocystinuria-megaloblastic anemia cblG complementation type
NDUFS2 1 Mitochondrial complex I deficiency
NLRP3 1 CINCA syndrome
NTRK1 1 Insensitivity to pain congenital with anhidrosis
ORC1 1 Meier-Gorlin syndrome 1
PEX10 1 Peroxisome biogenesis disorder 6A (Zellweger)
PEX11B 1 Peroxisome biogenesis disorder 14B
… … ...
The complete Supplementary Table 2 is available upon request.
Supplementary Table 3. Results of gene-based association analyses for 396 ID-related genes with ADHD 
risk in the PGC ADHD GWAS-MA data (n=19,210). Results for both KGG and MAGMA analyses, using a 100 
kb flanking region, are shown.
Symbol EntrezID Chromosome
KGG MAGMA
# SNPs P # SNPs P
MEF2C 4208 5 699 0.000013 546 0.0001497
ST3GAL3 6487 1 1189 0.0000618 776 0.00068088
BBS7 55212 4 628 0.000347 537 0.0013212
GPR56 9289 16 585 0.00278 533 0.0017071
ASL 435 7 594 0.000773 498 0.0025384
TRAPPC9 83696 8 2241 0.000000781 1979 0.0035331
ARFGEF2 10564 20 995 0.00927 728 0.0040172
PEX26 55670 22 543 0.0248 470 0.0046159
GUSB 2990 7 513 0.0153 431 0.0058534
ALG1 56052 16 321 0.00461 272 0.014585
MAT1A 4143 10 852 0.00515 709 0.017966
LIG4 3981 13 536 0.00445 451 0.019828
ATR 545 3 945 0.0228 591 0.021092
ALG2 85365 9 564 0.053 455 0.022287
ABCC9 10060 12 572 0.036 451 0.023248
RFT1 91869 3 647 0.00377 545 0.0269
NDUFA11 126328 19 203 0.192 179 0.027452
TCF4 6925 18  N/A  N/A 1016 0.027539
CRBN 51185 3 973 0.0185 773 0.028749
KCTD7 154881 7 773 0.0207 655 0.029168
BSCL2 26580 11 242 0.0428 181 0.031856
SMOC1 64093 14 1283 0.0334 1092 0.033258
SLC35C1 55343 11 575 0.0275 499 0.037417
RMND1 55005 6 817 0.117 652 0.041922
NDUFS4 4724 5 1371 0.0271 1009 0.045524
RNASEH2A 10535 19 138 0.0464 123 0.047939
DIP2B 57609 12 928 0.0385 662 0.049517
… … … … … … …
N/A: no gene-based result obtained for this gene.
The complete Supplementary Table 3 is available upon request.
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Supplementary Table 4. Summary of results of functional characterization of dMef2 and dTRAPPC9 
knockdown in Drosophila in 12-hour light:dark cycle.
Number 
of flies (N)
Total RD 
activity
P-value
Total RN 
activity
P-value
Total RD 
sleep
P-value
Total RN 
sleep
P-value
Pan-neuronal
dMef2 control 62 92.63 176.65 308.69 282.78
dMef2 RNAi 135 100.13 0.50 235.25 0.0059 308.66 1.0 263.72 0.014
dMef2 RNAi 1 68 114.76 0.10 214.30 0.092 306.92 0.64 270.71 0.14
dMef2 RNAi 2 67 85.29 0.52 256.51 0.0026 311.45 0.63 256.62 0.0049
dTRAPPC9 control 66 62.78 143.33 324.20 293.48
dTRAPPC9 RNAi 68 69.82 0.58 167.14 0.19 321.97 0.70 285.50 0.22
Dopaminergic neurons
dMef2 control 132 61.09 43.36 324.85 333.36
dMef2 RNAi 185 65.74 0.57 121.43 1.8x10-15* 319.76 0.24 295.92 5.1x10-15*
dMef2 RNAi 1 119 71.52 0.25 94.09 3.5x10-09* 316.65 0.086 309.90 5.7x10-08
dMef2 RNAi 2 66 55.33 0.60 170.72 8.1x10-10* 325.37 0.93 270.72 8.6x10-12*
dTRAPPC9 control 84 62.54 49.22 325.63 331.70
dTRAPPC9 RNAi 79 31.06 0.0022* 66.75 0.0931 338.74 0.013* 327.93 0.47
Circadian neurons
dMef2 control Not tested
dMef2 RNAi Not tested
dMef2 RNAi 1 Not tested
dMef2 RNAi 2 Not tested
dTRAPPC9 control 56 58.30 83.22 322.48 316.39
dTRAPPC9 RNAi 53 71.22 0.19 193.96 4.2x10-05 320.73 0.80 279.80 0.00022
*Welch correction was performed. RD=relative day. RN=relative night.
Supplementary Table 5. Summary of results of functional characterization of dMef2 and dTRAPPC9 
knockdown in Drosophila in constant darkness.
Number 
of flies (N)
Total RD 
activity
P-value Total RN 
activity
P-value Total RD 
sleep
P-value Total RN 
sleep
P-value
Pan-neuronal
dMef2 control 62 164.99 126.95 269.14 299.56
dMef2 RNAi 133 188.18 0.17 183.37 0.0088 270.45 0.95 271.17 0.00037*
dMef2 RNAi 1 67 195.66 0.13 183.03 0.023 268.76 0.97 272.25 0.0022
dMef2 RNAi 2 66 180.58 0.39 183.72 0.030 272.16 0.74 270.07 0.0047*
dTRAPPC9 control 66 164.47 104.77 269.70 306.25
dTRAPPC9 RNAi 66 176.08 0.56 110.72 0.72 269.99 0.72* 299.15 0.35*
Dopaminergic neurons
dMef2 control 128 135.52 22.63 294.56 346.07
dMef2 RNAi 173 200.79 4.5x10-07* 99.08 1.6x10-17* 239.79 2.6x10-17* 294.47 9.5x10-26*
dMef2 RNAi 1 112 190.39 8.5x10-05* 86.06 5.5x10-13* 246.57 1.0x10-11* 301.43 8.7x10-17*
dMef2 RNAi 2 61 219.88 0.00016* 122.98 1.4x10-07* 227.34 8.9x10-09* 281.69 2.1x10-11*
dTRAPPC9 control 83 145.91 21.78 289.57 345.81
dTRAPPC9 RNAi 78 127.61 0.23 40.35 0.012* 303.54 0.030* 336.82 0.015*
Circadian neurons
dMef2 control Not tested
dMef2 RNAi Not tested
dMef2 RNAi 1 Not tested
dMef2 RNAi 2 Not tested
dTRAPPC9 control 55 149.22 69.96 278.91 311.48
dTRAPPC9 RNAi 53 206.00 0.067 157.03 0.00017 272.45 0.62 283.35 0.011
*Welch correction was performed. RD=relative day. RN=relative night.
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Abstract
Mental disorders, including Attention-Deficit/Hyperactivity Disorder (ADHD), have a 
complex etiology, and the identification of underlying genetic risk factors has been 
challenging. This study used a multi-step approach to identify and validate a novel risk 
gene for ADHD and psychiatric comorbidity. In a single family, severely affected by ADHD 
and comorbid disorders, we applied microarray analysis to detect Copy Number Variants 
(CNVs) linked to disease. Genes present in the identified CNV were subsequently tested for 
their association with ADHD in the largest data set currently available (n=55,374); this analysis 
was based on common genetic variants and used the MAGMA software. Significant findings 
were taken forward for functional validation using Drosophila melanogaster as biological 
model system, altering gene expression with the GAL4-UAS system and a pan-neuronal 
driver and subsequently characterizing locomotor activity and sleep as functional read-
out. We identified a copy number gain in 8p23.3, which segregated with the psychiatric 
phenotypes in the family and that was confirmed by quantitative PCR. Common genetic 
variants in this locus were associated with ADHD, especially the FBXO25 and TDRP genes. 
Only FBXO25 is conserved in Drosophila. Overexpression of the orthologue in two models 
consistently led to increased locomotor activity and reduced sleep compared to the genetic 
background control. Our integrative approach combines ADHD risk gene identification in 
an individual family with genetic association testing in a large case-control data set and 
functional validation in a model system to show that FBXO25 contributes to key features of 
ADHD and comorbid neuropsychiatric disorders.
Keywords: ADHD, psychiatric comorbidities, FBXO25, TDRP, Drosophila melanogaster
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder with a high 
prevalence, affecting 5–6% of children and 2.5%–4.9% of adults (Faraone et al., 2015). 
Individuals with this disorder are at high risk of developing co-morbid psychiatric disorders 
across the entire lifespan(Franke et al., in revision). Twin and adoption studies have shown 
that ADHD is highly heritable, with heritability estimates of approximately 80% in both 
children and adults(Faraone et al., 2005; Larsson et al., 2014). ADHD is a heterogeneous 
disorder with a complex, multifactorial background. The identification of genes affecting 
the disorder has been challenging (Demontis et al., 2017; Franke et al., 2012; Gizer et al., 
2009). In the last decade, genome-wide association studies (GWAS) have been performed 
with increasing sample sizes, and the first genome-wide significant risk variants for ADHD 
from a GWAS meta-analysis, all of them having small individual effect sizes, have recently 
been reported (Demontis et al., 2017). In addition to studies of common genetic variants 
contributing to ADHD, a second wave of studies has focused on rare variants, which 
potentially have larger effect sizes. So far, those studies mainly investigated copy-number 
variations (CNV) and identified rare CNVs in patients with ADHD (Akutagava-Martins et al., 
2014; Elia et al., 2010; Elia et al., 2011; Jarick et al., 2014; Lesch et al., 2011; Lesch et al., 2008; 
Martin et al., 2014; Ramos-Quiroga et al., 2014; Williams et al., 2012; Williams et al., 2010; 
Yang et al., 2013), currently only few exome sequencing studies are available (Corominas et 
al., in revision; Demontis et al., 2016; Kim et al., 2017). In addition to the case-control study 
design, CNVs have been identified in studies using a family-based approach (Lesch et al., 
2008). Now that first risk factors for ADHD have been identified from common and rare 
variant approaches, it becomes clear that at least part of ADHD’s comorbidity with other 
disorders, like major depression and the psychotic disorders, is based on genetic factors 
(Demontis et al., 2017; Lee et al., 2013; van Hulzen et al., 2017).
If a variant is only seen once in a case-control study of rare variants or in a single family, 
it is hard to prove the association with a psychiatric phenotype based on statistics. Similarly, 
in studies of common genetic risk factors for psychiatric phenotypes, it is often difficult to 
go beyond association and prove causality of a specific gene, as variants tested through 
GWAS are just anonymous markers. An effective way forward in this is the use of suitable 
animal models, where one can specifically manipulate the expression of individual genes of 
interest. We have recently shown that the fruit fly Drosophila melanogaster is an appropriate 
model for ADHD; we could show that the fly exhibits increased locomotor activity, when 
expression of ADHD candidate genes is altered (van der Voet et al., 2016). Around 75% of 
human genes have a clear orthologue in the fly (van der Voet et al., 2016). The Drosophila 
model combines a vast genetic toolbox based on decades of research with a large range of 
quantifiable behaviors (van Alphen and van Swinderen, 2013) and is inexpensive in its use.
5
114 115
Converging evidence from man and fly supports FBXO25 as an ADHD risk geneChapter 5
In this study, we used a multi-step approach to identify and validate a novel risk gene for 
ADHD and comorbid psychiatric conditions. In a single family, severely affected by ADHD 
and comorbid disorders (especially psychosis), we applied genome-wide single nucleotide 
polymorphism (SNP)-based array analysis to detect rare copy number variants (CNVs) co-
segregating with disease. Genes present in the CNV were tested - as a set and individually 
- for association with ADHD and other relevant psychiatric disorders based on common 
genetic variants, using the largest internationally available data sets. The significantly 
associated gene FBXO25 was taken forward for functional validation in Drosophila. We 
characterized the effects of CG11658 (dFBXO25) over-expression using locomotor activity 
and sleep behavior as functional read-outs.
Methods and materials
Study participants and cohorts
Dutch family
The male index patient had diagnoses of ADHD, anxiety disorder, and multiple complex 
developmental disorder (MCDD) at the age of four years; he also showed aggressive 
behavior and suicidal tendencies, had experienced a psychotic episode, and reported 
somatic abnormalities including gastric reflux and clinodactyly (Supplementary Methods). 
His parents (mother diagnosed with ADHD, father without diagnosis), the mother’s brother 
(psychotic episode, aggressive behavior, alcohol addiction, childhood ADHD symptoms, 
currently homeless), the mother’s sister (learning difficulties), and two of the mother’s 
cousins (ADHD) were also ascertained for genetic testing (see Figure 1 for the pedigree). 
For these members of the family, saliva (using Oragene containers; DNA Genotek, Ottawa, 
Ontario, Canada) or blood was collected. All human material was collected after approval 
by the local ethic committees, and participants in this study gave written informed consent.
Figure 1: Pedigree of the family under study. Patients with ADHD with or without psychiatric comorbidity 
are depicted in black (see Supplementary Methods for an exhaustive description of their phenotypes), 
unaffected family members are shown by white symbols. Grey symbols show family members with learning 
difficulties. The index patient is marked by an diagonal arrow. An asterisk beneath an individual’s code 
indicates that DNA was used for qPCR analysis.
GWAS meta-analyses data sets for ADHD and schizophrenia
We obtained genome-wide association study meta-analysis (GWAS-MA) results in the form 
of summary statistics (p-values and odds ratios) from the largest currently available data sets 
on ADHD and schizophrenia (SCZ). GWAS-MA data on ADHD were obtained from the ADHD 
Working Group of the Psychiatric Genomics Consortium (PGC) and the ADHD iPSYCH-SSI-
Broad collaboration. Data were downloaded from (https://www.med.unc.edu/pgc/results-
and-downloads; n=55,374 (Demontis et al., 2017)). GWAS-MA data on schizophrenia were 
obtained from the SCZ working group of the PGC (n=82,315; https://www.med.unc.edu/pgc/
results-and-downloads (Schizophrenia Working Group of the Psychiatric Genomics, 2014)). 
Only variants with an imputation quality score INFO >0.8 and minor allele frequency (MAF) 
>0.01 were taken forward for further analyses. Details of inclusion criteria, genotyping, and 
phenotype characteristics are described in the original publications (Demontis et al., 2017; 
Schizophrenia Working Group of the Psychiatric Genomics, 2014) and the Supplementary 
Methods.
Copy number analysis in the Dutch family
Genome-wide single nucleotide polymorphism (SNP)-based array analysis was performed 
on DNA from peripheral blood of the index patient and his parents using the Affymetrix 
CytoScan HD array platform (Thermo Fisher Scientific, Waltham, MA, USA) following the 
manufacturer’s protocols. The probe values from 2.6 million markers, consisting of 750,000 
SNPs and 1.9 million non-polymorphic probes, were analyzed using the Affymetrix software 
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package ChAS (Chromosome Analysis Suite) at an average resolution of approximately 20 
kb and based on human genome build 37 (hg19). Detection and reporting criteria were 
used as previously described (Kooper et al., 2014). Follow-up testing by Fluorescence in situ 
hybridization (FISH) was performed with a subtelomeric 8pter probe (TelVysion 8p (D8S504); 
Abbott Molecular, Des Plaines, IL, USA).
The observed CNV was subsequently confirmed by real-time, quantitative PCR (qPCR) 
in the index patient and his mother, and three additional family members were analyzed 
using this method. Genomic DNA was either isolated from saliva or from EDTA blood 
samples according to manufacturer’s protocol at the department of Human Genetics 
of the Radboud university medical center, Nijmegen, The Netherlands. PrimeTime® 
Mini qPCR assay (Integrated DNA Technologies [IDT], Coralville, IA, USA) was used to 
determine the copy number of FBXO25 (for details see Supplementary Methods). Primer 
sequences are displayed in Table S1. Results were analyzed with the 7500 Software v2.0.6 
(Life Technologies) using an automatic threshold (Supplementary Methods). Data was 
visualized using GraphPad prism (version 5.03), and the mean and a 95% confidence interval 
are shown.
Gene-set and gene-based analyses in the PGC+iPSYCH ADHD and PGC 
schizophrenia data sets
The cumulative effect of common variants in the set of protein-coding genes altered in the 
family (as a set and individually) was tested using summary statistics of the ADHD and the 
SCZ GWAS-MA (Supplementary Methods (Demontis et al., 2017; Schizophrenia Working 
Group of the Psychiatric Genomics, 2014)). Statistical analyses were performed using the 
Multi-marker Analysis of GenoMic Annotation (MAGMA) software package (version 1.05; 
http://ctglab.nl/software/magma (de Leeuw et al., 2015)) using the SNP-wide mean model for 
gene-based association analysis (for detailed description see Supplementary Methods). A 
correction for linkage disequilibrium (LD) was applied, based on the estimates from the 1000 
Genomes Phase 1 European ancestry samples (Genomes Project et al., 2010). Protein-coding 
genes were considered gene-wide significant, if they reached the Bonferroni-corrected 
threshold adjusted for the number of genes tested (three tests; P<0.0167).
Brain gene expression
We determined the messenger-RNA (mRNA) expression of genes located within the 
identified CNV. Using the publicly available data set provided by the Human Brain 
Transcriptome Project (Kang et al., 2011) at http://hbatlas.org, we assessed mRNA expression 
trajectories in six regions of the developing and adult human brain. Spanning periods from 
embryonic development to late adulthood, this data set provides genome-wide exon-level 
transcriptome data generated using the Affymetrix GeneChip Human Exon 1.0 SS Arrays 
from over 1,340 tissue samples from both hemispheres of postmortem human brains (n=57) 
(GTEx Consortium, 2013).
Functional Characterization of FBXO25 in Drosophila
Drosophila stocks and maintenance
Conditional overexpression of CG11658 (two-to-one orthologue of FBXO25 and FBXO32) 
was achieved by using the GAL4-UAS system and the pan-neuronal driver UAS-Dcr-2 hs(X); 
nSyb-GAL4. UAS overexpression lines were obtained from the stock centers in Kyoto and 
Bloomington (FBXO25 overexpression-1: Kyoto stock 203566 and FBXO25 overexpression-2: 
Bloomington stock 17663). The genetic background of the overexpression lines was 
outcrossed for eight generations using an isogenic wild-type background (Iso31, gift from 
A. Sehgal; (Kumar et al., 2012)). Flies were raised on standard medium (cornmeal, sugar, 
yeast) and maintained on a 12 hours light dark cycle. Crosses with the pan-neuronal driver 
and the UAS over-expression lines were raised at 28°C.
Locomotor activity and sleep measurement
Locomotor activity and sleep were assessed with the Drosophila Activity Monitor system 
(DAM), which measures locomotor activity by infrared photoelectric barriers (Trikinetics, 
Waltham, MA, USA). Activity of individual 3–5 day-old male flies was recorded over 4 days 
on a 12h light:dark cycle and subsequently 2 days in constant darkness. Single adult flies 
were transferred to monitor tubes, which contained standard food. Activity counts were 
collected in 30-s bins and analyzed in 1-min bins. Five minutes of inactivity of a fly was 
defined as sleep. The analysis was performed with the pySolo software package, and activity 
and sleep in the light-off period (relative night) (between 12–24h) was analyzed. Activity 
counts represent the amount of infrared detection beam passes of the fly. Statistical analysis 
was performed with the GraphPad Prism software package 5.03 for Windows (GraphPad 
Software, San Diego California USA, www.graphpad.com). T-tests were performed, adding 
a Welch correction, when variances of groups were significantly different.
Quantification of relative gene expression
Flies carrying the UAS element driving the overexpression of CG11658 (Bloomington 17663 
and Kyoto 203566) and their genetic background control were crossed with yw; UAS-
Dcr-2 hs(X); nSyb-GAL4 driver and raised at 28°C. Per condition, three biological replicates 
of 10 heads of 3-day-old flies were collected and snap frozen. RNA was extracted using 
the ARCTURUS PicoPure RNA Isolation Kit (Applied Biosystems, Waltham, MA, USA), total 
RNA concentration was measured with the Nanodrop (Thermo fisher scientific, Waltham, 
MA, USA). Complementary cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, USA). Relative gene expression per sample (3 biological replicates) 
was quantified in technical triplicates using a powerSYBR Green PCR master mix (Applied 
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Biosystems, Waltham, MA, USA) on a 7900HT Real-Time PCR Systems (Applied Biosystems). 
Crossing-point (CP) values of the CG11658 (dFBXO25) gene were normalized to the reference 
genes αTub84B and elF-1A. For primer sequences see Table S1.
Whole-exome sequencing (WES) in Dutch family
Genomic DNA of the index patient and both parents isolated from blood was used for 
whole exome sequencing (WES) to search for de novo mutations using protocols described 
previously (Neveling et al., 2013). In short, exome capture was performed with the Agilent 
SureSelect Human All Exon enrichment kit (Agilent Technologies, Santa Clara, California, 
USA). WES was performed on the Illumina HiSeq platform (BGI, Copenhagen, Denmark). 
Data were analyzed with Burrows-Wheeler Alignment (BWA) read alignment (Li and Durbin, 
2009) and Genome Analysis Toolkit (GATK) variant calling (McKenna et al., 2010) software 
packages. Variants were annotated using an in-house developed pipeline(Neveling et al., 
2013). Prioritization of variants was done by an in-house designed ‘variant interface’ and 
manual curation in line with international standards and guidelines for the interpretation 
of sequence variants (Richards et al., 2015).
Results
8p23.3 microduplication identified in a family with ADHD-affected members
In a family with several members affected with ADHD in the presence or absence of 
psychiatric comorbidity (Figure 1), microarray analysis revealed that the index patient, 
his mother, and mother’s brother carried a copy number gain of approximately 540 kb at 
the distal end of the short arm of chromosome 8 (arr[hg19] 8p23.3(158,049–541,637)x3), 
which spanned 590 probes (Figure 2). Follow-up testing by FISH revealed that the gain in 
copy number was the result of a duplication rather than an unbalanced translocation. The 
microduplication encompassed three protein-coding genes, ZNF596, FBXO25, and TDRP, 
and the pseudo-gene RPL23AP53. The copy number gain was confirmed by qPCR through 
analysis of FBXO25 (Figure S1). The qPCR analysis showed that duplication of FBXO25 was 
absent in one ADHD-affected family member, but was present in the mother’s sister, who 
had learning difficulties (Figure S1).
Common variants in the 8p23.3 locus are associated with ADHD
Focusing on protein-coding genes within the 8p23.3 duplicated region (ZNF596, FBXO25, and 
TDRP), we performed a gene-set analysis to provide additional evidence for a role of genetic 
variation in this region in ADHD and/or psychotic disorders. This was done using summary 
statistics of ADHD GWAS-MA data of 20,183 patients with ADHD and 35,191 controls 
(Demontis et al., 2017) and SCZ GWAS-MA summary statistics from the analysis of 34,241 
cases and 45,604 controls (Schizophrenia Working Group of the Psychiatric Genomics, 2014). 
Joint analysis of the three genes showed significant association of the gene-set with ADHD in 
both self-contained and competitive tests (Pself-contained=0.000184 and Pcompetitive=0.039151; see 
also Figure S2A). No significance was observed for association with SCZ (Pself-contained=0.7123 
and Pcompetitive=0.90596, see also Figure S2B).
To identify the most likely candidate gene for ADHD among the three protein-coding 
genes in the microduplication, the genes were subsequently tested individually. Gene-based 
analysis revealed that the two more proximal genes, FBXO25 and TDRP, were significantly 
associated with ADHD (PFBXO25=0.010756 and PTDRP=0.000285; Table S2).
Brain gene expression
We determined the distribution of mRNA expression for FBXO25 and TDRP in the developing 
and adult human brain using data on six brain regions available from the Human Brain 
Transcriptome Project. As the mRNA expression figures in Figure S3 show, both genes 
appear to be widely expressed, both in the developing and the adult human brain.
Overexpression of the FBXO25 orthologue in Drosophila induces increased 
activity and reduced sleep
To further establish the relevance of the associated genes as candidates for ADHD, we set 
out to study the effect of overexpression on ADHD-relevant behavioral phenotypes in 
Drosophila melanogaster. Only FBXO25 has a direct orthologue (CG11658) in the fruit fly. We 
induced overexpression of CG11658 using two unrelated Drosophila lines. Quantitative PCR 
confirmed the overexpression of this gene: in overexpression-line 1, expression of CG11658 
was 450% compared to the control line; in overexpression-line 2, it was 650%. Using our 
earlier established tests of locomotor activity and sleep as ADHD-relevant read-outs (van 
der Voet et al., 2016), we found adult flies from either line to exhibit significantly elevated 
activity and reduced sleep in the relative night period compared to the genetic background 
control (Figure 3). In line with the qPCR results, overexpression-line 2 showed the more 
severe behavioral phenotypes (Figure 3).
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Figure 2: Microduplication of 8p23.3 in the index patient ID3-2. (A) Array CGH plot of chromosome 8 of 
patient ID3-2 with a terminal duplication of 535 kb in 8p23.3 spanning 590 probes (arr[hg19] 8p23.3(158,049–
541,637)x3). Zoom-in of this region is shown in panel (B). (C) Schematic representation of chromosome 8 
with the 8p23.3 region enlarged in the lower part of the figure (screenshot of the UCSC Genome Browser 
Build 37/hg19 (http://genome.ucsc.edu/)); the small vertical bars show the probe coverage of the CytoScan 
HD array platform, the horizontal bars represent the genes in the duplicated 8p23.3 region (RPL23AP53, 
ZNF596, FBXO25, and TDRP).
Figure 3: Activity monitoring upon pan-neuronal overexpression of the FBXO25 orthologue in Drosophila 
melanogaster. (A) Flies show increased activity (top graph) and decreased sleep (bottom graph) in the relative 
night (12h–24h). (B) Quantification of the activity counts (amount of infrared detection beam passes) of 
individual flies in FBXO25 overexpression–1 (n=64) and overexpression–2 (n=56) lines shows that the activity 
in the relative night is significantly higher in both compared to control (n=63) flies (FBXO25 overexpression–1: 
P=0.0013; FBXO25 overexpression-2: P<0.0001). (C) Quantification of sleep in minutes of single flies shows 
that both FBXO25 overexpression lines sleep significantly less in the relative night compared to control flies 
(FBXO25 overexpression–1: P=0.0076; FBXO25 overexpression-2: P<0.0001). *P<0.05, **P<0.001, ***P<0.0001.
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Whole-exome sequencing
Given the additional somatic features and early onset of severe psychiatric problems in 
the index patient, we performed clinical WES to identify additional rare variants that may 
contribute to the more severe clinical phenotype. Upon trio whole-exome data analysis of 
the index patient and his parents, one de novo candidate variant was found in the index 
patient. This was a heterozygous insertion variant in DUSP16 (c.813_814insGC [p.Arg272fs] 
[GenBank: NM_030640.2]) leading to a frameshift; located at the end of exon 5 and it 
possibly affects the nearest splice site. This frameshift variant is not present in gnomAD 
(r.2.0.2). Exploratory gene-wide testing of common variants in DUSP16 in the ADHD and 
SCZ GWAS-MA data did not reveal evidence for association with ADHD (P=0.39186), but 
the gene showed nominal association with schizophrenia (P=0.0175).
Discussion
In this study, we identified and functionally validated a novel candidate gene for ADHD 
and comorbid psychiatric phenotypes. We report a microduplication in band p23.3 of 
chromosome 8, which segregated with a broad spectrum of psychiatric problems, including 
ADHD, in a family with several affected individuals in two generations. Common genetic 
variants in this locus were associated with ADHD risk; in particular, we observed significant 
gene-based associations for the genes in the proximal part of the microduplication, 
FBXO25 and TDRP. One out of the two genes has an orthologue in Drosophila melanogaster, 
FBXO25, and we were able to confirm that overexpression leads to a night-specific increase 
of locomotor activity and decrease of sleep. Since we have previously identified the same 
behavioral signature in several Drosophila models of ADHD (van der Voet et al., 2016), these 
findings suggest FBXO25 as a novel risk gene for ADHD and comorbid mental disorders.
The identified microduplication in 8p23.3 has not previously been reported in conjunction 
with ADHD or other neuropsychiatric disorders. A recent study combined data from eleven 
CNV studies that had identified rare CNVs occurring in patients with ADHD (Harich et al., 
submitted). We queried these existing data sources and found an additional ADHD patient, 
among 6,176 reported ones, who carried a duplication encompassing 77% of the FBXO25 
gene. This duplication was not found in 25,026 controls (Elia et al., 2010; Harich et al., 
submitted).
The microduplication co-segregated with different psychiatric phenotypes, ranging 
from mild learning difficulties to ADHD, psychosis, substance use, and aggressive behavior. 
Of the two cousins of the index patient’s mother, each with an ADHD diagnosis, one had a 
normal copy number for FBXO25, and for the second cousin no results were obtained due to 
poor quality DNA. Since ADHD is a rather common disorder in the population (Faraone et al., 
2015), we can only speculate that there may be additional variants contributing to psychiatric 
risk (e.g. coming from common variants (Demontis et al., 2017) and/or from environmental 
risk factors) present in this family, which contribute to the ADHD phenotype in addition to 
the structural variant. In that way, ADHD may not behave as a strictly monogenic disorder 
in any of the affected individuals in this pedigree, which is in line with findings from 
previous rare variant studies of the disorder (Corominas et al., in revision), and reminiscent 
of findings in previous linkage studies of ADHD (Lesch et al., 2008; Zhou et al., 2008) and 
other neurodevelopmental disorders (e.g. autism (Chapman et al., 2015)). Indeed, WES 
revealed an additional de novo frameshift variant in the DUSP16 gene in the index patient, 
who also showed additional somatic features, anxiety disorder, and psychiatric episodes at 
very young age. A recent study reported that Dusp16 plays a critical role in neurogenesis by 
balancing neural progenitor cell proliferation and neural differentiation (Zega et al., 2017). 
Moreover, mouse mutants lacking a functional Dusp16 gene developed fully-penetrant 
congenital obstructive hydrocephalus together with brain overgrowth (Zega et al., 2017). 
When focusing on common genetic variants, we also found nominally significant association 
of DUSP16 with schizophrenia. Therefore, we suggest that this de novo variant may have a 
modifying role in the early development of the patient’s severe psychiatric phenotypes.
After association testing of the microduplication region in the data from the world-wide 
largest genome-wide association data set on ADHD risk, we identified two genes, the F-Box 
Protein 25 (FBXO25) and the Testis development related protein (TDRP) to be associated with 
ADHD risk. While both genes are expressed in the developing and adult brain, a function 
in the nervous system has not been described for either, thus far. FBXO25 codes for an 
E3 ligase, which provides the substrate specificity for ubiquitin-dependent destruction or 
inhibition of transcription factors (Jang et al., 2011). FBXO25 plays a role in cardiomyocyte 
development, and reduced expression of FBXO25 appears to be involved in cell proliferation 
and migration in non-small-cell lung cancer (Jeong et al., 2015; Jiang et al., 2016). Knockdown 
of the gene in a cellular system has been linked to decreased phosphorylation of ERK1, 
whereas overexpression has an opposite effect on the MAPK signaling pathway (Teixeira 
et al., 2017). MAPK signaling plays a role in different psychiatric disorders, including ADHD 
and autism (Poelmans et al., 2013; Poelmans et al., 2011). Moreover, the brain relies on 
ubiquitination to fine-tune protein content in order to react to new stimuli (Hegde and van 
Leeuwen, 2017). Another E3 ligase, FBXO33, has been the top-finding of the first case-control 
genome-wide association study of persistent ADHD (Sanchez-Mora et al., 2015). Further 
F-box genes have been found associated with neurodevelopmental disorders, too, as e.g., 
reported in a patient with intellectual disability and seizures carrying a deletion of FBXO28 
(Au et al., 2014). TDRP, the second gene in the microduplication, is known to be involved 
in sperm motility (Mao et al., 2016). A rare missense variant in TDRP has been reported in 
monozygotic twins with gender dysphoria (Morimoto et al., 2017). Otherwise, little is known 
about this gene up to now.
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Many different complex behaviors can be studied in Drosophila, and it is a model for a 
wide range of neuropsychiatric phenotypes (van Alphen and van Swinderen, 2013). Among 
the behaviors that can be robustly assessed in Drosophila are locomotor activity and sleep, 
which are known to undergo a well-regulated day/night rhythm. In a previous study, we 
reported a distinctive behavioral signature upon knockdown of ADHD candidate genes 
encoding the dopamine transporter, latrophilin, and neurofibromin 1, which included 
increased activity and decreased sleep, especially during darkness (van der Voet et al., 2016). 
Further experiments strongly suggested this phenotype to result from abnormal activity of 
the dopaminergic system. Upon overexpression of the FBXO25 orthologue described here, 
we recapitulated this phenotype. This demonstrates that overexpression of FBXO25 in the 
nervous system is sufficient to trigger increased activity, suggesting that it accounts or at 
least contributes to the ADHD-related phenotypes in our family. This is also the first report 
providing evidence for FBXO25 having a role in the nervous system.
The findings described here need to be interpreted in light of several strengths and 
limitations of our study. The main strength of this study is its interdisciplinary setting and 
comprehensive approach across multiple levels. For this, we integrated complementary 
evidence from genetic, genomic, and animal model experiments to examine the potential 
causes of complex psychiatric phenotypes including ADHD segregating across generations 
in a single family. We combined rare variants approaches (CNV analysis and WES) with an 
analysis of common variants in the identified CNV using the largest meta-analysis data sets 
currently available. For our functional validation of the identified candidate gene, we used 
an unconventional, well-validated animal model. A clear limitation of our study is that we 
were not able to test the effects of overexpression of TDRP on locomotion and sleep patterns 
in Drosophila, because this gene is not conserved in Drosophila. We were therefore not able 
to collect data that would argue for or against a contribution of TDRP overexpression to the 
complex psychiatric phenotypes seen in the family, in addition to FBXO25. Similarly, it would 
be of interest to investigate the role of DUSP16 as a possible modifier of the phenotype of 
the index patient.
In conclusion, by integrating genetic and genomics studies with biological validation, 
we identified FBXO25 as a novel risk gene for ADHD and comorbid psychiatric disorders. 
Future research is warranted to discover the underlying molecular mechanisms and identify 
proteins regulated by FBXO25 in order to better understand the etiology of the aberrant 
behavior caused by variation in this gene.
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Supplementary methods
Study participants and cohorts
Clinical report of the Dutch family
We report a male index patient, born to non-consanguineous Dutch parents (Figure 1). 
Initially, he developed normally, however, at the age of two years, he became aggressive, 
hyperactive, and did not want to talk to others. The parents received video home training 
for his behavioral problems, which led to some improvement. When he went to school at 
the age of four years, he showed aberrant behavior. He had severe anxiety, could not be in 
large groups, showed aggressive behavior, and had to change school. He was diagnosed 
with ADHD and anxiety disorder by a pediatric psychiatrist. Later on, a diagnosis of multiple 
complex developmental disorder (MCDD) was made by another pediatric psychiatrist. 
Additionally, he suffered from a psychotic episode and showed suicidal tendencies. 
During his psychotic episode, he was hospitalized. The patient has an IQ of 95. At the age 
of 12 years, his behavioral problems became more severe, and he is currently living in a 
protected group home. The patient suffers from severe gastrointestinal reflux, for which he 
has undergone surgery at the age of nine years. He also suffers from severe constipation. 
The patient is treated with Concerta, Risperidon, and melatonin. His sleeping problems 
originated after the start of treatment with methylphenidate, but are now under control 
with melatonin. On physical examination, he had a length of 121 cm (-2.15 SD). His head 
circumference was 55.5 cm (+1.75 SD). He exhibits a triangular shaped face, an upturned 
nose, but otherwise has no remarkable facial dysmorphisms. He has clinodactyly of the 
5th fingers. The family history showed that the mother has ADHD (formally diagnosed by 
a psychiatrist), whereas the father is not affected. The mother’s brother suffered from a 
psychotic episode in the past and shows aggressive behavior. As a child, he was hyperactive 
and had concentration problems. He is addicted to alcohol and is homeless. He did not 
show dysmorphic features on physical examination by a clinical geneticist. The mother’s 
sister did not have neuropsychiatric disorders, she did report mild learning difficulties, but 
completed regular education without extra support. The grandparents of the patient did 
not report any neuropsychiatric problems. However, two of the mother’s cousins were 
diagnosed with ADHD at the Department of Psychiatry at the Radboud university medical 
center in Nijmegen, the Netherlands.
When the index patient was seen again by the clinical geneticist at the age of 12, his 
height was 142,8 cm (-2,3 SD), weight 35,5 kg (+0,7 SD) and his skull circumference 56 cm 
(+0,2 SD). He showed a triangular shaped face with minor dysmorphic features (broad front 
teeth, full lips, broad base to the nose). He had scapulae alatae and clinodactyly of the 5th 
fingers, but not other abnormalities.
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Genome-wide ADHD GWAS-MA summary statistics data
ADHD GWAS-MA data were acquired from the ADHD Working Group of the PGC and 
the ADHD iPSYCH-SSI-Broad collaboration (n=55,374; (Demontis et al., 2017), https://
www.med.unc.edu/pgc/results-and-downloads). Quality control and imputation were 
performed for each data set separately. Genotype imputation was with the pre-phasing/
imputation stepwise approach implemented in IMPUTE2/SHAPEIT (chunk size of 3 Mb 
and default parameters) using the 1000 Genomes Project data set (phase 1, August 2012). 
After imputation, only autosomal SNPs with high imputation accuracy across all samples 
were taken forward. For association testing, all data sets were analyzed separately using an 
additive logistic regression model including ancestry principal components as covariates. 
Subsequently, meta-analysis of data sets was conducted using an inverse-weighted fixed 
effects model. In total, 20,183 cases and 35,191 controls were used for the original analysis. 
ADHD GWAS-MA data only included SNPs with an imputation quality score of INFO ≥0.8 
and a minor allele frequency (MAF) ≥0.01 (8,047,420 SNPs).
Genome-wide schizophrenia GWAS-MA summary statistics data
SCZ GWAS-MA data were acquired from the SCZ Working Group of the PGC (n=82,315; 
(Schizophrenia Working Group of the Psychiatric Genomics, 2014), https://www.med.unc.
edu/pgc/results-and-downloads). Quality control and imputation were performed for each 
data set separately. Genotype imputation was with the pre-phasing/imputation stepwise 
approach implemented in IMPUTE2/SHAPEIT (chunk size of 3 Mb and default parameters) 
using the 1000 Genomes Project data set (phase 1, August 2012). After imputation, only 
autosomal SNPs with high imputation accuracy across all samples were taken forward. 
For association testing, all data sets were analyzed separately using an additive logistic 
regression model including ancestry principal components as covariates. Subsequently, 
meta-analysis of data sets was conducted using an inverse-weighted fixed effects model. 
In total 34,241 cases and 45,604 controls were used for the original analysis. SCZ GWAS-MA 
data only included SNPs with an imputation quality score of INFO ≥0.8 and a minor allele 
frequency (MAF) ≥0.01 (9,444,230 SNPs).
Gene-set and gene-based analyses in the PGC/iPSYCH ADHD and PGC 
schizophrenia datasets
Statistical analyses were performed using the Multi-marker Analysis of GenoMic Annotation 
(MAGMA) software package (version 1.05; http://ctglab.nl/software/magma; (de Leeuw et al., 
2015). Genome-wide SNP data from a reference panel (1000 Genomes, v3 phase1; (Genomes 
Project et al., 2010)) was annotated to NCBI Build 37.3 gene locations using a symmetric 100 
kb flanking window. The gene annotation file was used to map GWAS-MA data (ADHD and 
SCZ separately), to assign genetic variants to genes, and to calculate gene-based p-values 
for each data set. For gene-based analyses, single variant p-values within a gene were 
transformed into a gene-statistic by taking the mean of the χ2-statistic among variants in 
each gene. To account for LD, the 1000 Genomes Project European sample was used as a 
reference to estimate LD between variants within (the vicinity of) genes (http://ctglab.nl/
software/MAGMA/ref_data/g1000_ceu.zip). Gene-wide p-values were converted to z-values 
reflecting the strength of the association of each gene with ADHD or SCZ risk, with higher 
z-values corresponding to stronger associations. Subsequently, we tested whether all 
protein-coding genes in the gene-set were jointly associated with ADHD or SCZ risk, using 
an intercept-only linear regression model including a subvector corresponding to genes in 
the gene-set. The RPL23AP53 gene is a pseudo-gene and was therefore not included in the 
analyses. This self-contained analysis evaluated whether the regression coefficient of this 
regression was ≥0, testing whether the gene-set showed association with ADHD or SCZ risk. 
Next, we tested whether genes in this gene-set were more strongly associated with ADHD 
or SCZ than other genes in the genome. With this competitive test, differences between 
the association of the gene-set to all genes outside this gene-set is tested, accounting for 
the polygenic nature of a complex disorder like ADHD or SCZ. Potential confounders gene 
size and gene density, as well as their logarithms, were included in the competitive test. 
Because of this, we were more interested in the competitive than the self-contained test 
for the current analysis. Genes were considered gene-wide significant, if they reached the 
Bonferroni correction threshold adjusted for the number of genes within the gene-set (three 
tests; P<0.0167).
Copy number analysis in the Dutch family
The observed CNV was subsequently confirmed by real-time, quantitative PCR (qPCR) in 
the index patient and his mother, and three additional family members were analyzed 
using this method. Genomic DNA was either isolated from saliva or from EDTA blood 
samples according to manufacturer’s protocol at the department of Human Genetics of the 
Radboud university medical center, Nijmegen, The Netherlands. PrimeTime® Mini qPCR assay 
(Integrated DNA Technologies [IDT], Coralville, IA, USA) was used to determine copy number 
of FBXO25. Primer sequences are displayed in Table S1. DNA concentrations were adjusted 
to 10 ng/µl before genotyping. RNAseP was taken along as endogenous control. Each qPCR 
reaction mix contained 0.25 µl FBXO25/RNAseP PCR primers, 5 µl TaqMan Universal PCR 
Master Mix (2x; Applied Biosystems Inc [ABI], CA, USA), 3.75 µl of water, and 1 µl genomic 
DNA (10 ng/µl). The amplification protocol for the reaction was 50°C for 2 min and 95°C for 
10 min, followed by 95°C for 15 sec and 60°C for 1 min for 40 cycles. All measurements were 
performed in triplicate, and blanks were taken along as quality control during expression 
assessment. Results were analyzed with the 7500 Software v2.0.6 (Life Technologies) using 
an automatic threshold. As a calibrator sample the mean delta cycle threshold (∆CT) of the 
control samples was used. Copy Caller software (ABI, version 2.0) was used to calculate the 
integer copy number of each probe based on the real-time PCR data. The mean and standard 
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deviation (SD) of triplicates of ∆CT for each subject was calculated. Data was visualized using 
GraphPad prism (version 5.03), and the mean and a 95% confidence interval are shown.
Supplementary tables
Table S1. Primer sequences for quantitative PCR.
Gene Forward primer (5’-3’) Reverse primer (5’-3’)
FBXO25 GTCTTCACTAAGCATATACAACGTG ACCTTCCTCTGCACATGC
RNAseP AGGGACATGGGAGTGGAG CTGGGAAATCACCATAAACGTG
d-eIF-1A_rg ATCAGCTCCGAGGATGACGC GCCGAGACAGACGTTCCAGA
d_ αTub84B -alpha-tubulin_rg TGTCGCGTGTGAAACACTTC AGCAGGCGTTTCCAATCTG
dFBXO25_CG11658 GTGAGGCTGTGAAGCGTCT GGCTGTCATTTACATGCGAGG
Table S2. Gene-based association results for the three protein-coding genes within the 8p23.3 locus using 
data from the ADHD GWAS-MA (Demontis et al., 2017).
Gene Start Stop N SNPs Zstat P
ZNF596 82200 297339 646 1.8938 0.029127
FBX025 256808 519876 1295 2.2989 0.010756*
TDRP (C8orf42) 339790 595781 1195 3.4458 0.000285*
*Significant association after Bonferroni correction (three tests, P<0.0167).
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Supplementary figures
Figure S1: Validating gain of copy number of FBXO25 gene by PrimeTime® Mini qPCR assay. Patient IDs 
correspond to IDs presented in Figure 1. Bar charts represent mean and 95% confidence interval. Copy 
number has been calculated from raw results by using the CopyCaller software (ABI, version 2.0). The 
patient’s father DNA sample was not available for testing. DNA of ID2-2 was of too poor quality to be 
analyzed.
Figure S2: Regional association plot for 8p23.3 locus (±100 kb) using (A) the ADHD GWAS-MA data (Demontis 
et al., 2017) and (B) the schizophrenia GWAS-MA data (Schizophrenia Working Group of the Psychiatric 
Genomics, 2014). Results are shown as –log (p value) for genotyped and imputed single nucleotide 
polymorphisms (SNPs). The color of the markers reflects local linkage disequilibrium (r2) of the strongest 
associated SNP (indicated by the purple dot), as shown in the legend. The local recombination rate is 
depicted by the bright blue peaks (magnitude indicated by the right-hand y axis). cM/Mb, centimorgan/
megabase. Chr, chromosome. Plot was made using the Locuszoom software (Pruim et al., 2010).
Figure S3: Expression trajectories of FBXO25 and TDRP (C8orf42) in the developing and adult human brain. 
Line plots show the log2-transformed gene exon array signal intensity from the early fetal period to late 
adulthood in six brain regions. The solid line between periods 7 and 8 (approximately post-conception day 
280) separates prenatal from postnatal periods. Data were generated using Affymetrix GeneChip Human 
Exon 1.0 ST Arrays by the Human Brain Transcriptome project, and accessed via their publicly available 
database at http://hbatlas.org (Kang et al., 2011). Abbreviations: NCX=neocortex; HIP=hippocampus; 
AMY=amygdala; STR=striatum; MD=mediodorsal nucleus of the thalamus; CBC=cerebellar cortex.
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Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder 
with a complex genetic background, hampering identification of underlying genetic risk 
factors. We hypothesized that combining linkage analysis and whole exome sequencing 
(WES) in multi-generation pedigrees with multiple affected individuals can point towards 
novel ADHD genes. Three families with multiple ADHD-affected members (Ntotal=70) and 
apparent dominant inheritance pattern were included in this study. Genotyping was 
performed in 37 family members, and WES was additionally carried out in 10 of those. 
Linkage analysis was performed using multi-point analysis in Superlink Online SNP 1.1. 
From prioritized linkage regions with a LOD score ≥2, a total of 24 genes harboring rare 
variants were selected. Those genes were taken forward and were jointly analyzed in gene-
set analyses of exome-chip data using the MAGMA software in an independent sample of 
patients with persistent ADHD and healthy controls (N=9,365). The gene-set including all 
24 genes together, and particularly the gene-set from one of the three families (12 genes), 
were significantly associated with persistent ADHD in this sample. Among the latter, gene-
wide analysis for the AAED1 gene reached significance. A rare variant (rs151326868) within 
AAED1 segregated with ADHD in one of the families. The analytic strategy followed here is an 
effective approach for identifying novel ADHD risk genes. Additionally, this study suggests 
that both rare and more frequent variants in multiple genes act together in contributing 
to ADHD risk, even in individual multi-case families.
Keywords: ADHD, genetics, linkage analysis, whole-exome sequencing, AAED1
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a multifactorial neurodevelopmental 
disorder, characterized by age-inappropriate inattention, hyperactivity and increased 
impulsivity. ADHD is frequent in children, and in up to 60% of the cases impairments 
persist into adulthood (Faraone et al., 2006). ADHD presents a high risk for developing co-
morbid disorders, increasing the burden on social, educational, and professional aspects 
of life (Biederman, 2004; Faraone et al., 2015). Family and twin studies showed that ADHD 
is highly heritable, both in childhood and in adulthood, with heritability estimates range 
between 70 and 90% (Chang et al., 2013; Faraone et al., 2005; Larsson et al., 2014). Despite 
this considerable heritability, the identification of risk genes has been challenging (Faraone 
et al., 2015; Franke et al., 2012), and one reason for this could be the genetic complexity of the 
disease. Identified candidate genes so far mainly belong to monoaminergic neurotransmitter 
pathways, especially dopaminergic and serotonergic signaling (Bralten et al., 2013; Franke 
et al., 2010; Gizer et al., 2009; Weber et al., 2015; Wu et al., 2012). Different (hypothesis-free) 
approaches, including genome-wide linkage analyses and genome-wide association studies 
(GWASs), have been performed in order to detect additional genetic factors for ADHD. In 
line with the ‘common disease-common variant’ model, mostly common genetic factors 
have been investigated, which generally convey very small effect sizes (Faraone et al., 2015). 
However, GWASs of ADHD are only just reaching sufficiently large samples sizes to produce 
genome-wide significant results. Linkage analysis, a method useful for identification of 
genetic risk factors of larger effect size using family data, has also contributed to the 
identification of risk loci for ADHD. A meta-analysis of linkage studies in ADHD reported a 
significant region in the distal part of chromosome 16q (Zhou et al., 2008). Within this region, 
the CDH13 gene was repeatedly found among the top-findings in GWASs (Lesch et al., 2008). 
In addition, linkage analysis in families from a genetic isolate in combination with association 
testing identified the ADGRL3/LPHN3 gene as an ADHD risk factor (Arcos-Burgos et al., 2010; 
Ribases et al., 2011). More evidence for involvement of less frequent genetic variants with 
potentially larger effect sizes comes e.g. from genome-wide studies of copy number variants 
(CNVs) (Lesch et al., 2011; Merker et al., 2017; Thapar et al., 2016; Williams et al., 2012; Williams 
et al., 2010) and initial exome-chip (Zayats et al., 2016) and whole-exome sequencing work 
(Demontis et al., 2016; Kiser et al., 2015). In addition, whole-exome sequencing (WES) has 
been successful in identifying rare risk alleles for other neurodevelopmental/psychiatric 
disorders, such as autism spectrum disorders (ASDs) and schizophrenia (e.g. (Iossifov et al., 
2014; Purcell et al., 2014)).
In this study, we explored whether a combination of linkage analysis and WES in large 
multi-generational pedigrees is a viable approach to gene-finding in ADHD. We narrowed 
down the search area for rare variants by linkage analysis in three multi-generation 
pedigrees with multiple ADHD-affected members. Based on the WES applied to subsets of 
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family members, we selected rare variants present in all (suggestive) linkage regions in each 
family. In line with the polygenic nature of ADHD, in which both common and rare genetic 
variants are likely to contribute to disease etiology, we subsequently used the extracted 
gene-sets to analyze the cumulative role of common and rare variants in persistent ADHD 
in an independent exome-chip data set (IMpACT consortium; N=9 365 (Zayats et al., 2016)).
Materials and methods
Study participants
Multigenerational pedigrees
The study included three multi-generational families with multiple ADHD affected 
individuals (Ntotal=70, NADHD=41). The structure of the three families (Pedigree 1-3; P1-P3) is 
summarized in Table 1 and shown in Supplementary Figure 1. All families were of German 
origin and were ascertained through affected children referred to the outpatient clinic of 
the Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital 
Würzburg, Germany. For the index-child, strict inclusion and exclusion criteria were applied. 
Included index-children were aged ≥6 years and met criteria for ADHD combined subtype 
according to DSM-IV. Index-children had a birth weight >2,000 grams and Intelligence 
Quotient (IQ) >80, did not show any neurological or severe somatic disorder, drug abuse 
or ASDs, and did not receive psychotropic medication (except for stimulant medication for 
ADHD). Detailed description of the diagnostic procedure for family members was reported 
previously (Romanos et al., 2008). The study was approved by the Ethics Committee of the 
Julius-Maximilians-University of Würzburg. Written informed consent was obtained from 
all participating individuals.
Table 1. Summary of the families included in this study.
Family Total Affected Unaffected Unknown WES Genotyping
P1 11 9 1 1 5 7
P2 29 15 6 8 2 15
P3 30 17 8 5 3 15
WES=whole-exome sequencing; genotyping indicates the number of family members with available 
genome-wide genotyping data for linkage analyses.
Exome-chip data set
The data set, which did not include members of the families above, was genotyped on the 
Infinium Human CoreExome chip (Illumina, San Diego, CA, USA) and comprised 1,846 adults 
with persistent ADHD and 7,519 controls recruited from four different countries: Spain (615 
cases and 932 controls), Norway (597 cases and 2,598 controls), Germany (340 cases and 2,286 
controls), and The Netherlands (294 cases and 1,703 controls). Part of the Dutch controls were 
derived from the Nijmegen Biomedical Study (NBS, www.nijmegenbiomedischestudie.nl), 
a population-based survey conducted by the Departments of Epidemiology & Biostatistics 
and Clinical Chemistry of the Radboud University Medical Center (Galesloot et al., 2017). 
Part of the Norwegian controls were derived from The Nord-Trøndelag Health Study (The 
HUNT study), a large population-based cohort (Krokstad et al., 2013). Part of the German 
controls were derived from the Heinz-Nixdorf-Recall cohort, a large population based cohort 
(Schmermund et al., 2002). Persistent adult ADHD was diagnosed according to DSM-IV 
criteria. A detailed description of all samples and (genotyping) procedures was recently 
published (Zayats et al., 2016), and a shortened version is included in the Supplementary 
Methods. ADHD cases were of European descent and were part of the International 
Multicenter persistent ADHD Collaboration (IMpACT (Franke and Reif, 2013)). The study 
was approved by the Ethics Committees of the respective universities and/or hospitals. All 
participants signed informed consent.
Single Nucleotide Polymorphism (SNP) Genotyping and Linkage Analysis
Genome-wide SNP genotyping was performed on Affymetrix Genome-Wide Human SNP 
Array 6.0 (Affymetrix, Santa Clara, CA, USA). Microarray quality control parameters and 
genotype calls were generated with Affymetrix Genotyping Console v4.2.0.26 software 
(call rate >0.99). Individuals were excluded if their call rate was below 97%. Genotyping data 
were filtered by removing SNPs with minor allele frequency (MAF) <5%, missing genotypes 
>5%, Mendelian errors >10% for variants, or deviations from Hardy-Weinberg equilibrium 
(HWE, P≤10-6). The remaining 665,362 SNPs were pruned to reduce linkage disequilibrium 
(LD) between markers using PLINK v1.07 software (http://pngu.mgh.harvard.edu/purcell/
plink/ (Purcell et al., 2007)) with pairwise R2 >0.01 in sliding windows of 50 SNPs, moving in 
intervals of five SNPs. In total, 10,842 autosomal SNPs were included in the linkage analyses.
Multi-point linkage analyses of genome-wide SNP data were performed using Superlink 
Online SNP 1.1 (Silberstein et al., 2013), which can handle large pedigrees. Through 
parametric analysis, we computed logarithm of odds (LOD) scores using groups of markers 
with a window size of 10 markers. Based on the phenotypic characteristics of the pedigrees, 
a dominant model was specified with an allele frequency of 0.01 and a penetrance value of 
0.99. The significance level was set at a LOD score of 3.3, but a score ≥2 was used to select 
candidate regions for further analyses (Supplementary Figure 2). The linked regions were 
bounded using 1 LOD-score intervals upstream and downstream from the marker with the 
highest LOD-score. Haplotypes of the regions of interest were constructed by using the 
haplotyping tool of Superlink Online SNP 1.1 (Silberstein et al., 2013).
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Whole-Exome Sequencing (WES)
For each family, two or more affected family members were strategically selected for WES 
based on meiotic distance and/or position in the pedigree (Table 1 and Supplementary 
Figure 1). Genomic DNA was extracted from blood samples according to standard protocols 
(Romanos et al., 2008). The exome was targeted by Agilent Sure Select Human All Exon 50 
Mb Target Enrichment kit (Agilent Technologies, Santa Clara, CA, USA) and sequenced by 
single-end sequencing on the 5500xl SOLiDTM System (Life Technologies, Carlsbad, CA, USA). 
High quality reads were mapped to the hg19 reference genome (UCSC genome browser) 
using the Lifescope 2.1 software (http://www.lifetechnologies.com/lifescope/) with default 
parameters. In addition, the SOLiD Lifescope Software v2.1 was used to call single nucleotide 
variants (SNVs) using the diBayes algorithm. Variant annotation was done at the Department 
of Human Genetics of the Radboud university medical center using a pipeline developed 
in-house (de Ligt et al., 2012). Variants were selected according to the following criteria: i) 
variants with ≥20 reads, ii) variants with a MAF <1% in dbSNP (http://www.ncbi.nlm.nih.
gov/SNP/), and iii) variants present in all sequenced family members. Functional effects 
of variants were predicted by three different softwares: SIFT (Sim et al., 2012), PolyPhen-2 
(Adzhubei et al., 2010), and MutationTaster (Schwarz et al., 2014). Conservation of variants 
was estimated by PhyloP (Pollard et al., 2010) and Grantham score (Grantham, 1974).
Gene-based and gene-set analyses in the exome-chip data set
The cumulative effect of common and rare variants in selected genes and gene-sets 
was tested using the independent, recently published IMpACT exome-chip data set 
(Supplementary Methods; (Zayats et al., 2016)). Statistical analyses were performed using 
the Multi-marker Analysis of GenoMic Annotation (MAGMA) software package (version 
1.02; http://ctglab.nl/software/magma (de Leeuw et al., 2015)) and the SNP-wide mean 
model for gene-based association analysis (for detailed description see Supplementary 
Methods). Importantly, all data sets (Spanish, Norwegian, German, and Dutch) were 
analyzed individually, followed by meta-analysis on the level of gene-based statistics. Fixed 
effects were used to perform meta-analysis by using the square root of the sample sizes as 
weights. An LD correction was applied, based on the estimates of the 1000 genome phase 
1 European ancestry samples (Genomes Project et al., 2010). Data was analyzed following 
a step-wise approach (see also Supplementary Figure 2): First, an overall gene-set was 
created, including all genes identified by the approach described above (24 genes). We 
tested whether all genes together were jointly as a gene-set associated with persistent 
ADHD. Post-hoc to the analysis of the overall gene-set, we also tested family-specific gene-
sets to localize the effect. Subsequently, we performed a gene-based look-up of genes from 
family P2 (12 genes), and genes were considered gene-wide significant, if they reached the 
Bonferroni-corrected threshold adjusted for the number of genes within the gene-set (12 
tests; P<0.0042).
Gene Ontology (GO) enrichment analysis
To assess whether the 12 prioritized genes from family P2 converge on biological shared 
functions, we tested for enrichment in Gene Ontology (GO) terms for biological processes 
using FUMA (Watanabe et al., 2017). Overrepresentation of biological functions of prioritized 
genes was tested for by comparison with gene-sets obtained from the Molecular Signature 
Database (MsigDB) v5.2 (i.e. GO gene sets), using hypergeometric tests. The sets of 
background genes were derived from 19,264 protein-coding genes. Benjamini-Hochberg 
correction (FDR) was used for multiple test correction method for gene-set enrichment 
testing. Gene-set enrichments were considered significant at an adjusted P-value level <0.05.
Segregation analysis in family P2
To validate the presence of selected rare variants in the two sequenced individuals and to 
allow segregation analysis, all individuals of family P2 were genotyped for chr9:99404124G>C 
(rs151326868) and chr8:124346225T>C using PCR-based DNA sequencing. The locus of 
interest was amplified by conventional PCR and sequenced by direct Sanger sequencing 
(details and primer sequences are available upon request). Data obtained for the two 
variants was used to analyze the segregation with ADHD diagnosis.
Results
Linkage Analysis across three families with ADHD
The main aim of the linkage analyses was to provide an additional filtering step for the 
WES data by narrowing down the genomic regions of interest. Linkage analysis was 
performed for each family individually, but also for all possible combinations of the three 
families. Informative individuals from each family were enrolled in the linkage study: nine 
individuals from family P1, 19 individuals from family P2, and 16 individuals from family P3 
(Supplementary Figure 1). A total of 13 linkage regions with LOD-score ≥2 on chromosomes 
6, 8, 9, 10, 11, 13, and 16 were identified (Supplementary Table 1, Supplementary Figure 
3 and 4), and all were taken forward for subsequent analyses. Several significantly linked 
regions were observed by analyzing families together. The highest LOD-scores (3.99 and 
3.79) were located on chromosome 16 in the analysis combining P1 and P3 (Supplementary 
Table 1, Supplementary Figure 3 and 4). In family P1, six linkage regions were selected 
(LOD-score ≥2) for further analyses, but all of them needed the contribution of at least one 
additional family to reach significance. In family P2, nine linkage regions were identified, 
three of which specific to this family, and in family P3, nine linkage regions were identified 
of which five were specific to this single family (all linkage regions with LOD-score ≥2 ; Table 
2 and Supplementary Table 1).
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Table 2. List of candidate regions and genes selected based on the linkage analysis in each family. Genes 
were included if they were present in the linkage region (LR; ± 1Mb) with LOD ≥2, to which), the family was 
contributing and if they harbored a rare variant (according to our selection criteria).
Family LR selected
Genes with rare variants in WES
Pself-contained
Gene-set analysis
Pcompetitive
P1
8:118608158-124649389 -----
0.2838 0.4512
9:7754113-15568230 TYRP1, FREM1
9:97466973-102213749 -----
11:115218677-120365028 NXPE1,TMEM25, HYOU1, VPS11, ABCG4, CCDC153
16:63079319-66386711 HSF4
16:81159781-83154022 DYNLRB2, PKD1L2, PLCG2, OSGIN1, MBTPS1
P2
8:118608158-124649389 DEPTOR, ATAD2
0.0066 0.0042
9:7754113-15568230 PTPRD, TYRP1, FREM1
9:97466973-102213749 HSD17B3, AAED1, ANP32B*, TBC1D2
10:56177098-58789387 PCDH15
10:64668048-65875491 -----
11:21968768-29134515 ANO3
11:115218677-120365028 BUD13, VPS11
13:106701406-109091885 -----
16:63079319-66386711 -----
P3
6:203878-460901 -----
0.1368 0.1393
6:3446942-4470581 -----
9:97466973-102213749 -----
10:14311273-15844850 -----
10:64668048-65875491 -----
11:115218677-120365028 BUD13, TMEM25, VPS11
13:106701406-109091885 -----
16:63079319-66386711 CDH5
16:81159781-83154022 MBTPS1
*No variants were observed in the ANP32B gene in IMpACT exome-chip data. Gene-set-based association 
analysis used meta-analytic exome-chip data from 9,365 individuals (1,846 ADHD patients and 7,519 controls 
(Zayats et al., 2016)).
Whole-exome sequencing analysis
A total of ten ADHD-affected family members were included in WES: five from family P1 (ID1, 
ID2, ID4, ID5, and ID11), two from family P2 (ID21 and ID26), and three from family P3 (ID17, 
ID19, and ID20)) (Supplementary Figure 1). We obtained an average of 5.46 billion bases of 
sequence per individual and about 82.2% (approximately 4.49 billion bp) of the total bases 
mapped to the exomes, with a mean of 85-times coverage (for WES sequencing statistics per 
individual see Supplementary Table 2). Based on our selection criteria, the average number 
of shared rare variants present in each family was 1 235 across the exome. Applying filtering 
based on the identified linkage regions, a total of 20 variants were selected from family 
P1, 13 variants from family P2, and five variants from family P3 (Supplementary Table 3).
Association analyses and candidate gene identification in an independent 
sample
All genes within linkage regions containing at least one of the selected rare variants were 
included in a list of candidate genes (Table 2). Gene-set analysis was performed based 
on this list using exome-chip data from an independent sample of 1,846 adults with 
persistent ADHD and 7,519 controls (Zayats et al., 2016). Following testing of the overall 
gene-set (24 genes), we also tested gene-sets resulted from each family separately (Table 
2). Meta-analysis of the individual exome-chip samples showed significant association of 
the overall gene-set in both self-contained and competitive tests (Pself-contained=0.0063 and 
Pcompetitive=0.0103, Table 2). The significant effect of the general gene-set was mainly driven 
by the effect of genes selected based on the linkage analyses in family P2 (Pself-contained=0.0066 
and Pcompetitive=0.0042, 12 genes, Table 2), with additional minor contributions of the gene-
sets resulting from the linkage analysis in the other two families (Supplementary Table 
4). Focusing on individual genes of the P2 gene-set, gene-based analysis revealed that 
the AAED1 gene was significantly associated with persistent ADHD (P=0.0039). Another 
gene in this gene set - ATAD2 - yielded suggestive significance after correction for multiple 
testing (P=0.0072, Table 3). For both genes, association was driven entirely by rare variants 
(Supplementary Table 5 and 6).
To assess whether the 12 prioritized genes of the family P2 gene-set converged on 
biological functions or pathways, we tested for enrichment in GO-terms (biological 
processes). Four significantly enriched GO-terms were detected, including ‘regulation of 
vesicle fusion’ (Padjusted=0.0166) and ‘cell-cell adhesion via plasma membrane adhesion 
molecules’ (Padjusted=0.0328) (Supplementary Figure 5).
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Table 3. Gene-based association results for the family P2 gene-set using IMpACT exome-chip data of 9,365 
individuals (1,846 ADHD patients and 7,519 controls; (Zayats et al., 2016)).
Gene N variants P
AAED1 5 0.0039*
ATAD2 5 0.0072
BUD13 11 0.0136
ANO3 9 0.1308
DEPTOR 6 0.2279
TYRP1 8 0.2824
TBC1D2 12 0.3181
VPS11 9 0.3258
PCDH15 27 0.3434
PTPRD 28 0.6350
HSD17B3 5 0.7097
FREM1 23 0.9460
*Significant association after Bonferroni correction (12 tests, P<0.00417).
Single variant validation and familial segregation analysis
Going back to the WES data of family P2, one rare missense variant was identified in both 
candidate genes (AAED1 and ATAD2) from the gene-based analysis. The variant rs151326868, 
located in AAED1 (chr9:99404124G>C), was predicted to be deleterious in all pathogenicity 
tests (Polyphen2, SIFT, and MutationTaster), was highly conserved (PhyloP >2.7 and Grantham 
score >80; Supplementary Table 7), and rare (MAF=4.38x10-4 in the ExAC browser). The 
SNV chr8:124346225T>C in ATAD2 was predicted to be deleterious only by MutationTaster, 
showed low conservation scores, and had very low MAF in the ExAC browser (8.24x10-
06; Supplementary Table 7). The variant rs151326868 in AAED1 was also present in the 
exome-chip data (exome-chip marker exm764638; Supplementary Table 5 and 6), the 
SNV chr8:124346225T>C in ATAD2 was not.
Sanger sequencing of these two rare variants in AAED1 and ATAD2 in all members of 
family P2 for whom DNA was available confirmed the presence of these variants in the two 
sequenced individuals and allowed segregation analysis. None of the healthy individuals 
carried either of the variants, 93% of the affected individuals (14/15) carried at least one of 
the two variants, and 60% of the affected individuals (9/15) carried both variants (Figure 1).
Figure 1. Segregation analysis for rs151326868 (chr9:99404124G>C; AAED1 gene) and the SNV at 
chr8:124346225T>C (ATAD2 gene) in family P2. ADHD-affected individuals are depicted by black symbols, 
unaffected family members are shown by white symbols and individuals with unknown ADHD status are 
represented by a question mark in the symbol. An asterisk beneath an individual indicates that DNA was 
used for whole-exome sequencing analysis. Non-reference alleles are depicted in bold.
Discussion
In this study, we aimed to identify novel genetic risk factors for ADHD by combining 
linkage analyses and WES in multi-generation families. We predicted that through a family-
based approach, we would be able to limit genetic heterogeneity, since rare variants with 
potentially higher penetrance may cause the disorder in familial ADHD cases. Linkage 
analyses revealed four genomic regions with a LOD score ≥3.3 and 15 additional regions 
with a LOD score ≥2. Within these regions, we identified 38 rare variants within 25 genes 
across the three families. All genes together, and particularly the gene-set from family P2, 
were significantly associated with persistent ADHD in the independent exome-chip sample. 
Moreover, the AAED1 gene reached gene-wide significance in that sample, and a rare variant 
in AAED1 (rs151326868) segregated with ADHD in family P2.
Different designs can be used for WES studies aiming at identifying rare variants linked to 
complex diseases. In schizophrenia (Purcell et al., 2014) and ASDs (Neale et al., 2012; O’Roak 
et al., 2012; Sanders et al., 2012), large sample sizes of cases and controls have been used 
to find genes implicated in disease through rare variants in multiple patients. For ADHD, 
data sets have not yet reached the critical size to allow for a genome-wide, hypothesis-free 
analysis of WES data, but an initial study analyzed a pre-defined gene-set of interest and 
found evidence for enrichment of rare variants in cases (Demontis et al., 2016). A second 
approach, that has successfully been applied in other neurodevelopmental disorders, 
especially in ASDs (Hashimoto et al., 2016; O’Roak et al., 2012), is a trio-approach in sporadic 
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patients and their parents. In this approach, one is assuming that the occurrence of the 
disorder in the patient is due to a de novo mutation. In ADHD, this design may seem less 
promising since the disorder does not reduce reproductive fitness as it does in ASDs (Ploeger 
and Galis, 2011) and, therefore, sporadic cases are less frequently described and familial 
aggregation of ADHD is frequently observed (Chen et al., 2016). However, recent evidence 
from Swedish population registries suggests that ADHD risk is strongly increased in the 
offspring of fathers older than 45 years (D’Onofrio et al., 2014), which seems to be linked to 
an age-related increasing mutation rate in the paternal germline (Kong et al., 2012). Our own 
work also suggests that the cognitive profile of families with only one affected individual 
differs from that of families with more cases (Oerlemans et al., 2015a; Oerlemans et al., 
2015b), which may suggest that the trio-design could also be successful in ADHD. The third 
design, which we employed in the current study, is the extended pedigree-based approach, 
in which one screens for segregation of rare variants with disease across multiple affected 
individuals. Knowledge on the etiology of ADHD is, however, still limited, and therefore, 
ranking and prioritization of potential candidate genes is challenging. With this in mind, 
our combined linkage and WES approach did help to efficiently limit the list of potentially 
causative variants in a data-driven way. Filtering WES variants by linkage analysis has earlier 
been shown to be an effective tool for prioritizing common and exome variants in extended 
families with ADHD (Lesch et al., 2008) or ASD (Chapman et al., 2015).
We extended the family-based approach by testing the effects of observed genes 
carrying rare variants in an independent, large sample of exome-chip data. Importantly, 
most of the selected rare variants in the genes included in the gene-set analysis of family 
P2 are exonic and non-synonymous variants, so the overall result in the case-control 
analyses would not be affected by more stringent selection criteria for rare variants that are 
frequently used in WES studies (e.g., being functionally relevant). Specifically, the significant 
gene-based association of AAED1 would remain. Utilizing this independent sample, we 
showed that (some of the) identified genes may be relevant to ADHD in the population, 
thereby generalizing the findings from the single family. This approach also enabled us to 
study the cumulative effect of rare and common genetic variants in the identified candidate 
genes for association with persistent ADHD, maximizing power to find association by taking 
into account allelic heterogeneity (Bralten et al., 2013; Zayats et al., 2016).
Importantly, our work supports the notion that - despite the apparent dominant 
segregation pattern - ADHD is not a monogenic disorder in the pedigrees investigated. 
Linkage analyses revealed several (suggestive) signals per family, suggesting that several 
genes/loci may carry risk variants for ADHD in each of those. Based on the linkage 
analyses, we did not expect a single gene or single locus to be associated with the clinical 
phenotype nor perfect co-segregation pattern of the rare, non-reference allele with ADHD in 
subsequent segregation analyses. A main contributing factor to the observed patterns may 
be assortative mating, which is common in ADHD (Boomsma et al., 2010) (and e.g. present in 
family P1). Although we were quite liberal in selecting regions for further analysis (through 
including suggestive linkage signals), the observed pattern is similar to findings in previous 
linkage studies of ADHD (Lesch et al., 2008; Zhou et al., 2008) and other neurodevelopmental 
disorders (e.g. for ASDs (Chapman et al., 2015)).
 The prioritized genes in the gene-set of family P2 converged on the biological 
function of vesicle fusion, which adds to the relevance of our findings, since the process of 
vesicle fusion to plasma (e.g., synaptic) membrane is closely related to the mechanism of 
neurotransmitter release. The AAED1 gene (coding for the AhpC/TSA Antioxidant Enzyme 
Domain Containing 1 protein) was significantly associated with persistent ADHD in the 
exome-chip sample, and the rare variant in this gene (rs151326868; MAF for C-allele in 
ExAC=4.38x10-4) segregated with ADHD risk in family P2. AAED1 strongly binds and interacts 
with the Protein Kinase C-Alpha-Binding Protein (PICK1) (Huttlin et al., 2015). PICK1 binds 
to the dopamine transporter (DAT), more specifically to its carboxyl terminus, and is an 
important regulator of DAT trafficking in presynaptic sites of dopaminergic neurons (Torres, 
2006). Additionally, a direct and functional interaction between PICK1 and dopamine D₃ 
receptors (D₃R) has been reported (Zheng et al., 2016). Furthermore, PICK1 has a role in 
glutamate receptor regulation (Perroy et al., 2002), and a recent study revealed that a 
glutamate gene-set showed association with the severity of hyperactivity/impulsivity in 
an ADHD case-only sample (Naaijen et al., 2017). In addition, adult Pick1 knockout mice show 
several behavioral abnormalities, such as hyperactivity and electrophysiological deficits in 
the prefrontal cortex (Nomura et al., 2016). With the prominent involvement of dopamine 
regulation in ADHD, as e.g. the dopaminergic system plays an important role in planning 
and initiation of motor responses, activation, switching, reaction to novelty, and reward 
processing (Faraone et al., 2015), these molecular findings suggest a link between genetic 
variation in AAED1, dopaminergic and glutamatergic signaling, and ADHD risk. Thus, studies 
of the AAED1 variant’s functional impact in carrier-derived neurons of dopaminergic and 
glutamatergic specification, which have been differentiated from induced pluripotent stem 
cells (iPSCs), are currently being conducted (E. Svirin & K.P. Lesch, unpublished results).
Our combined approach of linkage and WES also identified a rare genetic variant in the 
ATAD2 gene, coding for the ATPase family AAA domain-containing protein 2, and gene-
based analysis of this gene revealed suggestive association with persistent ADHD. However, 
a neuronal function of this gene has not been described yet.
The findings described here need to be interpreted in light of several strengths and 
limitations. Although we considered only three families, we identified AAED1 as a novel 
ADHD candidate gene, showing that combining linkage analysis and WES can be an efficient 
strategy to prioritize ADHD-associated genes/variants. In contrast to previous studies 
focusing on pre-defined gene-sets (Demontis et al., 2016; Hawi et al., 2016), we performed 
an exome-wide search for rare variants. Additionally, we validated the association of the 
newly identified ADHD risk genes in an independent sample. However, two main types of 
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genetic variation, which may have helped us to find contributing genes in families P1 and 
P3, remained unstudied. Firstly, genetic variation located in intronic and intergenic regions 
may be discovered by using whole-genome sequencing approaches. Alternatively, common 
variants in regulatory regions close to the genes of interest may be imputed and then 
included in association analyses. Since we know from studies in other psychiatric disorders 
that many risk variants are located within regulatory regions (Roussos et al., 2014), genetic 
variation in those regions probably also contributes to the genetic architecture of ADHD. 
Secondly, CNVs could play a role in the etiology of ADHD, since prior studies have noted an 
enrichment of large CNVs in ADHD cases (Elia et al., 2010; Lesch et al., 2011; Stergiakouli et 
al., 2012; Williams et al., 2012), particularly in genes related to neurodevelopment (Williams 
et al., 2010). Moreover, future studies may aim to integrate data from both rare variants and 
the common polygenic load in those families, in order to obtain a more complete picture 
on the genetic architecture of ADHD in the individual families.
In conclusion, we provide evidence for the role of rare variants in protein-coding genes in 
the etiology of ADHD. Our data adds to the notion that less frequent variants provide an 
additional source of relevant genetic risk factors, which received little attention in ADHD 
genetics so far. Moreover, we show that genes harboring rare genetic variants in individual 
families are associated with persistent ADHD in an independent sample. Therefore, this 
study suggests that the combination of linkage analyses and WES provides a practical 
approach for gene identification in genetically complex neurodevelopmental disorders, 
such as ADHD.
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Supplementary methods
Exome-chip sample
Subjects
The exome-chip sample has been described previously (Zayats et al., 2016). All adult ADHD 
patients examined in the original study (Zayats et al., 2016) were volunteers enrolled 
through the International Multicenter persistent ADHD CollaboraTion (IMpACT; http://
www.impactadhdgenomics.com/). All patients were diagnosed with ADHD according to 
DSM-IV criteria, i.e. ADHD symptoms were present before 7 years of age. Controls were 
recruited either at an IMpACT site (Germany, The Netherlands, UiB Norway, and Spain) or 
through population studies (Germany, The Netherlands, and Norway [The Nord-Trøndelag 
Health Study; The HUNT study]). All subjects were of European descent which was proven 
by means of self-report, together with multi-dimensional scaling (MDS; reported in the 
original publication; (Zayats et al., 2016)). All participants provided signed informed 
consent in accordance with the Declaration of Helsinki. The study was approved by ethics 
committees in each collaborating country at the corresponding recruitment center (for 
details see (Zayats et al., 2016)). Discovery samples were available from four European 
IMpACT sites: Germany, The Netherlands, Norway, and Spain. Additional Dutch controls 
for the discovery analyses were derived from the Nijmegen Biomedical Study (NBS, www.
nijmegenbiomedischestudie.nl), a population-based survey conducted by the Departments 
of Epidemiology & Biostatistics and Clinical Chemistry of the Radboud University Medical 
Center (Galesloot et al., 2017). Approval to conduct the study was obtained from the 
Institutional Review Board. Controls were unselected for ADHD symptoms. A detailed 
description of all samples is provided in the Supplementary Appendix 1 of the original 
publication (Zayats et al., 2016). The replication sample was not utilized in this study. The 
gene-sets were analyzed in the discovery sample only.
Genotyping, genotype calling and quality control
All subjects of the discovery stage were genotyped on the InfiniumHumanExome array 
(Illumina, San Diego, CA, USA). The German cases, the full Dutch sample, and the full 
Spanish sample were genotyped on HumanExome-12v1-1_A; the German controls and 
the HUNT Norwegian sample of controls were genotyped on HumanExome-12v1_A; and 
the UiB Norwegian sample was genotyped on HumanExome-12v1_B version of the chip. All 
genotypes were processed using Illumina GenomeStudio V2011.1 software, with additional 
genotype assignments implemented in zCall (Goldstein et al., 2012). Best practice guidelines 
were used to perform quality control (QC) of genotype calls in GenomeStudio (Grove et al., 
2013). Further QC was carried out on all data sets using PLINK (Purcell et al., 2007), with the 
following steps: (1) genotyping rate threshold was set to 98% both for individuals and for 
SNVs, (2) Hardy–Weinberg test threshold was set to P<1.00x10−05, (3) overall heterozygosity 
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of individuals was screened based on common (minor allele frequency (MAF)⩾1%) and 
rare (MAF<1%) SNVs separately, with outliers defined as those outside the range of mean 
± 3SD of the total heterozygosity observed in a sample, (4) relatedness (PI_HAT) threshold 
was set to 10% and (5) ethnic homogeneity was guaranteed by means of MDS with 
HapMap3 populations. Genotype calling and all QC steps were performed for each data set 
individually. Those samples that were collected in the same country (namely German cases 
and German controls, Dutch cases and Dutch controls, Norwegian UiB and HUNT samples) 
were merged using PLINK and additional QC steps were implemented. Specifically, the 
screening for heterozygosity, cryptic relatedness, and population outliers was performed 
once more as described above. Finally, four data sets were produced: a combined German 
sample, a combined Dutch sample, a combined Norwegian sample, and a Spanish sample.
Statistical analyses
Statistical analyses were divided into two main stages: (1) examination of rare coding 
SNVs (MAF < 1%) and (2) examination of common SNVs (MAF ≥ 1%) with replication in and 
independent sample.
Prior to the analyses, each subject’s genetic substructure characteristics were estimated 
with principal components analysis implemented in EIGENSTRAT software for each data set 
individually (Price et al., 2006). Calculation of principal components was performed based 
only on individuals and SNVs revealing high genotyping rate (⩾99%) and common variants 
(MAF⩾ 1%) after removal of strand ambiguous SNVs and those in high LD (r2<0.2). Long 
stretches of LD were also removed prior to calculation of principal components (Price et al., 
2008). Rare variants were defined as those with MAF < 1%. The variants were combined per 
gene and tested for association with adult ADHD in RAREMETAL (Feng et al., 2014). Common 
SNVs were defined as those with MAF ≥ 1%. The variants were tested using PLINK(Purcell et 
al., 2007), assuming an additive model.
Gene-based and gene-set analyses in the exome-chip dataset
Statistical analyses were performed using the Multi-marker Analysis of GenoMic Annotation 
(MAGMA) software package (version 1.02; http://ctglab.nl/software/magma (de Leeuw et 
al., 2015)). The subjects’ genetic substructure was taken into account by including principal 
components, reflecting their genetic characteristics, as covariates (Zayats et al., 2016). 
Genome-wide SNP data from a reference panel (1000 Genomes, v3 phase1 (Genomes Project 
et al., 2010)) was annotated to NCBI Build 37.3 gene locations. This gene annotation file was 
used to map the exome chip data from the different samples to assign genetic variants to 
genes, followed by the calculation of gene-based p-values for each sample. For this, a degree 
of association was calculated for each gene based on both common and rare variants by 
using principal component regression. Rare variants were defined as those with MAF < 1%, 
and a burden score was generated for each gene, computed as weighted sum of all rare 
variants in that gene. Burden scores are implemented as a pre-processing step. A threshold 
is first specified on either MAF or MAC to designate SNPs as ‘rare’. For each gene, one or more 
burden scores are then created by summing the rare variants in that gene. The individual 
rare variants are then removed from the gene and replaced by these burden scores. Analysis 
of that gene then proceeds as normal, using the chosen gene analysis model (specified by 
--gene-model) to analyze the burden scores and remaining common variants (if any). No 
variants in ANP32B were observed in the IMpACT exome-chip data and, therefore, only 24 
genes were analyzed. For gene-based analyses, single variant p-values within a gene were 
transformed into a gene-statistic by taking the mean of the χ2-statistic among variants in 
each gene. To account for LD, the 1000 Genomes Project European sample was used as a 
reference to estimate the LD between variants within (the vicinity of) genes (http://ctglab.nl/
software/MAGMA/ref_data/g1000_ceu.zip). Gene-wide p-values were converted to z-values 
reflecting the strength of the association of each gene with ADHD risk, with higher z-values 
corresponding to stronger associations. Subsequently, we tested whether all 24 genes in the 
overall gene-set were jointly associated with persistent ADHD, using an intercept-only linear 
regression model including a subvector corresponding to the genes in the gene-set. This 
self-contained analysis evaluates whether the regression coefficient of this regression was 
≥0, testing whether the overall gene-set showed association with persistent ADHD. Next, 
we tested whether genes in this gene-set were more strongly associated with persistent 
ADHD than others genes in the genome. With this competitive test, differences between 
the association of the gene-set to genes outside this gene-set is tested, accounting for the 
polygenic nature of a complex disorder like ADHD. Potential confounders, such as gene 
size and gene density, were included in the competitive test. Because of this, we were more 
interested in the competitive than the self-contained test for the current analyses.
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Supplementary tables
Supplementary Table 1. Candidate linkage regions selected for further analysis containing a maximum 
logarithm of the odds (LOD) score higher than 2 in at least one of analysis performed.
Chr Start 
marker
End 
marker
Region Max. LOD 
score
Analysis
6 rs9392298 rs1113387 203878-460901 3.003 Pedigree 3
6 rs6596970 rs12211028 3446942-4470581 3.003 Pedigree 3
8 rs1993979 rs11776334 118608158-124649389 2.2030 Pedigree 1 and 2 combined
9 rs10758897 rs7875367 7754113-15568230 3.6246 Pedigree 1 and 2 combined
9 rs7847004 rs7847405 97466973-102213749 2.0735 All pedigrees combined
10 rs10906640 rs17395983 14311273-15844850 2.3948 Pedigree 3
10 rs1612430 rs7919353 56177098-58789387 2.5803 Pedigree 2
10 rs10509177 rs2601705 64668048-65875491 2.713 Pedigree 2 and 3 combined
11 rs324256 rs4923591 21968768-29134515 2.0918 Pedigree 2
11 rs4938200 rs12364480 115218677-120365028 3.3631 Pedigree 1 and 3 combined
13 rs9558670 rs16972472 106701406-109091885 2.5168 Pedigree 2 and 3 combined
16 rs153331 rs7198762 63079319-66386711 3.9898 Pedigree 1 and 3 combined
16 rs7200569 rs11150541 81159781-83154022 3.7949 Pedigree 1 and 3 combined
Supplementary Table 2. WES sequencing statistics per individual.
Family ID bp sequenced
bp mapped 
on-target
Total 
number 
reads
Total mapped 
reads on-
target
Percentage of
on-target 
reads (%)
Mean 
Coverage
1 1 4432495337 3900102767 91460024 79681085 87.12 65.08
1 2 5012989993 4411768262 103829553 90405567 87.07 73.31
1 4 4185095550 3543760472 86630343 72553451 83.75 57.42
1 5 4769484984 4217957342 99420668 87006501 87.51 71.26
1 11 4453320723 3911917639 92094198 80066716 86.94 64.52
2 21 6455493150 5851516254 135431851 121571589 89.77 106.42
2 26 7308540150 6672649219 153224671 138653596 90.49 121.56
3 17 6270779135 5667764511 133028891 118744178 89.26 103.01
3 19 4931660430 4303489528 101845716 87873677 86.28 72.42
3 20 6818067496 6191537997 144434109 129623720 89.75 112.32
Supplementary Table 3. List of rare variants identified using WES within linkage regions. In total, we 
identified 38 rare variants, of which 32 were unique and located within a gene.
Family Variant ID rs ID Gene name Gene component Type
1 chr9:12708958->A ------ TYRP1 Splice site -------
1 chr9:14775859G>A rs10733289 FREM1 Exon Synonymous
1 chr11:114421857T>C rs78453693 NXPE1 Intron ------
1 chr11:114421861G>A rs76118887 NXPE1 Intron ------
1 chr11:114421895G>A rs78257939 NXPE1 Intron ------
1 chr11:114421927G>A rs78842965 NXPE1 Intron ------
1 chr11:114421962G>A rs75409523 NXPE1 Intron ------
1 chr11:118405343G>A rs512849 TMEM25 Intron ------
1 chr11:118927013->C rs75923954 HYOU1 Intron ------
1 chr11:118939939->C rs199535207 VPS11 Exon Non-synonymous
1 chr11:119031841->C ------ ABCG4 UTR ------
1 chr11:119065484->C ------ CCDC153 Intron ------
1 chr16:67197776->G ------ HSF4 Intron ------
1 chr16:80581631G>A rs6564764 DYNLRB2 Intron ------
1 chr16:81145675T>C rs8059153 PKD1L2 Intron ------
1 chr16:81242198G>A rs7499011 PKD1L2 Exon Non-synonymous
1 chr16:81816787T>A rs4476171 PLCG2 Intron ------
1 chr16:83992785G>A rs2665296 OSGIN1 Intron ------
1 chr16:84132628->AC rs202131529 MBTPS1 Intron ------
2 chr8:120940874T>C rs62528677 DEPTOR Intron ------
2 chr8:124346225T>C ------ ATAD2 Exon Non-synonymous
2 chr9:9425588->ACTT rs200022326 PTPRD Intron ------
2 chr9:12694274G>A rs61752937 TYRP1 Exon Non-synonymous
2 chr9:14775859G>A rs10733289 FREM1 Exon Synonymous
2 chr9:99064202->A ------ HSD17B3 Intron ------
2 chr9:99404124G>C rs151326868 AAED1 Exon Non-synonymous
2 chr9:100756891->T ------ ANP32B Intron ------
2 chr9:100995758G>T rs879368 TBC1D2 Exon Non-synonymous
2 chr10:55590946CAGAC>T ------ PCDH15 Intron ------
2 chr11:26574783G>- rs143835466 ANO3 Splice site ------
2 chr11:116633913A>G ------ BUD13 Exon Non-synonymous
2 chr11:118939939->C rs199535207 VPS11 Exon Non-synonymous
3 chr11:116633913A>G ------ BUD13 Exon Non-synonymous
3 chr11:118405343G>A rs512849 TMEM25 Intron ------
3 chr11:118939939->C rs199535207 VPS11 Exon Non-synonymous
3 chr16:66432304ACCACCCC>- rs113303884 CDH5 Intron ------
3 chr16:84132628->AC rs202131529 MBTPS1 Intron ------
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Supplementary Table 4. Results of the gene-set association analyses of the individual IMpACT exome-chip 
samples (Zayats et al., 2016).
Cohort N (cases/controls) Gene-set N genes Pself-contained Pcompetitive
Spain (615/932)
General 23 0.074232 0.034095
P1 13* 0.8862 0.8772
P2 12 0.00067007 0.00013433
P3 5 0.10719 0.026187
Norway (597/2,598)
General 23 0.038002 0.055531
P1 13* 0.038847 0.05538
P2 12 0.051919 0.078343
P3 5 0.67716 0.65549
Germany (340/2,286)
General 24 0.21395 0.30365
P1 14 0.38634 0.50658
P2 12 0.50793 0.53963
P3 5 0.074312 0.18876
Netherlands (294/1,703)
General 24 0.16794 0.11289
P1 14 0.63434 0.66457
P2 12 0.30359 0.16463
P3 5 0.41871 0.41045
*No variants were observed in the DYNLRB2 gene in this sample of the IMpACT exome-chip data.
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Supplementary Table 6. Count data for all markers of the exome-chip data is shown per site.
Variant CHR BP genotypes counts_in_controls counts_in_cases
exm717719 8 120940733 CC 2597 597
GC 1 0
exm717740 8 120977489 CC 2 1
CT 194 38
TT 2402 558
exm717741 8 120977542 CT 44 20
TT 2554 577
exm717755 8 121013770 CC 1410 338
TC 1017 218
TT 171 41
exm717770 8 121015349 GG 2595 597
TG 3 0
exm717787 8 121061879 AA 279 62
AG 1132 265
GG 1187 270
exm718925 8 124335225 AA 2563 585
GA 35 12
exm718965 8 124348685 AA 2598 596
GA 0 1
exm718971 8 124351667 CC 2595 596
TC 3 1
exm718973 8 124357252 CC 2593 595
TC 5 2
exm719045 8 124382144 CT 0 1
TT 2598 596
exm2248310 9 8319965 CC 2598 596
TC 0 1
exm738865 9 8331667 CC 2596 597
… … … … … …
… … …
Tab 1=Norway, tab 2=Spain, tab 3=Germany, tab 4=Netherlands
The complete Supplementary Table 6 is available upon request.
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Supplementary Figures
Supplementary Figure 2. Schematic overview of the study design and statistical approach. Our study 
included five main steps for the identification of novel ADHD genes. By combining linkage analysis and 
whole-exome sequencing (WES) in three multigeneration pedigrees with multiple affected individuals, we 
prioritized those genes emerging from linkage regions and harboring rare variants. Those 24 genes were 
taken forward and were jointly analyzed in gene-set analyses of IMpACT exome-chip data. Subsequently, 
family-wise gene-set analysis was performed, and 12 genes from family P2 were taken forward for gene-
based analyses. One gene showed significant gene-based association, and a rare variant was validated.
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Supplementary Figure 3. Genome-wide logarithm of the odds (LOD) score graph for families P1, P2, and 
P3 individually. The lower horizontal, black line represents a LOD score of 2 and the upper horizontal, grey 
line indicates the significance level at a LOD score of 3.3.
Supplementary Figure 4. Genome-wide logarithm of the odds (LOD) score graph for the different 
combinations of the three families. The lower horizontal, black line represents a LOD score of 2 and the 
upper horizontal, grey line indicates the significance level at a LOD score of 3.3.
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Abstract
Neurodevelopmental disorders are defined by highly heritable problems during 
development and brain growth. Attention-deficit/hyperactivity disorder (ADHD), autism 
spectrum disorders (ASDs), and intellectual disability (ID) are frequent neurodevelopmental 
disorders, with common comorbidity among them. Imaging genetics studies on the role 
of disease-linked genetic variants on brain structure and function have been performed 
to unravel the etiology of these disorders. Here, we reviewed imaging genetics literature 
on these disorders attempting to understand the mechanisms of individual disorders 
and their clinical overlap. For ADHD and ASD, we selected replicated candidate genes 
implicated through common genetic variants. For ID, which is mainly caused by rare variants, 
we included genes for relatively frequent forms of ID occurring comorbid with ADHD or 
ASD. We reviewed case-control studies and studies of risk variants in healthy individuals. 
Imaging genetics studies for ADHD were retrieved for SLC6A3/DAT1, DRD2, DRD4, NOS1, 
and SLC6A4/5HTT. For ASD, studies on CNTNAP2, MET, OXTR, and SLC6A4/5HTT were found. 
For ID, we reviewed the genes FMR1, TSC1 and TSC2, NF1, and MECP2. Alterations in brain 
volume, activity, and connectivity were observed. Several findings were consistent across 
studies, implicating e.g. SLC6A4/5HTT in brain activation and functional connectivity related 
to emotion regulation. However, many studies had small sample sizes, and hypothesis-
based, brain region-specific studies were common. Results from available studies confirm 
that imaging genetics can provide insight into the link between genes, disease-related 
behavior, and the brain. However, the field is still in its early stages, and conclusions about 
shared mechanisms cannot yet be drawn.
Keywords: ADHD, ASD, ID, brain imaging genetics, neurodevelopmental disorders
Introduction
Neurodevelopmental disorders are broadly defined as disorders in the development and 
growth of the brain (Goldstein and Reynolds, 1999), but this term is largely used to describe 
neurological and psychiatric disorders that have their onset prior to adulthood. Most 
neurodevelopmental disorders are highly heritable, either caused by single genetic defects, 
like many of the intellectual disability (ID) disorders (Deciphering Developmental Disorders 
Study, 2015), or with a more multifactorial background, in which several to multiple less 
penetrant genetic variants cause the disease in combination with environmental factors, like 
in many cases of autism spectrum disorders (ASDs; (Gaugler et al., 2014; Iossifov et al., 2014), 
as well as in attention-deficit/hyperactivity disorder (ADHD; (Faraone et al., 2015; Franke et 
al., 2012), oppositional defiant disorder, and conduct disorder (Salvatore and Dick, 2016).
While technological advances in the last decade, especially genome-wide association studies 
(GWASs) and next generation sequencing, have enabled the identification of many genetic 
factors involved, the biological mechanisms contributing to the neurodevelopmental 
disorders are still largely unknown. It is thought that gene variation/mutation will alter 
molecular and cellular processes, which leads to altered brain development, be it structurally 
and/or functionally, and subsequently to altered behavior and disease symptoms (Franke 
et al., 2009). Measures that mediate the effects of genes on behavioral/disease phenotypes 
have been termed endophenotypes or intermediate phenotypes (Gottesman and Gould, 
2003; Kendler and Neale, 2010).
Much research into the consequences of gene aberrations is performed in animal 
models. However, brain imaging methods like magnetic resonance imaging (MRI), 
electroencephalography (EEG), and magnetoencephalography (MEG) offer excellent ways 
to investigate the effects of genetic variation on brain structure, function, and connectivity 
directly in humans in vivo. Such ‘imaging genetics’ approaches can unveil the brain-biological 
consequences of molecular changes induced by genetic variants – both common and rare 
– linked to neurodevelopmental disorders. In that way they can help to understand the 
mechanisms through which differences in behavior arise. It has been argued that the effects 
of disease-linked (common) genetic variation on the brain would be larger than those on 
behavior and clinical phenotypes (Gottesman and Gould, 2003; Rose and Donohoe, 2013)), 
although more recent work using hypothesis-free imaging genetics approaches argues 
against this – at least for brain structural phenotypes (Franke et al., 2016).
Different neuroimaging methods can be used in imaging genetics studies, including 
different forms of structural and functional MRI as well as EEG and MEG. They have 
complementary characteristics enabling information to be gathered on different aspects of 
(gene effects on) brain anatomy and function, like location (especially MRI-based methods) 
and timing (especially EEG and MEG). In this review, we concentrated on those methods 
that have most frequently been used in imaging genetics studies of neurodevelopmental 
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disorders, i.e. MRI-based methods evaluating gene effects on brain structure, function, and 
connectivity.
With structural magnetic resonance imaging (sMRI) it is possible to noninvasively 
characterize the structure of the human brain. Thereby, the different magnetic properties 
of brain tissues are used to map the spatial distribution of these structural properties of 
the brain. In this way, the different brain tissues (grey and white matter) and cortical and 
subcortical structures of the brain can be mapped. By adapting scanning parameters, 
different weighting techniques of the signal can be used, such as T1-weighted imaging (used 
to visualise anatomy) and T2-weighted imaging (which is useful for demonstrating lesions 
and pathology). Different aspects of brain structure can be used for quantitative analyses. To 
investigate whether volumetric differences are global or regional, specific brain regions of 
interest (ROIs) can be selected a priori and studied individually. In contrast, global changes 
in grey or white matter intensity can be detected by using voxel-based morphometry (VBM) 
analyses. Next to volumetric differences observed in grey matter, structural differences of 
white matter connectivity can also be quantified. With the help of diffusion tensor imaging 
(DTI), it is possible to non-invasively investigate the macrostructural integrity and orientation 
of white matter fibre bundles. Thereby, the directional diffusion of water molecules along 
neuronal membranes is measured, allowing to map white matter connection within the 
brain. Multiple measures can be derived from DTI. A frequently measured parameter is 
fractional anisotropy (FA). Basically, anisotropy indicates that diffusion takes place in a 
directional manner, whereas isotropy indicates diffusion in all directions. Additional DTI-
derived parameters include mean diffusivity (MD; average of axial diffusivity (AD) and 
perpendicular diffusivities), and radial diffusivity (RD; average of perpendicular diffusivities), 
the mode of anisotropy (sensitive to crossing fibres), and the apparent diffusion coefficient 
(indicating the magnitude of diffusion) (Le Bihan, 2003; Le Bihan et al., 2001; Yoncheva et 
al., 2016).
Resting state functional MRI (rs-fMRI), allows to analyse the temporal correlations of 
neural activity across anatomically disparate brain regions and thereby to examine the 
functional connectivity based on spontaneous brain activity, neural organization, and circuit 
architecture.
To investigate potential changes in brain activity, functional magnetic resonance 
imaging (fMRI) can be used. Since fMRI is sensitive to the oxygenation of the blood, the 
so-called blood-oxygen-level-dependent (BOLD) signal can be measured. Thereby brain 
function is measured, based on the premise that active cells consume oxygen, thus causing 
changes in blood oxygenation, and subsequently leading to increased blood flow. However, 
the exact link between cell activation, oxygen saturation, and cerebral blood flow changes 
is debatable (Hillman, 2014). Generally in fMRI, alterations in blood flow after e.g. a task-
induced stimulus or during a resting condition are measured.
Here, we systematically reviewed the imaging genetics literature for three frequent 
neurodevelopmental disorders, ADHD, ASDs, and selected intellectual disability (ID) 
disorders. The choice for those three neurodevelopmental disorders was based on their 
frequent comorbidity (Vorstman and Ophoff, 2013) and robustly established associations 
with specific genetic variants. The aim of this work was to extract core brain mechanisms 
affected by disease-linked genetic factors related to the individual disorders as well as their 
clinical overlap.
ADHD is one of the most common neurodevelopmental disorders, with a prevalence of 
5-6% in childhood (American Psychiatric Association, 2013; Polanczyk et al., 2007). ADHD can 
be clinically characterized by two core symptom domains: inattention and hyperactivity/
impulsivity (American Psychiatric Association, 2013; Faraone et al., 2015). Up to 60% of all 
patients diagnosed in childhood show ADHD symptoms and/or meet formal diagnostic 
criteria for the disorder in adulthood, and prevalence rates of persistent ADHD in adults 
range between 2.5 and 4.9% (Simon et al., 2009). ASD affects approximately 0.6% to 1% 
of the children, making it one of the most prevalent disorders in childhood (Elsabbagh 
et al., 2012). Although there are some important differences in core symptom definition, 
the co-occurrence between ADHD and ASD is supported by clinical (Craig et al., 2015), 
common biological (Rommelse et al., 2010), and non-biological risk factors (Kroger et 
al., 2011). Moreover, several studies identified that symptoms of autism or autistic traits 
appear in 20% to 30% of children with ADHD (Grzadzinski et al., 2011; Kochhar et al., 2011). 
Additionally, ADHD is a common comorbid disorder in children with ID, and the risk increases 
with increasing severity of ID (Voigt et al., 2006). Studies of children with mild and borderline 
ID have identified ADHD in 8% to 39% of the cases (Baker et al., 2010; Dekker and Koot, 2003; 
Emerson, 2003). ADHD is highly heritable (heritability 70-80%) (Burt, 2009; Faraone et al., 
2005). However, identification of ADHD risk genes has been difficult (Franke et al., 2009; Gizer 
et al., 2009), mainly due to ADHD’s complex genetic background (Faraone et al., 2015; Franke 
et al., 2012). Mostly genetic variants, which occur quite frequent in the population and have 
generally small effects on disease risk have been investigated for their role in ADHD until 
today, either through candidate gene studies or hypothesis-free GWASs. Only a few of the 
candidate genes have been confirmed through meta-analysis (Gizer et al., 2009). However, 
none of the eleven GWAS (Hinney et al., 2011; Lasky-Su et al., 2008a; Lasky-Su et al., 2008b; 
Lesch et al., 2008; Mick et al., 2010; Neale et al., 2008; Neale et al., 2010a; Sanchez-Mora et 
al., 2014; Sonuga-Barke et al., 2008; Stergiakouli et al., 2012; Yang et al., 2013) nor a meta-
analysis of many of them (Neale et al., 2010b) published to date, reported any genome-wide 
significant risk variant.
ASDs refer to a heterogeneous group of neurodevelopmental disorders diagnosed in 
approximately 1 of 88 children (Autism and Developmental Disabilities Monitoring Network 
Surveillance Year 2008 Principal Incestigators and Centers for Disease Control and Prevention, 
2012). It is characterized by deficits in social behavior and language development, as well as 
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restricted or stereotypic interests (American Psychiatric Association, 2013). About 70% of 
individuals with ASDs have some level of ID while the remaining 30% have some disability 
(speech, behavior) other than cognitive dysfunction (Mefford et al., 2012). Whereas early 
reports estimated ASD heritability to be higher than 90% (Bailey et al., 1995; Folstein and 
Rutter, 1977; Ritvo et al., 1985; Steffenburg et al., 1989), recent population-based studies 
provided an estimate of ~50% heritability (Gaugler et al., 2014; Sandin et al., 2014). ASDs are 
genetically highly complex, as part of the cases has oligogenic or even monogenic causes 
(with an important role for de novo mutations (Iossifov et al., 2014)), whereas the concerted 
action of common genetic variants of individually small effect sizes and environmental 
factors is likely to cause most of the disease burden of ASDs (Iossifov et al., 2014) (Gaugler 
et al., 2014; Zhao et al., 2007). Several of those common variants contributing to ASD risk 
have been identified through hypothesis-driven studies. Until now, three GWASs have 
been performed for ASDs (Anney et al., 2010; Wang et al., 2009; Weiss et al., 2009), which 
identified a single locus on chromosome 5p14, in-between CDH10 and CDH9 (Wang et al., 
2009). Association with this locus might be driven by markers located within the MSNP1AS 
pseudogene (Ma et al., 2009).
ID refers to a highly heterogeneous group of disorders characterized by below average 
intellectual functioning (IQ < 70) in conjunction with significant limitations in adaptive 
functioning with onset during development. ID may occur as an isolated phenomenon or 
accompanied with malformations, neurological signs, impairment of the special senses, 
seizures and behavioral disturbances (van Bokhoven, 2011). ID has an estimated prevalence 
of approximately 2% to 3%, and approximately 0.3% to 0.5% of the population is severely 
handicapped (Perou et al., 2013). Comorbidity with ADHD and ASDs is frequently observed 
(Vorstman and Ophoff, 2013). Disease etiology of ID is thought to be largely monogenic, but 
with many different genetic anomalies implicated (van Bokhoven, 2011). Genetic causes of 
ID range from large cytogenetically visible chromosomal aberrations, such as trisomy 21, to 
translocations, subchromosomal abnormalities (such as Prader-Willi syndrome (15q11.2-q13)), 
copy number variations, and to single gene defects. We concentrated only on the latter in 
our review, based on the assumption that we can learn most from understanding effects 
of specific genes/variants on brain structure, function and connectivity. While in many ID 
disorders, a defect in a single gene can be identified as the cause of the disorder, only a 
few genes are hit more frequently and cause relatively common ID disorders. To prevent 
bias of our review by single case reports, we concentrated on those common forms of 
ID, especially selecting those, in which comorbidity with ADHD and ASD is common. This 
resulted in five ID disorders included in this review: fragile X syndrome, tuberous sclerosis, 
neurofibromatosis type 1, Rett syndrome, and Timothy syndrome. Fragile X syndrome (FXS), 
caused by genetic defects in the FMR1 gene, is associated with a variable clinical phenotype, 
including intellectual disabilities with a broad range of severities. IQ is 40 on average for 
affected men (Merenstein et al., 1996) and normal or borderline in females (de Vries et al., 
1996), who show a milder phenotype because the disorder is X-chromosome-linked. High 
rates of autism and autistic behaviors are seen in individuals with FXS (Hagerman et al., 2009), 
and 59% of FXS subjects shows ADHD symptoms (Sullivan et al., 2006). Neurofibromatosis 
type 1 (NF1), caused by mutations in NF1, is associated with the presence of usually benign 
neurofibromas. While IQ in general is average to low average, up to 8% of children with NF1 
have an IQ below 70. Learning difficulties and neuropsychological deficits are common, and 
the core cognitive impairments are in visual spatial function, attention, executive function, 
and language skills. About 38% of children with NF1 meet diagnostic criteria for ADHD, and 
a substantial proportion of subjects show social deficits related to ASD (Hyman et al., 2005; 
Walsh et al., 2013). Tuberous sclerosis complex (TSC) is caused primarily by mutations in the 
genes TSC1 and TSC2 and is characterized by benign hamartomas in multiple organ systems, 
including the brain. Intellectual ability in TSC ranges from normal to profoundly impaired, 
and neurobehavioral abnormalities and epilepsy are common. Both ASD and ADHD are 
reported in about 50% of individuals with TSC, with an even higher number of diagnoses 
in intellectually impaired individuals (Prather and de Vries, 2004). Rett syndrome, caused by 
mutations in the MECP2 gene, primarily affects females. Language problems and cognitive 
and motor deficits start to become obvious around the age of 6 months in the patients. 
Testing of cognitive dysfunction is difficult because of a characteristic absence of speech, 
but ASD-related features, such as avoidance of eye contact, are common (Armstrong, 
2005). Timothy syndrome is a multisystem disorder caused by missense mutations in the 
CACNA1C gene. Neurodevelopmental features include global developmental delays and 
ASDs. Average age of death is 2.5 years, usually caused by ventricular tachyarrhythmia, 
infection, or complications of hypoglycemia (Splawski et al., 1993).
With this review, we aimed at providing a comprehensive overview on the imaging 
genetics literature for the three neurodevelopmental disorders. To prevent bias, we 
excluded reports including less than 10 cases and focused on specific genetic variants, 
which for ADHD and ASDs resulted in a focus on genes/loci implicated through variants that 
are common in the population, and for ID, we restricted the review to the genes causing 
the single-gene ID disorders described above. While imaging genetics studies have been 
performed in patients, the underlying candidate genes and their common genetic variants 
are also frequently studied in healthy individuals. This allows analysis of effects of common 
genetic variation in candidate genes on imaging correlates in the general population and 
offers the opportunity to study brains not influenced by chronic disease and medication. 
Previous studies showed that neuroimaging correlates of common genetic variants are likely 
to be similar in typical and psychiatric populations (Hibar et al., 2015b). As such studies of 
healthy individuals may also be informative regarding the biological mechanisms leading 
to the diseases of interest, they were also included in this review.
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Methods
Search terms
Pubmed was searched for research articles describing imaging genetics studies (April, 
14th, 2015; http://www.ncbi.nlm.nih.gov/pubmed). Only studies using magnetic resonance 
imaging (MRI) were reviewed, specifically structural MRI (sMRI), functional MRI (fMRI), resting-
state functional MRI (rs-fMRI), and diffusion tensor imaging (DTI). A general search term 
was created and was extended by adding the disorder (for ADHD and ASD) or syndrome 
name and gene (for ID) of interest. The following search term shows an example for ADHD 
(for [Title/Abstract]): ((((ADHD OR Attention-Deficit Hyperactivity Disorder) AND (gene* OR 
genetic* OR imaging genetic OR imaging genetics OR genotype OR polymorphism OR 
SNP OR single nucleotide polymorphism OR meta-analysis OR genome wide association 
OR GWA OR GWAS)) AND (structural magnetic resonance imaging OR volume OR sMRI 
OR voxel-based morphometry OR brain morphometry OR brain volumetry OR VBM OR 
functional magnetic resonance imaging OR fMRI OR diffusion tensor imaging OR diffusion 
imaging OR connectivity OR tractography OR DTI OR resting-state functional magnetic 
resonance imaging OR voxel-wise analysis OR rsfMRI)) NOT “review”[Publication Type]). 
For ID syndromes, the search term did not include (gene* OR genetic* OR imaging genetic 
OR imaging genetics OR genotype OR polymorphism OR SNP OR single nucleotide 
polymorphism OR meta-analysis OR genome wide association OR GWA OR GWAS), as the 
genes of interest were added specifically. Titles and abstracts of the retrieved records were 
evaluated for relevant publications. Case-reports and reports describing less than 10 cases 
were excluded to prevent bias, and review articles, medical hypotheses, non-English articles, 
and studies on animal models were not considered (for a graphical summary of the selection 
procedure, please see Figure 1).
Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) flowchart of the 
literature search and study selection for qualitative analysis. Note: see http://www.prismastatement.org/ 
for more information on this reporting system. ADHD = Attention-Deficit/Hyperactivity Disorder, ASD = 
Autism Spectrum Disorder, ID = Intellectual Disability. Records excluded for ID contain unrelated records 
identified by screening as well as records describing non-ID samples. The number of studies for ADHD and 
ASD * The number of studies for ADHD candidate genes also include the records for SLC6A4 (5-HTTLPR), 
which is also a candidate gene for ASD.
Candidate gene selection for ADHD, ASD, and ID studies
Taking into account the differences in the genetic architecture of the three 
neurodevelopmental disorders of interest, we defined selection criteria for the genes to be 
included in this review as similar as possible. The restriction to studies with 10 or more cases 
and single genetic variants/single-gene mutations largely defined our search strategy, which 
resulted in a focus on common genetic variants for ADHD and ASDs (minor allele frequency 
≥ 1%); for ID disorders, this lead to the selection of relatively common forms of the disorder. 
For ADHD and ASDs, we selected the most promising genes containing common variants 
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associated with the disorder based on meta-analyses, successful replication studies, and/
or significant findings from hypothesis-free (genome-wide) studies.
For ADHD, we included all genes and genetic variants mentioned in Table 1 of the meta-
analytic study by Gizer and coworkers (2009) that had reached a significant result at P ≤ 0.05 
for association with ADHD. In addition to this, we also included genes with reported and 
replicated evidence for association with ADHD from more recent studies. These included 
two meta-analytic studies (Pan et al., 2015; Wu et al., 2012), a research article (Ribases et 
al., 2011), and the more recently observed replicated candidate genes NOS1 and SLC9A9 
(Stergiakouli et al., 2012; Weber et al., 2015) (total number of candidate genes = 10; Table 
1). A recent overview of these ADHD candidate genes has been published by Hawi and 
colleagues (2015).
For the ASD genes, we based our selection on the review of the most consistently 
replicated genes harboring common variants associated with autism by Persico and 
Napolioni (2013). Additionally, the CDH9/CDH10 locus was included, because it has shown 
genome-wide significant association with ASD (Prandini et al., 2012; Wang et al., 2009). 
Selection of the candidate polymorphisms in the selected genes was based on recent 
research articles, as meta-analyses were only available for the OXTR and RELN gene (total 
number of candidate genes = 11; Table 2).
For the ID, the restrictions to relatively common forms of the disorder resulting from 
single gene mutations (as opposed to structural genetic variants involving several to many 
genes) as well as our aim to study potential brain mechanisms contributing to comorbidity 
among the three disorders lead to the inclusion of the following 5 syndromes: fragile X 
syndrome (FMR1), tuberous sclerosis (TSC1 and TSC2), neurofibromatosis type 1 (NF1), Rett 
syndrome (MECP2), and Timothy syndrome (CACNA1C) (Table 3). For our selection, we used 
Table 1 from Vorstman and Ophoff (2013), describing genetic anomalies associated with ID. 
We included all disorders with known genetic cause including a single gene (FMR1, TSC1 
and TSC2, NF1, and CACNA1C). Patients with these disorders also show a high rate of ASD 
and/or ADHD phenotypes (Vorstman and Ophoff, 2013). Additionally, we included the Rett 
syndrome (MECP2), because of its known ASD- and ADHD-related features (Armstrong, 2005; 
Rose et al., 2016; Suter et al., 2014).
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Table 3: Genes causing prevalent and well-studied single-gene ID disorders with behavioral and cognitive 
overlap with ADHD and/or ASD.
Gene Protein Chr 
position
Associated ID 
disorder
Reported rate of ASD-
related phenotype
Reported rate of ADHD-
related phenotype
FMR1 Fragile X mental 
retardation protein
Xq27 Fragile X 
syndrome
30% (Hagerman et al., 
2009)
59% (Sullivan et al., 2006)
NF1 Neurofibromin 17q11 Neurofibromatosis 
type 1
40% (Walsh et al., 2013) 38% (Hyman et al., 2005)
TSC1
TSC2
Hamartin
Tuberin
9q34
16p13
Tuberous sclerosis 
complex
50% (Prather and de 
Vries, 2004)
30-60% (D’Agati et al., 
2009)
MECP2 Methyl-CpG-binding 
protein 2
Xq28 Rett syndrome 42-58% (Wulffaert et al., 
2009)
unknown
CACNA1C Voltage-dependent 
L-type calcium channel 
subunit alpha-1C
12p13 Timothy 
syndrome
60% (Splawski et al., 
2004)
unknown
Phenotypic overlap as adapted from (Vorstman and Ophoff, 2013); ID= intellectual disability; ASD= Autism 
spectrum disorder; ADHD= Attention deficit/hyperactivity disorder; Chr= chromosome; in grey no imaging 
genetics studies found.
Results
Imaging genetics of ADHD candidate genes
A total of 76 records were retrieved for the ADHD search term, and a total of 16 research 
articles describing case-control studies were eligible for review according to our criteria. 
To those, we added three more recent papers from our own group ((Onnink et al., 2016; 
Sokolova et al., 2015; van der Meer et al., 2015); Figure 1). Most of the studies investigated a 
single gene (all in Caucasians), and three studies investigated multiple genes (2 in Caucasians, 
1 in Asians). In addition, we obtained 295 records for the ADHD candidate gene studies 
in healthy population samples, of which 98 were eligible (Figure 1). Of those, 73 studies 
investigated a single gene (68 in Caucasians, 5 in Asians), and 25 studies tested more than 
one gene (1 Asian). The ADHD case-control samples consisted of both childhood/adolescent 
and adult samples, whereas the studies in the healthy population were largely restricted to 
samples of (young) adults. Single-gene findings of ADHD case-control studies and studies 
in the healthy population of both Caucasian and Asian ethnicities can be found in Table 4, 
multi-locus studies are shown in Table 6. Most of the genes investigated in brain imaging 
genetics studies in ADHD are from the dopaminergic and serotonergic neurotransmitter 
systems (SLC6A3/DAT1, DRD2, DRD4, SLC6A4/5-HTT/SERT). SNAP25, DRD5, HTR1B, and LPHN3 
had also been selected for this study, but for these genes no imaging genetics studies using 
MRI were found with our search terms.
The dopamine transporter gene DAT1 (official name SLC6A3) codes for a solute 
carrier protein, responsible for the reuptake of dopamine from the synaptic cleft into the 
presynaptic neuron, representing a primary mechanism of dopamine regulation in the 
striatum (Ciliax et al., 1999). The most widely studied polymorphism in SLC6A3/DAT1 is a 
variable number of tandem repeat (VNTR) sequence in the 3’ untranslated region (3’UTR) 
that is 40 base pairs (bp) in length. Most common alleles are those with 9 and 10 repeats. 
Additionally, a 30 bp VNTR in intron 8 of the gene (most common alleles with 5 and 6 
repeats), is sometimes studied together with the 3’UTR VNTR as a haplotype. The 10R/10R 
genotype of the 3’UTR VNTR and the 10-6 haplotype of the two VNTRs are thought to be risk 
factors for ADHD in children (Asherson et al., 2007; Brookes et al., 2006; Faraone et al., 2005). 
In contrast, the 9R/9R genotype and the 9-6 haplotype are associated with persistent ADHD 
(Franke et al., 2010). The sMRI and fMRI studies for SLC6A3/DAT1, the latter investigating 
several cognitive domains known to be impaired in ADHD, i.e. reward processing, working 
memory, and response inhibition, are summarized in Table 4 and 6. The main focus of the 
studies for this gene has clearly been on the striatum, which shows highest gene expression.
The two sMRI case-control studies were performed in children, and both reported a 
smaller volume of the caudate nucleus in homozygotes for the 10R allele as compared to 
children with the 9R/10R genotype (Durston et al., 2005; Shook et al., 2011). A third study, 
including a large sample of children and adults with and without ADHD, showed that only 
in the adult ADHD case-control cohort, carriers of the DAT1 adult ADHD risk haplotype 9-6 
had a 5.9% larger striatum volume relative to participants not carrying this haplotype. The 
effect was depended on diagnostic status, since the risk haplotype affected striatal volume 
only in patients with ADHD (Onnink et al., 2016).
Two fMRI studies in case-control design investigated the SLC6A3/DAT1 haplotype using 
reward paradigms. Independent of the genotype, a recent meta-analysis has shown that in 
reward-processing paradigms, most studies report lower activation of the ventral striatum 
in patients with ADHD in anticipation of reward than controls (Plichta and Scheres, 2014). 
Consistent with this, a study in adolescents (including only males) found the activation of 
the caudate nucleus to be reduced in the ADHD group as the number of 10-6-haplotype 
copies increased (Paloyelis et al., 2012). The other study, in adult ADHD cases and controls 
(in whom the 9-6 allele is the ADHD risk allele), found no effect of DAT1 haplotype on 
striatal activity (Hoogman et al., 2013). Studies in healthy adult individuals point in different 
directions. One found higher activation during reward anticipation in 9R-carriers (Dreher 
et al., 2009). Another also found increased striatal activation in 9R-carriers in a rewarded 
task-switching task, especially in high reward conditions (Aarts et al., 2010). A third study 
in healthy adults suggested that a link between reward sensitivity and striatal activation 
during reward anticipation is only present in 10R/10R individuals, and is lost in 9R-carriers 
(Hahn et al., 2011). In studies of response inhibition in children/adolescents, the 10R/10R 
genotype was found linked to lower (Durston et al., 2008) but also higher (Bedard et al., 2010) 
striatal activation. Methylphenidate was able to increase activity in the caudate nucleus (as 
well as a thalamocortical network and inferior frontal gyrus) during successful inhibition in 
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healthy adult male 9R-carriers, but decreased activity in 10R/10R individuals (Kasparbauer 
et al., 2015). A working memory task in healthy adults elicited more activation in fronto-
striatal-parietal regions in 9R/10R individuals under high memory load (Stollstorff et al., 
2010). Additionally, a resting-state fMRI study in healthy adults showed stronger connectivity 
between midbrain (mainly striatal) and prefrontal regions in 9R/10R heterozygotes 
compared with 10R/10R homozygotes (Gordon et al., 2015).
Beyond striatum, SLC6A3/DAT1 genotype effects have also been observed in fMRI studies 
of cortical regions, especially (pre)frontal, medial (pre-SMA, dorsal ACC), and (temporo)
parietal regions (Bedard et al., 2010; Braet et al., 2011) (Table 4 and 6). As expression of 
DAT is limited outside of striatum and cerebellum, these effects are likely due to direct or 
indirect connections between the regions of gene expression and the rest of the brain. This 
is in line with the fact that no effect of SLC6A3/DAT1 genotype on cortical development has 
been observed in a longitudinal study (Shaw et al., 2007). Of particular interest might be 
studies showing effects of SLC6A3/DAT1 genotype on amygdala reactivity upon exposure to 
threatening faces (Bergman et al., 2014) as well as on cerebellar activation during response 
inhibition (Durston et al., 2008). These regions are currently understudied in ADHD. A first 
study using DTI did not suggest a strong effect of SLC6A3/DAT1 genotype on structural brain 
connectivity (Hong et al., 2015) (Table 4).
In summary, although SLC6A3/DAT1 is one of the best-studied genes in imaging genetics 
literature covered in this review, existing studies do not yet clarify sufficiently the role of 
ADHD-linked genetic variation in brain activity and connectivity related to symptoms/
cognitive deficits or their structural brain correlates. A complicating matter for this gene 
is the switch in ADHD risk allele from childhood to adulthood. Furthermore, interactions 
between genotype and diagnosis are observed in some studies, which suggest that studying 
effects of SLC6A3/DAT1 in healthy individuals will not suffice to fully understand the brain 
mechanisms linking this gene to ADHD.
The dopamine D2 receptor gene (DRD2) codes for a G protein-coupled receptor, which 
inhibits adenylate cyclase (Andersen et al., 1990). Consistent with its broad expression in 
the brain being highest in striatum, DRD2 plays a key role in regulating mesolimbic reward 
processing pathways (Usiello et al., 2000) and is also implicated in other cognitive domains, 
such as cognitive flexibility and learning (Puig et al., 2014). The gene has been implicated in 
many different psychiatric disorders, including schizophrenia and substance use disorders 
(Patriquin et al., 2015; Schizophrenia Working Group of the Psychiatric Genomics, 2014) 
and is the target of several antipsychotics (Moore et al., 2014). The risk factor for ADHD is 
the most frequently investigated common genetic variant of DRD2 rs1800497 (also known 
as Taq1A restriction fragment length polymorphism). This SNP actually lies downstream of 
DRD2 in an exon of a neighboring gene, ANKK1 (Neville et al., 2004). It affects dopamine D2 
receptor expression and striatal dopamine metabolism, with the A1-allele (the ADHD risk 
allele) reducing the number of DRD2 receptors (Laakso et al., 2005). No studies in ADHD 
case-control design are yet available for DRD2. The risk SNP has, however, been investigated 
in healthy individuals using structural and functional MRI covering the cognitive domains 
of reward processing, task-switching and reversal learning, working memory, emotion 
recognition, and language (Table 4 and 6).
Structural MRI showed that the SNP affects the volume of midbrain structures, with A1-
allele carriers having smaller volumes of substantia nigra (Cerasa et al., 2009), cerebellum 
(Wiener et al., 2014), and ACC (in interaction with BDNF; (Montag et al., 2010)).
Functional MRI during reversal learning tasks revealed that A1-allele carriers showed 
reduced response of the rostral cingulate to negative feedback and had a reduced 
recruitment of the right ventral striatum and right lateral occipital frontal cortex (OFC) 
during reversals (Jocham et al., 2009). Pharmacological fMRI in a reversal learning task 
showed that cabergoline (D2 receptor agonist) administration induced an allele-specific 
response, where A1-allele carriers showed increased neural reward responses in medial 
OFC, cingulate cortex, and striatum (consistent with increased D2-mediated dopamine 
signaling); this was coupled, however, to worse task performance and lower fronto-striatal 
functional connectivity (Cohen et al., 2007). The reward-related paradigms showed that A1-
allele carriers exhibited increased anterior insula (Richter et al., 2013) and increased nucleus 
accumbens activation, the latter observed only in a three-way interaction analysis looking 
for differences between a placebo and bromocriptine (D2 receptor agonist) administration 
condition (Kirsch et al., 2006). Two multi-locus studies including the DRD2 Taq1A variant 
suggested higher activation during reward anticipation, but blunted activity during reward 
receipt with increasing number of risk factors (Table 6).
In summary, the effects of the ADHD risk factor in DRD2 in fMRI appear to be relatively 
consistent across most of the studies currently available, with stronger brain activity in parts 
of the wider reward processing and memory/learning circuits. It seems that this stronger 
activity is linked to worse functional connectivity and/or performance, thus potentially 
reflecting compensatory processes. Currently, no data from patients with ADHD are 
available.
The dopamine D4 receptor (encoded by the DRD4 gene) is another G protein-coupled 
receptor and belongs to the dopamine D2-like receptor family (Oldenhof et al., 1998). The 
most widely studied DRD4 polymorphism in ADHD has been the 48 bp VNTR in exon 3, 
with the 2-, 4-, and 7-repeat alleles being the most common alleles. Allele frequencies vary 
significantly across ethnic groups (Chang et al., 1996; Van Tol et al., 1992), and the ADHD 
risk allele in the Caucasian population (7R) seems to be a different one from that in Asians 
(Nikolaidis and Gray, 2010; Wang et al., 2004).
Structural MRI suggested that patients with ADHD carrying the 7R-allele have smaller 
volumes of the superior frontal and cerebellar cortex (Monuteaux et al., 2008), while no 
differences were found in another study (Castellanos et al., 1998) (Table 4). Interestingly, 
carriership of the DRD4 7R-allele seemed to affect cortical development in a longitudinal 
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study, with 7R-carriers showing thinner prefrontal and parietal cortex and ADHD patients 
with this allele having a distinct trajectory of cortical development characterized by 
normalization of parietal cortical regions (Shaw et al., 2007) (Table 6). Structural connectivity 
was investigated in two studies in Asians using DTI, and while one did not find effects for 4R 
homozygotes (Hong et al., 2015), a very large recent study reported widespread increases 
in mean diffusivity in 5R-carriers (Takeuchi et al., 2015) (Table 4).
With the role of the D4 dopamine receptor in cognition not sufficiently characterized 
yet, and DRD4 being expressed in large parts of the cortex (predominantly in frontal lobe 
regions, such as the OFC and ACC (Floresco and Tse, 2007; Noain et al., 2006)), fMRI studies 
have investigated the DRD4 gene in healthy Caucasians covering different cognitive domains, 
i.e. emotion processing, response inhibition, reward, stimulus-response incompatibility, and 
time discrimination tasks, as summarized in Table 4. Depending on the type of paradigm 
used in the fMRI studies, DRD4 genotype was found to modulate brain activity in prefrontal 
and temporal, but also in striatal and cerebellar brain regions in the healthy adults (Table 4).
Thus, though existing evidence does not support firm conclusions, DRD4 may mark a 
particular developmental trajectory in cortical brain structure related to adult outcome of 
ADHD, and plays a role in structural connectivity. With only one fMRI study per cognitive 
domain published to date, no clear picture of DRD4 action on brain activity emerges, but 
those studies do clearly indicate that DRD4 (like DAT1) influences brain activity beyond its 
regions of expression, possibly due to its effects on white matter connectivity (Takeuchi 
et al., 2015).
The serotonin transporter gene (SLC6A4, 5HTT, SERT) codes for a solute carrier protein 
responsible for the reuptake of serotonin from the synaptic cleft back into the presynaptic 
neuron, which is the primary mechanism for regulation of serotonergic activity in the brain 
(Lesch et al., 1996). A functional polymorphism in the promoter region of the gene (referred 
to as 5HTTLPR) is a 44-bp insertion/deletion yielding short (S) and long (L) alleles. The long 
variant is associated with more rapid serotonin reuptake, resulting in lower levels of active 
serotonin (Lesch et al., 1996). However, allele frequencies vary across different ethnic groups 
(Haberstick et al., 2015). A SNP in the long allele, rs25531, can modify the activity of this 
allele (Lesch et al., 1996). SLC6A4/5HTT has been implicated in emotion regulation as well 
as (emotional) memory and learning processes (Araragi and Lesch, 2013; Barzman et al., 
2015; Meneses and Liy-Salmeron, 2012). Expression of the transporter is observed in regions 
implicated in attention, memory, and motor activities, such as the amygdala, hippocampus, 
thalamus, putamen, and ACC (Frankle et al., 2004; Oquendo et al., 2007).
Only one recent imaging genetics study in patients with ADHD has been performed 
for the 5HTTLPR, showing that stress exposure, which is associated with increased ADHD 
severity in S-allele carriers, was associated with reduced cortical gray matter volume in 
precentral gyrus, middle and superior frontal gyri, frontal pole, and cingulate gyrus in these 
individuals. Interestingly, this paper showed that only some of these regions, the frontal 
pole and the ACC, actually mediated the effects of the gene-environment interaction on 
ADHD severity. In sMRI studies in healthy individuals, the 5HTTLPR has been associated with 
volume of the ACC and amygdala as well as hippocampus, though the direction of effect 
seemed to differ with gender and/or in interaction with environmental factors (Table IV). 
Few studies have looked at effects of the 5HTTLPR on structural connectivity (Table 4). A 
large study observed reduced connectivity of amygdala with PFC in S-allele carriers (Long 
et al., 2013), while another reported increased hippocampus-putamen connectivity for this 
genotype group (Favaro et al., 2014).
Brain activation patterns in task-based fMRI have been studied extensively for the 
5HTTLPR following hallmark studies by the Weinberger lab (Hariri et al., 2005; Hariri et al., 
2002). They were the first to report increased activation of the amygdala in S-allele carriers in 
response to negative-emotional faces. Since then, increased amygdala activation has been 
observed in S-allele carriers in many tasks activating the amygdala (Table 4 and 6). In 2013, 
34 studies investigating effects of the 5HTTLPR on amygdala activation were meta-analyzed, 
confirming the increased activation in S-allele carriers (although only borderline significant) 
(Murphy et al., 2013). However, this meta-analysis also showed strong heterogeneity between 
studies and a potential publication bias (towards studies reporting significant associations). 
Linked to the increased activation seems to be a reduced functional connectivity of the 
amygdala, as first observed by Pezawas and colleagues (2005) and subsequently also seen 
in additional studies (Table 4). Not only the amygdala, but also other cortical and subcortical 
brain regions (forming the ‘threat circuit’) seem to be influenced by 5HTTLPR genotype. A 
recent, replicated fMRI study, for example, also showed stronger activity in dorsomedial 
prefrontal cortex (dmPFC), insula, thalamus, and regions of the midbrain, in reaction to threat 
in S-allele carriers (Klumpers et al., 2014); interestingly, also in this study (like in the one by 
van der Meer and coworkers (2015)) only some of the activated regions actually mediated 
the genotype effects on psychophysiological responsivity to pending threats (in this case 
the dmPFC activation, Table 4).
 Increasing evidence suggests that S-allele carriers are hypervigilant to environmental 
stimuli (Homberg and Lesch, 2011). Potential sustained effects of environmental factors 
have not sufficiently been addressed in imaging genetics studies published to date. Several 
studies have taken stressful life events into account, and these studies suggested effects on 
both brain volume and activation. Only one study to date has directly looked at methylation 
of the promoter of the SLC6A4/5HTT gene, and found correlations with the volume of several 
regions in the ‘threat circuit’ of the brain, though these appeared genotype-independent 
(Dannlowski et al., 2014). Also a combined PET, sMRI plus fMRI study indicated that 5HTTLPR 
genotype did not influence current (midbrain) serotonin transporter availability (Kobiella 
et al., 2011), suggesting that other factors (like environmental ones) might overrule this 
effect. Taking into account epigenetic effects on the SLC6A4/5HTT gene might thus help 
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explain the strong heterogeneity observed in the meta-analysis of amygdala reactivity 
studies (Murphy et al., 2013).
In summary, functional genetic variation in the SLC6A4/5HTT gene is clearly linked to 
emotion regulation through effects on brain activation in the amygdala and the wider ‘threat 
circuit’, with those carrying the risk factor for emotional dysregulation showing increased 
activation in tasks related to emotion processing and learning. Those experiments link 
reduced availability of the transporter (at some point in development) - and thus increased 
serotonin signaling capacity - to increased brain activation. This increased activation seems 
to be linked to functional dysconnectivity, however. Whether brain volume and structural 
integrity are influenced by the 5HTTLPR, remains to be clarified. Importantly, genotype 
effects are likely to be sensitive to environmental factors.
The nitric oxide synthase 1 (encoded by the NOS1 gene) is an enzyme which 
synthesizes nitric oxide from L-arginine. Nitric oxide is a reactive free radical, which acts 
as a biological mediator in several processes, including dopaminergic and serotonergic 
neurotransmission (Kiss and Vizi, 2001). The NOS1 gene has a complex structure, including 
12 alternative untranslated first exons (exon 1a-1l). In exon 1f, a functional VNTR that affects 
gene expression has been linked to hyperactive and impulsive behavior in humans (Reif et 
al., 2009; Weber et al., 2015), with the short allele being the risk factor for ADHD. In addition, a 
recent Nos1 knock-out mouse model showed dysregulation of rhythmic activities mimicking 
ADHD-like behaviors (Gao and Heldt, 2015).
So far, only one case-control study investigated the effect of the VNTR polymorphism on 
the brain, in his case on reward-related ventral striatal activity (Hoogman et al., 2011) (Table 
4). The study revealed that homozygous carriers of the short allele of NOS1 demonstrated 
higher ventral striatal activity than carriers of the other NOS1 VNTR genotypes (Hoogman 
et al., 2011). This effect was comparable for both patients and healthy individuals. Similar 
effects of the genotype were also observed for behavioral impulsivity, with those carrying 
the ADHD risk factor acting more impulsive than other participants.
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Imaging genetics of candidate genes for autism spectrum disorders
A total of 193 records were retrieved for the ASD search terms, and a total of six research 
articles were eligible for review according to our criteria. All studies investigated a single 
gene and were performed in Caucasian populations. For studies in the healthy population, 
we obtained 120 records, and 17 were included in the review (Figure 1). Twelve of those 
investigated a single gene in a Caucasian study sample, and five studies used Asian samples 
(studies for SLC6A4/5HTT are included in the ADHD section above). Generally, the ASD case/
control samples included mainly childhood and adolescent study samples, whereas the 
studies in healthy population samples mostly used samples of (young) adults. From the 
eleven genes selected and listed in Table 5, imaging genetics studies could only be retrieved 
for genetic variants in CNTNAP2, MET, OXTR, and the SLC6A4/5HTT gene.
The contactin-associated protein-like 2 (CASPR2), encoded by the gene CNTNAP2 
(the largest gene in the human genome), is a neural transmembrane protein involved in 
neuronal-glial interactions and in clustering K+-channels in myelinated axons; as such, it 
is involved in neuronal cell adhesion, migration, and the formation of neuronal networks 
(Rodenas-Cuadrado et al., 2014). Several single nucleotide polymorphisms (SNPs) in CNTNAP2 
have been associated with ASDs. During human brain development, CNTNAP2 expression is 
broad, with highest levels in frontal and anterior lobes, striatum, and dorsal thalamus. This 
cortico-striato-thalamic circuitry is important for higher order cognitive functions, including 
speech and language, reward, and frontal executive function (Rodenas-Cuadrado et al., 
2014). This is reflected in the imaging genetics studies having been performed for CNTNAP2, 
which cover studies of brain volume and structural connectivity as well as brain activity and 
functional connectivity during tasks related to rewarded learning and language (Table 5).
Two studies performed DTI in healthy individuals. For the SNP rs2710102 it was found 
that carriers of the CC risk genotype showed reduced overall path length and increased 
small-worldness of brain-wide structural connectivity, which appeared to be a general 
phenomenon rather than being localized to individual tracts (Dennis et al., 2011). A large 
study in healthy individuals combining sMRI with DTI for the SNP rs7794745 showed that 
carriers of the ASD risk genotype exhibited reduced gray and white matter volume as well 
as reduced white matter integrity in the cerebellum, fusiform gyrus, occipital and frontal 
cortices; distribution of reductions was found to be sex-specific (Tan et al., 2010).
In a case-control study, an association between the SNP rs2710102 and medial prefrontal 
cortex activation during a rewarded implicit learning task was found, when collapsing 
patients and controls into one group. The non-risk allele was linked to reduced activation. 
Furthermore, the risk carriers had more widespread and bilateral connectivity throughout 
the frontal cortex and anterior temporal poles. The latter finding was confirmed in an 
independent healthy sample (Scott-Van Zeeland et al., 2010). An additional fMRI study using 
a sentence completion paradigm showed that carriers of the risk genotype for one of two 
SNPs had increased activation of the IFG (Broca’s area), the lateral temporal cortex, or right 
middle temporal gyrus (Whalley et al., 2011).
The Met proto-oncogene encoded by the MET gene is a cell surface receptor with 
tyrosine-kinase activity. In the forebrain, MET gene and protein expression is regulated in 
excitatory projection neurons during synaptogenesis (Judson et al., 2011) and is restricted 
to regions of temporal, occipital, and medial parietal cortex in humans. These regions are 
known to be of relevance to the processing of socially relevant information (Rudie et al., 
2012). The effects of the ASD risk variant rs1858830 have been studied in two imaging 
genetics studies (Table 5).
A case-control study combining fMRI (emotional face task), resting-state fMRI, and 
DTI modalities showed that the ASD risk genotype predicted wide-spread atypical brain 
activity patterns to social stimuli, with increased activation in amygdala and striatum, and 
impaired deactivation patterns in part of the default mode network (DMN) in the posterior 
cingulate cortex. In addition, reduced functional and structural connectivity was observed in 
temporo-parietal regions belonging to the DMN suggesting altered white matter integrity. 
In general, the effects were more pronounced in the ASD group (Rudie et al., 2012). An sMRI 
study in a large sample of healthy individuals revealed that cortical thickness in temporal, 
pre- and postcentral gyri, anterior cingulate, and frontopolar cortex was reduced in risk-
allele carriers, with reductions increasing with increasing number of risk alleles (Hedrick et 
al., 2012).
The oxytocin receptor (OXTR) gene encodes the receptor protein for oxytocin, which 
has an important role in the regulation of social cognition and behavior (Meyer-Lindenberg 
et al., 2011). So far, no imaging genetic studies were performed for risk variants in the OXTR 
gene in ASD case-control samples, but twelve studies in healthy samples were found (Table 
5). Various different SNPs and combinations of those were investigated, not all related to 
ASD risk.
Two sMRI studies showed that adolescents homozygous for the rs2254298 risk factor 
for psychopathology displayed an overall increased gray matter volume, but a decreased 
amygdala volume (Furman et al., 2011a); for carriers of the rs53576 SNP, a risk factor for 
disorders associated with social impairment, a smaller hypothalamus gray matter volume 
was reported in healthy adults (Tost et al., 2010).
Functional MRI paradigms used to study OXTR all covered the cognitive domains of 
emotion processing and reward (Table 5). In a face matching task, adult carriers of the 
rs53576 risk allele showed increased functional correlation of hypothalamus and amygdala 
during perceptual processing of facial emotion (Tost et al., 2010). Investigating a large 
group of 1445 healthy adolescents in a passive face viewing task for effects of 23 SNPs 
across OXTR, the IMAGEN Consortium found significant effects of one SNP on ventral 
striatal activity in a region of interest analysis. In the presence of stressful life events, this 
SNP modulated the occurrence of emotional problems in the participants, linking more 
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emotional problems to reduced striatal activation; no effects of the risk variants for ASD 
were observed (Loth et al., 2014). A study of brain regions related to processing of social 
stimuli observed increased functional connectivity between such regions in adult carriers of 
the risk genotype for rs53576 (Verbeke et al., 2013). Functional MRI of mesolimbic structures 
during reward processing was modulated by the rs2268493 risk factor for ASD: young adult 
carriers of the risk genotype showed reduced activation in mesolimbic reward circuitry 
(nucleus accumbens, amygdala, insula, thalamus, and prefrontal cortical regions) during 
the anticipation of rewards but not during reward receipt (Damiano et al., 2014). Using a 
mother-child interaction task, Michalska and coworkers (2014) showed that females carrying 
the ASD risk genotypes for rs53576 or rs1042778 had lower brain activity in OFC, ACC, and 
hippocampus in response to child stimuli. When healthy adult females were tested for 
empathic response and associated brain activation, carriers of the rs2254298 risk factor 
for psychopathology showed increased responsiveness of the superior temporal sulcus to 
observed pain (Laursen et al., 2014). In a pharmacologic imaging genetics study in adult 
males, one of three SNPs modulated the response of the amygdala (only) after oxytocin 
inhalation, with increased activation to directed gaze and decreased activation to averted 
gaze under oxytocin in the carriers of the variant allele (Montag et al., 2013). This study did 
not find any effects of rs2254298 on brain activation.
In summary, genetic variation in the OXTR gene has been linked to brain activation 
during emotional processing. Risk factors for ASD/psychopathology appear to reduce 
activation during most relevant paradigms, but may increase functional connectivity during 
those tasks.
Four ASD case-control imaging genetics studies investigated the gene encoding the 
serotonin transporter gene (SLC6A4, 5HTT) in addition to those in healthy individuals (and 
ADHD case-control samples) described in the section on ADHD candidate genes. Structural 
MRI, fMRI, and rs-fMRI were used to study the effect of either only the 5HTTLPR or the 
combination of this variant with rs25531 (Table 5).
Whereas a VBM study did not reveal an association between total gray or white matter 
volume and genotype in adult patients (Raznahan et al., 2009), another sMRI study showed 
that in 2-4 year old boys with ASD, carriers of the 5HTTLPR S-allele had increased total 
cortical and frontal lobe gray matter volume (Wassink et al., 2007), suggesting an age-
dependent effect of the variant.
The fMRI and rs-fMRI study, performed in overlapping samples of adolescent patients 
and controls, showed that carriers of alleles that mark low gene expression had increased 
amygdala activation during an emotional face task, an effect that was observed only in 
the patients (Wiggins et al., 2014b), and increased posterior-anterior connectivity during a 
resting-state condition in patients, where the converse was observed in the healthy group 
(Wiggins et al., 2012b).
The findings of those case-control studies are not easily reconciled with those observed 
in healthy individuals (Table 4 and 6), and indeed the latter two studies suggest the 
existence of differential effects in patients and healthy individuals.
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Imaging genetics in selected intellectual disability disorders
A total of 579 records were retrieved for the ID syndromes of interest. Eighty research 
articles were eligible for review according to our criteria, 30 for fragile X syndrome, 24 for 
neurofibromatosis type 1, 22 for tuberous sclerosis complex, and four for Rett syndrome 
(Figure 1). No imaging studies of Timothy syndrome patients were uncovered by our search 
term. The reviewed imaging genetics studies in ID syndromes are presented in Table 7.
The fragile X mental retardation 1 gene (FMR1) is located on the X chromosome and 
codes for fragile X mental retardation protein. Large expansions of a CGG repeat (>200 
repeats) in the 5’- untranslated (5’UTR) region of the gene, leading to protein deficiency, 
are the cause of fragile X syndrome (FXS). FMR1 has a prominent role in synaptic plasticity 
and maturation (Saldarriaga et al., 2014). In studies including participants with the FMR1 
full mutation, brain structure was most often investigated, followed by task-based brain 
activation (Table 7). A few studies investigated brain structural integrity and resting-state 
functional connectivity. Several studies compared individuals with FXS with and without 
ASD or included an idiopathic autism or IQ-matched group (Table 7).
The most robust finding in investigations of brain structure in FXS is an increased caudate 
nucleus volume. This enlargement was observed early in development (Hazlett et al., 2009), 
throughout adolescence (Bray et al., 2011; Hall et al., 2013; Lee et al., 2007) as well as in adult 
samples (Hallahan et al., 2011; Molnar and Keri, 2014; Wilson et al., 2009). Studies comparing 
individuals with FXS and with ASD found increased caudate volumes in children and adults 
with FXS compared to children/adults with idiopathic autism (Hazlett et al., 2009; Wilson et 
al., 2009). Consistent volumetric abnormalities have also been found for cerebellar regions in 
FXS; a reduction in the volume was observed in both children and adults with FXS (Hazlett 
et al., 2012; Hoeft et al., 2008; Wilson et al., 2009). Several studies found cerebellar volumes 
to be larger in children and adults with FXS relative to individuals with autism, in whom 
reduced volume of cerebellar regions compared to control subjects is often seen as well 
(Hazlett et al., 2012; Wilson et al., 2009). Few studies have investigated white matter integrity 
in people with the full FMR1 mutation, and deficits seem most prominent in fronto-striatal 
connections. Increased density of fibers was found in the left ventral fronto-striatal pathway 
in boys with FXS compared to typically developing and developmentally delayed controls 
(Haas et al., 2009), and differences in white matter in frontal-caudate circuits were found 
in females with FXS compared to controls (Barnea-Goraly et al., 2003). More widespread 
reductions in white matter integrity have also been observed (Villalon-Reina et al., 2013).
Cognitive and psychiatric characteristics associated with FXS include poor eye contact, 
repetitive motor behavior, language deficits, inattention, hyperactivity, inhibition, and 
anxiety (Saldarriaga et al., 2014). Functional neuroimaging studies have focused on these 
deficits, with a main focus on poor eye contact and behavioral inhibition. Several fMRI 
studies have investigated the circuitry underlying face/gaze processing in subjects with 
FXS, as eye-gaze avoidance is common in this population. Abnormal activation was found 
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in several regions, including superior temporal gyrus and fusiform gyrus (Garrett et al., 
2004), amygdala and insula (Watson et al., 2008), regions within the ventrolateral prefrontal 
cortex (vlPFC) (Holsen et al., 2008), and frontal cortex and cingulate and fusiform gyri (Bruno 
et al., 2014). These regions are associated with visual processing, social cognition, emotion 
processing, and executive functioning, indicating that eye-gaze avoidance in FXS may be 
linked to social anxiety. Investigating attention and inhibition, a study using a Go/No-go task 
found that boys with FXS show reduced activation in the right vlPFC and caudate head. The 
authors suggested that defective fronto-striatal signaling is a key feature of FXS, leading to 
impairments in executive functioning (Hoeft et al., 2007), which is in line with the altered 
white matter connectivity in fronto-striatal connections, described above.
The neurofibromin 1 gene (NF1) located on chromosome 17q11.2 codes for 
neurofibromin, a protein which is thought to be a regulator of the RAS signal transduction 
pathway and necessary for embryonic development. Neurofibromatosis type 1 (NF1) is 
caused by mutations in the gene, often leading to the synthesis of truncated or otherwise 
non-functional proteins. We found 14 studies investigating effects of NF1 on brain structure 
and four investigating brain function. Additional studies of brain structural and functional 
connectivity have been conducted. While most studies included children and adolescents, 
a few studies have included adults as well (Duarte et al., 2014; Karlsgodt et al., 2012; Pride et 
al., 2014; Violante et al., 2012; Wignall et al., 2010; Zamboni et al., 2007) (Table 7).
The structural brain abnormalities most commonly seen in subjects with NF1 are T2 
hyperintensities and an increased brain volume. T2 hyperintensities are areas of high signal 
intensity on T2-weighted MR images also referred to as ‘unidentified bright objects’ (UBOs). 
Although their association with cognitive and intellectual deficits remains controversial, 
thalamic hyperintensities have repeatedly been associated with cognitive impairments 
(Payne et al., 2010). Multiple studies have investigated the characteristics of UBOs. UBOs 
are found in almost all children with NF1, but reports on whether their volume and number 
increases or decreases with age are inconsistent (Gill et al., 2006; Griffiths et al., 1999; Kraut 
et al., 2004). A few studies have used diffusion tensor imaging (DTI) to characterize white 
matter microstructure and integrity of UBOs by measuring the degree and directionality 
of diffusivity. Higher apparent diffusion coefficient (ADC) and (radial) diffusivity values 
and lower fractional anisotropy (FA) values have been found in UBOs compared to normal 
appearing white matter (Ertan et al., 2014; van Engelen et al., 2008). These findings can be 
explained by myelin deficiency and axonal damage. An increase in brain volume is observed 
in children with NF1, which was found to be due to increases in white matter volume (Said 
et al., 1996; Steen et al., 2001), gray matter volume (with an increased gray to white matter 
ratio especially in younger subjects (Moore et al., 2000)), or both gray and white matter 
volume (Karlsgodt et al., 2012). These volume increases involve temporal, parietal, occipital, 
and frontal regions (Duarte et al., 2014; Greenwood et al., 2005; Pride et al., 2014). In addition, 
the corpus callosum seems larger in cases compared to controls, which has been found in 
children with NF1 as well as adults, marking it as a robust finding for NF1 (Duarte et al., 2014; 
Moore et al., 2000; Violante et al., 2013; Wignall et al., 2010). In addition to the investigation 
of UBOs, DTI studies have been used to study microstructural integrity in NF1 more broadly. 
Increased ADC values (Ertan et al., 2014; Nicita et al., 2014; van Engelen et al., 2008) and 
decreased FA values (Ertan et al., 2014; Ferraz-Filho et al., 2012) are found widespread across 
the brain. Karlsgodt et al. also found increased radial diffusion, which may be explained 
by decreased myelination or axonal packing density (2012). Differences in radial diffusivity 
have also been observed at the genu and anterior body of the corpus callosum (Wignall et 
al., 2010). The change in corpus callosum size and connectivity observed in NF1 may have 
functional importance, as they have been associated with academic achievement and visual-
spatial and motor skills (Moore et al., 2000).
Three fMRI studies have investigated visual-spatial processing in subjects with NF1, and 
one study investigated phonologic processing (Table 7). During visual-spatial processing, 
decreased activation in the primary visual cortex was found for individuals with NF1 
compared to controls (Clements-Stephens et al., 2008), although an earlier study reported 
contrasting findings of increased posterior (occipital) cortex activation relative to lateral/
inferior frontal activation (Billingsley et al., 2004). A later study did confirm that both children 
and adults with NF1 showed deficient activation of the low-level visual cortex during tasks 
specifically designed to activate magnocellular and parvocellular pathways (Violante et 
al., 2012). During such magnocellular-biased stimulation, NF1 patients did not deactivate 
regions belonging to the brain default-mode network as would be expected during 
cognitively demanding tasks (Violante et al., 2012).
The tumor growth suppressor genes tuberous sclerosis 1 (TSC1) and tuberous 
sclerosis 2 (TSC2) code for the hamartin and tuberin proteins, respectively. Mutations in 
either TSC1 or TSC2 disrupt the function of the GTPase-activating protein (GAP) complex 
formed by these proteins that regulates mTOR signaling. The neurocutaneous syndrome 
tuberous sclerosis complex (TSC), characterized by benign hamartomas in multiple organ 
systems, is caused primarily by these mutations. In the brain, the hamartomas manifest as 
subendymal giant cell astrocytomas, subendymal nodules (SEN), and tubers. Tubers show 
disrupted cortical architecture and contain a number of atypical cells. For TSC, structural MRI 
and DTI studies have been conducted investigating both typical neuropathological lesions, 
especially tubers, and normal-appearing brain matter (Table 7). A consistent imaging 
determinant of the cognitive phenotype in TSC has not been established. Findings of an 
inverse correlation of tuber number and cognitive functioning have not been consistent 
(Ridler et al., 2004). Tuber/brain proportion may be a better predictor of IQ than tuber load, 
although the age of seizure onset in patients seemed to predict cognitive functioning best 
(Jansen et al., 2008b). However, abnormal brain structure and connectivity unrelated to 
tubers are likely also important factors contributing to the neurobehavioral abnormalities 
in TSC. Decreased white matter volume of major intrahemispheric tracts has been found in 
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adults with TSC compared to age-matched controls, as has a decrease of gray matter volume 
in several cortical and subcortical structures (Ridler et al., 2001; Ridler et al., 2007). Reduced 
volume in the cerebellum has been associated with tuber-associated loss of the underlying 
parenchyma (Jurkiewicz et al., 2006; Marti-Bonmati et al., 2000). Reduced cerebellar volume 
was observed in all cerebellar regions in a more recent study, with strongest volume 
reductions in patients with a mutation in TSC2 (Weisenfeld et al., 2013). The finding of 
reduced cerebellar volume is in line with mouse models showing cerebellar involvement 
in TSC (Reith et al., 2011). White matter abnormalities are another typical finding in TSC. 
DTI studies generally report increased ADC values and decreased FA values in individuals 
with TSC compared to controls, in tubers and white matter lesions, but also in other white 
matter portions (Table 7). Compared to contralateral white matter or white matter in control 
subjects, increased ADC values were found in cortical tubers, and higher ADC and lower 
FA values were found in white matter lesions (Piao et al., 2009). A recent study also found 
increased radial diffusivity values and decreased FA values in cortical tubers and white 
matter lesions (Dogan et al., 2015). Hypomyelination, gliosis, and heterotopic cells may lead 
to ADC and FA changes observed in such lesions (Alexander et al., 2007). Abnormalities have 
also been reported in normal-appearing white matter in individuals with TSC compared 
to control groups. Decreased FA and increased ADC, especially in corpus callosum and 
internal and external capsules, have been reported repeatedly (Krishnan et al., 2010; Peters 
et al., 2012; Simao et al., 2010). A recent whole-brain analysis of white matter connectivity 
showed that increased radial diffusivity exists throughout the brains of TSC patients and 
that interhemispheric connectivity is decreased (Im et al., 2015).
The methyl CpG binding protein 2 gene (MECP2) is located on the short arm of 
chromosome X (Xq28) and codes for the protein MECP2. MECP2 acts as a modifier of gene 
expression and is highly expressed in the brain. Mutations in MECP2 are the cause of Rett 
syndrome, a disorder primarily affecting female patients. Brain weight is reduced in Rett 
syndrome, particularly that of cerebral hemispheres. Although the anatomical basis for 
this reduction is not completely clear, it has been suggested that it is caused by defective 
neuronal maturation for which MECP2 is essential, rather than by atrophy (Armstrong, 2005). 
Only few imaging studies have been conducted in series of patients with Rett syndrome 
(Table 7). All investigated brain structure in girls. These studies confirmed a wide-spread 
reduction in cerebral white and gray matter volumes, the latter most pronounced in 
subcortical nuclei including the caudate nucleus and in prefrontal, posterior-frontal, and 
anterior-temporal (Reiss et al., 1993; Subramaniam et al., 1997) and parietal regions (Carter et 
al., 2008). Using DTI, evidence of reduced white matter integrity was found in frontal regions, 
corpus callosum, and internal capsule. FA was also reduced in the superior longitudinal 
fasciculus, but only in patients who had little or no ability to speak (Mahmood et al., 2010).
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Discussion
In this review, we set out to summarize the literature on imaging genetics studies in 
neurodevelopmental disorders. This being a very broad field, we focused on three most 
frequent and often comorbid disorder spectra, ADHD, ASDs, and selected forms of ID, and 
we only considered MRI-based imaging genetics studies. Further restriction of the search 
space was achieved by focusing on genes harboring common genetic variants with the most 
consistent evidence for association with ADHD and ASDs, and by selecting five relatively 
common ID disorders with frequent ADHD/ASDs comorbidity implicating single genes. 
The review was driven by the wish to learn more about the mechanisms by which genetic 
factors influence disease-related behavior specific to the individual disorders and their 
clinical overlap.
At the level of the individual genes, the most extensively studied candidate gene is the 
SLC6A4 (5HTT) gene encoding the serotonin transporter (associated with both ADHD and 
ASDs). Limitations regarding power of individual studies and hypothesis-driven designs 
aside, the fMRI-based imaging genetics literature on this gene does show a remarkably 
coherent picture of functional genetic variation leading to hyperactivation of the amygdala 
and connected areas in conjunction with functional dysconnectivity amongst those areas. 
However, since much of this research has been performed in healthy individuals only, the 
link to cognition in ADHD and ASD patients needs further investigation. Findings for SLC6A3 
(DAT1) and DRD4, which have also been studied quite often already, still lack the consistency 
observed for SLC6A4 (5HTT), partly due to the much less restricted focus on a particular 
cognitive domain, and thus more ‘patchy’ literature.
The most consistent findings observed in all of the imaging genetics literature reviewed 
here are for the different genetic variants for ID. This is likely linked to the severity of 
the variants present in the patients, with those for ID being rare and most damaging. 
Consistent are finding for increased caudate volume and reduced cerebellum due to FMR1 
mutations, and for T2 hyperintensities and increased brain volume in patients carrying 
NF1 mutations. However, in terms of finding overlap between different forms of ID, we find 
that conclusiveness of studies still is limited, as most concentrated on a limited set of (often 
non-overlapping) features. Tubers and T2 hyperintensities have received a lot of attention 
in studies of TSC and NF1, for example, although reports on their contribution to cognitive 
deficits are inconsistent. In recent years, DTI studies have produced evidence that tissue 
microstructure and white matter connectivity patterns are affected in all ID disorders, and 
often in widespread brain areas. Effects on brain volumes are also often widespread, but 
can go in opposite directions, with reductions in total brain volume in Rett, but increases in 
NF1. One may conclude that while altered (structural) connectivity is likely to play a role in 
ID etiology, MRI at its current resolution (1.5 – 4 Tesla), does not allow a sufficiently detailed 
view on the brain to understand the neuroanatomical overlap between disorders (Williams 
and Casanova, 2011).
Similar to the situation amongst the ID disorders, there seems to be little overlap between 
the findings for different genes in ADHD or ASD. This is likely to be heavily influenced by the 
strong focus on regions and cognitive domains of interest (consistent with the limited power 
of many of the studies published to date). Some overlap is seen, e.g., for DAT1 and DRD2, 
both of which have been studied for their effects on striatal phenotypes. (Appropriately 
powered) brain-wide studies and phenome-wide association study (PheWAS)/RDoc-like 
approaches (Cuthbert and Insel, 2013; Pendergrass et al., 2011) would help to determine, 
whether the apparent specificity of brain phenotypes for individual genes is real. An 
important observation is that gene expression does not predict/limit the location of effects 
of a genetic factor ( e.g., SLC6A3/DAT1 shows effects outside of its region of gene expression), 
most likely through effects on structural and/or functional connectivity.
Did the reported imaging genetics findings help us understand the comorbidity 
between different neurodevelopmental disorders? This would be expected, since several 
of the genes implicated in ID, ASD, and ADHD function in the same or overlapping molecular 
networks (Poelmans et al., 2011; Rudie et al., 2012; van Bokhoven, 2011). However, the 
limited availability of genes investigated through imaging genetics to date might bias our 
interpretation of the data. In ID, the genes studied thus far are related to mTOR signaling, RAS 
signaling, and translation repression/regulation, thus functioning in very ‘basal’ cell signaling 
pathways in comparison to the genes investigated for ADHD, which regulate the dopamine 
and serotonin neurotransmitter systems specifically. This could explain the much more 
widespread cell proliferation/migration defects observed in ID, whereas in ADHD defects 
seem more specific, e.g. limited to individual neurotransmitter systems and or affecting 
cell-cell communication more acutely. ASD seems to be intermediate between the other 
two disorder spectra, but more studies are necessary to substantiate this view. What is 
already very clear from the available studies, is that the associations of genetic factors are 
with behavioral traits, and not with the disorders directly (e.g., (Hoogman et al., 2011). Some 
level of pleiotropy is highly likely, which may also form the basis of comorbidity between 
the neurodevelopmental disorders.
In general, we found the existing imaging genetics literature for the three 
neurodevelopmental disorders of our interest lacking in several aspects. Firstly, despite 
our focus on well-supported candidate genes, several of the selected genes had not been 
studied at all with MRI in humans. In several additional cases, only single studies were 
available for different MRI modalities (sMRI, DTI, fMRI), thus limiting the conclusiveness 
of the reported findings. Secondly, most imaging genetics studies, especially the earlier 
ones, suffer from being underpowered. The small sample sizes are severely hampering the 
generalization of findings to the population the samples are meant to represent (Button et 
al., 2013). Although the endophenotype concept postulates that measures, which mediate 
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a genetic effect on behavior (including some of those investigated in the imaging genetics 
studies), should have stronger effect sizes for gene effects than the behavioral/disease 
measures (Gottesman and Gould, 2003), the sample size of most studies would still have 
to be considered too small. The problem of limited number of samples becomes evident 
from e.g. a recent review by Strike and coworkers. They showed that at the most lenient 
threshold for significance (α = 0.05) studies with at least 1,566 participants would be needed 
to achieve the canonical 80% power threshold to detect a reasonable effect size (0.5% of 
the phenotypic variance explained) (Strike et al., 2015). Furthermore, recent work raises 
doubts about whether larger effect sizes can really be expected for neuroimaging (endo)
phenotypes, at least for volumetric MRI measures (Franke et al., 2016; Hibar et al., 2015b). 
Major challenges are the large inconsistency across genetic variants tested and genotype 
groups compared, differences in study designs and imaging modalities, and the fact that data 
acquisition and analysis protocols usually were not standardized across studies. Additionally, 
we observed large inconsistency across studies in the way how genotypic effects were 
reported and recommend a standardized way of reporting results, e.g. including at least 
effect estimates and standard errors. Nevertheless, meta-analyses are strongly needed in 
order to enable definition of robust findings and realistic effect estimates. Therefore, meta-
analytic studies would be beneficial for those brain measures covered by multiple studies, 
as it was shown for the effect of the serotonin transporter 5HTTLPR on amygdala activation 
(Murphy et al., 2013). Thirdly, to interpret observed links between genes, brain, and behavior 
properly, one needs to determine, whether a brain (endo)phenotype is really intermediate 
between a genetic factor and a behavioral outcome, or if it is only an epiphenomenon 
unrelated to the behavior of interest (Kendler and Neale, 2010; Preacher and Hayes, 2008). 
Only few studies have really studied this, e.g. by mediation analysis including environmental, 
behavioral, and/or physiological variables (Klumpers et al., 2014; van der Meer et al., 2015), 
by applying combinations of different imaging modalities (Kobiella et al., 2011; Zhang et al., 
2015b), or by using causal modeling (Sokolova et al., 2015). The results of those studies show 
that only part of the brain regions showing genotype effects actually do mediate between 
genetics and behavior, proving the importance of such multilevel investigations. Fourthly, 
age effects might also be of importance, but have been neglected in most studies. Our 
own work has shown, for example, that the risk factor for ADHD in DAT1 differs between 
children and adults, which resulted in effects of the 9-6 VNTR haplotype on caudate nucleus 
volume only in adult patients (Onnink et al., 2016). Age effects have also been observed for 
the 5-HTTLPR variant (Wiggins et al., 2014a). Fifthly, current brain imaging genetics studies 
often suffer from additional limitations, such as the low ethnic diversity, as most studies 
included cohorts of only Caucasian origin, and gender imbalance, especially in studies of 
childhood ADHD and ASD that showed an over-representation of males.
An important additional aspect is that this review enabled us to look at the overlap 
between studies in healthy individuals and those in patients (case-control designs). An 
interaction between genetic variant and diagnosis was indeed observed in some studies 
(e.g. (Durston et al., 2008; Monuteaux et al., 2008; Wiggins et al., 2012b; Wiggins et al., 2014b). 
With the available limited amount of evidence it is hard to judge though, whether this is 
a true difference between patients and healthy individuals, or whether it is simply due to 
power restrictions in the samples investigated. Recent genome-wide studies investigating 
the genetics of brain structure as part of the ENIGMA Consortium (Thompson et al., 2014) 
suggest that effects are largely similar for healthy individuals and those with a psychiatric 
disorder (Hibar et al., 2015b; Stein et al., 2012). This means, that brain imaging genetics 
studies with healthy participants can be very informative in discovering related brain 
correlates and in understanding the biological mechanisms leading to diseases of interest.
Did we overlook important literature through the choices made in our review? We did 
restrict our selection of genes to study. For ASD, we did not include genes harboring rare 
genetic variants, while those might result in stronger effect sizes, as observed for the ID 
genes. However, most of the rare variants linked to ASD have only recently been identified, 
making the availability of imaging genetics studies (with 10 or more cases) unlikely. A similar 
argument holds true for our selection of ID genes, where the imaging genetics literature 
is largely focused on the relatively common disorder subtypes we included in our study. 
We also restricted our search to MRI-based studies, following a first screen of the literature 
showing that this was the predominant method used for imaging genetics studies of the 
neurodevelopmental disorders. Nevertheless, for several genes/variants, also other imaging 
modalities have been employed, which may provide additional insights. EEG and MEG offer a 
much higher time resolution than MRI, and may allow investigation of genetic influences on 
neuronal functioning and oscillation patterns. PET can provide information on (acute) protein 
availability. Especially the integration of modalities in the study of individual participants 
can provide deeper insights into mechanisms (e.g. (Kobiella et al., 2011)). Moreover, future 
studies might want to investigate additional comorbid neurodevelopmental disorders, such 
as conduct disorder (CD) or obsessive-compulsive disorder (OCD), once robust association 
of genetic variants with these disorders has been established and investigated in imaging 
genetics studies.
To summarize, despite the considerable numbers of imaging genetics studies in 
neurodevelopmental disorders available for review, this field of research should still 
be considered in its early stages. More genes need to be studied, and individual genes 
need to be investigated in larger samples, with more hypothesis-generating brain- and 
phenome-wide methods. Gene-environment interactions and age effects should be taken 
into account. While we see consistent findings for single genes and variants, gene-wide 
and gene-set analyses, with polygenic scores explaining more phenotypic variance and 
thus improving study power (Bralten et al., 2011), are likely to take the stage in the future. 
Several early examples reviewed here already show the promise of this work (e.g. (Nikolova 
et al., 2011; Passamonti et al., 2008; Stice et al., 2012). As the genes in such sets often show 
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different gene expression patterns, (structural and functional) connectivity patterns are 
likely the best brain phenotypes to be studied with such approaches (see above). In the 
future, we are also likely to see studies approaching imaging genetics in a different way, by 
asking the question, whether genes contributing to brain structure/function observed in 
hypothesis-free, genome-wide approaches also contribute to disease-related phenotypes 
(Franke et al., 2016). First studies of this kind have been published for schizophrenia (Franke 
et al., 2016) and obsessive compulsive disorder (OCD) (Hibar et al., 2015a), based on results 
of findings from the ENIGMA GWAS of brain structure (Hibar et al., 2015b; Stein et al., 2012). 
To successfully map the biological pathways from gene to disease, imaging genetics studies 
need to be combined with complementary approaches (Klein et al., in press). Recent 
examples for this are provided by studies by our own group, in which we investigated 
effects of ADHD-associated genes for their effects in the fruit fly Drosophila melanogaster 
(Klein et al., 2015; van der Voet et al., 2016), as well as the study by Jia and coworkers, in which 
the authors identified a genetic variant significantly associated with dysfunctional reward, 
a cognitive and affective deficit frequently observed in ADHD, then verified gene function 
in locomotion in the fruit fly model (Jia et al., 2016). In conclusion, although still in its early 
stages, results from studies available thus far already confirm that the imaging genetics 
approach is suitable to provide more insight into the link between genes, the brain, and 
behavior in neurodevelopmental disorders.
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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common and often persistent 
neurodevelopmental disorder. Beyond gene-finding, neurobiological parameters, such 
as brain structure, connectivity, and function, have been used to link genetic variation 
to ADHD symptomatology. We performed a systematic review of brain imaging genetics 
studies involving 62 ADHD candidate genes in childhood and adult ADHD cohorts. Fifty-one 
eligible research articles described studies of 13 ADHD candidate genes. Almost exclusively, 
single genetic variants were studied, mostly focussing on dopamine-related genes. While 
promising results have been reported, imaging genetics studies are thus far hampered by 
methodological differences in study design and analysis methodology, as well as limited 
sample sizes. Beyond reviewing imaging genetics studies, we also discuss the need for 
complementary approaches at multiple levels of biological complexity and emphasize the 
importance of combining and integrating findings across levels for a better understanding 
of biological pathways from gene to disease. These may include multi-modal imaging 
genetics studies, bioinformatic analyses, and functional analyses of cell and animal models.
Keywords: ADHD, brain imaging genetics, endophenotype, candidate genes, animal models
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder 
(Faraone et al., 2015). The world-wide prevalence has been estimated at 5% in children 
and between 2.5 and 4.9% in adults (Polanczyk and Rohde, 2007; Simon et al., 2009). 
Approximately 55-75% still carry the diagnosis in adulthood or remit only partially displaying 
several impairments also in adulthood (Faraone et al., 2006). ADHD is characterized by age-
inappropriate levels of inattention and/or hyperactivity and impulsivity (Frances, 2000), but 
the clinical phenotype is heterogeneous (American Psychiatric Association, 2013; Frances, 
2000). Severity level and presentation of ADHD can change during a person’s lifetime, 
with adult patients displaying less obvious symptoms of hyperactivity and impulsivity 
(Buitelaar et al., 2011; Haavik et al., 2010). The phenotypic heterogeneity of the disorder 
is apparent from a large diversity of psychiatric co-morbidities, frequently seen both in 
children (Biederman and Faraone, 2005; Gillberg et al., 2004; Lycett et al., 2015; Rappley, 
2005; Reinhardt and Reinhardt, 2013) and in adults (McGough et al., 2005; Miller et al., 2007; 
Ollendick et al., 2008; Sobanski et al., 2007; Wilens et al., 2009).
Identification of ADHD candidate genes
The etiology of ADHD is strongly influenced by genetic factors, as demonstrated by twin 
and adoption studies (Burt, 2009; Faraone and Mick, 2010; Kotte et al., 2013; Thapar et al., 
2013). Heritability estimates range between 70 and 90% (Faraone and Mick, 2010; Larsson 
et al., 2013b). Despite this substantial heritability, identification of ADHD risk genes has 
been challenging (Franke et al., 2009; Gizer et al., 2009). One reason for this may be that 
ADHD has a complex, polygenic genetic background, in which multiple genetic variants 
(many of them with small effects) contribute to the etiology of the disorder in most patients. 
Although a substantial fraction of ADHD etiology is due to genes, many environmental risk 
factors and potential gene-environment interactions are also linked with an increased risk 
for the disorder (Banerjee et al., 2007; Han et al., 2015). Furthermore, it has been shown that 
persistent ADHD and its paediatric form are genetically linked, but overlap only partially 
(Chang et al., 2013).
Multiple molecular genetic studies, employing mostly hypothesis-driven and some 
hypothesis-free approaches, have been used to identify ADHD risk genes. Because of 
the high prevalence of ADHD in the population, the search for genetic factors has mainly 
focused on common genetic variants, which generally have small effect sizes (Li et al., 2014; 
Neale et al., 2010b).
While many of the individual hypothesis-driven, candidate gene-based association 
studies have been underpowered, meta-analysis of those studies identified significant 
associations for common genetic variants in several candidate genes (Faraone et al., 2005; 
Gizer et al., 2009; Li et al., 2006a). Those are the dopamine and serotonin transporter encoding 
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genes, SLC6A3/DAT1 and SLC6A4/5HTT, genes coding for the D4 and D5 dopamine receptors, 
DRD4 and DRD5, a serotonin receptor, HTR1B, and the gene for the synaptosomal-associated 
protein 25, SNAP25. Some additional genes (encoding dopamine beta-hydroxylase [DBH], 
adrenoceptor alpha 2A [ADRA2A], tryptophan hydroxylase 2 [TPH2], and monoamine oxidase 
A [MAOA]) were found suggestively associated with ADHD in meta-analyses (Faraone et al., 
2005; Gizer et al., 2009; Li et al., 2006a). In addition, an in depth analysis of 51 genes in a 
European multisite sample of 674 families with ADHD combined type probands, collected for 
the International Multisite ADHD Gene project (the IMAGE project), identified associations 
with ADHD candidate genes, such as ADRAB2, DAT1, DRD4, TPH2, and MAOA (Brookes et al., 
2006a). For more extensive reviews of ADHD candidate genes see references (Banaschewski 
et al., 2010; Faraone and Mick, 2010; Franke et al., 2012; Hawi et al., 2015; Li et al., 2014).
Genetic linkage studies provided a first possibility to perform hypothesis-free genetic 
studies in the early 2000s. However, gene identification through linkage analysis has been 
limited (Banaschewski et al., 2010). A meta-analysis of seven linkage studies revealed a locus 
on the short arm of chromosome 16 to be relevant for ADHD etiology (Zhou et al., 2008). 
An interesting candidate gene in the locus is cadherin 13 (CDH13), a gene also found in the 
top-ranks of several genome-wide association studies (Rivero et al., 2015). Linkage analysis 
also identified the latrophilin 3 (LPHN3) gene on chromosome 4, which was subsequently 
confirmed through association testing (Arcos-Burgos et al., 2010; Ribases et al., 2011). 
Genome-wide association studies (GWAS) of common single nucleotide polymorphisms 
(SNPs) have been the main hypothesis-free approach to studying the genetics of ADHD 
during the last ten years. However, with nine GWASs on ADHD and ADHD-symptoms 
published to date (Hinney et al., 2011; Lasky-Su et al., 2008b; Lesch et al., 2008; Mick et al., 
2010; Neale et al., 2008; Neale et al., 2010a; Sanchez-Mora et al., 2014; Stergiakouli et al., 
2012; Yang et al., 2013), no locus has yet been identified that meets genome-wide levels 
of significance (Li et al., 2014; Neale et al., 2010b), nor has meta-analysis of these studies 
provided one (Van Hulzen et al., 2016). An interesting genome-wide approach to identify 
ADHD genes has been the analysis of overlap with other psychiatric disorders. A cross-
disorder GWAS across five main neuropsychiatric disorders (schizophrenia [SCZ], bipolar 
disorder [BD], autism spectrum disorder [ASD], major depressive disorder [MDD], and 
ADHD) identified five genome-wide significant findings, four of which - in/near the genes 
ITIH3, AS3MT, CACNA1C, and CACNB2 - were shared with ADHD (Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013).
Following promising results in other psychiatric disorders (Cruceanu et al., 2013; Cukier et 
al., 2014; Kerner et al., 2013; Purcell et al., 2014), studies of rare variants were also performed 
for ADHD and were successful in identifying genetic variants related to the disorder (Elia et 
al., 2010; Lesch et al., 2011; Ramos-Quiroga et al., 2014; Williams et al., 2012; Williams et al., 
2010; Yang et al., 2013). Genome-wide analysis of (rare) copy number variants (CNVs) showed 
an enrichment of rare CNVs in patients with ADHD (Williams et al., 2010), and implicated 
the genes CHRNA7 and NPY in ADHD etiology (Lesch et al., 2011; Williams et al., 2012), as 
well as genes encoding several glutamate receptors (Akutagava-Martins et al., 2014; Elia et 
al., 2012), and regions on 15q11-15q13 (Valbonesi et al., 2015) and 16p13.11 (Williams et al., 
2010). The picture emerging from those initial studies is that the rare variant contribution 
of ADHD genetics is highly heterogeneous, similar to the common variant contribution. 
Nevertheless, given the success of CNV studies, exome and whole-genome sequencing 
are now being used, allowing the identification of rare single nucleotide variants and small 
insertions/deletions contributing to ADHD etiology. A first study indeed found enrichment 
of rare variants in a predefined set of 51 candidate genes in adult patients with persistent 
ADHD (Demontis et al., 2016).
The genetic factors associated with ADHD are distributed across the genome, but tend 
to be enriched within specific functional categories. By clustering ADHD-related genes 
within functional networks or pathways, several biological processes have been shown to 
be involved in the etiology of the disorder. Top-findings of five GWASs in ADHD showed 
convergence on the biological process of neurite outgrowth (Poelmans et al., 2011). 
Comparable enrichment analyses revealed that most significantly enriched functions 
for the ADHD-GWAS association signals were related to nervous system development, 
neuron projection morphogenesis, oxogenesis, cell-cell communication, glutamatergic 
synapse/receptor signalling, and multicellular organismal development (Hawi et al., 2015) 
or neuron projections and synaptic components (Yang et al., 2013), which is consistent with 
a neurodevelopmental pathophysiology of ADHD. These findings were strengthened by 
results from a recent study, that used two GWAS datasets to identify pathways associated 
with ADHD by applying six pathway analysis methods (Mooney et al., 2016). Cross-method 
convergent results revealed a number of brain-relevant pathways, such as RhoA signaling, 
glycosaminoglycan biosynthesis, fibroblast growth factor receptor activity, and pathways 
containing potassium channel genes (Mooney et al., 2016). Another study revealed that CNVs 
involved in ADHD converge on biologically meaningful gene clusters related to ion channel 
pathways, organonitrogen compound catabolic processes, and transmembrane transport 
(Thapar et al., 2015). A combined analysis of ADHD candidate genes, derived both from 
SNP-based and CNV-based studies, showed that genes involved in biological processes, 
such as synaptic transmission, catecholamine metabolic processes, G-protein signalling 
pathways, and cell migration were over-represented among the top-findings of such studies 
(Cristino et al., 2014). More generally, the genome-wide analysis of five major psychiatric 
disorders (also including ADHD), supported a role for calcium channel signalling genes for 
all five disorders, suggesting that genetic variation in calcium-channel activity genes can 
have pleiotropic effects in the development of psychopathology (Cross-Disorder Group of 
the Psychiatric Genomics Consortium, 2013).
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Brain correlates of ADHD
The effects of ADHD genetic risk factors on (aberrant) behaviour are likely to be mediated 
through effects on cell biology and brain system development and functioning. Several 
aspects of brain development, structure, function, and connectivity have been found 
altered in ADHD (Cortese et al., 2012; Glahn et al., 2010; Greven et al., 2015; Hoogman et al., 
submitted; Mostert et al., 2016; Onnink et al., 2015; Shaw et al., 2007b; Shaw et al., 2012; van 
Ewijk et al., 2012).
Two indirect neuroimaging techniques that have been used in imaging (genetics) studies 
in ADHD are positron emission tomography (PET) and single photon emission computed 
tomography (SPECT). Both are based on the measurement of a radionuclide’s decay, during 
which a positron or a γ-ray is emitted, generating photons. The high sensitivity and limitless 
penetration depth of PET and SPECT enable imaging to examine metabolic activity, cerebral 
perfusion, neurotransmitter turnover, and receptor binding potentials within examined 
brain regions or receptor systems (Rahmim and Zaidi, 2008). Until now, the majority of 
recent PET studies using ADHD samples have focused on examining differences and changes 
in neurotransmitter binding and receptor density (Zimmer, 2009). In vivo imaging of the 
dopamine transporter (DAT) is particularly relevant for ADHD, given that DAT is the target 
of stimulant medications and, subsequently, a target protein for studies of pathophysiology. 
PET and SPECT studies have been useful in comparing striatal DAT availability between ADHD 
patients and controls (Jucaite et al., 2005; Ludolph et al., 2008; Spencer et al., 2005). A meta-
analysis of nine PET studies revealed that striatal DAT density was 14% higher in patients 
with ADHD compared to healthy controls (Fusar-Poli et al., 2012). Besides that, striatal density 
in people with ADHD seems to depend on previous psychostimulant exposure, with lower 
density in drug-naive subjects and higher density in previously medicated patients (Fusar-
Poli et al., 2012). In addition to studies exploring DAT density and binding, Volkow and co-
workers examined postsynaptic dopamine receptor availability and found that medication-
naïve adults with ADHD showed decreased dopamine D2/D3 receptor availability in the left 
caudate compared to healthy controls. Following administration of methylphenidate (MPH), 
the ADHD group demonstrated decreased dopamine activity in the caudate compared with 
controls (Volkow et al., 2007). One SPECT study investigated D2 receptor availability as a 
function of MPH therapy in ADHD and concluded that D2 receptor availability is significantly 
reduced in patients with ADHD in all four regions of the striatum (Ilgin et al., 2001).
Structural magnetic resonance imaging (sMRI) allows to noninvasively characterize the 
structure of the human brain. With the help of sMRI, the different magnetic properties of 
brain tissues are used to non-invasively map the spatial distribution of these structural 
properties of the human brain. Thereby, the different brain tissues (grey and white matter) 
and cortical and subcortical structures of the brain can be accurately mapped, and different 
aspects of brain structure can be quantified and compared. In general, sMRI has pointed to 
total brain volume and total grey matter reductions up to 3-5% in ADHD patients compared 
to controls (Castellanos et al., 2002; Greven et al., 2015; Valera et al., 2007). To investigate, 
whether these reductions are global or regional, several brain regions of interest (ROIs) have 
been studied. A meta-analysis reported significant volume differences in cerebellar regions, 
total and right cerebral volume, right caudate, and frontal brain areas (Valera et al., 2007). To 
investigate the most prominent changes in grey matter intensity, detected by using voxel-
based morphometry (VBM) analyses, four meta-analyses have been performed to date 
(Ellison-Wright et al., 2008; Frodl and Skokauskas, 2012; Nakao et al., 2011). Most consistently, 
grey matter reductions in the ventrolateral prefrontal/insular-striatal regions, such as the 
right insula, putamen, globus pallidus, and caudate nucleus have been described in ADHD 
patients (Ellison-Wright et al., 2008; Frodl and Skokauskas, 2012; Nakao et al., 2011; Norman 
et al., 2016). A recent study could also show that participants with ADHD had significantly 
smaller grey matter volume in five clusters located in the precentral gyrus, medial and 
orbital frontal cortex, and (para)cingulate cortices (Bralten et al., 2015). Unaffected siblings 
of patients with ADHD showed intermediate volumes, significantly different from controls 
in four of these five clusters (all except the precentral gyrus), suggesting that the volume 
reductions are unlikely to be a consequence of disease, but may rather contribute to ADHD 
etiology (Bralten et al., 2015).
Brain differences observed in ADHD have been hypothesized to be partly attributable 
to a delay in maturational processes (Castellanos et al., 2002). Indeed, the few longitudinal 
imaging studies of ADHD patients support this hypothesis: for CT measures, Shaw and 
co-workers investigated growth trajectories of different points of the cortex and reported 
that cortical thickness maturation in participants with ADHD lagged behind that of healthy 
controls of approximately three years throughout the cerebrum, but most prominent in 
the PFC (Shaw et al., 2007a). In addition, also the SA developmental trajectory was found 
to be delayed in ADHD, especially in the right PFC (Shaw et al., 2012). Support for the 
developmental delay hypothesis in ADHD also came from cross-sectional meta-analyses 
of VBM studies, which found increasing age associated with more normal grey matter values 
in affected brain areas (Frodl and Skokauskas, 2012). The recent large mega-analysis of 
subcortical regions across 60 years of the lifespan by the Enhancing NeuroImaging Genetics 
Through Meta Analysis (ENIGMA) ADHD Working Group extended the delayed maturation 
theory also to the volumes of most subcortical regions (Hoogman et al., submitted). First 
of all, they observed significant smaller volumes for the nucleus accumbens, amygdala, 
caudate, hippocampus, putamen, and intracranial volume (ICV) in ADHD cases relative 
to controls (Hoogman et al., submitted). Age analyses suggested different brain volume 
trajectories across age for patients and controls. These results from the cross-sectional 
lifespan analyses were consistent with the early maturation delay hypotheses of ADHD 
and hint at delays in brain growth and degeneration across the lifespan (Hoogman et al., 
submitted; Rubia, 2007).
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Next to volumetric differences observed in grey matter, white matter structure has also 
been found to be altered in ADHD, leading to a potential disorganization of the brain’s 
connectivity. Diffusion tensor imaging (DTI) enables non-invasive investigations of the 
macrostructural integrity and orientation of white matter fibre bundles. DTI measures the 
directional diffusion of water molecules along neuronal membranes, allowing to map white 
matter pathways within the brain. One measure frequently derived from DTI is fractional 
anisotropy (FA). Anisotropy indicates that diffusion occurs in a directional manner, whereas 
isotropy indicates diffusion in all directions. Other measures derived from DTI include 
mean diffusivity (MD), which is an average of axial diffusivity (AD) and the perpendicular 
diffusivities, and radial diffusivity (RD), which is the average of perpendicular diffusivities, 
the mode of anisotropy, which is sensitive to crossing fibres, and the apparent diffusion 
coefficient, which indicates the magnitude of diffusion (Le Bihan, 2003; Le Bihan et al., 2001; 
Yoncheva et al., 2016). In a meta-analysis comparing DTI findings between patients with 
ADHD and healthy controls five areas with disturbed microstructural integrity in people 
with ADHD were highlighted, located in white matter tracts subserving the fronto-striatal-
cerebellar neurocircuitry (van Ewijk et al., 2012). Most consistently, studies reported white 
matter anomalies in the corpus callosum in childhood ADHD (van Ewijk et al., 2014) and 
adult ADHD (Dramsdahl et al., 2012; Onnink et al., 2015). Although the exact neurobiological 
meaning is not fully understood, reduced FA in the corpus callosum of adult patients with 
ADHD was driven by changes in RD rather than AD, suggesting that aberrant myelination is 
a pathophysiological factor in adult ADHD (Onnink et al., 2015). However, replication from 
longitudinal studies is still lacking, and the differences between patients and controls seem 
to be widespread and heterogeneous across studies (van Ewijk et al., 2012).
A method to investigate potential changes in brain activity is functional magnetic 
resonance imaging (fMRI). FMRI is primarily sensitive to the oxygenation of the blood, the so-
called blood-oxygen-level-dependent (BOLD) signal. It measures brain function based on the 
premise that active cells consume oxygen, thereby causing changes in blood oxygenation 
and subsequently leading to increased blood flow, although the exact link between cell 
activation, oxygen saturation, and blood flow is still under debate; for review see (Hillman, 
2014). Generally in fMRI, alterations in blood flow after a stimulus (e.g. a certain task) or 
during a resting state are measured. Comparing anatomical or functional brain measures 
in individuals with ADHD, their unaffected siblings, and healthy comparison subjects, is one 
of the best ways to examine the suitability of these neural markers as endophenotypes. 
With respect to functional brain studies, van Rooij and colleagues (2015c) recently reported 
a distinction in hemodynamic patters during a stop-signal task between patients with 
ADHD, their unaffected siblings, and control subjects, suggesting the familial nature of 
these activation patterns. Thus, inhibition-related neural activation could be considered as 
a valuable endophenotype for ADHD. Several reviews have provided excellent overviews 
of cognitive and brain (candidate) endophenotypes for ADHD (del Campo et al., 2012; Gallo 
and Posner, 2016; Rommelse et al., 2011). In accordance with those reports, dysregulation of 
structure and function of the fronto-subcortical-cerebellar pathways that control attention, 
response to reward, salience thresholds, inhibitory control, and motor behaviour are among 
the most promising endophenotype candidates, and task-based functional MRI studies in 
ADHD have largely focused on these neurocognitive domains. More specifically, fMRI studies 
using inhibitory control, working memory, and attentional tasks in patients with ADHD and 
healthy comparison subjects have shown underactivation of fronto-striatal, fronto-parietal, 
and ventral attention networks in the patients (Cortese et al., 2012). The fronto-parietal 
network mediates goal-directed executive processes, whereas the ventral attention network 
facilitates reorientation of attention towards salient and behaviourally relevant external 
stimuli. Meta-analyses of fMRI studies of inhibition and attention revealed that patients with 
ADHD have consistent functional abnormalities in two distinct domain-dissociated fronto-
basal ganglia networks. These include the inferior frontal cortex, supplementary motor 
areas, and anterior cingulate cortex (ACC) for inhibition and the dorsolateral prefrontal 
cortex (PFC), parietal, and cerebellar areas for attention processes (Hart et al., 2013). Studies 
using reward-processing paradigms reported reduced activation of the ventral striatum of 
participants with ADHD in the anticipation phase of reward relative to controls (Plichta and 
Scheres, 2014), and differences between patients and controls have also been observed 
during reward receipt (von Rhein et al., 2015). Additionally, a meta-analysis of fMRI studies 
of timing reported consistent reductions in activation in typical areas of timing, such as the 
left inferior frontal gyrus (IFG)/insula, cerebellum, and the left parietal lobe in ADHD patients 
relative to controls (Hart et al., 2012).
In resting state MRI (rs-fMRI), the temporal correlations in neural activity across 
anatomically disparate brain regions are analysed to examine functional connectivity 
based on spontaneous brain activity, neural organization, and circuit architecture. Rs-
fMRI studies of ADHD have mainly focused on neural circuits implicated in the disorder, 
especially the default-mode network (DMN), cognitive control network, and cortico-striato-
thalamo-cortical loops (Posner et al., 2014). It was shown that ADHD is associated with 
less-pronounced or absent anti-correlations between the DMN and the cognitive control 
network, lower connectivity within the DMN itself, and lower connectivity within the 
cognitive and motivational loops of fronto-striatal circuits (Posner et al., 2014). A recent 
study in a large sample of adult participants with ADHD and healthy controls, showed that 
functional connectivity in the executive control network, and to a lesser extent also the 
cerebellum network, was stronger in the ADHD group (Mostert et al., 2016). Additionally, 
hyperactivity/impulsivity symptoms were positively correlated with the connectivity 
strength in these networks (Mostert et al., 2016).
Functional near-infrared spectroscopy (fNIRS) measures concentration changes of 
oxygenated, deoxygenated, and total haemoglobin in brain haemodynamics by measuring 
the absorption of near-infrared light projected through the scalp (Gervain et al., 2011). 
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Thereby, fNIRS provides an indirect measure of neural activity based on changes in blood 
oxygenation due to metabolic processes within the cortex. Compared to fMRI, fNIRS is less 
sensitive to movement artefacts, and since the emitters and detectors can be worn in a 
cap, functional neural activity can be studied, while the participant is interacting with its 
environment. This makes fNIRS an ideal tool to study brain development, e.g. in children 
with ADHD (Vanderwert and Nelson, 2014). FNIRS has greater spatial resolution compared 
to event-related potential (ERP) or EEG techniques, however, since it is dependent on light 
penetration and reflection, fNIRS can only examine the cortical surface within 2-3 cm of the 
scalp (Vanderwert and Nelson, 2014). The majority of fNIRS studies on ADHD investigated 
children with the disorder. These studies particularly focused on alterations in PFC activity 
during different experimental paradigms, such as Stroop tasks (Negoro et al., 2010; Xiao et 
al., 2012), working memory tasks (Schecklmann et al., 2010), the Trail Making Test (Weber 
et al., 2005), or Go/NoGo paradigms (Inoue et al., 2012; Xiao et al., 2012); they consistently 
pointed towards an attenuated oxygen metabolism within the frontal lobe (Ehlis et al., 2014). 
Studies in adult ADHD patients suggest that this hypofunctionality is persistently observed 
throughout development (Ehlis et al., 2008; Schecklmann et al., 2013).
The functional brain imaging techniques electroencephalography (EEG) and 
magnetoencephalography (MEG) have also been used for the study of ADHD (genetics). 
EEG directly measures electrical activity from large populations of cells and therefore offers a 
very good temporal resolution, far superior to fMRI. However, it has a poor spatial resolution, 
as electric fields smear as they pass through the skull (Ahmad et al., 2016). Every electric 
field also has a magnetic field, which can be detected by MEG. The spatial resolution of MEG 
is slightly better compared to EEG, but MEG only measures information strictly from the 
sulci, thus it is more limited and misses information (van Diessen et al., 2015). The frequency 
bands mostly studied in ADHD are theta (θ), alpha (α), and beta (β), either individually, or 
compared to each other (such as theta/beta power or amplitude ratio). In a resting state, 
(lower frequency) θ band activity can reflect drowsiness or “cortical slowing”. The α band 
activity is usually observed during eyes closed conditions at rest, particularly in posterior 
brain regions, and it is negatively associated with central nervous system arousal. In contrast, 
β band activity generally accompanies mental activity and concentration. The θ/β power 
ratio has been proposed to capture the relative contributions of two relevant frequency 
bands for ADHD; however, the true functional significance of this measure remains 
unknown (Loo and Makeig, 2012). It has been reported that patients with ADHD exhibit 
increased fronto-central theta (θ) band activity and increased theta-to-beta (θ/β) power 
ratio during rest compared to non-ADHD controls (Loo and Makeig, 2012). While (limited) 
discriminant validity of these EEG measures for ADHD has been suggested, significant EEG 
heterogeneity also exists across ADHD-diagnosed individuals (Clarke et al., 2011). In addition 
to differences in frequency bands, event-related potential (ERP) studies explored various 
aspects of brain functioning in ADHD and identified a substantial number of ERP correlates 
of ADHD (Johnstone et al., 2013). Robust differences between ADHD patients and healthy 
controls have been reported in several components related to attention (among others 
including orienting and vigilance), inhibitory control, and performance monitoring, such 
as error and reward/punishment processes (Johnstone et al., 2013). MEG studies comparing 
ADHD patients to healthy controls are scarce and have been geared towards investigating 
attention-related processes. Alterations in oscillation patterns of brain regions involved in 
such processes have been observed in patients (Franzen et al., 2013; Heinrichs-Graham et 
al., 2014; ter Huurne et al., 2013).
Importantly, the brain phenotypes found affected in people with ADHD are often 
moderately to highly heritable. Findings from twin studies showed that brain structure is 
under strong genetic control. Additionally, twin studies showed that genetic effects varied 
regionally within the brain, with high heritability estimates (h2) for frontal lobe volumes 
ranging from 0.9 to 0.95, for region-based cortical surface areas ranging from 0.48 to 0.77, 
and moderate estimates for e.g. the hippocampus (h2-range = 0.4 – 0.69) (Peper et al., 2007). 
Surface area was predominantly more heritable than cortical thickness (h2-range = 0.34 – 
0.64) (McKay et al., 2014). Global fractional anisotropy (h2 = 0.55) as well as radial diffusivity 
(h2 = 0.72) of white matter showed high heritability (Kochunov et al., 2015; McKay et al., 
2014). Moreover, basal neural activity during a resting state condition has also been shown 
to be under genetic control, as functional connectivity within the default-mode network 
as a whole was significantly heritable (h2 = 0.42) (Glahn et al., 2010). Additional examples 
for moderate heritabilities of neural activity are e.g. brain activation in the cerebellum and 
cerebral cortex during working memory tasks (h2-range = 0.5 – 0.65) (Blokland et al., 2014). 
Strong genetic determination has also been reported for different psychophysiological brain 
phenotypes measured by EEG, e.g. (Iacono et al., 2014; Smit et al., 2010), and MEG, where 
different frequency band heritabilities have been described by van Pelt and coworkers 
(2012).
Rationale for this review
This review aims to provide a systematic overview of brain imaging genetics studies in 
ADHD, as brain imaging phenotypes are frequently used as endophenotypes in ADHD 
research. Endophenotypes (or intermediate phenotypes) have been considered a 
promising strategy in order to gain more insight into the mechanisms leading from a 
genetic/biological basis of the disease to the full clinical phenotype (Faraone et al., 2014a). 
Endophenotypes are (1) those characteristics of a disorder that are linked more closely 
to its neurobiological substrates than its clinical symptoms (Doyle et al., 2005) and (2) 
share genetic susceptibility factors with the disorder itself (Gottesman and Gould, 2003). 
As described above, neuroimaging phenotypes, e.g. derived from sMRI (Hulshoff Pol et 
al., 2006) and DTI measurements (Jahanshad et al., 2013) are highly heritable. Those brain 
phenotypes altered in ADHD have therefore been considered key endophenotypes for 
8
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the disorder, and investigating the genetic influences on these brain measures has been 
offered as a way for capturing underlying liability for ADHD (Dresler et al., 2014; Durston, 
2010; Wu et al., 2014). Compared to existing reviews of brain imaging genetics studies in 
ADHD (Dresler et al., 2014; Durston, 2003, 2010; Durston et al., 2009; Wu et al., 2014), this 
review is more comprehensive by including both childhood and adult ADHD studies, a large 
spectrum of brain imaging modalities, and by investigating a more complete list of ADHD 
candidate genes. Beyond the systematic review, we also emphasize the need for additional 
approaches, describing complementary methods, which provide insight from alternative 
angles into the biological pathways leading from an ADHD risk gene to disease. Especially, 
we argue that the integration of methods at different analytical levels (e.g. in silico, cell, brain, 
cognition, and behaviour) is needed to unravel the function of ADHD candidate genes.
Methods
For this review, we selected genes that were previously found associated with ADHD. The 
selection was based on a recent review of ADHD candidate genes, which described 70 
genes that are (with at least some evidence) related to ADHD risk (Li et al., 2014), see Table 
1. We discarded eight genes, for which we did not find evidence for association with ADHD 
based on the analysis of genetic variation: ARVCF, ATP2C2, CPLX4, DNM1, EMP2, IL20RA, MMP7, 
and TRIO (Table 1). On November 28th 2016, we searched for all remaining 62 genes, all 
brain imaging modalities, and ADHD using PubMed (www.ncbi.nlm.nih.gov/pubmed) with 
the following search algorithm (example is shown for the SLC6A3/DAT1 gene): (((SLC6A3 OR 
solute carrier family 6 neurotransmitter transporter, member 3 protein human OR DAT1 OR 
dopamine transporter gene OR dopamine transporter [All fields])) AND (gene* OR genetic* 
OR imaging genetic OR imaging genetics OR genotype OR polymorphism OR SNP OR single 
nucleotide polymorphism)) AND (structural magnetic resonance imaging OR functional 
magnetic resonance imaging OR sMRI OR fMRI OR electroencephalography OR diffusion 
tensor imaging OR DTI OR resting-state functional magnetic resonance imaging OR rsfMRI 
OR EEG OR magnetoencephalography OR MEG OR single photon emission computed 
tomography OR SPECT OR positron emission tomography OR PET OR near-infrared 
spectroscopy OR NIRS OR volume [Title/Abstract])) AND (ADHD OR Attention-deficit/
hyperactivity disorder OR [All fields] NOT “review” [Publication Type]). Titles and abstracts 
of the retrieved records were evaluated for relevant publications. Studies were required to 
investigate genetic variants in/near the selected ADHD candidate genes, and only studies 
including patients with ADHD were included. Review articles, medical hypotheses, non-
English articles, and studies on animal models were not considered. The preferred reporting 
items for systematic reviews and meta-analysis (PRISMA) diagram in Figure 1 describes the 
number of articles identified and their classification.
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Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) flowchart of the 
literature search and study selection for qualitative analysis. Note: see http://www.prismastatement.org for 
more information in this reporting system.
Results
For 25 out of the 62 ADHD candidate genes, we retrieved a total number of 171 reports 
linking genetic variation in/near the gene to neuroimaging by using the above mentioned 
search term in PubMed (Figure 1). To those, we added two recent papers from our own 
group (Sokolova et al., 2015; Van Ewijk et al., in revision) and three additional papers that 
were missing, from reading the retrieved reports (Albrecht et al., 2014; Dresler et al., 2010; 
Fernandez-Jaen et al., 2016). After removal of 54 duplicates, we screened 117 records and 
discarded an additional 66 papers, mostly because they described animal studies, did not 
include ADHD patients, or did not fulfil our eligibility criteria otherwise. We finally included 
51 original research articles on brain imaging genetics studies for 13 ADHD candidate 
genes (ADRA2A, COMT, DRD1, DRD4, HTR1B, LPHN3, MAOA, NOS1, SLC6A2/NET1, SLC6A3/DAT1, 
SLC6A4/5HTT, SNAP25, TPH2; Table 2 and 3). Most of the studies investigated a single gene 
(32 in Caucasians, 6 in Asians), thirteen studies investigated multiple genes (12 in Caucasians, 
1 in Asians). The dopamine transporter gene (SLC6A3/DAT1) and the dopamine D4 receptor 
gene (DRD4) were the most frequently studied ADHD candidate genes (Table 2 and 3).
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Findings for the dopamine transporter gene (SLC6A3, DAT1)
The gene DAT1 (official name SLC6A3) codes for a solute carrier protein (DAT) responsible for 
the reuptake of dopamine from the synaptic cleft into the presynaptic neuron, representing 
a primary mechanism of dopamine regulation in the striatum (Ciliax et al., 1999). The most 
widely studied polymorphism in SLC6A3/DAT1 is a variable number of tandem repeat (VNTR) 
sequence in the 3’ untranslated region (3’UTR) that is 40 base pairs (bp) in length. Most 
common alleles are those with 9 and 10 repeats (9R and 10R). Additionally, a 30 bp VNTR in 
intron 8 of the gene (most common alleles with 5 and 6 repeats [5R and 6R]), is sometimes 
studied together with the 3’UTR VNTR as a haplotype. The 10R/10R genotype of the 3’UTR 
VNTR and the 10-6 haplotype of the two VNTRs are thought to be risk factors for childhood 
ADHD (Asherson et al., 2007; Brookes et al., 2006a). In contrast, the 9R/9R genotype and 
the 9-6 haplotype are associated with persistent ADHD (Franke et al., 2010). This suggests 
a differential association of the gene with ADHD depending on age, and a role of DAT1 in 
modulating the ADHD phenotype across the lifespan. In addition to the VNTRs, several SNPs 
in DAT1 have been studied for their effect on ADHD and/or brain phenotypes.
Two studies performed PET to study the role of DAT1 genotype on DAT availability, one 
using 11Altropane as the ligand and one 11Cocaine. In an early study investigating a very small 
sample of 6 patients with ADHD and 9 controls, Drgon and colleagues studied a haplotype 
of two SNPs (rs2652511, rs2937639) in the 5’ regulatory region of the SLC6A3/DAT1 gene, and 
found the CG-allele associated with ventral striatal in vivo DAT availability independent of 
diagnosis; this finding was confirmed through investigation of striatal DAT expression in 
post-mortem brain samples (2006). Spencer and coworkers observed that, in adults, the 
9R genotype of the 3’UTR VNTR increased DAT binding in caudate nucleus both in patients 
and healthy controls, whereas the intron 8 VNTR and a haplotype of both variants were not 
associated with DAT binding (2013); (Table 3).
Four SPECT studies, using different ligands, investigated the effect of the 3’UTR VNTR 
on DAT availability (Table 3). Two early case-only studies, both in children with ADHD (n=8 
and 11, respectively), showed that basal ganglia DAT density was increased (Cheon et al., 
2005) and that the regional cerebral blood flow (rCBF) was larger in medial frontal and left 
basal ganglia during a continuous performance task (CPT) in response to MPH treatment 
in 10R/10R-homozygotes compared to 9R-carriers (Rohde et al., 2003). A somewhat larger 
study in adults with ADHD did not identify a difference in striatal DAT availability between 
10R/10R-homozygotes and 9R-carriers (Krause et al., 2006). Another SPECT study in boys with 
ADHD observed a genotypic effect of the 3’UTR VNTR variant increasing rCBF during a CPT 
only in the presence of risk alleles at both SLC6A3/DAT1 (10R/10R) and DRD4 (7R); this effect 
was present in the right middle temporal gyrus, an area associated with working memory 
and selective attention (Szobot et al., 2005); (Table 3). An interaction effect between the two 
polymorphisms was subsequently also shown by the same group in adolescent patients with 
ADHD plus substance use disorder (Szobot et al., 2011); (Table 3). In this case, participants 
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homozygous for the SLC6A3/DAT1 10R-allele and carrying the DRD4 7R-allele exhibited 
decreased DAT occupancy after MPH treatment in the right and left caudate nucleus and 
putamen (Szobot et al., 2011). A recent meta-analysis, including healthy subjects and patients 
with different psychiatric disorders including ADHD, assessed the association of the 3’UTR 
variant with DAT availability (Faraone et al., 2014b). The PET studies provided significant 
evidence that the 9R-allele was associated with increased DAT availability in human adults, 
independent of the diagnostic status. The SPECT studies were highly heterogeneous, but 
when the analysis was limited to the most commonly used ligand, stratification by affection 
status dramatically reduced heterogeneity and revealed a significant association of the 9R 
allele with increased DAT availability for healthy subjects. The authors concluded that in 
humans, the 3’UTR polymorphism of SLC6A3/DAT1 regulates dopamine activity in the striatal 
brain regions independent of the presence of neuropsychiatric illness.
Eight sMRI studies for SLC6A3/DAT1 were performed thus far (Table 3). Two studies 
reported a smaller volume of the striatal caudate nucleus in homozygotes for the 10R allele 
when compared to children with the 9R/10R genotype (Durston et al., 2005; Shook et al., 
2011). While Durston and coworkers found this effect to be most pronounced in children 
with ADHD, rather than their unaffected siblings or healthy comparison subjects, the 
overall genotype effect was independent of diagnosis. Two recent studies investigated 
cortical thickness in children and adolescents with ADHD. Fernández-Jaén and colleagues 
suggested that thickness of the lateral PFC and the cingulated cortex might be influenced 
by the presence of the 10R-allele (2016; 2015). Interestingly, homozygotes for the 10R allele 
showed increased thickness in the right cingulated gyrus (Fernandez-Jaen et al., 2016), but 
decreased cortical thickness in the lateral PFC (Fernandez-Jaen et al., 2015). In addition, a 
large observational study in an adolescent cohort revealed that irrespective of stimulant 
treatment, left striatal volume was reduced in participants with ADHD carrying one 10-6 
haplotype (Schweren et al., 2016). A recent cross-sectional sMRI study included three cohorts 
(a childhood/adolescent ADHD case-control sample, an adult ADHD case-control sample, 
and an adult population-based sample) and showed that only in the adult ADHD case-
control cohort, carriers of the DAT1 adult ADHD risk haplotype 9-6 had a 5.9% larger striatum 
volume relative to participants not carrying this haplotype. The effect varied by diagnostic 
status, with the risk haplotype affecting striatal volumes only in patients with ADHD (Onnink 
et al., 2016). A longitudinal study did not reveal any effect of SLC6A3/DAT1 genotype on 
cortical thickness (Shaw et al., 2007b), consistent with the predominant expression of 
DAT1 in subcortical (striatal) structures (and cerebellum). A recent gene-environment (GxE) 
interaction study reported differential age effects for SLC6A3/DAT1 9R-allele carriers for total 
grey matter volume and for SLC6A3/DAT1 10R-allele homozygotes on putamen volume, 
depending on positive peer affiliation (Richards et al., 2016) (Table 3). These findings were 
independent of ADHD severity. The presence of such differential age-dependent GxE effects 
might explain the diverse and sometimes opposing results of genetic and environmental 
effects on brain phenotypes (Richards et al., 2016). A single DTI study was performed in a 
sample of children with ADHD to assess DAT1’s effect on structural connectivity (Table 3). 
However, the investigated 3’UTR VNTR genotype did not appear to affect white matter 
integrity (Hong et al., 2014).
In total, nine fMRI studies were performed to investigate the effect of SLC6A3/DAT1 
genotype on brain activity related to different tasks, most often examining reward 
processing and different aspects of executive functioning (Table 3). The studies included 
childhood, adolescent, and adult ADHD samples. Three fMRI studies investigated the role of 
the SLC6A3/DAT1 VNTR haplotype using reward-processing paradigms. Reward processing 
is altered in ADHD, and meta-analysis has shown that activation of the ventral striatum in 
anticipation of reward is lower in patients with ADHD than in controls (Plichta and Scheres, 
2014). In a study in male adolescents, the activation of the caudate nucleus within the ventral 
striatum was found reduced in the ADHD group as the number of 10-6 haplotype copies 
increased (Paloyelis et al., 2012). A sizeable study in adult ADHD cases and controls, on the 
other hand, found no effect of SLC6A3/DAT1 haplotype on striatal activity (Hoogman et al., 
2013). The latter dataset was re-analyzed using a Bayesian constraint-based causal discovery 
algorithm; this analysis suggested that any links between the genetic haplotype in DAT1 
and reward anticipatory brain activity may be indirect only, mediated through inattention 
symptoms (Sokolova et al., 2015).
In studies of response inhibition, tested through a Go/No-Go task in children and 
adolescents, the 10R/10R genotype was found to be linked to higher (Bedard et al., 2010), 
but also lower (Durston et al., 2008) striatal activation. Interestingly, Durston and colleagues 
observed genotypic effects in the caudate nucleus in the patients and their unaffected 
siblings, but not in healthy controls (2008). Beyond the striatum, SLC6A3/DAT1 genotype 
effects were also found in additional brain regions, such as during cerebellar activation in 
children with ADHD (Durston et al., 2008), and in frontal, medial, and parietal regions, where 
activity was increased during response inhibition in adolescents homozygous for the 10R 
allele (Braet et al., 2011). Increased activity in the (temporo-)parietal regions in homozygous 
carriers of the 10R-allele was also observed in a second study, in addition to increased 
activity in the right dorsal premotor cortex (Bedard et al., 2010). The effects of the SLC6A3/
DAT1 haplotype and rs37020 genotype on neural activation during response inhibition 
have been investigated as well (van Rooij et al., 2015b) (Table 3). Homozygous carriers of 
the SLC6A3 10-6 haplotype exhibited increased activity related to successful stop-trials in 
pre-supplementary motor areas and reduced activity in superior frontal and temporal pole 
areas, whereas homozygous carriers of the rs37020 A-allele showed reduced activity during 
failed stop-trials in the IFG, pre-supplementary motor areas, and post-central gyrus (van 
Rooij et al., 2015b). Despite these wide-spread effects on neural activation changes of the 
response inhibition network, these changes were independent of ADHD diagnostic status 
(van Rooij et al., 2015b). As expression of DAT1 is limited outside of striatum and cerebellum, 
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these latter effects are likely due to direct or indirect connections between the regions of 
gene expression and the rest of the brain.
A working memory task in adult participants elicited increased activity in the dorsal 
ACC in patients homozygous for the 10R allele, whereas this genotype caused reduced 
activity in controls (Brown et al., 2011). Additionally, the authors showed a marginal 
association of the SLC6A3/DAT1 genotype with task-related suppression in the left medial 
PFC (Brown et al., 2011). Also in a multi-source interference task, the 10R/10R homozygotes 
had increased activity in the dorsal ACC compared to carriers of the 9R-allele (Brown et 
al., 2010). The dorsal ACC is thought to play a crucial role in numerous cognitive control 
functions including attention modulation, competition monitoring, complex motor control, 
novelty, error detection, working memory, anticipation of cognitively demanding tasks, 
and the modulation of reward-based decision making (Shenhav et al., 2013). Functional 
abnormalities associated with the dorsal ACC have been repeatedly reported in ADHD 
(Cao et al., 2009; Castellanos et al., 2008; Tamm et al., 2004; Tian et al., 2006; Zang et al., 
2007), and the results above suggest that these effects might be most pronounced in 
10R-allele homozygotes, which constitute approximately 71.9% of the Caucasian population 
(Doucette-Stamm et al., 1995).
No studies in patients have yet investigated effects of DAT1 genotype on functional brain 
connectivity assessed through resting state fMRI. A single study in healthy participants using 
seed-based analysis revealed that carriers of the 9R-allele showed stronger connectivity 
between dorsal caudate nucleus and insula, dorsal ACC, and dorsolateral prefrontal regions, 
as well as between ventral striatum and centrolateral prefrontal cortex, suggesting wide-
spread effects of the SLC6A3/DAT1 genotype on functional connectivity of striatal structures 
with the rest of the brain (Gordon et al., 2015).
Four EEG studies in ADHD childhood samples investigated the effects of SLC6A3/DAT1 
variation (Table 3). One study examined the influence of the common 9R and 10R alleles on 
prefrontal brain functioning and cognitive response control in participants with adult ADHD 
and healthy controls (Dresler et al., 2010). By means of a Go-NoGo task (CPT) they inspected 
a neurophysiological marker of cognitive response control (NoGo-anteriorization, NGA). The 
NGA is a endophenotypic marker of prefrontal functioning, reflecting neural correlates of 
both response inhibition and execution in a Go-NoGo test situation (Fallgatter and Strik, 
1999). It is a topographic event-related potential parameter quantifying the brain’s electrical 
field frontalization during motor inhibition (NoGo, when compared with response execution 
Go). As such, the NGA reflects “NoGo” activation of the medial PFC (anterior cingulate cortex, 
ACC) (Fallgatter et al., 2002). The NGA and the electrical field frontalization during NoGo 
trials have been found reduced in patients with ADHD (as well as those with schizophrenia) 
compared with healthy controls, reflecting diminished activation of the medial PFC in these 
patient groups (Fallgatter et al., 2005; Fallgatter and Muller, 2001). In the study of SLC6A3/
DAT1 genotype carriers of the 9R-allele within the ADHD group showed significantly reduced 
NGA, whereas no influence of genotype was observed in the control group (Dresler et al., 
2010). A second EEG study investigated the effect of the 10-6 haplotype on response control, 
by using a CPT task in a childhood case-control sample (Albrecht et al., 2014). Independent 
of ADHD diagnosis, 10-6 haplotype-carriers exhibited elevated brain activity related to 
inhibitory response control (Albrecht et al., 2014). Another study investigated the effect 
of the SLC6A3/DAT1 3’UTR genotype on neurophysiological correlates of performance 
monitoring by measuring event-related potentials (ERPs) during a feedback-based learning 
task. The authors showed that 10R/10R homozygotes had a smaller error-related positivity 
(Pe) response to errors and a smaller stimulus-preceding negativity (SPN) in the anticipation 
of negative feedback, especially with learning (Althaus et al., 2010), suggesting that SLC6A3/
DAT1 genotype influences a system that is sensitive to aversive stimuli and their conscious 
processing (Althaus et al., 2010). The third EEG study investigated MPH medication-related 
changes on cortical power spectra during a sustained attention and vigilance task in a 
patient-only sample. ADHD patients have been shown to have increased frontocentral θ 
band activity and increased θ/β ratio compared to non-ADHD controls during rest (Loo and 
Makeig, 2012). Generally, the β band activity has been associated with attentional arousal, 
and it has been suggested that the θ/β ratio may reflect increased impulsivity and difficulty 
negotiating the speed-accuracy trade-off (faster speed but poorer performance) in ADHD 
(Loo and Makeig, 2012). In their study of DAT1 genetic variation during MPH treatment, the 
authors reported that those children with ADHD homozygous for the 10R-allele, exhibited 
medication-related cortical changes of increased central and parietal β power, decreased 
right frontal θ power, and lower θ/β ratios; 9R carriers showed the opposite pattern (Loo 
et al., 2003).
Summarizing, sMRI studies (as well as PET/SPECT by definition) find SLC6A3/DAT1 
genotype effects mainly in regions, in which the gene is preferentially is expressed. These 
local effects can have widespread consequences on brain activity, as fMRI and EEG studies 
reveal. However, it is still unclear how the PET/SPECT findings, such as high DAT binding 
and density in nucleus accumbens and dorsal striatum (Kuczenski and Segal, 2002; Segal 
and Kuczenski, 1997) or the differences observed in brain activity are related to structural 
volume differences in the specific brain regions of ADHD patients. Therefore, studies could 
benefit from combining different imaging methodologies. The effects of genotype are 
often observed independent of diagnostic status, as would be expected for bona fide risk 
factors. Additionally, credibility of most of the existing studies can be questioned, since 
many of them are limited by their small sample sizes (Mier et al., 2010; Munafo et al., 2008). 
The actual neuroanatomical and brain activity-based mechanisms by which SLC6A3/DAT1 
genotype increases ADHD risk remain to be clarified, as the results of studies published 
thus far are too patchy (and based on too small samples) to allow a coherent story to be 
defined. Moreover, links with cognitive performance and behaviour have often not been 
investigated. A further complicating matter for the interpretation of studies on SLC6A3/DAT1 
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is the switch in ADHD risk allele from childhood to adulthood. Longitudinal studies or at 
least cross-sectional studies including large samples of both children and adult participants 
(preferably also including persistent and remitted forms of ADHD) are therefore needed to 
advance the field.
Findings for the dopamine receptor D4 gene (DRD4)
The dopamine D4 receptor, encoded by DRD4, is a G protein-coupled receptor and 
belongs to the dopamine D2-like receptor family (Oldenhof et al., 1998). The most widely 
studied DRD4 polymorphism in ADHD has been the 48 bp VNTR in exon 3 of the gene, 
with the 2-, 4-, and 7-repeat alleles being the most common alleles. Allele frequencies vary 
significantly across ethnic groups (Chang et al., 1996; Van Tol et al., 1992), and the ADHD risk 
allele in the Caucasian population (7R) seems to be a different one from that in Asians (Li 
et al., 2006a; Nikolaidis and Gray, 2010; Wang et al., 2004). The DRD4 48 bp VNTR seems to 
show differential association with ADHD in children, where it may be one of the strongest 
risk factors among the common genetic variants (Gizer et al., 2009), and adults, where 
no association with the disorder could be observed (Sanchez-Mora et al., 2011), though it 
might occur as part of gene-environment interactions (Sanchez-Mora et al., 2015). DRD4 is 
abundantly expressed in areas of the brain affected in ADHD, including frontal lobe regions, 
such as the orbitofrontal cortex and anterior cingulate (De La Garza and Madras, 2000; Lahti 
et al., 1995; Li et al., 2007b); the risk allele has been found to affect receptor binding and to 
produce a blunted response to dopamine (Asghari et al., 1995), although the functionality 
of the DRD4 VNTR has recently been challenged by meta-analysis (Pappa et al., 2015). The 
exon 3 VNTR has been the sole target of imaging genetic studies involving patients with 
ADHD, in which different imaging modalities have been used (Table 3).
An early sMRI study in children and adolescents did not report differences between 
carriers and non-carriers of the 7R-allele in selected regional and global brain volumes 
(Castellanos et al., 1998). A second study observed smaller prefrontal grey matter volumes 
in children homozygous for the 4R-allele, an effect that appeared particularly pronounced 
in unaffected siblings of patients with ADHD (Durston et al., 2005). In contrast, adult patients 
carrying the 7R-allele were found to have smaller volumes of the superior frontal and 
cerebellar cortex (Monuteaux et al., 2008). In a longitudinal study, DRD4 genotype also 
affected cortical development (by measuring cortical thickness), with 7R-carriers showing 
thinner prefrontal and parietal cortex; patients with ADHD carrying this allele had a distinct 
trajectory of cortical development characterized by normalization of parietal cortical 
regions (Shaw et al., 2007b). Additionally, an observational cohort study evaluating the 
effects of cumulative stimulant treatment, revealed associations between treatment and 
frontal and hippocampal volume dependent on DRD4 genotype and age (Schweren et al., 
2016). More specifically, carriers of the 7R-allele showed decreased frontal cortex volume at 
younger age and lower treatment levels, whereas left hippocampal volume was increased 
in those with treatment at younger age (Schweren et al., 2016) (Table 3). By studying GxE 
interaction effects, carriers of the 7R-allele were found to have larger putamen volumes 
over age when exposed to high positive peer affiliation (Richards et al., 2016). This result was 
independent of ADHD severity. Effects of DRD4 genotype on structural brain connectivity 
were investigated in a single study in Asian children with ADHD, resulting in a report of 
no effects for 4R-homozygotes (Hong et al., 2014). A very large recent study in healthy 
participants (n=765) revealed an absence of significant effects of the DRD4 5R-allele on FA as 
well (Takeuchi et al., 2015). However, widespread changes in another measure of structural 
connectivity, mean diffusivity (MD), were observed, with increased MD in 5R-carriers in grey 
and white matter areas of the cerebral cortex, and in subcortical areas including the globus 
pallidus, amygdala, midbrain areas, and the brain stem (Takeuchi et al., 2015).
An EEG study administering a CPT as a measure of response inhibition and sustained 
attention, reported that children with the 7R-allele showed increased frontal θ and reduced 
global β power. Similar effects of DRD4 genotype were also apparent on the β frequency 
band in the parents (Loo et al., 2010); in both generations, carriers of the 7R-allele had 
reduced cortical activation upon performing the CPT task compared to participants not 
carrying this allele (Loo et al., 2010). Similarly, Albrecht and colleagues also applied the 
CPT to a childhood case-control sample and reported significant effects of the 7R-allele 
on ERP components. Specifically, they observed reduced activity related to attentional 
orienting and cognitive or response preparation in 7R-carriers (2014). This effect was found 
to be independent of an ADHD diagnosis (Albrecht et al., 2014). Extrapolating to behaviour, 
a recent meta-analysis showed that longer DRD4 variants (including the 7R-allele) were 
associated with lower levels of executive functioning (Pappa et al., 2015). In contrast to the 
continuous performance measure, an EEG study of inhibition applying another Go/No-Go 
task to adults with and without ADHD did not find an effect of DRD4 genotype on the NGA 
neural correlate of prefrontal response control (Heinzel et al., 2013). However, in this study, 
an epistatic interaction between the DRD4 VNTR and a SNP in the COMT gene (rs4680; Val/
Met) was observed for the NGA; in homozygous carriers of the DRD4 7R-allele, the NGA 
followed a more pronounced U-relationship based on an increasing number of COMT Met-
alleles compared with 7R-heterozygotes. In COMT Val/Met carriers, DRD4 7R-homozygosity 
was associated with decreased NGA compared with 7R-heterozygosity. This interaction 
could be localized to the right premotor and supplementary motor areas (Heinzel et al., 
2013). These findings were independent of diagnostic status.
Thus, though existing evidence does not support firm conclusions about the pathways 
from gene to disease, genotypic variability in DRD4 may affect brain structure and/or activity 
and mark a particular developmental trajectory in cortical brain structure related to adult 
outcome of ADHD.
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Findings for other ADHD candidate genes
Adrenergic neurotransmitter systems influence attentional processes and certain aspects 
of executive control (Arnsten, 2006), and the gene encoding the alpha-2A adrenergic 
receptor (ADRA2A) has been found to be a candidate gene for ADHD. The alpha-2A 
adrenergic receptor is the most prevalent noradrenergic receptor in the PFC (Arnsten et 
al., 1996; Park et al., 2005). Two variants appear to be risk factors for ADHD, the rs1800544 
SNP in the promoter region, for which the G-allele was considered risk-increasing (Park et al., 
2005), and the rs553668 SNP in the promoter region, for which the T-allele was considered 
the risk allele (Park et al., 2005). However, meta-analyses have not confirmed associations 
with ADHD risk for either SNP (Gizer et al., 2009). Alpha-2 adrenoreceptors have also been 
implicated in other major neuropsychiatric diseases that are often comorbid with ADHD, 
such as major depressive disorder and schizophrenia (Langer, 2015).
Genotypic effects of ADRA2A on the brain were studied in only two studies of Asian 
children with ADHD. A SPECT study showed that carriers of the non-risk allele for rs1800544 
exhibited reduced perfusion in bilateral orbitofrontal regions (Kim et al., 2010). A DTI study 
investigated the effect of both SNPs (rs1800544 and rs553668) on white matter integrity. 
Carriers of the rs553668 non-risk-allele (C-allele) showed reduced fractional anisotropy (FA) 
in the right postcentral gyrus, whereas carriers of the rs553668 T-allele (non-risk group) 
showed reduced FA in the right middle frontal cortex (Park et al., 2013).
The Catechol-O-methyl-transferase enzyme (encoded by the COMT gene, located 
at 22q11.21) is involved in the degradation of the catecholamines dopamine and 
norepinephrine. It is highly expressed in the frontal lobe regions, where it is responsible for 
the regulation of dopamine levels (Hong et al., 1998). Studies investigating the association 
between COMT and ADHD have largely focused on a functional SNP (rs4860) in exon 4 that 
leads to an amino acid substitution (valine à methionine). This polymorphism has been 
shown to considerably affect COMT enzyme activity, such that homozygous carriers of the 
valine-allele show 3-4 times higher activity than homozygous carriers of the methionine-
allele, resulting in decreased dopamine availability in valine homozygotes (Chen et al., 
2004). An initial small study suggested that the valine-allele was associated with increased 
risk for ADHD (Eisenberg et al., 1999), although a recent meta-analysis failed to confirm 
this association (Lee and Song, 2015). The functional COMT rs4680 variant also seems 
relevant to other psychiatric and cognitive phenotypes. A recent study evaluating the 
association of the COMT genotype with schizophrenia in a systematic review and meta-
analysis in 32,816 subjects, revealing a significant association (Gonzalez-Castro et al., 2016). 
Another recent meta-analysis revealed an association of the COMT genotype and reward 
learning, suggesting that variability in dopamine signalling associated with COMT rs4680 
influences individual differences in reward processing, which may potentially contribute 
to psychopathology characterized by reward dysfunction, such as ADHD (Corral-Frias et 
al., 2016).
Two very small sMRI studies, both using VBM, examined the genotypic effect of rs4680 
on the brain in children with and without ADHD (Table 3). Villemonteix and colleagues 
observed that children with ADHD and at least one methionine-allele had reduced grey 
matter volume in the insula/IFG relative to children without ADHD (2015). In an additional 
ROI analysis within the small ADHD group only (n=34), the study showed that those children 
with ADHD who were homozygous for the valine-allele had increased grey matter volume 
in the caudate nucleus compared to ADHD children carrying the methionine-allele, and also 
compared to children without ADHD (Villemonteix et al., 2015). A second sMRI study in a 
Japanese childhood sample also found a relation of COMT genotype with striatal volume 
pointing in the same direction, as the authors showed that the smaller grey matter volume 
observed in the left putamen in children with ADHD was moderated by the methionine-
allele, whose carriers showed smaller volume than the valine homozygotes (Shimada et 
al., 2015). Effects of COMT on structural connectivity were investigated by two DTI studies. 
One study in Asian children with ADHD revealed that carriers of the methionine-allele 
showed a weakened network of white matter connections linking 18 different brain regions 
(Hong et al., 2014) (Table 3). This finding is in line with a report on healthy participants, 
showing that the methionine-allele was associated with impaired structural maturation 
of brain white matter connectivity (Thomason et al., 2010). Based on these findings, Hong 
and coworkers formulated the hypothesis that higher dopamine availability may inhibit 
myelination (2014). Recently, Kabukcu Basay and colleagues reported that children with 
ADHD, who were homozygous for the Valine-allele, had reduced FA and increased RD 
values in the right cingulum bundle (2016). This indicates demyelination effects in the white 
matter connections between the cingulated cortex to the PFC, premotor regions, cortical 
association areas in the parietal and occipital lobes, thalamus, and hippocampus (Kabukcu 
Basay et al., 2016). The cingulated cortex is known to be involved in complex cognitive 
processing (Bush et al., 2000) and functions that are believed to be impaired in ADHD (Bush, 
2011; Makris et al., 2008).
A single fMRI study investigated the association of COMT rs4680 genotype on task 
performance and whole-brain neural activation during response inhibition (van Rooij 
et al., 2015b). Although the COMT Val158Met variant resulted in differential activation 
patterns during successful and failed stop-trials in the combined ADHD-control sample, 
no interactions between genetic effects and ADHD diagnostic status were observed in any 
of the whole-brain fMRI results (van Rooij et al., 2015b) (Table 3). This indicates that genetic 
variation in the COMT gene exerts large-scale effects on neural activation changes of the 
response inhibition network, but these changes are independent of ADHD.
The single EEG study of COMT in ADHD, using a Go/No-Go task in adults with and without 
ADHD, did not reveal an effect of COMT genotype on brain activity individually. However, 
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an epistatic interaction of DRD4 x COMT genotype on neurophysiological correlates of 
prefrontal function was observed (Heinzel et al., 2013). In homozygous carriers of the 
DRD4 7R allele, the anteriorization of the NoGo response (NGA, explained above) followed 
a more pronounced U-relationship with increasing numbers of Met alleles compared with 
7R heterozygotes. In COMT Val/Met carriers, DRD4 7R homozygotes showed a significantly 
decreased NGA compared with 7R heterozygotes. The genotype-dependent effects on 
the NGA were localized in the right premotor and supplementary motor area. The epistatic 
interactions were independent of ADHD diagnosis (Heinzel et al., 2013). Given the role of 
fronto-striatal circuits and dopamine in reward processing (Plichta and Scheres, 2014; von 
Rhein et al., 2015), an important domain of impairment in ADHD (see above), it is surprising 
that no studies have yet investigated the role of COMT in brain activity related to reward 
anticipation and receipt.
The dopamine D1 receptor (encoded by the DRD1 gene) is the most abundant dopamine 
receptor subtype in the brain; it is highly expressed in the striatum and cerebral cortex 
(Bergson et al., 1995). Common genetic variation in the DRD1 gene (rs5326) has been 
associated with schizophrenia risk (Pan et al., 2014) and impaired cognition in patients with 
bipolar disorder (Zhao et al., 2015), both often found comorbid with ADHD. Several studies 
explored associations between ADHD and genetic variants of DRD1, such as SNPs rs4532 
and rs265981 (Bobb et al., 2005). In the initial study, participants with ADHD were more likely 
than healthy controls to have the C-allele or rs4532 and the A-allele of rs265981 (Bobb et 
al., 2005). However, results of a meta-analysis of rs4532 did not support its association with 
ADHD (Wu et al., 2012), and also replication for rs265981 is still pending. Nevertheless, two 
sMRI studies investigated the effect of genetic variation in DRD1 on cortical thickness (Shaw 
et al., 2007b) and on brain volume (Bobb et al., 2005). Neither study found an effect of DRD1 
genotype or group x genotype interactions (Table 3).
The 5-Hydroxytryptamine receptor 1B (encoded by the HTR1B gene) is the most widely 
studied serotonin receptor gene in relation to ADHD. HTR1B is a G protein-coupled receptor 
that inhibits cyclic AMP formation (Murphy et al., 1998). It is highly expressed in the dorsal 
raphe nucleus, which is involved in the sleep/wake cycle, and to lesser degrees in the 
striatum and frontal regions, such as the dorsolateral PFC (Ichikawa et al., 2005). The initial 
study, investigating 273 nuclear families with ADHD, reported preferential transmission 
of the rs6296 G-allele to ADHD probands (Hawi et al., 2002). Results of a meta-analysis 
supported this association between childhood ADHD and rs6296 genotype (Gizer et al., 
2009). A single fMRI study investigated the relationship of rs6296 genotype with neural 
correlates of response inhibition, using a stop-signal task in a childhood sample (van Rooij 
et al., 2015a). The rs6296 genotype was associated with widespread differential activation 
during successful and failed stop trials (Table 3). However, the direction of these effects 
was inconsistent, with both increased and decreased activation for the GG genotype being 
observed in frontal and posterior nodes, and the differential activation patterns were 
independent of ADHD diagnosis (van Rooij et al., 2015a).
The latrophilin 3 gene (LPHN3; official name Adhesion G Protein-Coupled Receptor L3 
[ADGRL3]) codes for a member of the LPHN subfamily of G-protein-coupled receptors 
(GPCRs). Subtype 3 is the most brain-specific LPHN (Ichtchenko et al., 1998; Sugita et al., 
1998) and is expressed in regions implicated in ADHD, i.e. the caudate nucleus, cerebellum, 
amygdala, and cerebral cortex (Arcos-Burgos et al., 2010). LPHN3 was identified as an ADHD 
risk gene downstream of genetic linkage studies in multicase families from a genetic isolate. 
In multisite association studies, initially, a haplotype of three SNPs (rs6551665, rs1947274, 
and rs2345039) was shown to be associated with ADHD (Arcos-Burgos et al., 2010). The 
association of LPHN3 genotypes with ADHD has been replicated in children (rs6551665) 
(Hwang et al., 2015) and adults with ADHD (multiple markers) (Ribases et al., 2011). By use of 
proton magnetic resonance spectroscopy (1H-MRS), Arcos-Burgos and colleagues showed 
that individuals carrying the LPHN3 susceptibility haplotype exhibited a decreased ratio of 
N-acetylaspartate to creatine (NAA/Cr ratio) in the left lateral and medial thalamus as well 
as the right striatum, and an increased ratio in inferior–posterior cerebellar vermis; this 
suggested that the maintenance of neuron viability is altered in those carrying the ADHD risk 
haplotype (2010). Since the ADHD susceptibility haplotype itself did not cause any significant 
coding region changes or canonical splice site alterations, it was suggested that non-coding 
variations may be likely contributors to ADHD (Domene et al., 2011).
Although LPHN3 is among the best-supported candidate genes for ADHD, thus far, imaging 
genetics studies of the gene are still limited in the literature. No studies on structural or 
connectivity alterations related to the risk variant of the gene in patients with ADHD have 
been published yet, nor have any fMRI studies. An EEG study using a Go/No-Go task revealed 
that adult patients with ADHD carrying a ‘high-risk’ LPHN3 haplotype (comprised out of 
rs2305339, rs734644, rs1397547, and rs1397548) showed a more anterior Go-centroid of 
the P300, had a reduced NGA, and had worse behavioural task performance due to more 
omission errors (Fallgatter et al., 2013).
Monamine oxidase A, encoded by MAOA, is an enzyme, which catalyzes the oxidative 
deamination of amines, such as dopamine, norepinephrine, and serotonin. For this gene 
located on the X-chromosome, studies have largely focused on a functional 30 bp VNTR 
1.2 kb upstream of the gene, which has been previously associated with impulsivity and 
aggression (Caspi 2002, Manuck 2000). The polymorphism consists of alleles of 2, 3, 3.5, 4, 
and 5 repeat copies, and evidence suggests that the 2 and 3 repeat (‘low-activity/MAOA-
L’) alleles are less efficiently transcribed than the longer (‘high-activity/MAOA-H’) alleles 
(Deckert et al., 1999). Although the MAOA gene has received a lot of attention as a candidate 
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gene for ADHD given the prior findings for impulsivity, a meta-analysis did not indicate a 
significant association between ADHD and the high activity alleles of the VNTR (Gizer et 
al., 2009). A SNP, rs1137070 (located in exon 14), has also been reported to contribute to 
impulsivity and the outcome of ADHD (Li et al., 2007a; Liu et al., 2011). Especially, the C-allele 
of rs1137070 has been associated with high ADHD scores and poor outcomes (Li et al., 2007a).
With evidence for a role of MAOA in aggression being more consistent than for ADHD (e.g. 
(Brunner et al., 1993; Byrd and Manuck, 2014; Caspi et al., 2002), imaging genetics studies 
have largely concentrated on population groups other than patients with ADHD, e.g. (Holz 
et al., 2016; Meyer-Lindenberg et al., 2006). A recent fMRI study forms an exception. Using a 
phonological working memory task in male Asian adults with and without ADHD, the authors 
showed that the effect of MAOA (rs1137070 T- versus C-allele) interacted with diagnosis in the 
left inferior frontal lobe, pars opercularis (Table 3); further analysis demonstrated that the 
increased brain activation observed in this region in patients was only significantly different 
to controls among those hemizygous for the T-allele (Ko et al., 2015).
The NOS1 gene codes for nitric oxide synthase 1, an enzyme that synthesizes nitric oxide 
from L-arginine. Nitric oxide is a reactive free radical, which can act as a biological mediator 
in several processes, including dopaminergic and serotonergic neurotransmission (Kiss and 
Vizi, 2001) and neurite outgrowth (Chen et al., 2006). The NOS1 gene has a complex structure, 
including 12 alternative untranslated first exons (exon 1a-1l). In exon 1f, a VNTR that affects 
gene expression has been linked to hyperactive and impulsive behaviour in humans (Reif 
et al., 2009; Weber et al., 2015); the short allele was shown to be the risk factor for ADHD, 
especially in females.
No studies have yet reported effects of NOS1 on brain structure. A recent case-control 
DTI study of structural connectivity in adolescents revealed that female homozygous carriers 
of the ADHD risk allele showed higher MD values in several major white matter tracts of the 
brain compared with long allele carriers. This effect was present in both female patients 
and controls (Van Ewijk et al., in revision). The white matter tracts found affected by NOS1 
genotype overlap with those earlier found associated with ADHD (Onnink et al., 2015; van 
Ewijk et al., 2012; Wu et al., 2016). Since higher MD values can be indicative of demyelination, 
lower axonal density, or axonal degeneration, homozygosity of the short allele might thus 
be a risk factor for aberrant development of white matter tracts involved in ADHD etiology.
NOS1 exon 1f is particularly highly expressed in striatum. Therefore, the single study 
of gene effects on brain function investigated the effect of the VNTR on ventral striatal 
activity during reward anticipation using fMRI (Hoogman et al., 2011) (Table 3). The study 
revealed that homozygous carriers of short alleles of NOS1 demonstrated higher ventral 
striatal activity than carriers of the other NOS1 VNTR genotypes (Hoogman et al., 2011). 
Again, this effect was independent of diagnostic status. Similar effects of the genotype were 
also observed for behavioural impulsivity, with those carrying the ADHD risk factor acting 
more impulsive than other participants. As the authors did not perform mediation studies, 
it remains to be investigated, whether the observed genotype effects on brain connectivity 
and/or activity directly link to behavioural effects.
The norepinephrine transporter gene (SLC6A2, NET1) codes for a protein responsible for 
the reuptake of norepinephrine (as well as dopamine) from the synaptic cleft back into the 
presynaptic neuron (Pacholczyck 1991). The gene is highly expressed in the frontal lobes 
(Stahl, 2003). Candidate gene studies of SLC6A2/NET1 selected numerous SNPs to test for 
association, but conflicting results have been reported, with each study yielding evidence 
of association, but differing in which specific SNPs were associated with ADHD (Gizer et al., 
2009).
A SPECT study examined the effects of rs5569 and rs28386840 on cerebral perfusion 
in response to MPH treatment in Asian children with ADHD (Table 3) (Park et al., 2012). At 
baseline, no differences were observed, but after eight weeks of MPH treatment increased 
regional brain perfusion in the right inferior temporal gyrus and middle temporal gyrus in 
homozygous carriers of the rs5569 G-allele was demonstrated (Park et al., 2012). Given that 
no previous studies had reported a significant association between this polymorphism 
and ADHD, no ‘risk’ allele was indicated. A PET study reported the influence of four genetic 
variants within the transporter gene on in vivo norepinephrine transporter binding in adults 
with and without ADHD (Table 3) (Sigurdardottir et al., 2015); the authors found differences 
in cerebellar and thalamic norepinephrine transporter binding depending on genotype 
between adult patients and controls (Sigurdardottir et al., 2015). For the two SNPs rs28386840 
and rs2242446, patients carrying the major alleles (A/T) showed increased norepinephrine 
transporter binding in the thalamus compared to controls carrying the major alleles. For 
the SNPs rs15534 and rs40615, controls carrying the major alleles (C/T) showed increased 
norepinephrine transporter binding in the cerebellum compared to patients carrying the 
major alleles (Sigurdardottir et al., 2015). In the patients with ADHD, a high correlation 
between hyperactivity/impulsivity symptoms and norepinephrine transporter binding 
in the cerebellum was detected, an effect which was strongly moderated by genotype 
(Sigurdardottir et al., 2015).
With this knowledge on SNP functionality related to ADHD, studies using additional 
imaging modalities are warranted, but thus far, only a single sMRI study investigated the 
effect of genetic variation in SLC6A2/NET1 on brain volume (Table 3). No effect of SLC6A2/
NET1 genotype (for SNPs rs998424 and rs3785157 – different SNPs from those having been 
investigated through PET and SPECT) and no group x genotype interactions were reported 
(Bobb et al., 2005).
The serotonin transporter gene (5HTT, SERT; official name SLC6A4) codes for a solute 
carrier protein responsible for the reuptake of serotonin from the synaptic cleft back into 
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the presynaptic neuron, which is the primary mechanism for regulating serotonergic activity 
in the brain (Lesch et al., 1996). A functional polymorphism exists in the promoter region 
of this gene (5HTTLPR) in the form of a 44-bp insertion/deletion yielding short (S) and 
long (L) alleles. The long variant is associated with more rapid serotonin reuptake, resulting 
in lower levels of active serotonin (Lesch et al., 1996). A SNP in the long allele, rs25531, 
additionally modifies its activity (Lesch et al., 1996). SLC6A4/5HTT has been implicated 
in emotion regulation, (emotional) memory, and learning processes (Araragi and Lesch, 
2013; Barzman et al., 2015; Meneses and Liy-Salmeron, 2012). The serotonin transporter is 
expressed in regions implicated in attention, memory, and motor activities, such as the 
amygdala, hippocampus, thalamus, putamen, and ACC (Frankle et al., 2004; Oquendo et 
al., 2007). The 5HTTLPR has been extensively studied for its role in depression and anxiety 
– especially in the context of environmental adversity, with the S-allele being the risk 
allele (Caspi et al., 2003; Oo et al., 2016). For ADHD, the evidence for association is more 
limited, although an earlier meta-analysis provided significant evidence of an association 
between ADHD (in children) and the ‘long’ variant of 5HTTLPR (Gizer et al., 2009). However, 
an international multicentre study reported a slight, non-significant overrepresentation of 
the S-allele in adult patients with ADHD (Landaas et al., 2010).
Given the evidence for SLC6A4 as a depression gene, imaging genetics research has 
largely concentrated on non-ADHD samples; in healthy individuals, functional genetic 
variation in the SLC6A4/5HTT gene has been linked to emotion regulation through effects 
on brain activation in the amygdala and the wider ‘threat circuit’, while effects on regional 
brain volumes are inconsistent (Jonassen and Landro, 2014; Klein et al., under review). 
Three sMRI studies have been performed for 5HTTLPR in ADHD thus far, all investigating 
GxE interactions. The initial study showed that the interaction between exposure to 
environmental stress and carriership of the 5HTTLPR S-allele, which was linked to increased 
ADHD severity in a longitudinal study of ADHD families (van der Meer et al., 2014), was 
associated with reduced cortical grey matter volume in the precentral gyrus, middle and 
superior frontal gyri, frontal pole, and cingulate gyrus in S-allele carriers compared with 
participants homozygous for the L-allele (van der Meer et al., 2015a). Importantly, this paper 
showed that only some of these regions, the frontal pole and the ACC, actually mediated 
the effects of the gene-environment interaction on ADHD severity. Similarly, van der 
Meer and colleagues reported that individuals carrying the NR3C1 risk haplotype, who 
were homozygous for the 5HTTLPR L-allele, showed a negative relation between stress 
and grey matter volume (2016). However, no mediation effects were found, meaning that 
the local effects of these interaction on grey matter volume did not significantly explain 
their association with ADHD severity (van der Meer et al., 2016). Such studies testing the 
mediation of effects through the observed brain phenotypes (as opposed to those just 
being epiphenomena of the genetic variation) are largely lacking in the imaging genetics 
literature thus far, but are critically needed to map gene to disease pathways. However, 
sample sizes will have to be substantial to allow valid conclusions to be drawn from such 
studies. Another sMRI study used the same dataset and revealed that, in agreement with 
age-related reductions of total grey matter volume found in longitudinal studies (Brain 
Development Cooperative, 2012; Raznahan et al., 2014), participants scoring high on positive 
peer affiliation and carrying two 5HTTLPR L-alleles had smaller total grey matter volumes 
with age (Richards et al., 2016). Moreover, participants with the same genotype, but low 
positive peer affiliation had larger GM volumes with age (Richards et al., 2016). These findings 
were independent of ADHD severity and were in line with a longitudinal study reporting 
regional GM reductions with age in adolescents exposed to high positive maternal behavior, 
but increased putamen volumes when exposed to maternal aggression (Whittle et al., 2014).
In contrast to the sMRI studies, which investigated GxE effects related to stress and social 
environments, the only fMRI study focused on the relationship between 5HTTLPR genetic 
variation and neural correlates of response inhibition using a stop-signal task (van Rooij 
et al., 2015a) (Table 3). Using a childhood sample, van Rooij and colleagues revealed that 
homozygous carriers of the 5HTTLPR S-allele showed decreased activation in the frontal 
nodes and increased activation in the posterior nodes in successful stop trials (2015a). 
However, no significant associations were found between differential neural activation and 
ADHD diagnosis or ADHD severity (van Rooij et al., 2015a).
The synaptosomal-associated protein 25 (encoded by the SNAP25 gene) is involved 
in axonal growth and synaptic plasticity, as well as in the docking and fusion of synaptic 
vesicles in presynaptic neurons necessary for the regulation of neurotransmitter release 
(Sollner et al., 1993). Several studies have tested for linkage and association between SNAP25 
and ADHD, and these studies have consistently genotyped multiple SNPs within the gene 
rather than focusing on any single polymorphism. An early meta-analysis of SNP rs3746544 
suggested SNAP25 as ADHD risk gene (Faraone et al., 2005). A more recent meta-analysis 
of rs3746544 also provided evidence of a modest but significant association between 
childhood ADHD and the T-allele, whereas no evidence of association with rs1051312 was 
found (Gizer et al., 2009).
Again, only a single imaging genetics study is currently available for this gene. In 
this case, the interaction of MPH treatment-related hemodynamic changes with genetic 
variation in SNAP25 (rs3746544 and rs1051312) was studied in small samples of children 
and adults with ADHD on and off single dose MPH using fNIRS (Table 3). Through fNIRS, 
brain haemodynamics in prefrontal cortices can be measured, since brain activation causes 
increased cerebral blood flow, but not all of this oxygenized blood is used, therefore 
oxygenated haemoglobin increases and deoxyhaemoglobin decreases during e.g. 
sustained attention (Villringer and Chance, 1997). Homozygous carriers of the rs3746544 
T-allele exhibited changes in right oxygenated haemoglobin and right as well as left 
deoxyhaemoglobin levels. Additionally, homozygous carriers of the rs1051312 T-allele 
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showed decreased right prefrontal deoxyhaemoglobin with treatment. Combination of 
the genotypes also showed interaction effects on right prefrontal deoxyhaemoglobin levels 
(Oner et al., 2011).
Tryptophan hydroxylase 2 catalyzes the reaction of tryptophan to 5-hydroxytryptophan, 
which is subsequently decarboxylated to form the neurotransmitter serotonin. Two isoforms 
of tryptophan hydroxylase have been identified (encoded by the TPH1 and TPH2 genes). The 
TPH2 gene codes for a rate-limiting enzyme in the production of serotonin in serotonergic 
neurons in the midbrain raphe nuclei, while TPH1 seems to be involved in synthesizing 
serotonin in peripheral tissues (Walther et al., 2003). For several SNPs of the TPH2 gene, an 
association with ADHD was found (Brookes et al., 2006a; Sheehan et al., 2005; Walitza et al., 
2005). For rs4570625, the G-allele was shown to be transmitted more often to offspring with 
ADHD (Walitza et al., 2005). For rs11178997, the T-allele was identified as the risk allele for 
ADHD (Walitza et al., 2005). However, the initial findings could not be replicated in a larger, 
multicentre study (Brookes et al., 2006a). Mouse models in conjunction with approaches 
focusing on TPH2 variants in humans described a role of serotonin in brain development 
and in disorders related to negative emotionality, aggression, antisocial behaviour, and 
bipolar disorder (Gao et al., 2016; Gao et al., 2012; Waider et al., 2011). The TPH2 gene has 
also been a candidate for the investigation of gene by environment interaction studies, in 
depression and suicidal behaviour as well as in aggression; for review see (Lesch et al., 2012; 
Mandelli and Serretti, 2013).
As the evidence for a role of TPH2 in ADHD is limited, only a single imaging genetics 
study involving patients with this disorder has yet been performed for this gene. This EEG 
study investigated the genotypic effect of the two SNPs of the TPH2 gene mentioned above 
(rs4570625 and rs11178997) on the NGA during a Go/NoGo task in adult patients with ADHD 
and healthy individuals (Table 3). Risk alleles of each of the SNPs were found associated with 
a reduction in the NGA in both participant groups, indicating an effect on ADHD-relevant 
prefrontal brain function independent of a specific psychiatric diagnosis (Baehne et al., 
2009). These promising first findings may warrant further analysis of TPH2 variants, especially 
in combination with adverse environmental factors.
Outlook
In this review we set out to summarize the current literature on imaging genetics studies 
of candidate genes involving patients with ADHD. As no genome-wide association studies 
have yet reported loci/genes with significant evidence for association with ADHD, we 
used a liberal definition of a candidate (having shown association with the disorder in at 
least one earlier study) and used an adapted version of the list of ADHD candidate genes 
recently compiled by Li and coworkers (2014). Of the 62 candidate genes selected for review, 
we found that only 12 had been studied with any brain imaging technique in an ADHD 
population. For most of those 12, only a very limited number of studies was available. The 
two most frequently studied ADHD candidate genes were the SLC6A3/DAT1 and DRD4 genes, 
and even for those two genes most findings await replication.
Brain imaging phenotypes offer an important level of investigation in mapping the 
biological pathways from gene to disease. Brain structure, function, and connectivity can 
provide endophenotypes (or intermediate phenotypes) for a disease (Gottesman and Gould, 
2003). As those brain endophenotypes are thought to lie in-between a genetic factor and 
the clinical phenotype, it has been argued that effect sizes for effects of genes on those brain 
phenotypes may be larger than the ones for effects on behaviour. However, for structural 
brain phenotypes (i.e. brain volumes) and for structural connectivity, this has been refuted 
by recent large-scale studies; see (Franke et al., 2016; Jahanshad et al., in preparation). For 
brain activity measured by fMRI, comparisons of cognitive and brain imaging studies for 
several genetic variants (Rose and Donohoe, 2013) and evidence from meta-analyses (Mier 
et al., 2010; Murphy et al., 2013) suggests that effect sizes might be larger. However, it is still 
unclear, how large the effects of publication bias on those results are (Murphy et al., 2013). 
Nevertheless, power estimates indicate that several hundred samples are needed, while 
the majority of studies discussed in this review had less than 50 participants per group (see 
Table 3). This has implications for the generalizability/replicability of positive findings (as the 
sample investigated may not sufficiently well represent the population it was sampled from) 
as well as harbouring the risk of false-negative findings (Button et al., 2013). Importantly, 
the term endophenotype has also often been misused in recent years, as for many of the 
so-called endophenotypes, the required criteria have not all been investigated. As such, 
many of the endophenotypes may not be intermediates between gene and behavioural 
phenotype, but rather be simple markers of disease (Kendler and Neale, 2010). Assessing, 
whether a brain phenotype observed for a risk genotype really mediates between the risk 
variant and the behavioural/clinical phenotype has been done in hardly any of the papers 
reviewed here. The paper by van der Meer and colleagues, in which such an analysis has 
been performed, shows the importance of such mediation analyses, as only a subgroup of 
the brain substrates of the gene-environment interaction investigated was also linked to 
ADHD severity (2015a).
Shortly summarizing the results of the review, our understanding of the mechanisms 
underlying the action of genetic risk factors for ADHD is still limited. A promising start has 
been made. We see, for example, that SLC6A3/DAT1 genotype regulates dopamine activity 
in striatal regions implicated in ADHD neurobiology (Spencer et al., 2013). Genetic variants 
also appear to affect brain structure and function beyond the regions of gene expression 
(Hong et al., 2014; van der Meer et al., 2014; Villemonteix et al., 2015), which is likely due 
to effects on structural and/or functional connectivity. Some studies reported differential 
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genotype effects for ADHD patients and controls, whereas others did not observe genotype 
by diagnosis interactions (Table 3). However, such findings have not been replicated yet, 
and genotype effects may differ in the context of other ADHD-related risk factors.
As there is room for improvement of study designs, and research focusing on new ADHD 
candidate genes identified through hypothesis-free, genome-wide association studies 
will soon be needed, we address main challenges and opportunities for imaging genetics 
studies in the following paragraph. Additionally, since imaging genetics approaches cannot 
explain the full complexity of a biological system such as the human brain, we also highlight 
additional levels of investigation and methodologies that can complement the insights 
provided by imaging genetics studies.
Main challenges and opportunities for imaging genetics studies
The size of individual studies is potentially the biggest challenge in imaging genetics today, 
as also discussed above. Given the small (to potentially modest) effect sizes to be expected 
(Franke et al., 2016; Murphy et al., 2013; Rose and Donohoe, 2013), larger samples are essential 
in order to gain the necessary statistical power.
Common confounding factors encountered in the published brain imaging genetics 
studies are mainly related to the study sample itself, and many are aggravated by the limited 
sample sizes used.
False-negative findings may occur due to the large variability of the ADHD phenotype. 
Additionally, comorbidities occur frequently in ADHD (Kessler et al., 2006; McGough et al., 
2005; Wilens et al., 2009), and differences in medication use may further increase phenotypic 
heterogeneity (Schweren et al., 2013). Together with the low effect sizes of individual 
common genetic variants and limited sample sizes, phenotypic heterogeneity in a sample 
challenges the discovery of effects. Meaningful subtyping of this heterogeneous condition 
to decrease phenotypic heterogeneity and maximize power might therefore be helpful. 
Besides that, potential differences of effects between age groups, with gender distribution, 
intelligence levels, and between ethnicities can still make it challenging to replicate and 
generalize findings.
Although most genetic risk factors investigated here were derived from studies of ADHD 
in children, our review shows that imaging genetics studies have employed childhood, 
adolescent, and adult ADHD samples. Knowing about the age-dependence of the genetic 
contribution to ADHD (Chang et al., 2013; Pingault et al., 2015), which e.g. results in differential 
association of SLC6A3/DAT1 (Franke et al., 2010) and DRD4 (Sanchez-Mora et al., 2011) with 
ADHD in children and adults, makes the definition of appropriate research questions highly 
important. Only one study thus far used a longitudinal approach, with a follow-up period of 
six years (Shaw et al., 2007b). Longitudinal samples are best suited to investigate potential 
age-dependent changes in the effects of genetic factors on the brain, and therefore more 
longitudinal studies of ADHD including imaging and genetic assessments are needed. This 
is especially important in light of a recent discussion on whether not only the onset of ADHD 
can occur in adulthood, but also whether childhood-onset and adult-onset ADHD may be 
distinct syndromes or trajectories (Agnew-Blais et al., 2016; Caye et al., 2016; Faraone and 
Biederman, 2016; Moffitt et al., 2015). Therefore, longitudinal studies including participants 
with remitted versus persistent ADHD, can help us in understanding the genetic and 
neurobiological correlates of this multifactorial disorder.
All of the imaging genetics studies reviewed here employed hypothesis-driven 
approaches. This means, that candidate genetic variants were only investigated in relation 
to specified candidate brain phenotypes and by this it severely limits our ability to create 
new knowledge on genetic effects on the brain. Even main effects of a variant may have 
been missed, as our ability to define the right hypotheses is hampered by the still so limited 
understanding of ADHD etiology. Besides that, most studies investigated single genetic 
variants (SNPs or VNTRs), although we know that frequently more than one risk allele exists 
in a single gene/locus; see e.g. (Schizophrenia Working Group of the Psychiatric Genomics et 
al., 2014). Also, only few studies looked for epistatic or gene-environment interaction effects.
In the face of limited sample sizes available for an imaging genetics study, data reduction 
strategies might help to preserve power. By moving to gene-based mass-univariate and 
multivariate statistics, it is possible to test the combined effect of multiple genetics variants 
in a single test statistic. Such models thus reduce the number of statistical tests, e.g. 
through gene-wide analyses, and - by explaining more phenotypic variance - may enable 
the discovery of gene effects that would have been otherwise undetectable with single 
variant methods (Bralten et al., 2011; Bralten et al., 2013; Hibar et al., 2011). Alternatively – or 
rather in addition - analyses of multiple genetic factors may be performed in the context 
of international collaborations, like ENIGMA and CHARGE (Psaty et al., 2009; Thompson et 
al., 2014) or using the publicly available data from large national research efforts (like the 
UK Biobank; http://www.ukbiobank.ac.uk/). These are mainly population studies, but since 
ADHD is currently viewed as an extreme on a continuum of population traits (Chen et al., 
2008; Larsson et al., 2013a), we can learn a lot from studies performed in healthy individuals. 
While for this review, we specifically selected studies that had included patients with ADHD, 
it is indeed apparent also from those studies that genes affect traits rather than disorders 
(Hoogman et al., 2011). We have referred to some relevant studies in healthy individuals 
already in the previous sections. An additional example is an fMRI study investigating a 
genetic variant in SNAP25, which was found associated with altered activation of the 
posterior cingulate cortex during a working memory task, a finding that was replicated in 
a second, independent sample (Soderqvist et al., 2010). With working memory being one of 
the cognitive domains affected in ADHD (Alderson et al., 2013), this finding can contribute 
to unravelling the biological pathways from gene to disease. However, some studies have 
also suggested differential genotype effects in subjects with ADHD and healthy participants 
(Durston et al., 2008; Monuteaux et al., 2008; Onnink et al., 2016). In those cases, imaging 
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genetics studies in healthy participants will not reveal the full spectrum of the genetic 
effects, and studies in patients are warranted. The ENIGMA-ADHD Working Group, with 
its sample spanning 60 years of the human lifespan (Hoogman et al., submitted), is an 
important resource for the investigation of diagnosis-specific effects.
There are a number of additional areas, in which we foresee that imaging genetics 
studies will profit from technical advances as well as recent insights into disease etiology. 
Importantly, a new GWAS meta-analysis is now underway by the ADHD Working Group 
of the Psychiatric Genomics Consortium (PGC) and the Danish iPSYCH consortium, which 
will provide several bona fide ADHD risk genes identified in hypothesis-free analyses (PGC 
and iPSYCH ADHD working groups, in preparation). Those will be interesting targets for 
investigation through imaging genetics approaches. In addition, the introduction of next 
generation sequencing (NGS) technology in psychiatric research will allow us to go beyond 
studying SNPs and VNTRs. It is likely that also more rare genetic variants, identified through 
exome and whole-genome sequencing will find their way into imaging genetics studies, 
e.g. through mutational load or burden tests (Medland et al., 2014).
Most imaging genetics studies in the field of ADHD have used MRI as their main brain 
imaging technique. For subcortical brain structures, grey matter volume has been the 
most frequently investigated characteristic. For the cortex, measurements of surface area 
(SA) and cortical thickness (CT) were found to be genetically and phenotypically rather 
independent (Winkler et al., 2010). Volume has been shown to be more closely related 
to SA than CT (Winkler et al., 2010). Therefore, it has been suggested that SA and CT 
measurements should be considered separately in imaging genetics studies (Winkler et al., 
2010), in addition or instead of cortical volume. Until now, only very few studies have made 
use of this opportunity, however. Because of its low invasiveness, high spatial resolution, 
and wide availability of MRI scanners, this technique dominates the brain imaging field. 
Imaging genetic studies investigating genetic variation in the SLC6A2/NET1, SLC6A3/DAT1, 
and DRD4 also used PET and SPECT (Table 3). These modalities enable direct localization 
and quantification of e.g. binding capacities of transporters and receptors, but are quite 
invasive. An alternative method for investigating the neurochemistry of the brain in vivo 
might be proton magnetic resonance spectroscopy (1H-MRS), which allows for non-invasive 
quantification of several neurometabolites, such as N-acetylaspartate, (phospho-) creatine, 
choline, myo-inositol, glutamate and glutamine, and gamma aminobutyric acid (GABA) 
(Naaijen et al., 2015). While no significant differences in GABA levels were found in ADHD 
compared with controls (Schur et al., 2016), a possible increased signal of a combination 
of glutamate, glutamine, and GABA in the striatum of ADHD patients was observed, as 
well as an increased signal in the ACC in a paediatric ADHD sample and a reduced signal 
in an adult ADHD sample; reviewed by (Naaijen et al., 2015). The neurodevelopmental 
changes in fronto-striatal glutamatergic circuits across the lifespan suggested by this 
might be interesting targets for future imaging genetics studies. By combining different 
methods, it should be possible to create a comprehensive picture of how polymorphisms 
in ADHD-related genes affect the brain at chemical, structural, and functional levels. To 
date, also no MEG genetics studies has been reported. The high temporal resolution of 
this modality might be of great additional value in understanding genetic effects on brain 
function. Resting-state fMRI studies are also still lacking from the imaging genetics literature. 
Especially the combination and integration of different modalities in the study of individual 
participants may provide more comprehensive insights into gene effects (Kobiella et al., 
2011). With respect to functional brain markers that might serve as a useful endophenotype, 
it is crucial to use a functional contrast that isolates brain activity specifically associated with 
the cognitive process of interest. For example, stop/NoGo and Go conditions in traditional 
stop-signal/Go-NoGo tasks not only differ in the involvement of response inhibition, but 
also in other processes such as novelty/probability of occurrence and perceptual processing 
(Boehler et al., 2010; Sanchez-Carmona et al., 2016). Results of a recent study highlight the 
importance of controlling for the different strategies adopted by participants to perform 
selective stopping tasks before analyzing brain activation patterns (Sanchez-Carmona et al., 
2016). Thus, activity emerging from a functional contrast (e.g., Go versus NoGo) will probably 
reflect a mixture of different processes. This is an important issue to be considered, when 
interpreting task-based fMRI studies and designing new studies.
Another opportunity to improve the design of imaging genetics studies is the use of 
mediation and moderation analyses. In mediation analysis, a causal explanation for the 
effect of an independent on a dependent variable is statistically modelled. The assumption 
of causality is important in this type of analysis and thus should be justified by a plausible 
biological theory or appropriate experimental constraints. In moderation analysis, the 
influence of a third variable on the association of an independent and dependent variable 
is modelled. The simple moderation and mediation models can be combined to account for 
more complex data structures and biological models (Hayes and Scharkow, 2013; van der 
Meer et al., 2014). Such models have e.g. been employed in psychological (Aram et al., 2010; 
Graziano et al., 2011) and medical research questions (Nigg et al., 2008), but could be also 
promising for analyses of the pathway from genes to phenotypes in complex disorders, such 
as ADHD, which involves different biological and non-biological factors acting synergistically 
during an individual’s developmental trajectory (Bale et al., 2010; Krain and Castellanos, 
2006). Indeed, van der Meer and coworkers recently used such analyses to inspect the 
moderation of the effect of stress on ADHD severity by the 5HTTLPR genetic variant. The 
researchers could show that an interaction of 5HTTLPR genotype and stress was associated 
with ADHD severity (van der Meer et al., 2014), and that this gene-environment interaction 
had several substrates in the brain. Importantly however, only a subset of those substrates 
did really mediate the effects of the gene-environment interaction, whereas others were 
epiphenomena (van der Meer et al., 2015a).
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While imaging genetics studies with the goal of mapping pathways from gene to disease 
up to now have always started with the selection of the candidate gene/variant to study, the 
advances brought about by international consortia now start to allow entirely data-driven 
approaches to be used for imaging genetics. For example, we have recently developed a 
comprehensive pipeline for the analysis of genetic overlap of GWAS results for disease risk 
(in that case schizophrenia risk data from the PGC) and the GWAS results for brain volume 
(Franke et al., 2016). The latter was based on data from the ENIGMA consortium (Medland 
et al., 2014; Stein et al., 2012; Thompson et al., 2014), in which MRI scans and genome-wide 
genotyping data from up to 30,717 individuals were analysed, and several genetic factors 
contributing to the volumes of specific brain structures were identified (Hibar et al., 2015). 
Finding such overlap between disease risk variants and those for brain phenotypes would 
be indicative of etiologic sharing, and would thus directly flag the pathways from gene 
to disease (Franke et al., 2016). For their previous studies, ENIGMA used mainly regional 
brain volume measures (Hibar et al., 2015; Stein et al., 2012), but one can also envisage 
more comprehensive voxel-wise genome-wide scans (vGWAS) to examine evidence 
for associations across the genome at each voxel in the brain image (Stein et al., 2010). 
While these approaches still are limited by the fact that a stringent correction for type 
I errors dramatically increases the threshold for statistical significance (as genomes and 
images are both highly dimensional), data reduction strategies are being devised that can 
preserve power in such settings (Medland et al., 2014). With respect to the different imaging 
modalities, structural MRI and DTI seem to be best suited for larger collaborations and data 
sharing, but also fMRI imaging genetics meta-analyses have been shown to be feasible (Mier 
et al., 2010; Murphy et al., 2013). First analyses of overlap between ADHD GWAS findings and 
results of the ENIGMA volume analyses are currently underway (Klein et al., in preparation).
Complementary methods for the evaluation of the mechanisms underlying 
ADHD risk genes
Imaging genetics analyses of the human brain provide information on the effect of ADHD risk 
genes/variants on brain structure, activity, and connectivity, but other levels of investigation 
are needed to provide a more complete picture (Figure 2). We also need information about 
the molecular networks, in which an ADHD gene acts, and the cellular processes that are 
affected by it. In the following section we highlight different methodologies and approaches 
that can be used to shed light on these additional levels of complexity contributing to the 
mechanisms underlying the effects of ADHD genes on behaviour and disease.
Figure 2: This schematic representation of the endophenotype concept shows the pathway from gene 
to disease at different levels of complexity in psychiatric genetics. The figure has been modified from a 
previous publication (Figure 1, (Franke et al., 2009)). Polygenicity (schematically depicted by gene A to 
I) is involved in causing disease symptoms. A reduced number of genes is involved in disease-related 
endophenotypes. These can be studied at various biological levels, e.g. biochemical processes and cell 
function can be assessed by biological assays in cell or animal models by measuring e.g. neuron morphology 
or synaptic functioning. Neuroimaging methods (structural and functional) can be applied to assess relevant 
endophenotypes at the level of brain morphology (‘Morphology brain region A-C’). Endophenotypes, 
related to the ‘function of brain units’, can be e.g. investigated by functional MRI or through performance 
measurements on neuropsychological tests. Aberrations at this level can result in altered behavior and 
disease-related behavioral traits, that subsequently lead to disease symptoms. Environmental influences 
can impact on all levels and need more attention in future studies. Bioinformatic pathway and network 
analyses can help to integrate data from various sources and to identify molecular networks or cellular 
processes in which ADHD-related genes are enriched.
Bioinformatics approaches help to integrate findings from different types of molecular studies
Bioinformatics is a broad field of research, which can support our efforts to map pathways 
from gene to disease in several different ways. A first goal to be pursued through 
bioinformatics analyses is the clarification of the actual effects of risk variants on gene 
expression and regulation. Risk variants for a disease are often found in non-protein 
coding sequences, and therefore the molecular consequences are difficult to evaluate 
(Civelek and Lusis, 2014; Paul et al., 2014). We will not go into this type of bioinformatics 
analyses any deeper, but would want to point the interested reader to a recent example 
for a comprehensive bioinformatic follow-up study demonstrating how to elucidate 
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the mechanisms by which a genetic risk variant (e.g. rs1344706; ZNF408A gene) confers 
susceptibility to disease, in this case schizophrenia and bipolar disorder (Hess et al., 2015).
Bioinformatics can also help to unravel the molecular networks and cellular processes 
that an ADHD risk gene is involved in. ADHD-associated genetic factors are distributed 
throughout the genome; however, they have been found to be enriched within functional 
categories. This clustering of ADHD-related genes within functional networks or pathways 
has helped to identify biological processes of importance to ADHD etiology. As also 
mentioned earlier, through those bioinformatics studies we learned that functions related 
to nervous system development, cell migration, neuron projection morphogenesis/neurite 
outgrowth, oxogenesis, cell-cell communication, glutamatergic synapse/receptor signalling, 
multicellular organismal development, RhoA signalling, glycosaminoglycan biosynthesis, 
fibroblast growth factor receptor activity, ion (potassium) channel function, transmembrane 
transport, as well as synaptic transmission, catecholamine metabolic processes, G-protein 
signalling and organonitrogen compound catabolic processes are enriched in the results of 
hypothesis-free, genome-wide ADHD-GWAS and CNV studies (Cristino et al., 2014; Hawi et 
al., 2015; Mooney et al., 2016; Poelmans et al., 2011; Thapar et al., 2015; Yang et al., 2013). Those 
studies mainly used childhood ADHD data; little is yet known about biological pathways 
leading to persistence of ADHD. A first, small-scale GWAS of rare and common genetic 
variants in adults with persistent ADHD showed that the top SNPs implicated biological 
pathways involved in the regulation of gene expression, cell adhesion, and inflammation 
(Zayats et al., 2015). The Network and Pathway Analysis Subgroup of the PGC focussed on 
common pathways underlying additional, ADHD-related psychiatric disorders in adults, 
i.e. schizophrenia, major depression, and bipolar disorder (The Network Pathway Analysis 
Subgroup of the Psychiatric Genomics Consortium, 2015). Histone methylation processes 
(playing important roles in the regulation of gene expression) showed the strongest 
association, and the researchers also found significant evidence for involvement of immune 
and neuronal signalling pathways and for processes occurring at the postsynaptic density 
(The Network Pathway Analysis Subgroup of the Psychiatric Genomics Consortium, 2015).
Comprehensive studies applied to the ADHD-related autism spectrum disorders (ASD) 
point out, how the combination and integration across several molecular modalities can 
advance our knowledge about pathways from gene to disease. For example, systematic 
integration of findings from multiple levels of genomics data and studies of mouse models 
highlighted the period of fetal development and the processes of chromatin structure, 
neurite outgrowth, steroidogenesis, synaptic function, and neuron-glial signalling (Chen 
et al., 2015; Poelmans et al., 2013). Additional studies revealed that ASD genes grouped 
together in terms of functional annotations, protein-protein interactions and coexpression 
(Ben-David and Shifman, 2012; Neale et al., 2012; O’Roak et al., 2012; Voineagu et al., 2011), 
and gene interaction and coevolutionary patterns (Gilman et al., 2011). By integrating gene 
expression data representing normal human fetal development, developmental timing and 
cellular specificity of the molecular pathways disrupted in ASD could be clarified (Parikshak 
et al., 2013; Willsey et al., 2013). Such integrative studies are still lacking for ADHD, but highly 
warranted in order to shed more light on the onset and neurodevelopmental trajectory of 
the disorder.
Animal models provide proof of causality for genes and molecular processes found associated 
with ADHD
The complexity and crucial role of the brain in the human body largely restrict studies in 
humans to the described non-invasive imaging methods for investigating brain structure 
and function. However, to fully understand the role of a disease gene in the fine-tuning 
of this sophisticated organ, we also need to be able to manipulate genes and monitor the 
effects of such manipulation on molecular and cellular processes. For this, animal models 
are indispensable. They can be genetically modified to enable determination of causality, 
have a natural complexity of the nervous system, and allow a tight control of environmental 
influences, including diet and drug delivery (Lange et al., 2012; van der Voet et al., 2016). 
During the last decades, studies were performed on several ADHD animal models, including 
monkey (Ma et al., 2005; Seu et al., 2009), rat (Ruocco et al., 2014; Russell et al., 1995; Williams 
et al., 2009b), mouse (Wallis et al., 2012; Zhu et al., 2014; Zimmermann et al., 2015), zebrafish 
(Lange et al., 2012), and fruit fly (van der Voet et al., 2016). The particularity of each model, 
like the different levels of complexity of the nervous system, provide complementary 
information to the broad picture of ADHD.
Most studies in monkeys were mainly based on drug administration to stimulate/inhibit 
certain brain regions or neurotransmitter receptors and to study its effect on a nearly as 
sophisticated brain structure as the human (Ma et al., 2005; Seu et al., 2009).
The rat and mouse models additionally provided evidence for involvement of genes 
in ADHD (Gainetdinov et al., 1999; Simchon et al., 2010; Wallis et al., 2012; Zhuang et al., 
2001; Zimmermann et al., 2015). This was done by measuring face-valid hyperactivity, 
inattentiveness, or impulsivity, and also looking for physiological and histological 
abnormalities in reverse and forward genetic approaches. Reverse genetic approaches 
are employed for disease candidate genes identified in human studies; the orthologues 
of the observed human genes are manipulated in the animal model to evoke measurable 
phenotypes and to study their involvement on cellular and/or behavioural levels (Rivero 
et al., 2013; Wallis et al., 2012). Forward genetics use the opposite tactic by studying inbred 
animal strains for ADHD-associated conducts, and analysing their protein expression 
pattern and behaviour (Dimatelis et al., 2015; Li et al., 2007b; Womersley et al., 2015). In 
reverse genetics approaches, early studies proved the involvement of candidate genes 
from association studies in ADHD, e.g. by showing ADHD-like behavioural phenotypes in 
Dat1 knock-out mice and the coloboma mouse showing a mutation in Snap25 (Giros et al., 
1996; Heyser et al., 1995). Most knock-out and transgenic mouse models targeted genes 
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involved in dopamine transmission. These mutant models provide an excellent opportunity 
to evaluate the contribution of dopamine-related processes to brain pathophysiology, to 
analyse the neuronal circuits and molecular mechanisms involved in the action of ADHD 
medication, and to test novel treatments for ADHD; for review see (Leo and Gainetdinov, 
2013). More recent studies of a mouse model containing a null mutation of the latrophilin 3 
gene (Lphn3), which showed a hyperactive phenotype in an open field test, revealed that this 
ADHD candidate gene is involved in gene expression regulation of monoamine signalling 
genes, such as dopamine and serotonin receptors and transporters, neurotransmitter 
metabolism genes, and neural development genes (Wallis et al., 2012). Additionally, actin 
depolymerising factor and n-cofillin double mutant mice displayed hyperlocomotion, 
impulsivity, impaired working memory, and disturbed morphology of striatal excitatory 
synapses, accompanied by strongly increased glutamate release (Zimmermann et al., 
2015). Of note, the hyperlocomotion and impulsivity were reversed by methylphenidate 
(Zimmermann et al., 2015).
While reverse genetics approaches are most often applied in ADHD research to date, 
forward genetics has led to new models to study ADHD, like the spontaneous hypertensive 
rat (SHR), which was created to study hypertension by inbreeding albino Wistar rats showing 
elevated blood pressure (Okamoto and Aoki, 1963). These rats also showed deficits in 
attention, and ADHD-associated conducts, such as increased impulsivity and hyperactivity, 
and are therefore widely employed as a model for ADHD (Li et al., 2007b; Williams et al., 
2009a, b, c). Studies of the molecular and cellular characteristics of this forward genetic model 
have provided evidence that proteins involved in energy metabolism, neurotransmitter 
function, neural development, and myelination are differently expressed in the striatum 
and PFC (Dimatelis et al., 2015; Womersley et al., 2015). The observed changes in the striatal 
energy metabolism support the neuroenergetics hypothesis of Killeen and colleagues, 
which states that inadequate neuronal energy supply can lead to ADHD symptoms (2013). 
Moreover, the GABAergic system was shown to be involved in ADHD-like behaviour of SHR 
rats by investigating the physiological response of GABA on hippocampal slices and finding 
GABA significantly altered during early-life stress in these animals (Sterley et al., 2013a, b).
Novel animal models for the study of ADHD include zebrafish (Danio rerio) and the 
fruit fly (Drosophila melanogaster) (Lange et al., 2012; van der Voet et al., 2016). These 
models have the great advantage of being relatively inexpensive, having a wide range 
of genomic tools available, and being highly suitable for fast, high throughput studies of 
(candidate) genes. The combination of those characteristics, with the availability of valid and 
quantifiable phenotypic readouts for ADHD-relevant traits makes these animal models a 
potent addition to non-invasive studies in humans. Even though both zebrafish and fruit fly 
diverged from the human lineage early in evolution, there is still a high level of conservation 
of neuronal genes; for example, in a screen for intellectual disability genes, more than 70% 
of candidate genes had an unambiguous orthologue in the fruit fly (Oortveld et al., 2013; van 
der Voet et al., 2014). Also genes involved in the phenotypic manifestation of hyperactivity 
were crucial during early evolution and thus can be found in species with a much simpler 
nervous system. Several studies show the strength of such models. In zebrafish, e.g. the 
orthologues of the human ADHD candidate genes LPHN3, PER1, and PER2 have been 
studied and shown to cause hyperactivity (Huang et al., 2015; Lange et al., 2012; Wang et 
al., 2015a). The lphn3.1 mutant fish showed, besides the behavioural phenotypes, misplaced 
dopamineric neurons in the brain (Lange et al., 2012). Functional studies on Per2 null mutants 
in zebrafish showed differential expression of the circadian clock genes aanat2 and bmal1b 
and indicated the involvement of Per2 in the circadian regulation (Wang et al., 2015a). In 
addition, per1b mutant fish display hyperactive and impulsivity-like behaviours and low 
levels of dopamine, of which hyperactivity could be rescued by ADHD medication (Huang 
et al., 2015). It could be shown that the circadian clock has direct influence on the structure 
and abundance of dopaminergic neurons and lower expression of transcription factors 
directly regulating development, maintenance and differentiation of these neurons (Huang 
et al., 2015). In the fruit fly, manipulation of the orthologues of the dopamine-related genes 
DAT1 and LPHN3, caused characteristic darkness-dependent hyperactivity, an ADHD-like 
behaviour (van der Voet et al., 2016). Also in those models, ADHD medication was able to 
reverse the behavioural phenotype (van der Voet et al., 2016). Finally, the vacuolar protein 
sorting-associated protein 4A (VPS4A) in the striatal node was significantly associated with 
dysfunctional reward, a cognitive (e.g. poor inhibitory control or timing estimation), but also 
affective (e.g. delay aversion or hyposensitivity to reward) deficit observed in ADHD (Jia et al., 
2016). The orthologue was studied in the fruit fly, showing that flies with an overexpression 
of Vps4 have a reduced overall activity similar to a Drd1 knockout fly, while a knockdown 
of Vps4 leads to hyperactivity, suggesting the involvement of VPS4A in the regulation of 
DRD1-mediated activity (Jia et al., 2016).
At the level of animal models, the integration of knowledge from models of different 
evolutional complexity will optimally support the elucidation of gene to disease pathways, 
as it is already apparent from the initial study of LPHN3 orthologues across mouse, zebrafish, 
and fruit fly.
Modelling psychiatric disorders at the cellular level by using human induced pluripotent stem 
cell (hiPSC)-derived neurons
ADHD is a multifactorial disorder, and in most patients, several to multiple genetic factors are 
likely to contribute to disease. Animal models are mostly based on highly penetrant single 
gene mutations, which limits the translation of findings from molecular and cellular levels 
to the human situation. A human model, especially one derived from a patient him-/herself, 
might therefore be preferable in certain situations. Until recently, the only way to study 
cellular processes and molecular pathways in patient brain cells was through post-mortem 
material. Due to the scarceness of available post-mortem brain tissues, only a very limited 
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number of studies was performed to date, concentrated on demonstrating an influence 
of ADHD-related genetic variants on gene expression (Brookes et al., 2010; Brookes et al., 
2007; Hawi et al., 2013b; Weber et al., 2015). Fortunately, cell reprogramming technology has 
been developed throughout the past decade, which provides a powerful tool to simulate 
neural developmental processes in vitro in a petri dish (Brennand et al., 2015b; Takahashi et 
al., 2007; Yu et al., 2007). Neurons from both healthy individuals and psychiatric patients can 
be derived by 1) reprogramming human skin fibroblasts or blood mononuclear cells into 
induced pluripotent stem cells (iPSCs) and then differentiating these into neurons (Zhang et 
al., 2013), or by 2) directly reprogramming skin fibroblasts into neural stem cells or neurons 
(Brennand and Gage, 2012; Pang et al., 2011; Vadodaria et al., 2015). The human induced 
pluripotent stem cell (hiPSC)-derived neurons from a patient then have a genetic background 
identical to the disorder state, and thereby provide the possibility to characterize the effects 
of the cocktail of genetic perturbations leading to disease in this patient (Brennand et al., 
2015a; Lim et al., 2015; Madison et al., 2015; O’Shea and McInnis, 2015; Wang et al., 2015b). 
Such effects may be specific to cell types and/or specific developmental stages (Duan, 2015; 
Hockemeyer and Jaenisch, 2016). Moreover, a temporal analysis of disease initiation and 
progression can be performed in the cell type(s) most relevant to a disorder (Brennand et 
al., 2012). For example, studying hiPSC neurons from patients with disease-associated large 
CNVs provides the opportunity to perform comprehensive molecular analyses of the effects 
of these large CNVs in several cell lineages (Urban and Purmann, 2015). Until now, several 
studies were published using hiPSC-derived neurons from patients with ASD, schizophrenia, 
or bipolar disorder (Ananiev et al., 2011; Brennand et al., 2011; Chiang et al., 2011; Marchetto 
et al., 2010; Sheridan et al., 2011; Urbach et al., 2010; Wen et al., 2014). For example, hiPSC-
derived neurons from patients with schizophrenia were shown to have synapse deficits and 
transcriptional dysregulation (Wen et al., 2014). Additionally, by comparing hiPSC-derived 
neurons from patients with bipolar disorder and controls, alterations in key components 
of the microRNA processing pathway were identified, potentially altering neuronal cell fate 
determination (O’Shea and McInnis, 2015). To overcome confounding effects of variable 
genetic backgrounds, when comparing cells from patients to those from healthy controls, 
genome-editing technology can be applied (Duan, 2015), such as Zinc-finger nucleases 
(ZFN) (Reinhardt et al., 2013), transcription activator-like effector nucleases (TALEN) (Wen et 
al., 2014), and recently developed clustered regularly interspaced short palindromic repeats 
(CRISPR) (Liu et al., 2016; Ran et al., 2013; Wang et al., 2015b). Such genome-editing enables 
the generation of isogenic hiPSC-derived neurons that differ only at the genetic site of 
interest (Bedell et al., 2012; Choi et al., 2013; Ding et al., 2013). In this way, specific mutations 
can be either introduced in control cells or corrected in patient cells to investigate causality 
(Duan, 2015; Hendriks et al., 2016).
Beyond mechanistic insights, hiPSC neurons might also serve as a platform for high 
throughput screening to identify novel therapeutics for psychiatric disorders (Schadt et al., 
2014). For example, the ability to test drugs to rescue synaptic deficiency in Rett syndrome 
neurons has been demonstrated (Brennand et al., 2012). Generally, it is suggested that these 
cell models are suited for longitudinal observations, studying on-off-medication effects, 
and investigating the mechanisms of comorbid disorders in individual patients (O’Shea 
and McInnis, 2015).
A current limitation of hiPSC-based models is the high heterogeneity of the derived 
differentiated neuronal populations (Gore et al., 2011; Hu et al., 2010; Lister et al., 2011; 
Osafune et al., 2008). Although almost pure glutamatergic neurons can be differentiated 
from hiPSCs, the differentiation efficiency for other types of neurons, such as dopaminergic, 
GABAergic, serotonergic, or cholinergic neurons, is relatively low, which can cause variability 
in the outcome of in vitro experiments (Hu et al., 2016; Liu et al., 2013b; Swistowski et al., 
2010; Vadodaria et al., 2015; Zhang et al., 2013). Therefore, ideally a comparison of several 
hiPSC-derived neuronal lines from multiple patients should be performed (Brennand and 
Gage, 2012). It seems advantageous to model the psychiatric disorders in a pure, specified 
type of neuron; however, it is also reasonable to carry out investigations at the network level 
in different types of neurons interacting, better mimicking the multidimensional integration 
in the brain through 3D culture systems or brain ‘organoids’, which are currently being 
developed (Kim et al., 2015; Lancaster et al., 2013).
Based on the above, it is clear that the reprogramming technology will revolutionize our 
use of model systems. Although still very much under development, and not yet applied to 
ADHD risk genes, first results for other psychiatric disorders already suggest that valuable 
findings about molecular and cellular pathways from gene to disease can be derived from 
iPSC-derived neurons.
Conclusion
Results from studies described in this review show that imaging genetics approaches are 
highly suitable to provide more insight into the pathways from gene to behaviour via 
the brain in ADHD. However, this field is clearly still in its early stages. Inconsistency of 
findings, due to the use of relatively small sample sizes, clinical and biological heterogeneity 
of ADHD, methodological differences in study design, and analysis methodology, make 
it difficult, yet, to draw firm conclusions about effects of genes on brain morphology, 
function, and connectivity. Individual genes need to be investigated more extensively and 
in larger samples, and additional genes need to be studied – preferably focussing on those 
implicated in ADHD through genome-wide, hypothesis-free approaches. We emphasize that 
a combination and integration of imaging genetics studies with complementary approaches 
at different levels of biological complexity - including bioinformatics as well as cell and 
animal models - will be necessary to fully map the biological pathways from gene to disease.
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Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neuropsychiatric disorder 
with a complex genetic background. The G protein-coupled receptor kinase interacting 
ArfGAP 1 (GIT1) gene was previously associated with ADHD. We aimed at replicating the 
association of GIT1 with ADHD and investigated its role in cognitive and brain phenotypes. 
Gene-wide and single variant association analyses for GIT1 were performed for three 
cohorts: (1) the ADHD meta-analysis data set of the Psychiatric Genomics Consortium 
(PGC, N=19,210), (2) the Dutch cohort of the International Multicentre persistent ADHD 
CollaboraTion (IMpACT-NL, N=225), and (3) the Brain Imaging Genetics cohort (BIG, N=1,300). 
Furthermore, functionality of the rs550818 variant as an expression quantitative trait locus 
(eQTL) for GIT1 was assessed in human blood samples. By using Drosophila melanogaster 
as a biological model system, we manipulated Git expression according to the outcome of 
the expression result and studied the effect of Git knockdown on neuronal morphology 
and locomotor activity. Association of rs550818 with ADHD was not confirmed, nor did a 
combination of variants in GIT1 show association with ADHD or any related measures in 
either of the investigated cohorts. However, the rs550818 risk-genotype did reduce GIT1 
expression level. Git knockdown in Drosophila caused abnormal synapse and dendrite 
morphology, but did not affect locomotor activity. In summary, we could not confirm GIT1 
as an ADHD candidate gene, while rs550818 was found to be an eQTL for GIT1. Despite GIT1’s 
regulation of neuronal morphology, alterations in gene expression do not appear to have 
ADHD-related behavioral consequences.
Keywords: GIT1, ADHD, brain imaging genetics, eQTL, Drosophila melanogaster
Introduction
Attention Deficit/Hyperactivity Disorder (ADHD) is a common and highly heritable 
neuropsychiatric disorder (heritability 70-80% (Burt, 2009; Faraone et al., 2005)), with 
prevalence rates of 5-6% in childhood (American Psychiatric Association, 2013; Polanczyk 
et al., 2007). Clinically, ADHD is characterized by two core symptom domains: inattention 
and hyperactivity/impulsivity (American Psychiatric Association, 2013). At least 15% and 
up to 60% of all patients diagnosed in childhood still meet full ADHD criteria when they 
reach adulthood; prevalence rates of persistent ADHD in adults range between 2.5 and 
4.9% (Simon et al., 2009). The clinical manifestation of adult ADHD may differ from that of 
childhood ADHD, i.e. by less obvious symptoms of hyperactivity and impulsivity (Buitelaar, 
2011; Haavik et al., 2010). However, adult individuals with ADHD might be the most severe 
cases, given the lifelong impairment (Dalsgaard et al., 2015; Franke et al., 2012).
Despite its high heritability, identifying ADHD risk genes has been difficult (Franke et 
al., 2009a; Gizer et al., 2009), Due to the disorder’s complex genetic background (Franke 
et al., 2012). Because of the high prevalence of ADHD in the population, the search for 
genetic factors has mainly focused on common genetic variants (mainly single nucleotide 
polymorphisms (SNPs)) that occur quite frequently and have generally small effect sizes (Li 
et al., 2014; Neale et al., 2010b). Hypothesis-free genome-wide association studies (GWAS) 
have thus been the main approach to study the genetics of ADHD during the last ten years. 
However, with eleven GWAS published to date (Hinney et al., 2011; Lasky-Su et al., 2008a; 
Lasky-Su et al., 2008b; Lesch et al., 2008; Mick et al., 2010; Neale et al., 2008; Neale et al., 
2010a; Sanchez-Mora et al., 2014; Sonuga-Barke et al., 2008; Stergiakouli et al., 2012; Yang et 
al., 2013), no genome-wide significant hit has yet been identified for ADHD (Li et al., 2014; 
Neale et al., 2010b). A review of the first five hypothesis-free GWAS approaches for ADHD 
reported only limited overlap between the different studies, except for an association with 
cadherin 13 (CDH13) (Franke et al., 2009b). So far, only a handful of susceptibility genes have 
been identified through meta-analysis, all of which confer only small increases in disease risk 
(Gizer et al., 2009). Recently, the G protein-coupled receptor kinase interacting ArfGAP 1 gene 
(GIT1; Gene ID 28964), was suggested as a novel candidate gene for ADHD (Won et al., 2011). 
The GIT1 gene comprises 21 exons and spans 16,123 base pairs. It is located on chromosome 
17p11.2 and plays an important role in the regulation of cell migration (Penela et al., 2014), 
neurite outgrowth (Albertinazzi et al., 2003; Za et al., 2006) and synapse formation (Kim et 
al., 2003; Menon et al., 2010; Saneyoshi et al., 2008; Segura et al., 2007; Zhang et al., 2003; 
Zhang et al., 2005). In this, the finding of association of GIT1 with ADHD fits well with earlier 
work of our group, showing convergence of top-findings from five genome-wide association 
studies in ADHD on the biological process of neurite outgrowth (Poelmans et al., 2011). Out 
of 27-tested single nucleotide polymorphisms (SNPs), the intronic SNP rs550818 in the GIT1 
gene was associated with ADHD in a Korean childhood sample (N=388; adjusted odds ratio 
9
360 361
Converging evidence does not support GIT1 as an ADHD risk geneChapter 9
= 2.66) (Won et al., 2011). The authors reported that the minor allele of this SNP caused a 
reduction of GIT1 transcription in a luciferase reporter assay in HEK293 cells, indicating that 
it is a functional variant (Won et al., 2011). In the same report, Git1-deficient mice displayed 
ADHD-like symptoms, such as hyperactivity, but also enhanced theta rhythms, and impaired 
memory. All of these symptoms were reversed by amphetamine, a stimulant medication 
used for ADHD treatment (Won et al., 2011). However, the association between the SNP 
rs550818 and ADHD risk was not replicated in a Brazilian childhood and adolescent ADHD 
sample (N=646) (Salatino-Oliveira et al., 2012). To our knowledge, no other replications of 
the finding has been published yet, although a recent review listed the GIT1 association as 
a reproducible genetic association for ADHD (Hawi et al., 2015).
In the current study we investigated the role of GIT1 (including SNP rs550818) in ADHD 
risk and related traits. First, we attempted to replicate the association between GIT1 and 
ADHD in the largest data set available, the Psychiatric Genomics Consortium’s (PGC; http://
www.med.unc.edu/pgc/) ADHD data (N=19,210). We then assessed the effect of GIT1 
variation on ADHD-related neurocognition, brain volume measures and white matter 
integrity in adult ADHD patients and controls. We further examined whether SNP rs550818 
alters GIT1 mRNA expression in blood cells from patients with ADHD and controls. Lastly, we 
characterized the effects of downregulating expression of Git in Drosophila melanogaster, 
using synaptic and dendritic morphology and locomotor activity as read-outs.
Material and Methods
Cohorts
PGC ADHD meta-analysis
Data from nine studies including 5,621 cases and 13,589 controls were available for analysis. 
Samples were of Caucasian or Han Chinese origin and met diagnostic criteria according 
to the DSM-IV (Supplementary Table 1). The meta-analytic data used in this study were 
available as summary statistics, including genome-wide SNP data with corresponding 
p-values and odds ratios.
Dutch cohort of the International Multicentre persistent ADHD CollaboraTion (IMpACT-NL)
A total of 225 individuals (115 adult ADHD patients, 110 healthy control subjects matched for 
age, gender, and IQ) from IMpACT-NL (Franke and Reif, 2013; Franke et al., 2010a) participated 
in this study. Participants were recruited from the department of Psychiatry of the Radboud 
university medical center in Nijmegen or through advertisements. Patients were included 
if they met DSM-IV-TR criteria for ADHD in childhood as well as in adulthood. Participants 
had a mean age of 37.42 years (range 18-63), and 43.1% of the sample was male. For genetic 
data analysis, subjects were not allowed to be genetically related to each other. The study 
was approved by the regional ethics committee. Written informed consent was obtained 
from all participants. A more detailed description of the IMpACT-NL cohort can be found 
in the supplementary material.
Brain Imaging Genetics Study (BIG)
The study sample consisted of healthy adult volunteers taking part in the diverse studies 
conducted at the Donders Institute for Brain, Cognition and Behaviour in Nijmegen, The 
Netherlands (Franke et al., 2010b). Genome-wide genotyping data and structural Magnetic 
Resonance Imaging (MRI) data was available for 1,300 subjects (Guadalupe et al., 2014; 
Hoogman et al., 2014). Participants were highly educated (80% with a bachelor student 
level or higher), of Caucasian descent, and had no self-reported neurological or psychiatric 
history. The mean age was 22.9 years (range 18-40 years), and 42.7% of the participants were 
males. All participants gave written informed consent and the study was approved by the 
regional ethics committee.
Demographic characteristics of the PGC, IMpACT-NL, and BIG cohorts are presented in 
Table 1.
Table 1. Demographic characteristics of the different cohorts.
PGC (N = 19,210) IMpACT-NL (N = 225) BIG (N = 1,300)
Age a NA 37.42 (10.94), 18-63 22.9 (3.82), 18-40
Gender NA 43.1% male 42.7% male
Cases/controls 5,621/13,589 115/110 ---
a Data are shown as mean (standard deviation), minimum – maximum.
Neuropsychological data
Data on cognitive functioning was available for participants of the IMpACT-NL cohort. They 
were assessed with a neuropsychological test battery composed to cover multiple cognitive 
domains earlier found affected in ADHD (Mostert et al., submitted). This included executive 
functioning, timing of motor output, reaction time, delay aversion, impulsivity, inhibition, 
attention, vigilance, working memory, motor speed, and set shifting. The neuropsychological 
tests were always administered in the same order across ADHD patients and healthy controls. 
The following tasks and variables were selected for association analyses with the GIT1 locus, 
because related tasks were either studied by Won and colleagues (continuous performance 
task; (Won et al., 2011)), or were affected in Git1 knockout mice (working memory (Won et 
al., 2011)): (1) sustained attention dots (SAD) task ((Huijbregts et al., 2008), variables: mean 
series completion time, standard deviation (SD) series completion time, SD series errors and 
the response bias) and (2) Digit span task ((Wechsler, 1997), variables: raw scores on forward 
and backward condition). Additionally, we explored the effect of the GIT1 locus on the 
9
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following tasks and variables, because performance on these cognitive domains was shown 
to be different between ADHD patients and controls in our IMpACT-NL cohort (Mostert et 
al., submitted): (1) Flanker task ((Huijbregts et al., 2002), variable: total SD of reaction time 
(RT)), (2) Sustained Attention to Response Task (SART, (Smit et al., 2004), variable: SD of 
RT for hits), (3) Delay discounting task ((Dom et al., 2006), K100), and (4) Trail-making task 
((Kortte et al., 2002), variables: time to complete part A and B). The following variables were 
log-transformed to achieve a normal distribution: SAD task standard deviation (SD) series 
completion time, SAD task SD series errors, SART SD of reaction time (RT), delay discounting 
task K100. For more detailed information on the tasks and variables see Supplementary 
Table 2.
Neuroimaging, MRI acquisition and data processing
Because altered brain volumes have been consistently found to be associated with ADHD 
(Castellanos et al., 2002; Frodl and Skokauskas, 2012), and Git1 was shown to affect neurite 
outgrowth (Albertinazzi et al., 2003; Za et al., 2006), spine morphogenesis (Segura et al., 2007; 
Zhang et al., 2005), and synapse formation (Kim et al., 2003; Menon et al., 2010; Saneyoshi 
et al., 2008; Segura et al., 2007; Zhang et al., 2003; Zhang et al., 2005) in mice, we aimed to 
investigate the role of genetic variation within the GIT1 locus on total brain volume, gray 
and white matter volume and white matter integrity in two different cohorts.
IMpACT-NL
T1-weighted MRI images were acquired previously and details of acquisition and processing 
are described in the supplementary material and elsewhere (Onnink et al., 2014). For 203 
samples (101 ADHD patients and 102 healthy controls) both MRI and genetic data was 
available.
BIG
Anatomical T1-weighted whole brain MPRAGE scans were either acquired at a 1.5 Tesla 
scanner (Sonata and Avanto, Siemens Medical Systems, Erlangen, Germany) or at a 3 Tesla 
scanner (Trio and TrioTim, Siemens Medical Systems, Erlangen, Germany) at the Donders 
Centre for Cognitive Neuroimaging (Nijmegen, The Netherlands). The imaging protocols of 
the T1 scans included slight variations, because images were acquired during several studies. 
Details of these variations on the protocol used in the IMpACT-NL study and parameters are 
described in the supplementary material and elsewhere (Hoogman et al., 2014). For 1,300 
subjects both MRI and genetic data were available.
Genetic data
PGC
We obtained access to genome-wide summary statistics from the most recent PGC ADHD 
meta-analysis. Detailed procedures of DNA isolation, whole-genome genotyping and 
imputation were described previously (Neale et al., 2010b). Shortly, genome-wide data was 
obtained from different genotyping arrays (Supplementary Table 1) and was imputed 
using 1000 Genomes data as a reference panel (Phase I integrated variant set release (v3) 
in NCBI build 37 (hg19) coordinates) for autosomal SNPs (Genomes Project et al., 2010). 
Meta-analytic data were processed through a stringent quality control pipeline applied at 
the PGC (Neale et al., 2010b).
IMpACT-NL
From all IMpACT-NL participants, DNA was either isolated from saliva using Oragene 
containers (DNA Genotek, Ottawa, Ontario, Canada) or from EDTA blood samples according 
to manufacturer’s protocol at the department of Human Genetics of the Radboud university 
medical center. Genome-wide genotyping of 235 IMpACT subjects (122 cases, 113 controls) 
was performed using the Human CytoSNP 12 version 2 genotyping BeadChip (Illumina Inc., 
San Diego, California, USA). Details on data quality control and imputation procedure can 
be found in the supplementary material.
BIG
DNA isolation, whole-genome genotyping, and imputation were described previously 
(Guadalupe et al., 2014; Hoogman et al., 2014). Shortly, saliva was collected using Oragene 
containers (DNA Genotek, Ottawa, ON, Canada). Whole genome genotyping was done 
using Affymetrix GeneChip SNP, 6.0 (Affymetrix Inc., Santa Clara, CA). For imputation, the 
1000 Genomes data was used as a reference panel (Phase 1.v3 EUR (Genomes Project et 
al., 2010)) and the imputation of autosomal SNPs was done following the Enhancing Neuro 
Imaging Genetics Through Meta Analysis (ENIGMA) protocol (according to NCBI build 37 
(hg19) coordinates; http://enigma.ini.usc.edu/).
Association of the GIT1 locus with ADHD and ADHD-related quantitative traits
Association analyses between GIT1, ADHD, and related traits were done in two ways. First, we 
performed a single SNP association between the earlier described ADHD-risk SNP rs550818, 
ADHD status, and/or ADHD-related quantitative traits. Second, we analyzed the association 
of the joint effect of all common genetic variants in the GIT1 locus with ADHD status and/
or ADHD-related quantitative traits.
9
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Single-SNP analyses
The SNP rs550818 lies within intron 20 of the GIT1 gene on chromosome 17, at base pair 
position 27901975 (hg19/build 37). The A-allele has been reported to be the risk allele. The 
minor allele frequency (MAF) and the R2 estimates for rs550818 in the different samples are 
shown in Supplementary Table 4.
For the PGC data, the association p-value for rs550818 and ADHD status was extracted 
from the summary statistics. For the IMpACT-NL sample, association analyses for the self-
reported symptom counts (hyperactivity/impulsivity, inattentive and combined symptoms) 
and the GIT1 locus were performed in cases only (N=115), given the known case-control 
differences for these phenotypes. We applied a linear regression with an additive genetic 
model and a missing data likelihood score test in SNPTEST (version 2.4.1) (Marchini et al., 
2007). Age and gender were used as covariates for all analyses. For the neuropsychological 
data, analyses were performed in the same way, including age, gender, and diagnostic status 
as covariates in the model (N≥178). For the analysis of MRI-derived traits, age, gender, and 
total white matter volume (when analyzing gray matter) or total gray matter volume (when 
analyzing white matter) were included as covariates for the association analyses (N=203). 
Diagnostic status was not used as a covariate, because we found no differences in brain 
volume between ADHD patients and healthy controls (Supplementary Table 5). For the 
BIG sample (N=1,300), association analyses for the GIT1 locus were performed using linear 
regression for total brain volume, gray and white matter by using genotypic data and the 
“linear” command in PLINK (version 1.07) (Purcell et al., 2007). Age, gender, magnetic field 
strength, and total white matter volume (when analyzing gray matter) or total gray matter 
volume (when analyzing white matter) were used as covariates. Association p-values for 
rs550818 were extracted from regression results of the individual analyses.
To test the effect of rs550818 genotype on local gray and white matter volumetric and 
integrity differences, we performed a voxel-based morphometry (VBM; (Ashburner and 
Friston, 2000)) analysis on the T1 (N=1,261) and DTI data (N=255) in the BIG cohort. The 
genotypes of SNP rs550818 were coded to represent a linear allelic additive effect (0, 1 or 
2). Age, gender, and magnetic field strength were used as covariates. Gray and white matter 
cluster extent was analyzed separately and tested across the entire brain using a PFWE < 
0.05 and a cluster-forming threshold of Puncorrected < 0.001 (Hoogman et al., 2014). Fractional 
anisotropy (FA) and mean diffusivity (MD) were tested in the same manner, except that FA 
comparisons were restricted to voxels having anisotropy > 0.1.
Gene-based analysis
The GIT1 locus was defined as the GIT1 gene ± 25 kb flanking regions in order to capture 
regulatory elements (Bralten et al., 2011). The gene range was selected according to the 
UCSC Genome Bioinformatics Site (http://genome.ucsc.edu/). Gene-based tests of the GIT1 
locus were performed using the offline version of the versatile gene-based test for genome-
wide association studies (VEGAS) software (Liu et al., 2010). This program uses SNP names 
(rs-numbers) and p-values as input to estimate gene-based effects. The approach takes LD 
between markers in a gene into account by using simulations based on the LD structure of a 
custom set of reference individuals (Liu et al., 2010). As a reference panel we used genotypic 
data from BIG (Guadalupe et al., 2014) imputed with 1000 Genomes Phase 1.v3 EUR reference 
panel (Genomes Project et al., 2010). VEGAS assigns SNPs to autosomal genes according to 
their position in hg19/build 37. A corresponding gene list was downloaded from http://www.
biomart.org/biomart/martview. Multiple testing was based on the number of simulations 
per gene and was set to 10,000.
For the PGC ADHD meta-analysis data set, SNPs were included in this analysis if they 
showed an imputation score (R2) ≥ 0.6 and MAF ≥ 0.01 in unaffected subjects and Hardy-
Weinberg equilibrium (HWE) P > 10−6. Out of 126 common genetic variants within the 
GIT1 locus, 97 SNPs had valid rs-numbers and were considered in the subsequent analysis 
(Supplementary Table 3). In the data from IMpACT-NL, we analyzed the association of 
the GIT1 locus (52 SNPs) with self-reported symptoms counts (total number of symptoms, 
number of inattentive symptoms, number of hyperactive/impulsive symptoms), 
neuropsychological variables, and MRI derived traits, such as total brain volume and gray 
and white matter volume (Supplementary Table 3). Subsequent gene-based tests used the 
results from the individual regression analyses as input for VEGAS described above. For the 
data from the BIG cohort, we analyzed the association of the GIT1 locus with MRI-derived 
traits, i.e. total brain volume, gray and white matter volumes. SNP data selected required 
an imputation score (R2) ≥ 0.3 and MAF ≥ 0.01. Forty-three SNPs within the GIT1 locus were 
considered in subsequent analyses (Supplementary Table 3). Gene-based tests of the 
GIT1 locus were performed with the offline version of VEGAS using the results from the 
individual regression analyses as described above. The multiple testing-corrected p-value 
for significance of the analyses described above, derived from 10,000 permutations, was 
determined as 0.05 divided by the number of tested variables.
Power calculation
The Genetic Power Calculator (GPC) (Purcell et al., 2003) was used to define the power 
our samples had at either a range of genotype relative risks (GRR, for the PGC ADHD 
meta-analytic data, testing for case-control discrete trait) or additive QTL variances (for 
the IMpACT-NL and BIG cohort, testing for quantitative association) at α=0.05. We used 
a disease prevalence of 5% (as estimated by Polanczyk et al.(Polanczyk et al., 2007), and 
a multiplicative model (power calculation based on the allelic test). The actual risk allele 
frequencies of SNP rs550818 for the individual cohorts were included in the power analysis.
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Functional characterization of GIT1: effect of rs550818 on GIT1 mRNA 
expression
We specifically tested for the effect of rs550818 genotype on mRNA expression of GIT1 
in human blood samples from the IMpACT-NL cohort. From 148 consecutive IMpACT-NL 
participants blood samples for RNA isolation were collected in PAXgene Blood RNA Tubes 
(produced by QIAGEN GmbH for PreAnalytiX GmbH, Hombrechtikon, Switzerland) at the 
Radboud university medical center.
Validation of rs550818 genotype by TaqMan genotyping assay
Rs550818 genotypes from the genome-wide genotyping array were validated for the 
IMpACT-NL samples prior to this analysis. Allelic discrimination of rs550818 was performed 
using Taqman® SNP Genotyping assay (Life Technologies, Nieuwerkerk a/d IJssel, The 
Netherlands; Assay ID: C_2416538_10). For a detailed description of the TaqMan genotyping 
assay conditions see the supplementary material.
RNA isolation and cDNA synthesis
Total RNA was extracted from PAXgene blood RNA tubes at the department of Human 
Genetics of the Radboud university medical center using the Qiagen PAXgene Blood RNA Kit 
(produced by QIAGEN GmbH for PreAnalytiX GmbH) according to manufacturer’s protocol. 
RNA integrity was assessed by gel electrophoresis. The cDNA was synthesized from 500 ng 
RNA in a reaction volume of 20 µl using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories 
B.V. Veenendaal, The Netherlands) according to manufacturer’s protocol. For the expression 
analysis a 1/3.75 dilution was used.
Gene expression analysis using Taqman assays
GIT1 mRNA gene expression was assessed using Taqman gene expression analysis (Taqman 
assay Hs01063104_m1 for GIT1 [Life Technologies]) according to manufacturer’s protocol. 
Glucuronidase beta (GUSB), was taken along as reference gene (Taqman assay Hs00939627_
m1 for GUSB [Life Technologies]). For a detailed description of the gene expression analysis 
conditions see the supplementary material. All measurements were performed in triplicate, 
and blanks were taken along as quality control during mRNA expression assessment. 
Results were analyzed with the 7500 Software v2.0.6 (Life Technologies) using an automatic 
threshold. Only samples with standard deviations of the triplicates ≤ 0.25 were considered 
for subsequent analysis, which resulted in 121 samples. As a calibrator sample the mean 
ΔCT of all control samples with the major genotype was used. Data was visualized using 
GraphPad prism (version 5.03), and the mean and a 95% confidence interval are shown.
Statistical analysis
GIT1 mRNA expression data was normally distributed (Supplementary Figure 1). We 
determined the effect of rs550818 genotype on GIT1 mRNA expression based on three 
genotype groups (independent variable) using linear regression analysis with an additive 
genetic model. We also assessed whether GIT1 mRNA expression levels differed between 
healthy controls and participants with ADHD using a two-tailed Student’s t-test. All data 
analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 
20.0 (IBM Corp. Released 2011, IBM SPSS Statistics for Windows, Version 20.0 Armonk, NY: 
IBM Corp.).
Functional characterization of Git in Drosophila
Genetics and breeding
Conditional knockdown of the Drosophila GIT1 ortholog Git (CG16728) in all or specifically in 
multidendrite neurons was achieved with the UAS-GAL4 system (Brand and Perrimon, 1993) 
using promoter lines w; UAS-Dcr-2; elav-GAL4 and 477-GAL4, UAS-mCD8::GFP; ppk-GAL4, 
respectively (Dietzl et al., 2007). The Git UAS-RNAi line (vdrc108123 UAS-RNAiGit/CyO) and its 
genetic background control (vdrc60100) were obtained from the Vienna Drosophila RNAi 
Centre (VDRC, (Dietzl et al., 2007). For synapse and dendrite experiments, stock vdrc108123 
was rebalanced with CyO-GFP to allow for selection of knockdown larvae. Crosses were 
cultured according to standard procedures at 28°C.
Neuronal morphology of synapses at the neuromuscular junction
Synapses at the type 1b neuromuscular junctions (NMJs) of muscle 4 were analyzed as 
described previously (Schuurs-Hoeijmakers et al., 2012). Male L3-stage larvae of the 
genotypes UAS-RNAiGit/UAS-Dcr-2; +/elav-GAL4 and the respective control +/UAS-Dcr-2; +/
elav-GAL4 were dissected following a dorsal midline incision (Brent et al., 2009). Dissected 
larvae were fixed in 3.7% paraformaldehyde for 25 min, washed in PBS containing 0.3% 
Triton X-100 (PBST), stained with 1:125 anti-brp (nc82), washed in PBST, and stained with 1:500 
Goat anti-Mouse Alexa Fluor 488 and 1:25 anti-dlg1 antibody covalently coupled to Goat 
anti-mouse Alexa Fluor 568 IgG1 (Developmental Studies Hybridoma Bank (DSHB), Iowa 
City, IA, USA; Zenon® Antibody Labeling Kit, Life Technologies). The larvae were mounted 
in Prolong anti-fade Gold (Life technologies). Images were taken with a Zeiss Axio Imager 
Z2 microscope (63x magnification), subsequently stacked and synaptic area, branches and 
active zones were analyzed in Fiji (Schindelin et al., 2012; Schuurs-Hoeijmakers et al., 2012).. 
For the Git RNAi genotype at least 19 synapses and for the control genotype at least 29 
synapses were analyzed. Statistical analysis was performed in Graphpad prism (version 5.00 
for Windows, GraphPad Software, San Diego California USA, www.graphpad.com).
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Dendritic morphology of class IV dendritic arborization neurons
Dissection and immunostaining was performed as described above, but for imaging 
the dorsal dendritic arborization C (ddaC) class IV dendritic arborization neurons larval 
were opened along the ventral midline (Brent et al., 2009). Genotypes analyzed were Git 
RNAi: UAS-RNAiGit/477-GAL4, UAS-mCD8::GFP; +/ppk-GAL4), and the control: +/477-GAL4, 
UAS-mCD8::GFP; +/ppk-GAL4. The 477 and ppk promoters simultaneously drive RNAi and 
expression of mCD8::GFP in a tissue-specific manner. Antibodies used were 1:100 Rat anti-
mCD8 primary antibody and 1:200 Goat-anti-Rat Alexa Fluor 488. Z-stack images were taken 
at a Zeiss LSM 510 confocal microscope with a 20x objective. Z-stacks were imported into 
NeuronStudio (version 0.9.92, http://research.mssm.edu/cnic/tools-ns.html) for generation 
of neuronal reconstructions and Sholl analysis (10 μm interval) (Wearne et al., 2005). Tracing 
files were analyzed with L-Measure (version v5.2, (Scorcioni et al., 2008)) and significance was 
analyzed using the Student’s (equal variance) or Welch’s t-test (unequal variance).
Drosophila locomotor activity
Locomotor activity of individual male flies was recorded with the Drosophila Activity Monitor 
(DAM) system (Trikinetics, Waltham, MA) (Catterson et al., 2010; Suh and Jackson, 2007) to 
assess whether Git pan-neuronal knockdown flies displayed hyperactive behavior or sleep 
regulation defects. Activity of 3–5 days old male flies was recorded over 4 days on a 12-h 
light:dark cycle and the average daily activity of at least 25 flies for each genotype was 
calculated. Locomotor activity data were analyzed in pySolo (Gilestro and Cirelli, 2009), 
modified to analyze activity and sleep (the latter defined as 5-min of inactivity (Rosato and 
Kyriacou, 2006)) between 120–540 min relative day and 840–1260 min relative night to 
reflect the stable locomotor activity in those intervals. Statistical analysis was performed in 
Graphpad prism (version 5.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com). T-tests were performed on summarized statistics.
Results
Association between the GIT1 locus and ADHD
Demographic characteristics of the different cohorts are presented in Table 1. Testing 
whether variation in the GIT1 locus (including SNP rs550818) altered ADHD risk we found 
that neither the SNP rs550818 (P=0.49; odds ratio 1.022; 95% confidence interval (CI) 0.959 
- 1.088) nor the GIT1 locus showed association with ADHD in the PGC ADHD meta-analysis 
data (N=19,210, P=0.465, Figure 1). Power analysis showed that the test was highly powered 
to detect an association with a genotype relative risk (GRR) ≥1.1 (for range of GRRs see 
Supplementary Table 6).
Figure 1. LocusZoom (Pruim et al., 2010) plot of association results of the PGC ADHD meta-analysis for GIT1 
including flanking regions of 25 kb on each site. Neither rs550818 (marked as purple index SNP), nor other 
SNPs within the gene range of GIT1 showed association with ADHD susceptibility.
Association between the GIT1 locus and quantitative measures related to 
ADHD in the IMpACT-NL cohort
We did not find an association of SNP rs550818 or the GIT1 locus with self-reported 
hyperactivity/impulsivity or inattentive symptom counts (N=115, Pcorrected > 0.05, and Table 
2) in the IMpACT-NL cohort (for details on demographics see Supplementary Table 7). 
Previously, Won and others investigated the effect of rs550818 on sustained attention in 
a continuous performance task and they studied the effect of Git1 deficiency in mice on 
working memory. Therefore, we tested the effect of rs550818 genotype and the GIT1 locus 
on neuropsychological performance in the same cognitive domains. The association results 
between our genetic variables and outcomes of the SAD task (mean series completion 
time, SD series completion time, SD series errors, and the response bias) or the Digit Span 
task (forward and backward condition) were not significant (all P-values > 0.05, Table 2). 
Testing neuropsychological measurements in additional domains of cognitive functioning 
(reaction time, sustained attention, inhibition, impulsivity, delay aversion, motor control, 
and set shifting; for description of variables see Supplementary Table 2) did not provide 
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evidence for association with the rs550818 genotype or the GIT1 locus (Pcorrected for all tests > 0.05, 
Supplementary Table 8). However, power of these analyses was limited; the IMpACT-NL 
sample provided 32% power to detect an association explaining 1% of the variance (see 
more elaborate power analysis in Supplementary Table 9).
Table 2. Results of single-SNP and gene-based (rs550818 and GIT1) association analyses for self-reported 
ADHD symptom counts, Sustained Attention Dots (SAD) task and Digit Span task in the IMpACT-NL cohort.
Trait Variable
N
(HC/ADHD)
P
rs550818
β 95% CI
P
GIT1 c
Self report 
symptom 
score a
Hyperactivity/impulsivity -/115 0.413 0.134 -0.191 - 0.458 0.477
Inattention -/115 0.593 0.088 -0.237 - 0.413 0.944
Total -/115 0.395 0.140 -0.186 - 0.466 0.614
Sustained 
Attention 
Dots Task b
Mean series completion 
time
99/95 0.445 -0.091 -0.324 - 0.143 0.696
Standard deviation series 
completion time*
99/95 0.142 -0.173 -0.405 - 0.059 0.563
Standard deviation series 
errors*
99/95 0.439 -0.089 -0.316 - 0.138 0.808
Response bias* 99/95 0.150 -0.163 -0.387 - 0.061 0.424
Digit Span 
Task b
Forward score raw* 100/98 0.511 -0.076 -0.304 - 0.152 0.433
Backward score raw 100/98 0.941 0.008 -0.217 - 0.233 0.831
a Age and gender were used as covariates and 52 SNPs were considered for the gene-based analysis. b Age, 
gender and diagnostic status were used as covariates. 52 SNPs were considered in the gene-based analysis. 
c Effect sizes and 95% confidence intervals could not be estimated for the gene-based association tests. 
* Variables that are significantly different between adult ADHD patients and healthy controls after correction 
for multiple testing (Mostert et al., submitted).
Association between the GIT1 locus, brain volume and white matter integrity 
of microstructure
We investigated the effect of the GIT1 locus on brain volume measurements in the case-
control sample IMpACT-NL (N=203) and the population-based cohort BIG (N=1,300). Given 
the known involvement of Git1 in neuronal development (Segura et al., 2007; Za et al., 
2006; Zhang et al., 2005), we tested associations of genetic variation in GIT1 with global 
brain measures for gray matter, white matter, and total brain volumes. None of these 
analyses yielded significant associations (Pcorrected for all tests > 0.05, and Table 3). Additionally, 
we performed exploratory voxel-wise brain-wide analyses of gray and white matter volume, 
and of microstructural integrity in the BIG cohort for rs550818 to identify potential local 
effects of GIT1 variation. Neither the VBM analyses for gray or white matter volume, nor 
the voxel-wise analyses for mean diffusivity and fractional anisotropy showed significant 
associations with rs550818 genotype (data not shown). While the IMpACT-NL sample again 
only provided limited power for this analysis (Supplementary Table 9), the analyses in the 
BIG cohort were highly powered to detect associations explaining between 1% (>95%) and 
0.5% (>72%) of variance (Supplementary Table 9).
Table 3. Results of single-SNP and gene-based (rs550818 and GIT1) association analyses for brain volumes 
in the IMpACT-NL and BIG cohort
IMpACT-NL cohort a BIG cohort c
P
rs550818
β 95% CI P
GIT1 b, e
P
rs550818
β 95% CI P
GIT1 d, e
Total brain 
volume
0.658 0.039 -0.134 - 0.211 0.563 0.897 0.511 -2.269 – 3.292 0.415
Total gray 
matter volume
0.622 -0.035 -0.175 - 0.105 0.497 0.970 0.069 -0.624 – 0.761 0.791
Total white 
matter volume
0.361 0.079 -0.084 - 0.229 0.154 0.934 0.150 -0.874 – 1.174 0.453
a N=203 (101 ADHD patients). Adult ADHD patients do not differ in brain volume from healthy controls 
(Supplementary Table 5). b 52 SNPs were considered for the gene-based analysis. c N=1,300. d 43 SNPs 
were considered for the gene-based analysis. Total brain volume is the sum of total gray and white volume. 
Age, gender, magnetic field strength, and gray matter when testing for white matter and vice versa were 
used as covariates. e Effect sizes and 95% confidence intervals could not be estimated for the gene-based 
association tests.
Functional characterization: effect of rs550818 on GIT1 mRNA expression
Previously, it was reported that the minor allele (A) of the SNP rs550818 caused a reduction 
in luciferase transcription in HEK293 cells (Won et al., 2011). We therefore investigated this 
effect in blood samples of adult ADHD patients and healthy controls from the IMpACT-NL 
cohort. High quality RNA samples were available for 121 individuals (55 healthy controls 
and 66 individuals with ADHD); the G allele was the major allele in our European Caucasian 
sample. Indeed, SNP rs550818 genotype significantly affected GIT1 mRNA expression in the 
total sample independent of diagnostic status (N=121, bstandardized=-0.220, P=0.015); carriers of 
the common allele (GG; N=63) had highest expression, while heterozygotes (GA; N=53) had 
intermediate expression and the carriers of the risk-associated genotype (AA; N=5) showed 
lowest expression (Figure 2A). GIT1 mRNA expression levels did not differ significantly 
between healthy controls and participants with ADHD (t=1,559 df=119, P=0.1217) (Figure 2B).
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Figure 2. GIT1 mRNA expression in human blood samples was dependent on rs550818 genotype but not 
diagnostic status in participants from the IMpACT-NL cohort. A) The minor A allele reduced GIT1 mRNA 
expression in human blood samples (N=121, b=-0.116, t(119)=-2.462, P=0.015, R
2=0.048). Bar charts represent 
mean and 95% confidence interval. B) GIT1 mRNA expression fold change did not differ in healthy controls 
compared to individuals with ADHD (P=0.1217; two-tailed Student’s t-test). Individuals with ADHD were 
distributed across the different genotype groups as following: NGG=26, NGA=26 and NAA=3.
Functional characterization: effect of Git RNAi on neuronal morphology and 
locomotor activity in Drosophila
The fruit fly Drosophila melanogaster is a suitable model to study the behavioral and cellular 
consequences of genes associated to genetic disorders (van der Voet et al., 2014). To model 
the ADHD risk allele and validate the function of GIT1 in neuronal morphology, we targeted 
the Drosophila GIT1 ortholog, Git, using conditional RNA interference. The effect of the 
neuronal Git knockdown on synaptic organization was studied at the neuromuscular 
junction (NMJ). The Drosophila larval NMJ is a well-established synaptic model system that 
shares major features with central excitatory synapses in the mammalian brain (Koh et al., 
2000) and has successfully been used for characterizing a number of Drosophila models of 
neurological diseases, including schizophrenia (Dickman and Davis, 2009) and intellectual 
disability disorders (Bayat et al., 2011; Liu et al., 2011; Schenck et al., 2003; Zweier et al., 
2009). Pan-neuronal knockdown of Git resulted in a significant decrease in the number of 
neurotransmitter release sites, so-called active zones, per synaptic terminal compared to 
controls (0.87 fold, P=0.027), whereas the total area of the neuromuscular junction (NMJ) 
was not changed (P=0.96) (Figure 3A+B). Quantitative evaluation of synaptic terminal 
morphology revealed abnormal branching of synaptic terminals in the Git RNAi knockdown 
condition (Figure 3B). Both the number of branches and branching points were significantly 
increased at NMJs of the Git RNAi line when compared to control flies (1.49 and 1.86 fold, 
P=0.0002 and 0.0032, respectively).
Drosophila class IV dendritic arborization (da) neurons are complex and provide a good 
model for studying dendritic morphology (Jan and Jan, 2010). Knockdown of Git in these 
neurons induced abnormal dendritic complexity (Figure 3C). Quantification of the traced, 
reconstructed neurons revealed a reduced number of branches, bifurcations, and terminal 
tips in the knockdown condition compared to control (0.63 fold, P=0.0003 for all three 
parameters) (Figure 3D, Supplementary Figure 2). The average branch length did not 
differ significantly (P=0.061), but the total branch path length was decreased in the mutant 
neurons (0.74 fold, P=0.0002) (Supplementary Figure 2, Figure 3D). These data suggest 
that Git knockdown results in a branching defect. Consistently, the maximum branch order 
was reduced (0.84 fold, P=0.017) and a Sholl analysis that plots the branch order as a function 
of soma distance, reveals a reduction in branch order throughout the neuron (Figure 3D). 
Other dendritic parameters, namely branch contraction and partition asymmetry, were not 
significantly different (Supplementary Figure 2).
We have recently demonstrated increased locomoter activity and decreased sleep in 
ADHD Drosophila models (van der Voet et al., 2015). We therefore assessed whether Git pan-
neuronal knockdown flies also affect locomotor behavior. No defects in activity levels were 
found (day: P=0.4 and night: P=0.1, respectively; Figure 3E). Sleep of Git knockdown flies 
did also not differ from their genetic background controls (P=0.4 and P=0.2, respectively; 
Figure 3E). These data suggest that despite a role in regulating synapse and dendrite 
morphogenesis, Git knockdown does not cause increased locomotion.
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Figure 3. Git knockdown in Drosophila interfered with synapse and dendrite morphology, but did not alter 
locomotor activity. A) Representative Drosophila synaptic terminal at the neuromuscular junction (NMJ) 
for control and Git RNAi larvae. Overall morphology of synaptic terminals were visualized with an antibody 
against the disc large 1 (dlg1) protein, active zones, the presynaptic sites of neurotransmitter release, with an 
antibody against the active-zone component bruchpilot (brp). Each white foci represents one active zone. 
Images were quantitatively analyzed using an in house-developed Fiji macro (Schuurs-Hoeijmakers et al., 
2012). Scale bar 10 μm. B) Quantitative analysis of NMJs showed a significant decrease in active zone count 
(P=0.027), increase of branch count (P=0.0002) and branching point count (P=0.0032), while the area was 
not different (P=0.96). Scatter plots represent individual measurements (Git RNAi N≥19 and control N≥29), 
mean and error bars indicate the 95% confidence interval. C) Representative Drosophila class IV da neurons 
show abnormal dendritic morphology in Git RNAi compared to wildtype control animals. Scale bar 50 μm. 
D) Quantitaive analysis of dendritic trees revealed that Git RNAi (N=5) reduces the number of branches 
(P=0.0003) and total branch path length (P=0.0002), compared to the control (N=7). Sholl analysis reveals 
that the branch order throughout the neuron is reduced. Scatter plots represent individual measurements. 
Error bars indicate the 95% confidence interval. E) Locomotor activity profiling of adult Git RNAi and control 
flies revealed normal activity or sleep parameters (values for day (Zeitgeber 0-12h, white bar) and night 
(Zeitgeber 12-24h, black bar) periods indicated). * P < 0.05; ** P < 0.01; ***P < 0.001. P-values were derived 
from two-sided Student’s t-tests, except for not-normally distributed data, then a Wilcoxon-ranked test 
was performed.
Discussion
In the original publication of GIT1 as a risk gene for ADHD, 27 SNPs in a 19 kb region 
encompassing the GIT1 gene had been analyzed. Of those, eight SNPs had been shown to 
be polymorphic in a Korean childhood sample (N=388), and rs550818 was found associated 
with ADHD (Won et al., 2011). In addition, homozygous deficiency of Git1 in mice resulted 
in increased locomotor activity (Won et al., 2011). In this study we performed a multilevel 
investigation of the role of the GIT1 locus in ADHD risk and related traits (behavioral and MRI-
derived) as well as functional characterization of the GIT1 gene in humans and in Drosophila. 
Our results clearly show that the GIT1 locus is not associated with ADHD risk, ADHD symptom 
counts, neuropsychological performance, or brain volume and white matter integrity 
variation in large human data sets. However, we demonstrated that rs550818 is indeed 
functional, as it lowered GIT1 mRNA expression in human blood samples independently 
of ADHD diagnostic status. Using Drosophila as a model system, we showed that neuron-
specific Git knockdown altered synaptic and dendritic morphology, whereas locomotor 
activity parameters remained unchanged.
Using the largest currently available ADHD sample, the PGC ADHD meta-analysis sample 
(Ncases=5,621, Ncontrols=13,589) we analyzed SNP rs550818 as well as the combined effects of 
all SNPs within the GIT1 locus. Although our study had sufficient statistical power to detect 
an association, we were unable to replicate the initial finding by Won and coworkers. This 
is consistent with the results of an earlier replication attempt in a Brazilian childhood ADHD 
sample (Salatino-Oliveira et al., 2012). Despite the non-significant association, we showed 
that the effect is in the same direction as previously reported (Won et al., 2011), whereas 
the Brazilian study reported an odds ratio of 0.749, indicating an opposite directionality 
(Salatino-Oliveira et al., 2012). Importantly though, samples used in our and in the Brazilian 
study consisted (mainly) of participants of Caucasian ethnic origin, while all participants in 
the first study had an Asian ethnic background (Salatino-Oliveira et al., 2012; Won et al., 2011). 
Whereas allele frequencies of the present study and the Brazilian study (Salatino-Oliveira 
et al., 2012) are consistent with frequencies found in the European population (MAF=0.27 
for allele A), frequencies in Asian populations – including the Korean one (Won et al., 2011) 
– strongly differ from this (MAF between 0.06 and 0.09). Therefore, the lack of replication 
can be difficult to interpret, as diverse genetic backgrounds and variable environmental 
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exposures may lead to distinct causal genetic variants in different populations (Campbell 
and Rudan, 2002).
Individuals with ADHD frequently display cognitive deficits, including impairments in 
inhibition, attentional processing, and increased reaction time variability (Castellanos et 
al., 2006; Kofler et al., 2013; Sonuga-Barke et al., 2010). A number of such cognitive domains 
has also been found impaired in Git1-deficient mice. For example, Git1 knockout mice 
showed impaired spatial learning and memory in the Morris water maze task and impaired 
recognition memory during a novel-object recognition task (Won et al., 2011). Therefore, 
we tested the GIT1 locus for association with cognitive performance in relevant domains. 
However, in concordance with the findings of Won and coworkers, who had applied a 
continuous performance test in the Korean childhood sample (Won et al., 2011), we did 
not find an effect of rs550818 or the entire GIT1 locus on sustained attention in our adult 
ADHD sample, nor did neuropsychological performance in any of the other tested domains 
show association with GIT1. Additional cognitive deficits observed in Git1 knockout mice, 
which were not tested in the current study, include impaired fear response and reduced 
adaptation to novel and changing environments (Menon et al., 2010; Schmalzigaug et al., 
2009). Tasks quantifying fear response, like the eye blink component of the startle response 
(Davis, 2006; Hajcak et al., 2009), and those measuring reversal learning and tapping into 
adaptability might therefore be interesting phenotypes for future studies in humans in 
relation to genetic variation in the GIT1 locus.
Git1 knockout mice exhibit alterations in dendritic length and spine density (Fiuza et 
al., 2013; Menon et al., 2010; Zhang et al., 2005). ADHD has been associated with volume 
differences in the brain (Onnink et al., 2014; van Ewijk et al., 2012), and we have shown 
that ADHD symptoms are associated with total brain volume in the general population 
(Hoogman et al., 2012). Thus, we investigated the role of GIT1 in global and voxel-wise 
brain volume measures and microstructural integrity. However, we could not find an effect 
of GIT1 on any brain measurements. In a way, this is consistent with the findings in mice, 
where changes of neuronal morphology did not translate into structural abnormalities 
observable at the macroscopic level in 3-month-old mouse brains in Git1 knockout mice 
(Menon et al., 2010).
Won and colleagues had shown that the minor allele of rs550818 (A) reduced luciferase 
signal in an in vitro transcription assay (Won et al., 2011). In vivo, in human blood samples, 
we were able to confirm this effect of the A allele of rs550818, showing that GIT1 mRNA 
expression was reduced in carriers of the minor allele. Generally, eQTLs can be specific to 
certain tissues, cells, anatomical regions and diseases (GTex Consortium 2013; (Emilsson et al., 
2008). Therefore, our findings cannot necessarily be translated to other tissue types, e.g. the 
brain (McKenzie et al., 2014). However, a recent large study shows that there is also overlap 
between eQTLs from peripheral blood and eQTLs in brain (Wright et al., 2014), which implies 
that some local regulatory variants might show ubiquitous effects (Kim et al., 2014). In the 
case of the GIT1 eQTL, the fact that consistent effects have been found in vitro and in vivo 
might indeed indicate that effects are ubiquitous. However, this effect does not seem to be 
strong enough to modify brain structure, cognitive performance, or ADHD-related behavior.
Git1 is responsible for recruiting proteins to the synapse, and Git1 knockout mice 
displayed decreased dendritic length and spine density (Menon et al., 2010; Zhang et al., 
2005). A recent study identified Drosophila Git as a component of the active zone-associated 
cytomatrix and as a regulator of synaptic vesicle endocytosis and recycling (Podufall et 
al., 2014), although the actual number of active zones had not been evaluated in this 
study. Consistent with Git being a component of active zones, we did observe a mild but 
significant reduction in the number of active zones. We further showed that neuronal Git 
RNAi knockdown interferes with synaptic terminal branching and dendrite formation in 
Drosophila. This is consistent with earlier findings showing that various trafficking mutants 
of genes involved in organelle trafficking processes result in alterations of dendrite 
morphogenesis (Corty et al., 2009). Altogether, these observations support an important 
role for Git in synaptic and dendritic organization. Despite altered neuronal morphology, 
however, Git knockdown did not result in the locomotor hyperactivity that has been 
observed for other Drosophila models of ADHD-associated genes (van der Voet et al., 2015). 
Our knockdown is likely not to remove all of Git protein from the Drosophila brain. Also, 
the GIT1 variant, even if homozygous, causes only a slight reduction in GIT1 expression. 
Importantly, the two-fold higher spontaneous locomotor activity in an open-field test in Git1 
knockout mice (Won et al., 2011) was only observed in the homozygous condition with no 
detectable protein. Mice with a heterozygous deletion showed normal locomotor activity, 
in agreement with our findings in flies and humans.
At the cellular level, the effect of GIT1 knockdown has been demonstrated in different model 
systems. We showed in human blood samples, that rs550818 affects GIT1 gene expression. 
Interestingly, the cellular effects in the Git1 knockout mouse model of Won and others 
seemed to be cell specific, as specifically inhibitory synaptic transmission was decreased 
(Won et al., 2011). Won and colleagues suggested that the resulting increase in neuronal 
excitability might contribute to the development of ADHD-like phenotypes. Although 
we demonstrated that genetic variation in the GIT1 locus is not associated with ADHD in 
humans, we cannot rule out any other effects of the GIT1 locus on different behavioral 
characteristics. The observed effect of Git1 deficiency in mice on fear learning and adaptation 
to new environments, might be interesting starting points for future studies in humans.
The present findings should be viewed in light of several strengths and limitations. The main 
strengths of our study are its comprehensive approach on multiple levels and the use of 
the largest and well powered ADHD meta-analysis data set currently available. Moreover, 
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we did not only test association for a single SNP, but also investigated the combined effect 
of all SNPs within the GIT1 locus available in our data sets. We also studied the role of the 
GIT1 locus in various neuropsychological measures and investigated potential effects of 
GIT1 on brain morphology in humans, in patients as well as a large population sample. Next 
to the association analyses, we also assessed the functional role of SNP rs550818 by mRNA 
expression analysis. For our functional analyses we used a novel and validated fly model 
for ADHD-related hyperactivity, which has been shown to be very useful in characterizing 
effects of ADHD candidate genes on synapse morphology and locomotor behavior (van der 
Voet et al., 2015). A clear weakness of our study was the limited size of our patient sample 
for the neuropsychological analyses, which might have been underpowered to reliably 
detect genetic effects in a relevant range of explained phenotypic variance. Additionally, 
the association of rs550818 with ADHD was originally identified in a childhood sample 
(Won et al., 2011), whereas our association analyses for neuropsychological and brain-
related traits were performed in adult participants. This can be criticized as we know that 
differential genotype-phenotype association can exist at different ages and that genetic 
and neurocognitive mechanisms underlying ADHD may change throughout life (Greven et 
al., 2011; Larsson et al., 2011; Thissen et al., 2015). To overcome these limitations, it would be 
recommendable to also test for association with the number of ADHD symptoms in larger 
samples (of children) with ADHD. Furthermore, this study focused only on common genetic 
single nucleotide variants (SNVs), although it is known that these cannot completely explain 
the heritability of ADHD (Gratten et al., 2014). Therefore, rare genetic variation within the 
GIT1 locus, be it single nucleotide or structural variants, might still play a role in ADHD. 
However, we already showed that an alteration of GIT1 mRNA expression does – if not 
complete – not affect behavior. Even when Git is knocked down strongly in neurons, no 
behavioral changes in the model system were observed. Thus, we think it is unlikely that 
rare genetic variants within the GIT1 locus will contribute to ADHD. Lastly, the gene-based 
testing methods we used did not provide us with effect size measures, which can help to 
better interpret the results of association findings.
In summary, our findings do not provide evidence for an impact of the GIT1 locus on ADHD 
risk or the variation of ADHD-related traits in humans. Although rs550818 is associated with 
the variation of GIT1 expression in blood, this does not appear to be a risk factor for ADHD. 
Therefore, GIT1 is not supported as a candidate gene for this psychopathology, despite 
its reproduced and newly identified functional roles in neuronal morphology. Our study 
stresses the need for multi-level approaches in the study of genetic risk factors influencing 
the neurobiological mechanisms underlying ADHD etiology.
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Supplementary Material
IMpACT-NL cohort
Cohort description
All patients were assessed using the Diagnostic Interview for Adult ADHD (DIVA) (Kooij, 2010). 
This interview focuses on 18 DSM-IV symptoms of ADHD and uses concrete and realistic 
examples to thoroughly investigate whether a symptom is currently present or was present 
in childhood. In order to obtain information about ADHD symptoms and impairment in 
childhood, additional information was acquired from parent and school reports, whenever 
possible. The Dutch version of the Structured Clinical Interview for DSM-IV (SCID-I and SCID-
II) (Groenestijn, 1999; Weertman et al., 2000) was used for lifetime comorbidity assessment. 
The assessments were carried out by trained professionals (psychiatrists or psychologists). 
Also, a quantitative measure of clinical symptoms was obtained using the ADHD-DSM-IV Self 
Rating scale (Kooij et al., 2005). Exclusion criteria for participants were psychosis, alcohol or 
substance use disorder in the last 6 months, current major depression, full-scale IQ estimate < 
70 (estimated from Block Design and Vocabulary of the Wechsler Adult Intelligence Scale-III), 
neurological disorders, sensorimotor disabilities, non-Caucasian ethnicity, and medication 
use other than psychostimulants or atomoxetine. An exclusion criteria for healthy control 
subjects was a current neurological or psychiatric disorder according to SCID-I.
Neuroimaging, MRI acquisition and data processing
Shortly, the images were acquired using a T1.5 MRI scanner (Avanto, Siemens Medical 
Systems, Erlangen, Germany) at the Donders Centre for Cognitive Neuroscience. All scans 
covered the entire brain and had a voxel size of 1 x 1 x 1 mm3, TR 2730 ms, TI 1000 ms, TE 
2.95 ms, 176 sagittal slices, field of view 256 mm. To study local differences in gray and 
white matter related to genetic variation T1 scans were normalized to standard space 
(Montreal Neurological Institute; MNI; (http://www.mni.mcgill.ca/)), bias corrected, and 
segmented into gray matter and white matter using the VBM8-toolbox, (http://dbm.neuro.
uni-jena.de/vbm/), in SPM8 (http://www.fil.ion.ucl.ac.uk/spm) with default settings. Images 
were modulated by the non-linear part of their DARTEL warp field (Ashburner, 2007) and 
smoothed with an 8 mm FWHM Gaussian smoothing kernel. This provided images for an 
analysis of relative differences in regional grey and white matter volume, corrected for 
individual brain size. Total volume of gray and white matter was calculated by adding the 
resulting tissue probability maps. TBV was defined as the voxel-wise sum of white and gray 
volume.
Genetic data
Genome-wide genotyping of 220,000 single nucleotide polymorphisms (SNPs) was 
performed at the Lifelines facility (Groningen, The Netherlands). The following quality 
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control steps were performed for genotype data: SNPs were excluded from analyses if the 
call rate per SNP was less than 95%, minor allele frequency (MAF) was less than 1%, or if SNPs 
failed the Hardy-Weinberg equilibrium (HWE) test at a threshold of p≤10-6 (genome-wide). 
Participants were excluded from the analysis if the call rate per individual was lower than 
95% or if they were genetically related with each other (N=10). To increase genomic coverage, 
the genotyping data was imputed by using SHAPEIT (Delaneau et al., 2012; Delaneau et al., 
2013) (version 1) and IMPUTE2 (Howie et al., 2009) (version 2.2.2). For imputation, the 1000 
Genomes haplotypes were used as a reference panel (Phase I integrated variant set release 
(v3) in NCBI build 37 (hg19) coordinates, downloaded from http://mathgen.stats.ox.ac.uk/
impute/data_download_1000G_phase1_integrated.html) (Genomes Project et al., 2010). 
Average genome-wide concordance rate of genotypes versus imputed genotypes was 95%. 
Post-imputation quality control included the same control steps as described above for 
pre-imputation data cleaning. After these steps we had 9,329,570 SNPs across the whole 
genome. After quality control of MAF ≥ 0.01 and INFO-score ≥ 0.9, 52 SNPs with valid rs-
numbers on the GIT1 locus remained for gene-based analysis (UCSC Genome Bioinformatics 
Site, http://genome.ucsc.edu/; Supplementary Table 3).
Validation of rs550818 genotype by TaqMan genotyping assay
Forward and reverse primer and probes are labeled with a FAMTM and VIC® dye (VIC-
GAGGCTGGACCTTGGACTTTAAGCC, FAM-CCAGCTGAGATCAGGGCCCAGTTTG). A total of 
0,0625 µl of the GIT1 rs550818 assay was added to 2,5 µl of Taqman® Universal PCR Mastermix 
containing a PCR buffer, Amplitaq Gold® DNA polymerase and dNTPs (all Life Technologies). 
MilliQ was added to adjust the volume to 5 µl. One µl of 10 ng/µl DNA was added to the 
mix. The PCR protocol included activation of AmpliTaq Gold enzyme for 12 minutes at 95°C, 
followed by 40 cycles of denaturation of DNA at 92°C for 15 seconds, and annealing and 
extension of primers at 60°C for 1 minute. As controls, 5-10% duplicates and at least 3-4% 
blanks were used in the plates.
Gene expression analysis using Taqman assays
The mRNA gene expression analysis of GIT1 and GUSB was carried out in a volume of 10 µl. 
The PCR mix for one reaction contained 17 ng of RNA in 2.5 µl, 5 µl of 2x Taqman master 
mix, 0.25 µl of the Taqman assay, and 2.25 µl of purified water. The amplification protocol 
consisted of an initial step at 50°C for 2 min, followed by a denaturation step at 95°C for 10 
minutes, 15 seconds at 95°C, and 1 min at 60°C. The latter two steps were repeated 40 times. 
PCR was run and the fluorescent signal was measured on an Applied Biosystems 7500 Fast 
Real-Time PCR System (Life Technologies). All Taqman gene expression assays were validated 
before use, using a 2-fold dilution series and assessing PCR efficiency (slope) and R2 (GUSB: 
slope=1.1782, R2=0.9976 and GIT1: slope=1.2567, R2=0.9730).
BIG cohort
Neuroimaging, MRI acquisition and data processing
To study local differences in gray and white matter related to genetic variation, we used 
the same processing protocol as in the IMpACT study (Hoogman et al., 2014). For a subset 
of the BIG subjects (N=255), DTI data was acquired in conjunction with the T1-scan, using 
a standard eddy-current compensated pulsed gradient spin echo - echo planar imaging 
(PGSE-EPI) (Reese et al., 2003) with some variation in the number of diffusion directions 
(30-92), b-value (700-1500 s/mm2) and resolution (2-2.5 mm isotropic).
Images were realigned (affine) and diffusion tensors robustly estimated (PATCH) (Zwiers, 
2010). To assess the microstructure of gray and white matter, two diffusion tensor derivatives, 
i.e. the mean diffusivity (MD) and fractional anisotropy (FA) were computed and normalized 
to standard space using the T1 DARTEL warp field.
9
390 391
Converging evidence does not support GIT1 as an ADHD risk geneChapter 9
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
. D
es
cr
ip
tio
n 
of
 in
di
vi
du
al
 s
am
pl
es
St
ud
y 
na
m
e
St
ud
y 
de
si
gn
A
nc
es
tr
y
Ca
se
s 
(N
a )
Co
nt
ro
ls
 
(N
a )
G
en
ot
yp
in
g 
pl
at
fo
rm
Re
fe
re
nc
eb
Sh
or
t
Fu
ll 
sa
m
pl
e 
na
m
e
CA
RD
Ca
rd
iff
 U
ni
ve
rs
it
y
Ca
se
/
co
nt
ro
l
Ca
uc
as
ia
n
64
1
1,
75
2
Ill
um
in
a 
H
um
an
66
0W
-
Q
ua
d 
Be
ad
Ch
ip
 (A
D
H
D
 
ca
se
s)
 a
nd
 Il
lu
m
in
a 
H
um
an
 
1.
2M
 B
ea
dC
hi
p 
(c
on
tr
ol
s)
(S
te
rg
ia
ko
ul
i e
t 
al
., 
20
12
)
CH
IN
Pe
ki
ng
 U
ni
ve
rs
it
y
Ca
se
/
co
nt
ro
l
H
an
 C
hi
ne
se
1,
01
2
93
0
A
ff
ym
et
rix
 6
.0
 a
rr
ay
(Y
an
g 
et
 a
l.,
 2
01
3)
G
ER
M
A
D
H
D
 p
at
ie
nt
 s
am
pl
e 
co
ns
is
te
d 
of
 c
hi
ld
re
n 
an
d 
ad
ol
es
ce
nt
s 
A
ac
he
n,
 C
ol
og
ne
, E
ss
en
, M
ar
bu
rg
, 
Re
ge
ns
bu
rg
, a
nd
 W
ür
zb
ur
g
Ca
se
/
co
nt
ro
l
Ca
uc
as
ia
n
49
4
1,
29
7
Ill
um
in
a 
H
um
an
66
0W
-
Q
ua
dv
1(
A
D
H
D
 c
as
es
) a
nd
 
Ill
um
in
a 
H
um
an
H
ap
55
0v
3 
(c
on
tr
ol
s)
(H
in
ne
y 
et
 a
l.,
 
20
11
)
IM
AG
E2
Ph
as
e 
II 
of
 IM
AG
E
Ca
se
/
co
nt
ro
l
Pr
ed
om
in
an
tly
 
Eu
ro
pe
an
 o
rig
in
78
7
7,
08
2
A
ff
ym
et
rix
 5
.0
 a
rr
ay
 (A
D
H
D
 
ca
se
s)
 a
nd
 A
ff
ym
et
rix
 6
.0
 
ar
ra
ys
 (c
on
tr
ol
s)
(N
ea
le
 e
t a
l.,
 2
01
0)
SP
A
N
Ba
rc
el
on
a 
U
ni
ve
rs
it
y
Ca
se
/
co
nt
ro
l
Ca
uc
as
ia
n
59
1
43
2
Ill
um
in
a 
H
um
an
O
m
ni
1-
Q
ua
d 
Be
ad
Ch
ip
 p
la
tf
or
m
(S
an
ch
ez
-M
or
a 
et
 
al
., 
20
14
)
CH
O
P
Ch
ild
re
n’
s 
H
os
pi
ta
l o
f P
hi
la
de
lp
hi
a
Tr
io
Eu
ro
pe
an
 
de
sc
en
t
35
8
Ill
um
in
a 
In
fin
iu
m
 II
 
H
um
an
H
ap
55
0 
Be
ad
Ch
ip
(E
lia
 e
t a
l.,
 2
01
0)
CR
O
S
To
ro
nt
o 
U
ni
ve
rs
it
y,
 S
ic
kK
id
s 
pr
oj
ec
t
Tr
io
M
ai
nl
y 
Ca
uc
as
ia
n
17
0
A
ff
ym
et
rix
 6
.0
 a
rr
ay
(L
io
ne
l e
t a
l.,
 
20
11
)
IM
AG
E1
Ph
as
e 
I o
f t
he
 In
te
rn
at
io
na
l M
ul
tis
ite
 
A
D
H
D
 G
en
et
ic
s 
Pr
oj
ec
t
Tr
io
W
es
te
rn
 
Eu
ro
pe
an
 o
rig
in
86
6
Pe
rle
ge
n 
Sc
ie
nc
es
 6
00
 K
(N
ea
le
 e
t a
l.,
 
20
08
)
TO
TA
L
5,
62
1
13
,5
89
a 
Ba
se
d 
on
 s
am
pl
e 
of
 p
rim
ar
y 
pu
bl
ic
at
io
n 
b 
Pr
im
ar
y 
pu
bl
ic
at
io
n 
re
po
rt
in
g 
in
di
vi
du
al
 s
tu
dy
 s
am
pl
e.
Su
pp
le
m
en
ta
ry
 T
ab
le
 2
: O
ve
rv
ie
w
 o
f n
eu
ro
ps
yc
ho
lo
gi
ca
l t
as
ks
 a
nd
 v
ar
ia
bl
es
 u
se
d 
in
 th
is
 s
tu
dy
.
Ta
sk
Co
gn
it
iv
e 
do
m
ai
n
O
ut
co
m
e 
m
ea
su
re
 u
se
d 
in
 th
is
 s
tu
dy
Re
fe
re
nc
e
Su
st
ai
ne
d 
at
te
nt
io
n
do
ts
 ta
sk
 (S
A
-d
ot
s)
A
tt
en
tio
n 
an
d 
in
hi
bi
tio
n
- 
M
ea
n 
se
rie
s 
co
m
pl
et
io
n 
tim
e
- 
SD
 s
er
ie
s 
co
m
pl
et
io
n 
tim
e*
- 
SD
 s
er
ie
s 
er
ro
rs
 (S
D
 o
f t
he
 e
rr
or
s 
m
ad
e 
ac
ro
ss
 b
lo
ck
s)
 *
- 
Re
sp
on
se
 b
ia
s 
(t
he
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
nu
m
be
r o
f m
is
se
s 
an
d 
th
e 
nu
m
be
r o
f f
al
se
 a
la
rm
s 
ac
ro
ss
 th
e 
en
tir
e 
ta
sk
).
Pa
rt
 o
f t
he
 A
N
T 
te
st
in
g 
ba
tt
er
y 
(H
ui
jb
re
gt
s 
et
 a
l.,
 2
00
8)
W
A
IS
-I
II 
D
ig
it
 S
pa
n 
ta
sk
W
or
ki
ng
 m
em
or
y
- 
Fo
rw
ar
d 
di
gi
t s
pa
n 
sc
or
e 
(r
aw
)
- 
Ba
ck
w
ar
d 
di
gi
t s
pa
n 
sc
or
e 
(r
aw
)
Su
bt
es
t o
f t
he
 W
ec
hs
le
r A
du
lt 
In
te
lli
ge
nc
e 
Sc
al
e 
(W
ec
hs
le
r, 
19
97
)
Fl
an
ke
r t
as
k
In
hi
bi
tio
n
- 
To
ta
l S
D
 o
f R
T 
(a
ve
ra
ge
 o
ve
r p
ar
t 1
 a
nd
 2
)
Pa
rt
 o
f t
he
 A
N
T 
te
st
in
g 
ba
tt
er
y 
(H
ui
jb
re
gt
s 
et
 a
l.,
 2
00
2)
Su
st
ai
ne
d 
A
tt
en
ti
on
to
 R
es
po
ns
e 
Ta
sk
(S
A
RT
)
A
tt
en
tio
n 
an
d 
in
hi
bi
tio
n
- 
SD
 o
f R
T 
hi
ts
*
(S
m
it 
et
 a
l.,
 2
00
4)
D
el
ay
 D
is
co
un
ti
ng
D
el
ay
 a
ve
rs
io
n 
an
d 
im
pu
ls
iv
it
y
- 
K 
10
0 
(im
pu
ls
iv
it
y 
hi
gh
 re
w
ar
ds
)*
(D
om
 e
t a
l.,
 2
00
6)
Tr
ai
l m
ak
in
g 
ta
sk
M
ot
or
 c
on
tr
ol
 a
nd
 
se
t-
sh
ift
in
g
- 
Ti
m
e 
to
 c
om
pl
et
e 
pa
rt
 A
- 
Ti
m
e 
to
 c
om
pl
et
e 
pa
rt
 B
(K
or
tt
e 
et
 a
l.,
 2
00
2)
A
N
T 
= 
‘A
m
st
er
da
m
se
 N
eu
ro
ps
yc
ho
lo
gi
sc
he
 T
ak
en
’ (
D
e 
So
nn
ev
ill
e,
 1
99
9)
; R
T 
= 
re
ac
tio
n 
tim
e;
 S
D
 =
 s
ta
nd
ar
d 
de
vi
at
io
n;
 *
 =
 v
ar
ia
bl
es
 w
er
e 
lo
g-
tr
an
sf
or
m
ed
 to
 g
ua
ra
nt
ee
 a
 
no
rm
al
 d
is
tr
ib
ut
io
n 
(M
os
te
rt
 e
t a
l.,
 s
ub
m
it
te
d)
.
9
392 393
Converging evidence does not support GIT1 as an ADHD risk geneChapter 9
Supplementary figures
Supplementary Figure 1. Frequency distribution of GIT1 fold change of 121 IMpACT-NL RNA samples. 
Distribution meets criteria of normality (Skewness statistic=0.691, standard error=0.220 and Kurtosis 
statistic=-0.159 and standard error=0.434).
Supplementary Figure 2. Quantification of additional dendrite branching parameters. Quantification of 
dendrite branching in Drosophila class IV da neurons revealed that Git RNAi (N=5) altered several dendrite 
branching parameters, compared to the control (N=7). Scatter dot plots represent individual measurements 
mean, and error bars indicate the 95% confidence interval. Group differences were assessed by two-tailed 
Student’s or Welch’s t-tests.
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Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and highly heritable 
neurodevelopmental disorder with a complex pathophysiology. Intracranial volume 
(ICV) and volumes of nucleus accumbens, amygdala, caudate nucleus, hippocampus, and 
putamen are smaller in people with ADHD compared to healthy individuals. In this study, 
we investigated the overlap between common genetic variation associated with ADHD 
risk and these brain volume measures in order to identify underlying biological processes 
contributing to the disorder. We combined genome-wide association results from the 
largest available studies of ADHD (N=55,374) and brain volumes (N=11,221-24,704) using 
a set of complementary methods to investigate overlap at the level of global common 
variant genetic architecture and the single variant level. We discovered a negative genetic 
correlation between ADHD and ICV (rG=-0.22, p=0.0001543). Meta-analysis of single variants 
revealed two significant loci of interest associated with both ADHD risk and ICV; four 
additional loci were identified for ADHD and amygdala, caudate nucleus, and putamen 
volumes. Exploratory gene-based and gene-set analyses in the ADHD-ICV meta-analytic 
data showed association with variation in neurite outgrowth-related genes. This is the first 
genome-wide study to show significant genetic overlap between brain volume measures 
and ADHD, both on the global and the single variant level. Variants linked to smaller ICV were 
associated with increased ADHD risk. These findings can help us to develop new hypotheses 
about biological mechanisms, by which brain structure alterations may be involved in ADHD 
disease etiology.
Keywords: ADHD, ICV, MRI brain imaging, genetics, neurite outgrowth
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common, highly heritable 
(Faraone et al., 2015; Faraone et al., 2005) neurodevelopmental disorder with a complex 
and heterogeneous pathophysiology. Pathways towards disease are hypothesized 
to be mediated by alterations in diverse brain networks (Faraone et al., 2015). A recent 
neuroimaging mega-analysis reported subtle but consistent differences in volumes of 
subcortical brain regions and intracranial volume (ICV) in ADHD, across diverse cohorts 
worldwide: compared to healthy controls, patients with ADHD showed decreased volumes 
of the nucleus accumbens, amygdala, caudate nucleus, hippocampus, putamen, and ICV 
(Hoogman et al., 2017). How such alterations contribute to the disease phenotype, is still 
poorly understood. However, brain volume alterations are also present, on average, in 
unaffected relatives of patients with ADHD (Bralten et al., 2016; Greven et al., 2015), and 
both ADHD and brain volumes have high heritability (60-70%(Faraone et al., 2005; Larsson 
et al., 2014) and 70-90%(Hibar et al., 2015), respectively). This suggests that genetic variants 
underlying ADHD pathophysiology may also influence brain volume variation. Recently, the 
first genome-wide significant loci for ADHD were identified and a SNP-based heritability 
of 20.16% has been reported (Demontis et al., 2017). In the current study, we aimed to 
investigate the genetic covariance between ADHD risk and structural brain phenotypes; 
we set out to determine, if common genetic variants are shared between ADHD risk and 
brain volumes found altered in ADHD (ICV, nucleus accumbens, amygdala, caudate nucleus, 
hippocampus, putamen). These volumes were selected to focus on the most robust imaging 
phenotypes in ADHD (Hoogman et al., 2017).
Genome-wide association studies (GWAS) have identified ten genome-wide significant 
loci associated with hippocampal volume (Bis et al., 2012; Hibar et al., 2017; Hibar et al., 2015; 
Melville et al., 2012; Stein et al., 2012), eight with ICV (Adams et al., 2016; Hibar et al., 2015; 
Ikram et al., 2012; Stein et al., 2012), four with putamen volume (Hibar et al., 2015), and one 
with caudate volume (Hibar et al., 2015). These variants explain only a small fraction of the 
heritability of these brain volumes (Bis et al., 2012; Hibar et al., 2015; Ikram et al., 2012; Melville 
et al., 2012; Stein et al., 2012). Recently, Franke and colleagues reported a battery of statistical 
tools to comprehensively examine genetic overlap between brain volumes and risk for 
brain disease at the genome-wide level and at the level of individual risk variants, using 
schizophrenia as an example (Franke et al., 2016). Here, we applied a similar set of methods 
to identify and dissect genetic sharing between ADHD and brain volumes implicated in 
ADHD based on the latest mega-analysis (Hoogman et al., 2017).
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Material and methods
Ethics statement
This study used summary statistics of GWAS meta-analyses (GWAS-MA) that had been 
approved by local ethics committees and had required informed consents (described in 
earlier publications (Adams et al., 2016; Demontis et al., 2017; Hibar et al., 2017; Hibar et al., 
2015)).
Participant samples
We used summary statistics data from three consortia (Supplementary Methods and 
Supplementary Table 1). GWAS-MA data on ADHD were from the ADHD Working Group 
of the PGC and the ADHD iPSYCH-SSI-Broad collaboration (ncases=20,183, ncontrols=35,191)
(Demontis et al., 2017).
GWAS-MA summary statistics data on ICV and volumes of nucleus accumbens, amygdala, 
caudate nucleus, hippocampus, and putamen (subcortical volumes were adjusted for ICV 
to identify specific genetic contributions to individual volumes) were from ENIGMA (Hibar 
et al., 2015). For the initial GWAS-MA analysis, MRI brain scans and genome-wide genotype 
data were available for 11,840 subjects. During the reviewing process, we added analyses 
on the other two subcortical volumes (pallidum and thalamus) for which large-scale GWA 
data was available (Hibar et al., 2015); results for those can be found in the extended data 
sheet in the supplementary material.
Lastly, we obtained summary statistics of additional GWAS-MA data on ICV 
(n=12,803(Adams et al., 2016)) and hippocampal volume (n=13,039(Hibar et al., 2017)) 
from the CHARGE Consortium. Importantly, we did not have access to the original or pre-
processed MRI scans, but rather used already existing summary statistics data based on 
initial GWAS-MA that were performed for the different brain volumes of interest.
Prior to all analyses, cohorts including ADHD cases (n=154) were removed from the 
ENIGMA data (Supplementary Methods). The summary statistics data from CHARGE were 
meta-analyzed with the ENIGMA data sets (Supplementary Methods).
To shed some light on the potential role of IQ in the relation between ADHD and 
brain volume genetics, we also used summary statistics from a GWAS-MA on intelligence 
performed in 269,867 participants (Savage et al., 2018).
Linkage disequilibrium score regression (LDSR)
GWAS-MA data sets underwent additional filtering (Supplementary Methods). The ADHD 
analysis included only results from studies with samples of European (Caucasian) genetic 
background (ncases=19,099 and ncontrols=34,194). For the ENIGMA amygdala results, the mean 
χ2 was too low (1.0) to reliably estimate SNP heritability using LDSR. Table 1 shows genetic 
correlations between brain volumes.
The analysis used a two-step procedure with the LD-scoring analysis package (Bulik-
Sullivan et al., 2015). An unconstrained regression estimated regression intercepts for each 
phenotype. Since we took measures to exclude sample overlap, we also performed the 
analysis with regression intercept defined as zero (Supplementary Table 2). To compute 
p-values, standard errors were estimated using a block jackknife procedure.
Table 1. Genetic correlations between brain volumes1
Trait
Intracranial 
volume#
Nucleus 
accumbens
Caudate 
nucleus
Hippocampus# Putamen
rg P rg P rg P rg P rg P
Intracranial volume# --- --- --- --- --- --- --- --- --- ---
Nucleus accumbens 0.02727 0.8353 --- --- --- --- --- --- --- ---
Caudate nucleus 0.1158 0.2323 0.4191 0.007684 --- --- --- --- --- ---
Hippocampus# 0.2559 0.001704 0.1891 0.2218 -1.725 0.1991 --- --- --- ---
Putamen 0.08746 0.306 0.4357 1.67x10-3 0.175 0.173 0.08832 0.3802 --- ---
1Amygdala mean χ2 was too small to allow a valid analysis (N=11,757). rg=genetic correlation. #Using GWAS-
MA summary statistics from the meta-analysis of ENIGMA and CHARGE cohorts. Genetic correlations were 
estimated by using free intercepts. In accordance with the number of tests performed, we set a Bonferroni-
corrected significance level at P=0.05/10=0.005. P-values in bold are significant after Bonferroni correction.
SNP effect concordance analysis (SECA)
Post-processing of genetic data
To statistically compare ADHD and six brain volume GWAS-MAs, we used SNPs that passed 
quality control and filtering rules in all data sets (Supplementary Methods). Clumping 
procedure in PLINK (Purcell et al., 2007) identified an independent SNP from every LD-
block across the genome, providing independent SNP sets representing the total variation 
explained across the genome conditioned on the significance in each brain volume 
GWAS-MA (Supplementary Methods). For each of these SNP sets, we determined the 
corresponding ADHD GWAS-MA test statistic for each independent index SNP and used 
these data sets for subsequent analyses.
Tests of pleiotropy and concordance
We used SNP Effect Concordance Analysis (SECA)(Nyholt, 2014) to determine the extent 
and directionality of genetic overlap between ADHD and each brain volume. Within 
SECA, we performed a global test of pleiotropy using a binomial test at 12 p-value levels 
(Supplementary Methods). Similarly, a two-sided Fisher’s exact test estimated concordance, 
the agreement in SNP effect directions across two traits. We determined whether there was 
a significant (P≤0.05) positive or negative trend in the effect of the overlapping SNPs at 
each p-value threshold (Supplementary Methods). In total, we tested for pleiotropy and 
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concordance between ADHD and six brain volumes. The Bonferroni-corrected significance 
level was set at P=0.05/(2*6)=4.17x10-3.
SNP sign test in the top GWAS-MA findings
To investigate a potential accumulation of same- or opposite-direction effects of SNPs 
between ADHD and brain volumes, we counted the number of opposite direction effects 
(as expected from the imaging results in (Hoogman et al., 2017)) for top-findings from the 
ADHD data set in the different brain structure data sets. The ADHD GWAS-MA data were 
clumped to define independent loci (Supplementary Methods) for all variants with P<1x10-
5 in the ADHD GWAS-MA using 1KGP3v5(The 1000 Genomes Project Consortium, 2015) data 
on European ancestry populations as reference.
The proportion of variants with a discordant direction of effect in the individual brain 
GWAS-MA was evaluated using a binomial test against a null hypothesis of 0.5 (i.e. chance 
level). This test was done for loci passing p-value thresholds of P<5x10-8 (14 LD-independent 
genome-wide significant SNPs), P<1x10-6 (44 LD-independent SNPs), and P<1x10-5 (132 LD-
independent SNPs) in the ADHD GWAS-MA. Details on the sign tests in the intelligence 
GWAS-MA data (Savage et al., 2018) are described in the Supplementary Methods.
Weighted meta-analysis of ADHD and brain volume data sets
Independent of the results of the global overlap analyses, we also performed meta-analyses 
combining results from the ADHD GWAS-MA with results from brain volume GWAS-MAs. 
We used a modified sample size-based weighing method, integrating the binary ADHD 
trait (ADHD risk) with the continuous trait (brain volume traits), as described in (Demontis 
et al., 2017). The modified sample size-based weights were derived to account for the 
respective heritabilities, genetic correlation, and measurement scale of the GWAS-MAs 
(Supplementary Methods and article (Demontis et al., 2017)). For all brain volumes, we 
additionally performed naive meta-analyses given their low genetic correlations with ADHD 
risk. We set the threshold for genome-wide significance at P=5x10-8/6=8.33x10-9.
Gene-based and gene-set analyses for ADHD+brain GWAS-MA data
Genome-wide summary statistics of ADHD, individual brain, and weighted meta-analysis 
ADHD+brain volume GWAS-MA data sets were used as input for gene-based analyses, using 
the Multi-marker Analysis of GenoMic Annotation (MAGMA) software package (version 
1.05,(de Leeuw et al., 2015), Supplementary Methods). For the ADHD+brain GWAS-MA, 
only SNPs shared between ADHD and brain volume data sets were included. Overlapping 
significant genes (P<2.731x10-6) were determined and selected for further investigation 
(Supplementary Methods).
For gene-set analyses, we used self-contained and competitive testing and tested, 
whether genes in the neurite-outgrowth gene-set (defined previously, Ngenes=45; 
Supplementary Methods (Poelmans et al., 2011b)) were jointly associated with results 
of the weighted meta-analytic data of ADHD+ICV (Supplementary Methods). Post-hoc, 
individual genes in the set were investigated, by reviewing gene test-statistics of the 
weighted ADHD+ICV GWAS-MA results. Genes reaching Bonferroni correction threshold 
(P=0.05/45=0.00111) were considered gene-wide significant. Subsequently, we reviewed 
gene-based associations in the ADHD GWAS-MA and ENIGMA+CHARGE ICV GWAS-MA 
results separately.
Reciprocal lookup of significant GWAS-MA loci
Evidence for an effect of ADHD-associated SNPs on brain volume was studied through a look-
up of results in the ENIGMA (+CHARGE) GWAS-MAs. LD-independent loci with corresponding 
index SNPs were obtained by clumping the summary statistics of the ADHD GWAS-MA 
(Demontis et al., 2017) (Supplementary Methods). Similarly, effects of 21 independent 
SNPs significantly associated with brain volumes in the original publications of the brain 
volume GWAS-MAs (Adams et al., 2016; Hibar et al., 2017; Hibar et al., 2015) on ADHD risk 
were looked-up in the ADHD GWAS-MA data. If the index variant was not present in the 
other data set, a proxy variant was selected through LDlink (https://analysistools.nci.nih.gov/
LDlink/). The Bonferroni-corrected significance levels were set at P=0.05/(14*8)=0.000446 
for look-up of ADHD SNPs in brain volume GWAS-MAs and at P=0.05/21=0.002381 for brain 
volume SNPs in ADHD GWAS-MA data.
Expression quantitative trait loci and brain gene expression
Expression quantitative trait loci (eQTL) were examined using data from the GTEx portal 
(https://www.gtexportal.org/home/)(GTEx Consortium, 2013) and the Blood eQTL Browser 
(http://genenetwork.nl/bloodeqtlbrowser/)(Westra et al., 2013).
We investigated the spatio-temporal expression pattern in brain tissue for selected 
genes using data from the Human Brain Transcriptome Project (http://hbatlas.org). We 
assessed messenger RNA (mRNA) expression trajectories in six regions of the developing 
and adult human brain (Supplementary Methods). Gene expression over the lifespan from 
the spatio-temporal atlas was graphed using custom R scripts (Kang et al., 2011).
Results
Comparison of common variant genetic architectures
Linkage disequilibrium score regression. SNP-based heritability estimates for the MRI measures 
were consistent with prior reports (Adams et al., 2016; Franke et al., 2016; Hibar et al., 2017) 
and ranged from 13.32% to 28.15% (Table 2). The amygdala mean χ2 was too small to 
allow a valid analysis. We observed a significant negative genetic correlation between 
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ADHD and ICV (rg=-0.227, P=0.00015). All other correlations were non-significant (Table 2; 
Supplementary Table 2 shows results when using constrained intercepts).
Table 2. SNP heritability analyses for MRI brain volumes and genetic correlation with ADHD1.
Brain region N Herita-
bility
SE Genetic 
correlation 
with ADHD
SE Z P
Nucleus accumbens 11,709 0.1332 0.0518 0.005558 0.09487 0.05858 0.9533
Caudate nucleus 11,772 0.2456 0.0455 -0.06426 0.07321 -0.8778 0.3801
Hippocampus2 24,704 0.1418 0.0286 -0.02354 0.06902 -0.3411 0.733
Intracranial volume2 24,024 0.2318 0.0325 -0.2266 0.05989 -3.784 0.0001543
Putamen 11,646 0.2815 0.056 0.006433 0.07077 0.09089 0.9276
Hippocampus 
ENIGMA only
11,665 0.1363 0.0488 -0.04202 0.09965 -0.4217 0.6733
Hippocampus 
CHARGE only
13,039 0.16 0.042 -0.0126 0.0832 -0.1516 0.8795
Intracranial volume 
ENIGMA only
11,221 0.1745 0.0461 -0.2348 0.09452 -2.485 0.01296
Intracranial volume 
CHARGE only
12,803 0.283 0.0466 -0.2305 0.071 -3.2479 0.0012
1Amygdala mean χ2 was too small to allow a valid analysis (N=11,757). 2 Using GWAS-MA summary statistics 
from the meta-analysis of ENIGMA and CHARGE cohorts. Heritability and genetic correlation were estimated 
by using free intercepts. In accordance with the number of tests performed, we set a Bonferroni-corrected 
significance level at P=0.05/6=0.0083. P-values in bold are significant after Bonferroni correction.
SNP effect concordance analysis. SECA found significant evidence of global pleiotropy for 
variants affecting ADHD risk for volumes of four subcortical brain regions and ICV (Table 3 
and Supplementary Fig. 1). Discordant SNP effects for ADHD and ICV were significant, i.e. 
variants increasing the risk for ADHD were associated with decreased ICV (PICV<0.001; Table 
3 and Supplementary Fig. 2). Evidence for concordant SNP-effects reached significance 
for ADHD and nucleus accumbens (Paccumbens=0.002), and for ADHD and caudate nucleus 
(Pcaudate=0.004, Table 3 and Supplementary Fig. 2).
Sign tests. Based on the phenotypic observation that patients with ADHD have, on 
average, smaller brain volumes compared to healthy controls (Hoogman et al., 2017), we had 
expected discordant rather than concordant SNP effects. As both discordant and concordant 
effects were seen in the SECA, we specifically determined directionality of genetic overlap 
between ADHD and brain volume for the top-associations per trait. Thus, we zoomed in 
further on the most strongly associated and LD-independent SNPs and compared the 
signs of the regression coefficients of those top-associations per trait. None of the sign 
tests showed a consistent direction of discordance, after correction for multiple testing 
(Supplementary Table 3). Additionally, LD-independent ADHD+ICV-associated SNPs 
showed an overrepresentation of discordant effects in GWAS-MA data for intelligence (30 
out of 43 SNPs, proportion=0.698, P=0.0069; Supplementary Table 4(Savage et al., 2018)).
Table 3. Results of pleiotropy and concordance test of SNP Effect Concordance Analysis. Brain volume 
GWAS-MA was conditioned on ADHD GWAS-MA.
Brain volume P pleiotropy CI pleiotropy P concordance CI concordance Direction of 
SNP effects
Nucleus accumbens 0.034 0.0244-0.0471 0.002 0.000548-0.00726 concordant
Amygdala <0.001 5.12x10-5-0.00564 0.006 0.00275-0.013 discordant
Caudate nucleus <0.001 5.12x10-5-0.00564 0.004 0.00156-0.0102 concordant
Hippocampus1 0.002 0.000548-0.00726 1 0.996-1 /
Intracranial volume1 <0.001 5.12x10-5-0.00564 <0.001 5.12x10-5-0.00564 discordant
Putamen <0.001 5.12x10-5-0.00564 0.01 0.00544-0.0183 concordant
Hippocampus 
ENIGMA only
0.005 0.00214-0.0116 1 0.996-1 /
Intracranial volume 
ENIGMA only
<0.001 5.12x10-5-0.00564 <0.001 5.12x10-5-0.00564 discordant
P-values and confidence intervals (CI) were obtained based on 1,000 permutations. 1 Using GWAS-MA 
summary statistics from the meta-analysis of ENIGMA and CHARGE cohorts. In accordance with the number 
of tests performed, we set a Bonferroni-corrected significance level at P=0.05/(2*6)=0.00416. P-values in 
bold are significant after Bonferroni correction.
Analyses at the single genetic variant level
Weighted SNP meta-analyses. Based on the findings of both concordant and discordant 
links between ADHD and the brain volume SNPs, we performed a genome-wide search for 
specific genetic loci associated with both ADHD and each brain trait. We used a weighted 
SNP meta-analysis design allowing the combination of findings from GWAS of binary and 
quantitative variables (Demontis et al., 2017), enabling us to specifically look for concordant 
effects at the level of single genetic variants; there is currently no suitable method to study 
discordant effects. The weighted GWAS-MA for ADHD and ICV identified two significant loci 
of interest: chromosome 15 (SEMA6D) and chromosome 16 (intergenic; Table 4, Figures 1 
and 2). Four additional loci passed the study-wide threshold for genome-wide significance, 
but those were related to a single phenotype and did not meet criteria for cross-trait 
relevance (Figure 1).
We also performed weighted GWAS-MAs for ADHD and the four subcortical brain 
structures (Supplementary Figures 3-7). For amygdala volume, a naïve sample size-
weighted meta-analysis was performed, as no genetic correlation with ADHD had been 
estimated; the six novel and/or improved LD-independent genome-wide significant loci 
observed in these analyses are summarized in Table 4. Among those, the SEMA6D locus 
was significantly associated with ADHD and putamen volume (P=3.62x10-9; Table 4, Figure 
2, and Supplementary Fig. 7).
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Figure 1: Common genetic variants associated with ADHD, ICV and ADHD+ICV. Shown here are Manhattan 
plots, in which every point represents a single genetic variant plotted according to its genomics position (x-
axis) and its –log10(P) for association with the respective trait (y-axis). The solid bright red line represents the 
study-wide genome-wide significance of P<8.33x10-9, and the dashed dark red line represents the genome-
wide significance of P<5x10-8. (a) PGC+iPSYCH ADHD GWAS-MA. (b) ENIGMA+CHARGE ICV GWAS-MA. (c) 
ADHD+ICV weighted GWAS-MA.
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Gene-wide GWAS-MAs. To maximize power of the meta-analysis, we ran genome-wide gene-
based GWAS-MAs in MAGMA; for gene-based results of all genes see Supplementary 
Tables 5-10. For ADHD+ICV, three genome-wide significant genes (MEF2C, KIZ, and SEMA6D) 
showed stronger association in the cross-trait meta-analysis compared to the separate 
analyses of ADHD and ICV (Supplementary Table 11). Additionally, the genome-wide 
significant genes FEZF1 (amygdala), ADD1 (caudate nucleus), and MANBA (hippocampus) 
showed increased significance in the cross-trait meta-analyses, compared to the individual 
analyses of ADHD and brain volumes (Supplementary Tables 12-16).
Reciprocal lookup of genome-wide significant associations. No significant associations 
were observed between the 14 previously identified genome-wide significant ADHD SNPs 
(Demontis et al., 2017) and brain volumes (Supplementary Table 17). Conversely, among 
21 SNPs previously associated with the brain volumes (Adams et al., 2016; Hibar et al., 2017; 
Hibar et al., 2015), association of two ICV-linked variants (rs8756 and rs2195243) with ADHD 
survived correction for multiple testing (Supplementary Table 18; P<0.00238).
Expression quantitative loci and brain gene expression
Previously, it was shown that many SNPs in the SEMA6D locus were strongly associated 
with expression of SEMA6D in fibroblasts (Demontis et al., 2017; GTEx Consortium, 2013). 
Indeed, repeating this analysis for the most strongly associated variants identified by the 
(weighted) cross-phenotype SNP meta-analyses and the two significant variants of the 
reciprocal lookup using the GTEx data (GTEx Consortium, 2013), we found rs281320 to be a 
significant eQTL for SEMA6D in transformed fibroblast tissue (P=1.2x10-20; Supplementary 
Table 19), as was rs281323 (P=1.2x10-21). The alternative alleles of both rs281320 and rs281323, 
which are associated with increased risk for ADHD and larger ICV, also increased SEMA6D 
expression (Supplementary Fig. 9, a and b). Additionally, rs12653396 was a significant 
eQTL for the CTC-498M16.4 and MEF2C genes, in brain (P=2x10-7)(GTEx Consortium, 2013) 
and blood tissue (P=6.53x10-7)(Westra et al., 2013), respectively, with the disease-associated 
A-allele being associated with increased MEF2C expression (Supplementary Table 19). Both 
rs8756 and rs2195243 were eQTLs of HMGA2 and CCDC53, respectively. All other top-SNPs 
were not present in either of the two eQTL databases.
We determined mRNA expression for SEMA6D and MEF2C, the only protein-coding genes 
identified in the SNP-based cross-phenotype GWAS-MAs and four significant genes (FEZF1, 
ADD1, MANBA, KIZ) identified in the gene-based cross-trait analyses, in six brain regions of 
the developing and adult human brain using data from the Human Brain Transcriptome 
Project (Kang et al., 2011). All genes are globally expressed in the developing and adult 
human brain, with SEMA6D and MEF2C showing highest mRNA expression in prenatal 
periods (Supplementary Fig. 8).
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Neurite outgrowth gene-set analysis
In an exploratory analysis, we found an association between a pre-defined gene-set 
of 45 neurite outgrowth genes (Poelmans et al., 2011b) and the meta-analytic data for 
ADHD+ICV using MAGMA (Pcompetitive=0.00338). It is current practice to use competitive 
tests, for completeness, we also report results from the self-contained analysis, which was 
Pself-contained=1.55x10
-6. Associations of this set with ADHD, separately, were restricted to 
the self-contained test (Pself-contained=5.53x10
-9); for ICV, no significant associations with the 
gene-set were found (Supplementary Table 20). In the ADHD+ICV GWAS-MA, the most 
strongly associated individual neurite outgrowth gene in the set was CREB5 (P=0.000553); 
nine additional neurite outgrowth genes showed nominally significant associations 
(Supplementary Table 21; for gene-based results of all genes see Supplementary 
Table 10).
Discussion
In this study we set out to investigate genetic covariance between ADHD risk and structural 
brain phenotypes. We found significant - though modest - genetic covariation between 
ADHD risk and brain volumes, both on global and gene-wide/single variant levels. On 
the global level, significant negative genetic correlation between ADHD and ICV was 
demonstrated. The direction of effect was supported by SNP effect concordance analysis. 
Our ICV finding was highly consistent across approaches and in the expected direction, 
given the previous observation that patients with ADHD have smaller ICV relative to controls 
(Hoogman et al., 2017). For most subcortical brain volumes, pleiotropic effects were also 
found. On the single variant and gene-wide levels, meta-analyses found significant loci 
associated with both ADHD risk and brain volumes. We identified SEMA6D, KIZ, and MEF2C as 
potential key-loci contributing to both ADHD risk and ICV, and exploratory gene-set analysis 
revealed association of ADHD-ICV overlap with variation in neurite outgrowth genes.
A reduction of subcortical brain volumes and ICV is not unique to an ADHD diagnosis, 
but is also seen in depression and bipolar disorder (Hibar et al., 2016; Schmaal et al., 2016). 
However, genetic correlation between ADHD and ICV shows some specificity to this 
disorder, as it was not found in studies of other mental disorders, i.e. schizophrenia (Adams 
et al., 2016; Franke et al., 2016), major depressive disorder (Wigmore et al., 2016), or autism 
(Adams et al., 2016), using similar methods. On the other hand, power issues should not 
yet be discarded as a reason for the lack of finding genetic correlations, despite the large 
sample sizes, and results of a recent study found that schizophrenia and brain structure 
volumes share genetic risk factors using a conditional false discovery rate (FDR) analysis 
(Smeland et al., 2018).We observed significant pleiotropy also between ADHD and amygdala, 
caudate nucleus, hippocampus, and putamen volumes. This global genetic covariation 
was substantiated by local effects, which we observed in the weighted cross-phenotype 
meta-analyses. In addition to ICV, caudate nucleus, and putamen volumes variation also 
showed significant genetic concordance with ADHD. However, whereas results for ICV 
were in line with our expectation, concordant effects for ADHD and nucleus accumbens 
and caudate nucleus volume are counterintuitive (ADHD patients have smaller volumes for 
these structures (Hoogman et al., 2017)), suggesting a reverse or more complex pattern of 
causation. Importantly, the subcortical regions were corrected for ICV phenotypically, so 
that their genetic correlation was limited.
On the single variant level, we only had tools available to perform a meta-analysis by 
looking at concordant effects (Demontis et al., 2017), we therefore had to ignore locus-
specific discordant effects. Still, the strongest association of single genetic markers 
was observed for ADHD and ICV, additional associations were identified for ADHD and 
subcortical volumes. The weighted meta-analysis of ADHD and ICV found two potentially 
pleiotropic loci. One of those was SEMA6D, coding for the semaphorin 6D, a transmembrane 
molecule important for maintenance and remodeling of neuronal connections (Qu et al., 
2002). Animal studies showed that it acts as ligand for PlexinA1, which is involved in neuronal 
development in the spinal cord (Yoshida et al., 2006). Together with the gene-based cross-
trait result identifying the MEF2C gene and the findings in the exploratory gene-set analysis, 
our findings suggest that neurite outgrowth dysregulation may act as a neural mediator 
of ADHD. Dysregulation of neurite outgrowth may pose a more general genetic risk for 
psychopathology, as it has been shown to not only be involved in ADHD (Mooney et al., 
2016; Poelmans et al., 2011b) and the hyperactive/impulsive symptom domain of ADHD 
(Bralten et al., 2013), but also in dyslexia (Poelmans et al., 2011a) and autism (Poelmans et 
al., 2013). We also found the SEMA6D locus in the cross-phenotype meta-analysis for ADHD 
and putamen volume, even though this volume had been corrected for ICV, suggesting 
that genetic variation in SEMA6D may influence specific brain regions to a different extent. 
In line with our gene-set association results, a recent study using data from the UK Biobank 
mainly found associations between MRI measures and genes involved in brain development 
and plasticity (Elliott et al., 2017). Since most of these genes have also been demonstrated 
to contribute to different psychiatric and neurodegenerative disorders (Elliott et al., 2017), 
specificity of our findings for ADHD requires additional investigation.
The current results raise a number of questions concerning the way that alterations 
in the brain mediate etiological risk pathways in ADHD. The first question is about the 
role of cognitive performance in this relationship. ADHD and ICV have recently shown 
to be genetically correlated with intelligence (ADHD is negatively genetically correlated 
with IQ (rg=-0.37, p=2.21x10-2), and ICV is positively correlated with IQ (Sniekers et al., 
2017) (rg=0.29, p=3.44x10-4). Similarly, educational attainment is linked to both ICV and 
ADHD (rg=0.34, p=1.2×10-6; rg=-0.54, p=1.44x10-80), as well as to IQ (Demontis et al., 2017; 
Okbay et al., 2016). It may therefore be possible, that the genetic link between ADHD 
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and ICV is mediated by IQ and its proxies. We attempted to test this - in the absence of 
IQ/educational attainment data to correct for in the ADHD GWAS-MA - using a sign test 
based on data from the recent large intelligence GWAS-MA (Savage et al., 2018). Here, 
we found an overrepresentation of opposite direction effects of ADHD-ICV SNPs in the 
intelligence GWAS-MA data, suggesting that intelligence may indeed play a role in the 
ADHD-ICV overlap. However, out of the 43 SNPs included in the analysis, only 15 (34.8%) 
were nominally significant associated with intelligence, suggesting that the genetic link 
between ADHD and ICV is additionally driven by intelligence-independent effects. More 
in depth research will be needed to fully understand the role of intelligence in ADHD-ICV 
overlap in the future; it may occur upstream and/or downstream of our correlation finding. 
Secondly, the degree of sharing observed was statistically modest. At first sight, this seems 
to be inconsistent with the general hypothesis that ADHD is a genetic-based brain disorder. 
However, there are a number of possible explanations for this modest sharing. We examined 
brain structure at a gross anatomical scale: compared to more precise methods, such as 
voxel-based or surface-based morphometry, atlas-based brain segmentations might be 
too coarse to identify subtler volumetric differences. Importantly, for the type of imaging 
genetics analyses described in here, we were strongly dependent on the availability of 
GWAS data for brain phenotypes. These GWAS data have to be derived from large-scale 
studies in order to allow sufficiently powered analyses. Such data is so far available only for 
subcortical volumes and ICV, published by the ENIGMA and CHARGE consortia. The sample 
sizes of the few voxel-wise GWASs available to date are not large enough to offer sufficient 
statistical power for the genome-wide approaches presented here. Moreover, it may be 
more informative to study structural and functional connectivity measures. In addition, as 
pointed out previously (Franke et al., 2016), the limited SNP-heritability of (subcortical) brain 
volumes further challenges the identification of genetic overlap, and more highly powered 
studies of brain phenotypes may lead to higher estimates of overlap. Also, the field may 
advance by applying more sophisticated imaging approaches to imaging genetics studies, 
such as redefining imaging phenotypes through dimension reduction approaches (Fan 
et al., 2018). Finally, it is also possible that some of ADHD’s association with reduced brain 
volumes is driven by environmental effects, either independently or in interaction with 
genetic factors (Faraone et al., 2015).
Previous brain imaging genetics studies in ADHD mainly focused on single genetic 
variants and were hampered by limited sample sizes (Klein et al., 2017). This study combined 
the largest data sets available to investigate the genetic overlap between ADHD and 
brain volumes by using a complementary battery of statistical methods. Nevertheless, 
some limitations apply. Firstly, this study focused on a limited set of mainly subcortical 
MRI measures, and future work should be extended to cortical regions and connectivity 
measures, once large-scale GWAS-MA becomes available (Bralten et al., 2016; Wu et al., 2017). 
To support highly sophisticated imaging genetics analyses, which can provide granular 
information on specific circuits of relevance, there is also an increasing need for large-scale 
imaging cohorts with access to raw imaging and genetic data that allow maximal flexibility 
in the application of analysis methods. Secondly, for the cross-phenotype GWAS-MA, we 
used a recently described weighted meta-analysis method (Demontis et al., 2017). However, 
we observed that with low and moderate genetically correlated phenotypes, the association 
signals did generally not improve over a naïve meta-analysis, performed without adding 
additional weights (Supplementary Fig. 10 and Supplementary Table 22). In addition, we 
could only investigate concordant SNP effects with this method. Thirdly, generalization of 
our findings to other ethnicities should be assessed in future studies. Fourthly, it is possible 
that this study underestimated genetic correlations, as we did not take into account the 
known role of rare and structural variants in the genetic architecture of ADHD (Demontis 
et al., 2016; Williams et al., 2010). Future studies investigating heritability and genetic 
correlation could also benefit from including variants with low minor allele frequency and in 
low-LD regions, which may reveal stronger relationships between ADHD and brain volumes.
This is the first study to show significant global and single gene/variant level genetic 
correlations derived from polygenic overlap between ADHD and brain volumes. The 
modest genetic overlap between ADHD and variation in brain volumes is consistent with 
models implicating alterations in brain structure in ADHD-related genetic risk pathways and 
provides new hypotheses about neuro-biological mechanisms involved in ADHD.
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Supplementary material
Participant samples
ADHD Working Group of the PGC and the ADHD iPSYCH-SSI-Broad collaboration
ADHD GWAS-MA summary statistics data were acquired from the ADHD Working Group of 
the PGC and the ADHD iPSYCH-SSI-Broad collaboration (n=55,374 (Demontis et al., 2017), 
https://www.med.unc.edu/pgc/results-and-downloads). Detailed quality control and 
imputation parameters are described in the original publication (Demontis et al., 2017). 
Briefly, genotype imputation was done using the bioinformatic pipeline “ricopili” and with 
the pre-phasing/imputation stepwise approach implemented in IMPUTE2/SHAPEIT using 
the haplotypes from the 1000 Genomes Project, phase 3, version 5 (1KGP3v5) (The 1000 
Genomes Project Consortium, 2015) data. Association analyses using the imputed marker 
dosages were performed separately for the 11 PGC samples and the 23 waves in iPSYCH by 
an additive logistic regression model using PLINK v1.9 (Chang et al., 2015), with the derived 
principal components included as covariates as described in the original publication 
(Demontis et al., 2017). Subsequently, meta-analysis, including summary statistics from 
GWASs of the 23 waves in iPSYCH and 11 PGC samples, was conducted using an inverse-
weighted fixed effects model. In total, 20,183 cases and 35,191 controls were used for the 
original analysis (Supplementary Table 1). Only SNPs with imputation quality (INFO score) 
>0.8 and MAF >0.01 were included in the meta-analysis. PGC+iPSYCH ADHD GWAS-MA 
summary statistics data only included markers which were supported by an effective sample 
size greater than 70% (8,047,420 markers) (Demontis et al., 2017).
ENIGMA
GWAS-MA summary statistics data on ICV and volumes of nucleus accumbens, amygdala, 
caudate nucleus, hippocampus, and putamen were from ENIGMA (http://enigma.ini.usc.
edu/) (Hibar et al., 2015). In the GWAS-MAs on subcortical volumes those volumes had been 
adjusted for ICV to identify specific genetic contributions to individual volumes. The five 
subcortical volumes indicated and ICV were selected for the current study based on a recent 
mega-analysis reporting significant volume reductions in patients with ADHD compared 
to healthy controls (Hoogman et al., 2017). Access to the summary statistics of ENIGMA can 
be requested via their website (http://enigma.ini.usc.edu/download-enigma-gwas-results/). 
For the initial GWAS-MA analysis, MRI brain scans and genome-wide genotype data were 
available for 11,840 subjects from 22 cohorts. Genomic data were imputed to a reference 
panel (1000 Genomes, phase1, v3 (1KGP1v3) (Genomes Project Consortium et al., 2010)) 
comprising only European samples and with monomorphic SNPs removed. Imputation was 
performed at each site using MaCH for phasing and minimac for imputation (Fuchsberger 
et al., 2015). Only SNPs with an imputation score of RSQ >0.5 and minor allele counts >10 
within each site were included. Tests of association were conducted separately for eight MRI 
volumetric phenotypes (nucleus accumbens, amygdala, caudate nucleus, hippocampus, 
pallidum, putamen, thalamus and ICV) with the following covariates in a multiple linear 
regression framework: age, age2, sex, four MDS components (to account for population 
structure) and ICV (for subcortical brain phenotypes). GWA statistics from each of the 
22 sites were combined using a fixed-effect inverse variance-weighted meta-analysis as 
implemented in METAL (Willer et al., 2010). Prior to all analyses, a cohort including ADHD 
cases (NeuroIMAGE cohort, n=154) was removed from the ENIGMA data.
CHARGE
We obtained genome-wide GWAS-MA summary statistics data on ICV and hippocampal 
volume from the CHARGE Consortium (n=12,803 and n=13,039, respectively (Adams et 
al., 2016; Hibar et al., 2017)) and CHARGE summary statistics data had been requested 
by the principal investigator of the study described by Adams et al. (Adams et al., 2016). 
Genotyping was performed using a variety of arrays across contributing sites. Samples 
and variants underwent quality control procedures based on genetic homogeneity, call 
rate (< 95%), MAF <0.01, and Hardy-Weinberg Equilibrium (HWE p-value <1×10−6). Good 
quality variants were used as input for imputation to the 1000 Genomes reference panel 
(1KGP1v3; (Genomes Project Consortium et al., 2010)) using different software packages 
(MaCH/minimac, IMPUTE2, BEAGLE, GenABLE). Only SNPs with an imputation score of RSQ 
>0.5 and MAF>0.5% within each site were included in the meta-analysis. Full details on 
the site-specific genotyping and quality control can be found in Supplementary Table 2 of 
the original publication (Adams et al., 2016). GWAS of ICV and hippocampal volumes were 
performed for each site separately, controlling for age, sex, and, when applicable age2, 
population stratification variables, study site, and diagnosis (when applicable). Summary 
statistics, including effect estimates of the genetic variant with ICV or hippocampal 
volume under an additive model, were exchanged to perform a fixed-effects meta-analysis 
weighting for sample size in METAL (Willer et al., 2010). After the final meta-analysis, variants 
were excluded if they were only available for fewer than 5,000 individuals.
Removal of duplicated individuals
Subject overlap between all PGC ADHD and ENIGMA cohorts was evaluated using a 
checksum algorithm to ensure the robustness of our results, given that some analyses 
were sensitive to the presence of duplicate individuals. For each individual, ten checksum 
numbers were created based on ten batches of 50 SNP genotypes and compared between 
individuals from both consortia. Based on these comparisons no subjects needed to be 
removed from the data sets. As no Danish cohort was included in the ENIGMA or CHARGE 
study, we assumed that there is no sample overlap between cohorts studying brain volume 
and iPSYCH.
10
420 421
Genetic markers of ADHD-related variations in intracranial volumeChapter 10
GWAS meta-analysis of ENIGMA and CHARGE data sets
To increase the sample size for the hippocampal volume and ICV data, summary statistics 
of GWAS-MA results from ENIGMA (Hibar et al., 2015) (after removal of ADHD cases) and 
CHARGE (Adams et al., 2016; Hibar et al., 2017) were combined using a fixed-effects sample 
size-weighted meta-analysis framework as implemented in METAL (Willer et al., 2010). After 
the final meta-analysis, variants were excluded if they were only available for fewer than 
5,000 individuals or a MAF ≤0.005. After filtering, the meta-analyses results included more 
than 9,145,464 markers. Importantly, the ENIGMA and CHARGE discovery data sets only 
included cohorts of European ancestry (all individuals had both imaging and genetics data). 
This overview is presented in the original publication of Adams and colleagues (Adams et 
al., 2016) in Supplementary Table 1.
Linkage disequilibrium score regression (LDSR)
For LDSR, each GWAS-MA data set underwent additional filtering. Only markers overlapping 
with HapMap Project Phase 3 SNPs and passing the INFO score ≥0.9 and MAF ≥0.01 filters 
were included (where available). SNPs with missing values, duplicate rs-numbers, too low 
a sample size (where available SNPs with an effective sample size less than 0.67 times the 
90th percentile of sample size were removed), or that were strand-ambiguous - as well as 
indels - were removed. As described in the original ADHD GWAS-MA paper (Demontis et al., 
2017), for LDSR analysis the European only subset was used (ncases=19,099 and ncontrols=34,194), 
since LDSR requires linkage disequilibrium [LD] data from a sample of comparable ethnic 
background). For the ENIGMA amygdala results, the mean χ2 was too low (1.0) to reliably 
estimate SNP heritability using LDSR. Table 1 shows genetic correlations between the 
regional brain volumes; subcortical volumes are not strongly genetically correlated with ICV.
The analyses used a two-step procedure with the LD-scoring analysis package (Bulik-Sullivan 
et al., 2015). An unconstrained regression estimated regression intercepts for each pair of 
phenotypes. Since we adopted protocols to exclude sample overlap, we also performed 
the analyses with regression intercept for the genetic correlation analysis defined as zero 
(Supplementary Table 2). To compute p-values, standard errors were estimated using a 
block jackknife procedure.
SNP effect concordance analysis (SECA)
Post-processing of genetic data
To statistically compare the ADHD and six brain volume GWAS-MAs, we used SNPs passing 
quality control and filtering rules (for ADHD GWAS-MA INFO ≥0.9 and MAF ≥0.01 and for 
ENIGMA and CHARGE GWAS-MA RSQ ≥0.5 and MAF ≥0.005) in all data sets. With these 
data, we performed a clumping procedure in PLINK (Purcell et al., 2007) to identify an 
independent SNP from every LD block across the genome. The clumping procedure was 
performed separately for each of the brain volume GWAS-MAs using a 500 kb window, 
with SNPs in LD (r2 >0.2) in the European reference samples from the 1KGP1v3 (Genomes 
Project Consortium et al., 2010). The SNP with the lowest p-value within each LD block was 
selected as the index SNP representing that LD block and all other SNPs in the LD block 
were dropped from the analysis. The result after applying the clumping procedure was 
sets of independent SNPs representing the total variation explained across the genome 
conditioned on the significance in each brain volume GWAS-MA. For each of these sets 
of SNPs, we then determined the corresponding ADHD GWAS-MA test statistic for each 
independent, index SNP and used these data sets for the subsequent analyses.
Tests of pleiotropy and concordance
We used SNP Effect Concordance Analysis (SECA) (Nyholt, 2014) to determine the extent 
and directionality of genetic overlap between ADHD and each brain volume. Within SECA 
we performed a global test of pleiotropy using a binomial test at 12 p-value levels: P ≤(0.01, 
0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9). For a given brain volume and ADHD paired set, 
we separately ordered SNPs based on their p-value for association with each trait. For each 
of the 12 p-value levels, we determined the total number of SNPs overlapping between 
the two traits at each p-value threshold and compared that number to the expected 
random overlap under the null hypothesis of no pleiotropy using a binomial test. In total, 
144 comparisons were performed. We tallied the number of comparisons with evidence of 
overlap at a nominally significant level of P ≤0.05. To evaluate the global level of pleiotropy, 
we generated 1,000 permuted data sets for a given brain volume to ADHD comparison and 
determined, if the number of significance thresholds with genetic overlap was significantly 
greater than chance.
Similarly, we estimated concordance, the agreement in SNP effect directions across 
two traits. We determined whether or not there was a significant (P ≤0.05) positive or 
negative trend in the effect of the overlapping SNPs at each of the 12 p-value thresholds. 
This was done using a two-sided Fisher’s exact test. The direction of effect for each SNP 
was determined by the sign of the SNP regression coefficient (OR or beta value) from each 
meta-analysis. In the ADHD GWAS-MA, an odds ratio >1 for a SNP indicates that the A1 
reference allele was associated with an increased risk of developing ADHD (an odds ratio 
<1 indicates a protective allele). A positive Beta value for a SNP in a brain volume GWAS-
MA indicates that the A1 reference allele of that SNP is associated with an increase in brain 
volume (a negative Beta value indicates that the A1 reference allele of that SNP is associated 
with a reduction in brain volume). We estimated the global level of concordance between a 
given brain trait and ADHD by generating 1 000 permuted data sets, repeating the Fisher’s 
exact test procedure, and determined if the number of significant overlapping thresholds 
was significantly greater than chance (see Nyholt et al., 2014 (Nyholt, 2014) for details of 
the SECA analysis).
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In total, we tested for pleiotropy and concordance between ADHD and six brain volumes. In 
accordance with the number of tests performed, we set a Bonferroni-corrected significance 
level at P=0.05/(2*6)=4.17x10-3.
Independent genome-wide significant markers and loci
LD-independent markers associated at P <1x10-5 were defined using the clump flag in 
PLINK v1.9 (Chang et al., 2015). Clumping was used to group additional associated markers 
within a 0.5 Mb window surrounding the index SNP. Markers were grouped to the index 
SNPs if they were also associated (P <0.001) and were in LD with the index SNP (r2 >0.1). A 
genome-wide significant locus was defined as the physical region containing the identified 
LD independent index SNPs and their correlated variants (r2 >0.8) with P <0.001. Associated 
loci within 250 kb of each other were merged. All LD statistics were calculated using the 
1KGP3v5 (The 1000 Genomes Project Consortium, 2015) reference haplotypes.
SNP sign test in the intelligence GWAS-MA
We performed sign tests to investigate a potential accumulation of same or opposite 
direction effects of SNPs between ADHD+ICV, ADHD, and ICV GWAS-MA data and the 
intelligence GWAS-MA data (Savage et al., 2018). The ADHD+ICV GWAS-MA data were 
clumped to define independent loci (Supplementary Methods) for all variants with P<1x10-
5 and P<1x10-4 in the ADHD+ICV GWAS-MA using 1KGP3v5 data on European ancestry 
populations as reference. Based on the negative genetic correlation between ADHD and 
intelligence, we expected an overrepresentation of discordant SNP effects. In contrast, the 
positive genetic correlation between ICV and intelligence guided us in specifically looking 
for concordant SNP effects. However, for the ADHD+ICV GWAS-MA data set we did not 
favor any directionality a priori and therefore tested for both same and opposite direction 
effects in the intelligence data set (Savage et al., 2018). The proportion of variants with a 
concordant or discordant direction of effect in the intelligence GWAS-MA was evaluated 
using a binomial test against a null hypothesis of 0.5 (i.e. chance level). This test was done 
for SNPs, which (1) passed the p-value threshold of P<1x10-5 (64 LD-independent SNPs) 
and P<1x10-4 (327 LD-independent SNPs) in the ADHD+ICV GWAS-MA and (2) showed 
smaller p-values in the ADHD+ICV GWAS-MA compared to the ADHD and ICV GWAS-MA 
individually (43 and 225 LD-independent SNPs). We set a Bonferroni-corrected significance 
level at P=0.05/(2*3)=0.00833.
Weighted meta-analysis of ADHD and brain volume data sets
Independent of the results of the global overlap analyses, we also performed meta-analyses 
combining the results from the ADHD GWAS-MA with results from GWAS-MAs of brain 
volumes (amygdala, nucleus accumbens, caudate nucleus, hippocampus, putamen, and 
ICV). This was done using a modified sample size-based weighting method, integrating the 
binary ADHD trait (ADHD risk) with the continuous trait (brain volume traits), as described 
in Demontis et al.(Demontis et al., 2017). For the meta-analyses, modified sample size-
based weights were derived to account for the respective heritability, genetic correlation, 
and measurement scale of the GWASs. The adjusted samples sizes reflect differences in 
power between the studies due to measurement scale and relative heritability that is not 
captured by sample size. Thereby, the contribution of the continuous phenotype’s GWAS 
to the meta-analysis is reduced based on imperfect correlation with the dichotomous 
phenotype of interest (in this case ADHD risk). The adjustments are computed based on 
the sample and population prevalence of the dichotomous phenotype, the estimated SNP 
heritability of the two phenotypes (liability scale for dichotomous phenotype), and the 
genetic correlation between the two phenotypes, as well as the average SNP LD score, and 
the number of SNPs. Heritability and genetic correlation values to compute these weights 
are computed using LD score regression (Bulik-Sullivan et al., 2015) as described before. For a 
comprehensive description of the method for meta-analysis of continuous and dichotomous 
phenotype and notes on the implementation please see the supplementary information 
of the original ADHD GWAS-MA publication (Demontis et al., 2017). For all brain volumes, 
we also performed naive meta-analyses given the low genetic correlations with ADHD 
risk observed. Correcting for meta-analyzing six brain phenotypes with ADHD, we set the 
threshold for genome-wide significance at P=5x10-8/6=8.33x10-9. Additionally, loci were 
considered cross-disorder relevant if (i) those loci were genome-wide significant in the cross-
phenotype meta-analysis, (ii) and/or had a cross-phenotype p-value, which was improved 
by at least one order of magnitude, and (iii) had a cross-phenotype z-score, which (at least) 
equaled the ones observed in the GWAS-MAs for the individual phenotypes. The LD score 
intercept and ratio of the individual and meta-analyzed summary statistics are presented in 
Supplementary Table 23 in order to compare the estimates of the overall genetic signal.
The percentage variance explained by each genome-wide significant index SNP was 
determined based on the ENIGMA2 data set after correction for covariates using the 
following equation:
𝑅𝑅2g|c
1	– 	𝑅𝑅2c
= (𝑡𝑡, ( 𝑛𝑛 − 𝑘𝑘 − 1 + 𝑡𝑡,)) ∗ 100	
	
where the t-statistic is calculated as the beta coefficient for a given SNP from the regression 
model (controlling for covariates) divided by the standard error of the beta estimate, and 
where n is the total number of subjects and k is the total number of covariates included 
in the model (k=10). R2g|c is the variance explained by the variant controlling for covariates, 
and R2c is the variance explained by the covariates alone. R
2
g|c/(1 − R
2
c) gives the variance 
explained by the genetic variant after accounting for covariate effects.
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Gene-based and gene-set analyses for ADHD+brain GWAS-MA data
Genome-wide summary statistics of (i) ADHD GWAS-MA, (ii) individual brain GWAS-MAs, 
and (iii) weighted meta-analysis data for combined ADHD and brain volume GWAS-MAs 
were used as input for gene-based analyses. For the ADHD+brain GWAS-MA, only SNPs 
shared between ADHD and brain volume data sets were included. Statistical analyses were 
performed using the Multi-marker Analysis of GenoMic Annotation (MAGMA) software 
package (version 1.05, (de Leeuw et al., 2015)). Genome-wide SNP data from a reference 
panel 1KGP1v3 (Genomes Project Consortium et al., 2010) was annotated to NCBI Build 37.3 
gene locations using a symmetric 100 kb flanking window. Both files were downloaded from 
http://ctglab.nl/software/magma. The gene annotation file was used to map genome-wide 
SNP data from the different studies (ADHD GWAS-MA, brain GWAS-MAs, and ADHD+brain 
GWAS-MA), to assign SNPs to genes followed by the calculation of gene-based p-values. 
This step was done for each of the data sets individually. For the gene-based analyses, 
single SNP p-values within a gene were transformed into a gene-statistic by taking the 
mean of the χ2-statistic among the SNPs in each gene. To account for LD, the 1KGP1v3 
(Genomes Project Consortium et al., 2010) was used as a reference to estimate the LD 
between SNPs within (the vicinity of) the genes (http://ctglab.nl/software/MAGMA/ref_data/
g1000_ceu.zip). Gene-wide p-values were converted to z-values reflecting the strength of 
the association of each gene with the phenotype, with higher z-values corresponding to 
stronger associations. Genome-wide gene-based results were considered significant if they 
reached the Bonferroni-corrected P-value-threshold for testing 18,310 genes (P<2.731x10-6; 
for gene-based results of all genes see Supplementary Table 4-9). Then, we assessed the 
number of significant genes overlapping between the ADHD GWAS-MA results and the 
cross-trait ADHD+brain GWAS-MA results. Of those overlapping genes, we considered those 
as cross-trait relevant if (i) those genes were genome-wide significant in the cross-trait MA, 
(ii) and had a cross-trait association p-value that was smaller compared to the separate 
analyses of ADHD and brain volume, and (iii) had a nominally significant (P<0.05) P-value 
in the individual gene-based brain trait result. The latter criterion was established in order 
to distinguish the ‘true’ cross-trait effect from increase in association signal that is purely 
related to an increase in samples size when combining the two GWAS-MA data sets. Genes, 
meeting these criteria, were reported and selected for further investigation.
Based on our finding that SEMA6D is a key locus contributing to both ADHD risk and ICV 
– a loci involved in neuronal migration and axonal path finding – we investigated, whether 
neurite outgrowth-related genes in general have a role in ADHD–ICV genetic overlap. For 
the gene-set analyses we chose to use a pre-defined gene-set of 45 neurite outgrowth 
genes . In the initial study, Poelmans and colleagues investigated the presence of genomic 
convergence in the top findings of the five published GWASs of ADHD. Then, they carried 
out bioinformatics pathway analyses, using the Ingenuity and BiNGO tools, as well as a 
systematic literature analysis of 85 genes from the five published GWASs containing SNPs 
associated with ADHD at a p value <0.0001. Out of those 85 top-ranked ADHD candidate 
genes, 45 genes encode proteins that fit into a neurodevelopmental network involved in 
directed neurite outgrowth. Moreover, the authors added data on CNVs in patients with 
ADHD and data from animal studies and this provided further support for the involvement of 
this network in ADHD etiology. Additionally, they could show that several network proteins 
are directly modulated by stimulants (commonly used treatment for ADHD).
Subsequent to the genome-wide gene-based analysis, we also tested, whether genes 
in the neurite-outgrowth gene-set (defined previously, Ngenes=45 (Poelmans et al., 2011)) 
were jointly associated with results of the weighted meta-analytic data of ADHD+ICV using 
self-contained and competitive testing (de Leeuw et al., 2016). For the gene-set analyses, 
we used an intercept-only linear regression model including a subvector corresponding to 
the genes in the gene-set. This self-contained analysis tests whether the gene-set shows 
any association with the phenotype at all by evaluating whether the regression coefficient 
of this regression is larger than 0. Next, we tested whether genes in the gene-set were 
more strongly associated with phenotype than all other genes in the genome. Therefore, 
the regression model was then expanded including all genes outside the gene-set. With 
this competitive test, the differences between the association of the neurite-outgrowth 
gene-set to genes outside this gene-set is tested, accounting for the polygenic nature of 
such a complex trait. To account for the potentially confounding factors of gene size and 
gene density, both variables as well as their logarithms were included as covariates in the 
competitive gene-set analysis. Since self-contained tests do not take into account the overall 
level of association across the genome, gene size (number of principal components, or SNPs), 
and gene density, we were particularly interested in the competitive test for the current 
analysis. Basically, a significance in the self-contained tests but not the competitive test, 
suggests that the effect of the gene-set is not different from the background effect that 
captures the polygenic nature of ADHD. Moreover, a non-significant competitive p-value 
can be interpreted as not being able to disentangle the part of the polygenicity attributable 
to the genes in the gene set versus the polygenicity “remaining” (i.e. not captured by the 
set) on the rest of the genome and not that the selected gene-set has no effect on the 
outcome. Subsequently, we tested whether the gene-set was associated with the two 
individual data sets as well. In this, the same procedure was followed for analysis of the 
ADHD GWAS-MA and ENIGMA+CHARGE ICV GWAS-MA summary statistics individually. 
Post-hoc, the individual genes in the set were investigated, by reviewing gene test-statistics 
of the weighted ADHD+ICV GWAS-MA results. Genes of the neurite-outgrowth set were 
considered gene-wide significant, if they reached the adjusted Bonferroni correction 
threshold (P=0.05/45=0.00111). Subsequently, we reviewed gene-based associations in the 
ADHD GWAS-MA and ENIGMA+CHARGE ICV GWAS-MA results separately. For genome-wide 
gene-based comparisons we considered results significant, if they reached the Bonferroni-
corrected P-value-threshold for testing 18,411 genes (P<2.716x10-6). Then, we assessed the 
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number of significant genes overlapping between the ADHD GWAS-MA results and the 
cross-trait ADHD+brain GWAS-MA results. Of those overlapping genes, we considered those 
as cross-trait relevant if (i) those genes were genome-wide significant in the cross-trait MA, 
(ii) and had a cross-trait association p-value that was smaller compared to the separate 
analyses of ADHD and brain volume, and (iii) had a nominally significant (P<0.05) P-value 
in the individual gene-based brain trait result. The latter criterion was established in order 
to distinguish the ‘true’ cross-trait effects from increase in association signal that is purely 
related to an increase in samples size when combining the two GWAS-MA data sets. Genes, 
meeting these criteria, were reported and selected for further investigation.
Significant genes with lower association p-values in the meta-analysis, compared to the 
separate analyses of ADHD and ICV, were reported in Supplementary Table 10.
Expression quantitative trait loci and brain gene expression
To assess potential functionality in (brain) tissues, we tested the identified risk variants 
(Table 4) for association with gene expression. Expression quantitative trait loci (eQTL) 
were examined using data from the GTEx portal (https://www.gtexportal.org/home/) 
(GTEx Consortium, 2013). The data is presented in Supplementary Table 7 and is shown as 
normalized effect sizes (NES) and p-values. NES describes the slope of the linear regression 
of normalized expression data versus the three genotype categories using single-tissue 
eQTL analysis, representing eQTL effect size. The normalized expression values are based 
on quantile normalization within each tissue, followed by inverse quantile normalization 
for each gene across samples. The p-value results from a t-test that compares observed 
beta from single-tissue eQTL analysis to a null beta of 0. In addition, blood eQTL data were 
queried using the Blood eQTL Browser (http://genenetwork.nl/bloodeqtlbrowser/) (Westra 
et al., 2013).
We also investigated the spatio-temporal expression pattern in brain tissue for genes 
with significantly associated variants in the approaches described earlier (Table 4) using data 
from the Human Brain Transcriptome Project (http://hbatlas.org). We assessed messenger 
RNA (mRNA) expression trajectories in six regions of the developing and adult human brain. 
Spanning periods from embryonic development to late adulthood, this data set provides 
genome-wide exon-level transcriptome data generated using the Affymetrix GeneChip 
Human Exon 1.0 SS Arrays from over 1,340 tissue samples sampled from both hemispheres 
of postmortem human brains (n=57) (Kang et al., 2011). Gene expression over the lifespan 
from the spatio-temporal atlas was graphed using custom R scripts (Kang et al., 2011).
URLs
http://enigma.ini.usc.edu/download-enigma-gwas-results/
https://www.med.unc.edu/pgc/results-and-downloads
https://github.com/bulik/ldsc
https://neurogenetics.qimrberghofer.edu.au/SECA/
https://analysistools.nci.nih.gov/LDlink/
https://www.gtexportal.org/home/
http://hbatlas.org
http://ctglab.nl/software/MAGMA/ref_data/g1000_ceu.zip
http://locuszoom.sph.umich.edu/
Data availability
The genome-wide summary statistics that support the findings of this study are available 
at the consortia websites.
PGC ADHD working group and the ADHD iPSYCH-SSI-Broad collaboration: https://www.
med.unc.edu/pgc/results-and-downloads
ENIGMA and ENIGMA+CHARGE for ICV and hippocampus: http://enigma.ini.usc.edu/
download-enigma-gwas-results/
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Supplementary figures
Supplementary Figure 1 (a-h): Global evidence of pleiotropy between the ADHD GWAS and each brain 
volume GWAS (nucleus accumbens, amygdala, caudate nucleus, hippocampus, putamen, and intracranial 
volume). Plots show the results from SECA separated into separate panels, one for each comparison.
Supplementary Figure 1 (a): Global evidence of pleiotropy between ADHD GWAS and 
nucleus accumbens volume. P1 in the plot is the ADHD GWAS and P2 is the nucleus 
accumbens GWAS. The global evidence for pleiotropy was not significant after accounting 
for multiple testing (P=0.034).
Supplementary Figure 1 (b): Global evidence of pleiotropy between ADHD GWAS and amygdala volume. 
P1 in the plot is the ADHD GWAS and P2 is the amygdala GWAS. The global evidence for pleiotropy was 
significant after accounting for multiple testing (P<0.001).
Supplementary Figure 1 (c): Global evidence of pleiotropy between ADHD GWAS and caudate nucleus 
volume. P1 in the plot is the ADHD GWAS and P2 is the caudate nucleus GWAS. The global evidence for 
pleiotropy was significant after accounting for multiple testing (P<0.001).
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Supplementary Figure 1 (d): Global evidence of pleiotropy between ADHD GWAS and hippocampus 
volume (ENIGMA+CHARGE GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the hippocampus GWAS. 
The global evidence for pleiotropy was significant after accounting for multiple testing (P=0.002).
Supplementary Figure 1 (e): Global evidence of pleiotropy between ADHD GWAS and intracranial volume 
(ENIGMA+CHARGE GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the intracranial volume GWAS. 
The global evidence for pleiotropy was significant after accounting for multiple testing (P<0.001).
Supplementary Figure 1 (f): Global evidence of pleiotropy between ADHD GWAS and putamen volume. 
P1 in the plot is the ADHD GWAS and P2 is the putamen volume GWAS. The global evidence for pleiotropy 
was significant after accounting for multiple testing (P<0.001).
Supplementary Figure 1 (g): Global evidence of pleiotropy between ADHD GWAS and hippocampus 
volume (ENIGMA only GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the hippocampus GWAS. The 
global evidence for pleiotropy was not significant after accounting for multiple testing (P=0.005).
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Supplementary Figure 1 (h): Global evidence of pleiotropy between ADHD GWAS and intracranial volume 
(ENIGMA only GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the intracranial volume GWAS. The 
global evidence for pleiotropy was significant after accounting for multiple testing (P<0.001).
Supplementary Figure 2 (a-h): Global evidence of concordance between the ADHD GWAS and each brain 
volume GWAS (nucleus accumbens, amygdala, caudate nucleus, hippocampus, putamen, and intracranial 
volume). Plots show the results from SECA separated into separate panels, one for each comparison.
Supplementary Figure 2 (a): Global evidence for concordant effects between ADHD GWAS and nucleus 
accumbens. P1 in the plot is the ADHD GWAS and P2 is the nucleus accumbens GWAS. The global evidence 
for positive concordance was significant after accounting for multiple testing (P=0.002).
Supplementary Figure 2 (b): Global evidence for concordant effects between ADHD GWAS and amygdala. 
P1 in the plot is the ADHD GWAS and P2 is the amygdala GWAS. The global evidence for concordance was 
not significant after accounting for multiple testing (P=0.006).
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Supplementary Figure 2 (c): Global evidence for concordant effects between ADHD GWAS and caudate 
nucleus. P1 in the plot is the ADHD GWAS and P2 is the caudate nucleus GWAS. The global evidence for 
positive concordance was significant after accounting for multiple testing (P=0.004).
Supplementary Figure 2 (d): Global evidence for concordant effects between ADHD GWAS and 
hippocampus volume (ENIGMA+CHARGE GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the 
hippocampus volume GWAS. The global evidence for concordance was not significant after accounting 
for multiple testing (P=1).
Supplementary Figure 2 (e): Global evidence for concordant effects between ADHD GWAS and intracranial 
volume (ENIGMA+CHARGE GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the intracranial volume 
GWAS. The global evidence for negative concordance was significant after accounting for multiple testing 
(P<0.001).
Supplementary Figure 2 (f): Global evidence for concordant effects between ADHD GWAS and putamen. 
P1 in the plot is the ADHD GWAS and P2 is the putamen GWAS. The global evidence for concordance was 
not significant after accounting for multiple testing (P<0.001).
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Supplementary Figure 2 (g): Global evidence for concordant effects between ADHD GWAS and 
hippocampus volume (ENIGMA only GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the hippocampus 
volume GWAS. The global evidence for concordance was not significant after accounting for multiple testing 
(P=1).
Supplementary Figure 2 (h): Global evidence for concordant effects between ADHD GWAS and intracranial 
volume (ENIGMA only GWAS-MA). P1 in the plot is the ADHD GWAS and P2 is the intracranial volume GWAS. 
The global evidence for negative concordance was significant after accounting for multiple testing (P<0.001).
Supplementary Figure 3: Common genetic variants associated with ADHD, nucleus accumbens and the 
meta-analysis of ADHD and nucleus accumbens. Manhattan plots in which every point represents a single 
genetic variant plotted according to its genomics position (x-axis) and its –log10(P) for association with 
the respective trait (y-axis). The solid bright red line represents the study-wide genome-wide significance 
of P<8.33x10-9 and the dashed dark red line represents the genome-wide significance of P<5x10-8. (A) 
PGC+iPSYCH ADHD GWAS-MA. (B) ENIGMA nucleus accumbens GWAS-MA. (C) ADHD+ nucleus accumbens 
weighted GWAS-MA.
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Supplementary Figure 4: Common genetic variants associated with ADHD, amygdala and the meta-
analysis of ADHD and amygdala. Manhattan plots in which every point represents a single genetic variant 
plotted according to its genomics position (x-axis) and its –log10(P) for association with the respective trait 
(y-axis). The solid bright red line represents the study-wide genome-wide significance of P<8.33x10-9 and 
the dashed dark red line represents the genome-wide significance of P<5x10-8. (A) PGC+iPSYCH ADHD 
GWAS-MA. (B) ENIGMA amygdala GWAS-MA. (C) ADHD+amygdala naive GWAS-MA.
Supplementary Figure 5: Common genetic variants associated with ADHD, caudate nucleus and the meta-
analysis of ADHD and caudate nucleus. Manhattan plots in which every point represents a single genetic 
variant plotted according to its genomics position (x-axis) and its –log10(P) for association with the respective 
trait (y-axis). The solid bright red line represents the study-wide genome-wide significance of P<8.33x10-9 
and the dashed dark red line represents the genome-wide significance of P<5x10-8. (A) PGC+iPSYCH ADHD 
GWAS-MA. (B) ENIGMA caudate nucleus GWAS-MA. (C) ADHD+caudate nucleus weighted GWAS-MA.
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Supplementary Figure 6: Common genetic variants associated with ADHD, hippocampus and the meta-
analysis of ADHD and hippocampus. Manhattan plots in which every point represents a single genetic 
variant plotted according to its genomics position (x-axis) and its –log10(P) for association with the respective 
trait (y-axis). The solid bright red line represents the study-wide genome-wide significance of P<8.33x10-9 
and the dashed dark red line represents the genome-wide significance of P<5x10-8. (A) PGC+iPSYCH ADHD 
GWAS-MA. (B) ENIGMA+CHARGE hippocampus GWAS-MA. (C) ADHD+hippocampus weighted GWAS-MA.
Supplementary Figure 7: Common genetic variants associated with ADHD, putamen and the meta-analysis 
of ADHD and putamen. Manhattan plots in which every point represents a single genetic variant plotted 
according to its genomics position (x-axis) and its –log10(P) for association with the respective trait (y-axis). 
The solid bright red line represents the study-wide genome-wide significance of P<8.33x10-9 and the dashed 
dark red line represents the genome-wide significance of P<5x10-8. (A) PGC+iPSYCH ADHD GWAS-MA. (B) 
ENIGMA putamen GWAS-MA. (C) ADHD+putamen weighted GWAS-MA.
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Supplementary Figure 8: Expression trajectories of SEMA6D (A), MEF2C (B), ADD1 (C), MANBA (D), and 
C20ORF19 (alias KIZ (E)) in the developing and adult human brain. Line plots show the log2-transformed 
gene exon array signal intensity from the early fetal period to late adulthood in six brain regions. The solid 
line between periods 7 and 8 (approximately post-conception day 280) separates prenatal from postnatal 
periods. Data were generated using Affymetrix GeneChip Human Exon 1.0 ST Arrays by the Human Brain 
Transcriptome project, and accessed via their publicly available database at http://hbatlas.org (Kang et 
al., 2011). The FEZF1 gene was not present in the Human Brain Transcriptome database. Abbreviations: 
NCX=neocortex; HIP=hippocampus; AMY=amygdala; STR=striatum; MD=mediodorsal nucleus of the 
thalamus; CBC=cerebellar cortex.
Supplementary Figure 9: Effect of index SNPs from ADHD+brain meta-analyses on human gene expression. 
(A) Expression quantitative trait loci (eQTL) analysis in transformed fibroblasts demonstrates the effect of 
rs281320 on SEMA6D gene expression. (B) eQTL analysis in transformed fibroblasts demonstrates the effect 
of rs281323 on SEMA6D gene expression. (C) eQTL analysis in frontal cortex tissue demonstrates the effect 
of rs12653396 on CTC-498M16.4 gene expression. The data used here is publicly from GTEx Analysis Release 
V6p (GTEx Consortium, 2013).
Supplementary Figure 10: Common genetic variants associated with ADHD+ICV. Shown here are 
Manhattan plots, in which every point represents a single genetic variant plotted according to its genomic 
position (x-axis) and its –log10(P) for association with the respective trait (y-axis). The solid bright red line 
represents the threshold for study-wide genome-wide significance at P=8.33x10-9, and the dashed dark red 
line represents the threshold for genome-wide significance at P=5x10-8. (a) ADHD+ICV weighted GWAS-MA. 
(b) ADHD+ICV naïve (without additional weight factors) GWAS-MA.
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Supplementary tables
Supplementary Table 1: Sample characteristics of the different cohorts used in this study.
Cohort Trait Nsubjects
Ngenetic 
variants
Reference
PGC-iPSYCH ADHD
20,183 cases/ 
35,191 controls
8,047,420
(Demontis et al., 
2017)
ENIGMA only*
Nucleus accumbens volume 11,709 8,615,659
(Hibar et al., 2015)
Amygdala volume 11,757 8,601,199
Caudate nucleus volume 11,772 8,615,485
Hippocampus volume 11,665 8,610,806
Putamen volume 11,646 8,609,826
Intracranial volume 11,221 8,720,403
CHARGE
Hippocampus volume 13,039 12,438,667 (Adams et al., 2016; 
Hibar et al., 2017)Intracranial volume 12,803 12,460,951
MA ENIGMA*+CHARGE
Hippocampus volume 24,704 9,145,464
This manuscript
Intracranial volume 24,024 9,186,920
Nsubjects=number of subjects included in this study after quality control; Ngenetic variants=number of genetic 
variants available for this study after quality control. *ADHD cases from the NeuroIMAGE cohort (n=154) 
have been removed from this ENIGMA data set.
Supplementary Table 2. SNP heritability analyses for MRI brain volumes and genetic correlation with 
ADHD using constrained intercepts*.
Brain region N Heritability SE Genetic 
correlation 
with ADHD
SE Z P
Nucleus 
accumbens
11,709 0.0477 0.0315 0.144 0.1027 1.403 0.1606
Caudate nucleus 11,772 0.1714 0.0322 0.04699 0.05531 0.8495 0.3956
Hippocampus# 24,704 0.1412 0.0186 -0.01677 0.04085 -0.4104 0.6815
Intracranial 
volume#
24,024 0.2873 0.0229 -0.2066 0.03247 -6.363 1.98x10-10
Putamen 11,646 0.1736 0.0348 0.04018 0.05257 0.7643 0.4447
Hippocampus 
ENIGMA only
11,665 0.1318 0.0305 -0.03867 0.05958 -0.6491 0.5163
Intracranial volume 
ENIGMA only
11,221 0.1809 0.0307 -0.2117 0.0555 -3.814 0.000137
*Amygdala mean χ2 was too small to allow a valid analysis (N=11,757). #Using GWAS-MA summary statistics 
from the meta-analysis of ENIGMA and CHARGE cohorts. Heritability and genetic correlation were estimated 
by using constrained intercepts. P-values in bold are significant after Bonferroni correction.
Supplementary Table 3. Sign test results in brain volume cohorts.
P threshold Brain region N opposite direction Proportion P
< 5x10-8
Nucleus accumbens 4 0.40 0.828
Amygdala 6 0.60 0.377
Caudate nucleus 4 0.40 0.828
Hippocampus 4 0.40 0.828
Intracranial volume 2 0.20 0.989
Putamen 1 0.10 0.999
< 1x10-6
Nucleus accumbens 14 0.40 0.912
Amygdala 18 0.51 0.5
Caudate nucleus 11 0.31 0.992
Hippocampus 20 0.57 0.249
Intracranial volume 17 0.49 0.632
Putamen 12 0.34 0.979
< 1x10-5
Nucleus accumbens 48 0.49 0.619
Amygdala 52 0.53 0.307
Caudate nucleus 38 0.39 0.990
Hippocampus 57 0.58 0.065
Intracranial volume 56 0.57 0.094
Putamen 48 0.49 0.619
< 5x10-8
Hippocampus ENIGMA only 6 0.60 0.377
Intracranial volume ENIGMA only 3 0.33 0.910
< 1x10-6
Hippocampus ENIGMA only 17 0.49 0.632
Intracranial volume ENIGMA only 19 0.56 0.924
< 1x10-5
Hippocampus ENIGMA only 50 0.51 0.459
Intracranial volume ENIGMA only 50 0.51 0.419
Test of whether the proportion of index SNPs with estimated effects in the opposite direction as the ADHD 
GWAS-MA is greater than expected by chance. The expected proportion under the null hypothesis is 0.5. 
At threshold P<5x10-8 4 index SNPs were not available in the brain volume GWAS-MA data, so were 9 at 
threshold P<5x10-6 and 34 at threshold P<5x10-5. We set a Bonferroni-corrected significance level at P=0.05/
(3*6)=0.0027.
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Supplementary Table 4: Sign test results for the intelligence GWAS-MA summary statistics from (Savage 
et al., 2018).
P threshold Trait
Expected 
directionality
N SNPs 
included
N expected 
direction
Proportion P
< 1x10-5
ADHD+ICV
concordant 43 13 0.3023256 0.9973
discordant 43 30 0.6976744 0.006859*
ADHD discordant 45 15 0.3333 0.992
ICV concordant 58 19 0.3275862 0.9973
< 1x10-4
ADHD+ICV
concordant 225 96 0.4266667 0.9884
discordant 225 129 0.5733333 0.01633
ADHD discordant 234 133 0.5683761 0.02124
ICV concordant 289 120 0.4152249 0.9984
Test of whether the proportion of index SNPs with estimated effects in the same (concordant) or opposite 
(discordant) direction as the ADHD GWAS-MA is greater than expected by chance. This test was done for 
LD-independent SNPs, which (1) passed the p-value threshold of P<1x10-5 or P<1x10-4 in the ADHD+ICV 
GWAS-MA and (2) showed smaller p-value in the ADHD+ICV GWAS-MA compared to the ADHD and ICV 
GWAS-MA individually. The expected proportion under the null hypothesis is 0.5. We set a Bonferroni-
corrected significance level at P=0.05/(2*3)=0.00833; significant results are indicated by an asterisk (*).
Supplementary Table 5: Results of MAGMA gene-based associations of all genes for ADHD and amygdala 
volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 786 61 67131 7.2295 2.42E-13
5792 1 43891708 44189343 521 60 67131 7.1726 3.68E-13
23334 1 43755556 44019918 338 68 67131 6.9528 1.79E-12
9682 1 44015797 44271189 533 43 67131 6.693 1.09E-11
81888 1 43816674 44019938 272 57 67131 6.6747 1.24E-11
1848 12 89641837 89846296 419 96 67131 6.5685 2.54E-11
4208 5 87914058 88299922 558 85 67131 6.3061 1.43E-10
64834 1 43729068 43933745 266 53 67131 6.2814 1.68E-10
991 1 43724626 43928874 269 53 67131 6.2606 1.92E-10
4352 1 43703475 43920135 297 53 67131 6.1003 5.3E-10
112950 1 43749579 43955483 247 67 67131 6.0066 9.47E-10
80031 15 47376403 48166420 1966 166 67131 5.7416 4.69E-09
22986 10 1.06E+08 1.07E+08 2208 143 67131 5.7131 5.55E-09
7075 1 43666566 43888781 372 91 67131 5.5548 1.39E-08
9048 1 44298992 44502912 365 60 67131 5.464 2.33E-08
9670 1 44312478 44533694 417 82 67131 5.3459 4.5E-08
1006 16 61581169 62170939 1289 89 67131 5.1894 1.05E-07
389549 7 1.22E+08 1.22E+08 421 74 67131 5.1439 1.35E-07
149466 1 43647554 43851334 394 88 67131 5.1317 1.44E-07
93986 7 1.14E+08 1.14E+08 1141 150 67131 5.0418 2.31E-07
1802 1 44335653 44539043 396 72 67131 5.0381 2.35E-07
4126 4 1.03E+08 1.04E+08 572 65 67131 5.0236 2.54E-07
533 1 44340118 44543972 408 77 67131 4.9115 4.52E-07
128218 1 43635665 43839673 436 84 67131 4.8355 6.64E-07
8704 1 44344874 44556843 428 94 67131 4.8147 7.37E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA (de Leeuw et al., 2015) analysis. Entrez-ID (GENE), Chromosome 
(CHR), Start (START) and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective 
number of SNPs included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based p-values 
for ADHD GWAS-MA (tab 1), ENIGMA amygdala GWAS-MA (tab 2), and the weighted ADHD+amygdala 
GWAS-MA (tab 3) are shown. Genes were considered gene-wide significant, if they reached the Bonferroni 
correction threshold adjusted for the total number of genes (N=18,306; P<2.731x10-6; genes marked in bold).
The complete Supplementary Table 5 is available upon request.
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Supplementary Table 6: Results of MAGMA gene-based associations of all genes for ADHD and nucleus 
accumbens volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 786 61 67083 7.1157 5.57E-13
5792 1 43891708 44189343 521 60 67083 7.0727 7.6E-13
23334 1 43755556 44019918 338 68 67083 6.8405 3.95E-12
1848 12 89641837 89846296 419 96 67083 6.6496 1.47E-11
9682 1 44015797 44271189 533 43 67083 6.6225 1.77E-11
81888 1 43816674 44019938 272 57 67083 6.5592 2.71E-11
4208 5 87914058 88299922 558 85 67083 6.2858 1.63E-10
64834 1 43729068 43933745 266 53 67083 6.1636 3.55E-10
991 1 43724626 43928874 269 53 67083 6.1406 4.11E-10
4352 1 43703475 43920135 297 53 67083 5.9543 1.31E-09
80031 15 47376403 48166420 1966 166 67083 5.9187 1.62E-09
112950 1 43749579 43955483 247 67 67083 5.9108 1.7E-09
7075 1 43666566 43888781 372 91 67083 5.5191 1.7E-08
22986 10 1.06E+08 1.07E+08 2208 143 67083 5.4726 2.22E-08
93986 7 1.14E+08 1.14E+08 1141 150 67083 5.3608 4.14E-08
1006 16 61581169 62170939 1289 89 67083 5.3444 4.54E-08
9048 1 44298992 44502912 365 60 67083 5.3367 4.73E-08
9670 1 44312478 44533694 417 82 67083 5.2546 7.42E-08
389549 7 1.22E+08 1.22E+08 421 74 67083 5.2087 9.51E-08
149466 1 43647554 43851334 394 88 67083 5.0882 1.81E-07
1802 1 44335653 44539043 396 72 67083 4.9823 3.14E-07
128218 1 43635665 43839673 436 84 67083 4.8499 6.17E-07
533 1 44340118 44543972 408 77 67083 4.8473 6.26E-07
4126 4 1.03E+08 1.04E+08 572 65 67083 4.8401 6.49E-07
3769 2 2.34E+08 2.34E+08 486 42 67083 4.8298 6.83E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA (de Leeuw et al., 2015) analysis. Entrez-ID (GENE), Chromosome 
(CHR), Start (START) and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective 
number of SNPs included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based 
p-values for ADHD GWAS-MA (tab 1), ENIGMA nucleus accumbens GWAS-MA (tab 2), and the weighted 
ADHD+nucleus accumbens GWAS-MA (tab 3) are shown. Genes were considered gene-wide significant, 
if they reached the Bonferroni correction threshold adjusted for the total number of genes (N=18,306; 
P<2.731x10 -6; genes marked in bold).
The complete Supplementary Table 6 is available upon request.
Supplementary Table 7: Results of MAGMA gene-based associations of all genes for ADHD and caudate 
nucleus volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 786 61 67146 6.949 1.84E-12
5792 1 43891708 44189343 521 60 67146 6.863 3.37E-12
23334 1 43755556 44019918 338 68 67146 6.663 1.34E-11
1848 12 89641837 89846296 419 96 67146 6.5652 2.6E-11
4208 5 87914058 88299922 558 85 67146 6.4967 4.11E-11
9682 1 44015797 44271189 533 43 67146 6.4939 4.18E-11
81888 1 43816674 44019938 272 57 67146 6.3903 8.28E-11
64834 1 43729068 43933745 266 53 67146 5.9628 1.24E-09
991 1 43724626 43928874 269 53 67146 5.9289 1.52E-09
112950 1 43749579 43955483 247 67 67146 5.7776 3.79E-09
4352 1 43703475 43920135 297 53 67146 5.6684 7.21E-09
1006 16 61581169 62170939 1289 89 67146 5.406 3.22E-08
389549 7 1.22E+08 1.22E+08 421 74 67146 5.3697 3.94E-08
7075 1 43666566 43888781 372 91 67146 5.2062 9.64E-08
22986 10 1.06E+08 1.07E+08 2208 143 67146 5.2059 9.65E-08
93986 7 1.14E+08 1.14E+08 1141 150 67146 5.1629 1.22E-07
9048 1 44298992 44502912 365 60 67146 5.077 1.92E-07
151648 3 20102085 20327724 850 71 67146 4.9298 4.11E-07
118 4 2745454 3031803 770 146 67146 4.9086 4.59E-07
9670 1 44312478 44533694 417 82 67146 4.9029 4.72E-07
8850 3 19981524 20295896 1066 89 67146 4.8604 5.86E-07
3769 2 2.34E+08 2.34E+08 486 42 67146 4.852 6.11E-07
80031 15 47376403 48166420 1966 166 67146 4.8249 7E-07
149466 1 43647554 43851334 394 88 67146 4.7758 8.95E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA (de Leeuw et al., 2015) analysis. Entrez-ID (GENE), Chromosome 
(CHR), Start (START) and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective 
number of SNPs included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based p-values 
for ADHD GWAS-MA (tab 1), ENIGMA caudate nucleus GWAS-MA (tab 2), and the weighted ADHD+caudate 
nucleus GWAS-MA (tab 3) are shown. Genes were considered gene-wide significant, if they reached the 
Bonferroni correction threshold adjusted for the total number of genes (N=18,306; P<2.731x10-6; genes 
marked in bold).
The complete Supplementary Table 7 is available upon request.
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Supplementary Table 8: Results of MAGMA gene-based associations of all genes for ADHD and 
hippocampus volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 796 64 67039 7.2257 2.49E-13
5792 1 43891708 44189343 522 60 67039 7.1666 3.85E-13
9682 1 44015797 44271189 534 45 67039 6.8439 3.85E-12
23334 1 43755556 44019918 339 69 67039 6.5507 2.86E-11
81888 1 43816674 44019938 272 57 67039 6.3541 1.05E-10
4126 4 1.03E+08 1.04E+08 577 67 67039 5.9974 1E-09
29979 9 86174878 86423168 478 57 67039 5.7392 4.76E-09
991 1 43724626 43928874 271 59 67039 5.7224 5.25E-09
64834 1 43729068 43933745 267 56 67039 5.7073 5.74E-09
22986 10 1.06E+08 1.07E+08 2225 147 67039 5.6764 6.88E-09
23245 9 1.19E+08 1.2E+08 3253 433 67039 5.6558 7.76E-09
4790 4 1.03E+08 1.04E+08 604 78 67039 5.5479 1.45E-08
112950 1 43749579 43955483 248 68 67039 5.5059 1.84E-08
9670 1 44312478 44533694 429 87 67039 5.4926 1.98E-08
4352 1 43703475 43920135 299 52 67039 5.4338 2.76E-08
414328 9 86137964 86359045 433 72 67039 5.3148 5.34E-08
9048 1 44298992 44502912 376 64 67039 5.3105 5.47E-08
1848 12 89641837 89846296 425 98 67039 5.2898 6.12E-08
80318 9 86254336 86544431 566 41 67039 5.2093 9.48E-08
7075 1 43666566 43888781 376 93 67039 5.1493 1.31E-07
1802 1 44335653 44539043 405 78 67039 5.1296 1.45E-07
80031 15 47376403 48166420 1978 169 67039 5.0847 1.84E-07
57497 6 40259373 40655126 1369 138 67039 5.0741 1.95E-07
1006 16 61581169 62170939 1298 93 67039 5.0376 2.36E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA (de Leeuw et al., 2015) analysis. Entrez-ID (GENE), Chromosome 
(CHR), Start (START) and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective 
number of SNPs included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based 
p-values for ADHD GWAS-MA (tab 1), ENIGMA+CHARGE hippocampus GWAS-MA (tab 2), and the weighted 
ADHD+hippocampus GWAS-MA (tab 3) are shown. Genes were considered gene-wide significant, if they 
reached the Bonferroni correction threshold adjusted for the total number of genes (N=18,306; P<2.731x10-6; 
genes marked in bold).
The complete Supplementary Table 8 is available upon request.
Supplementary Table 9: Results of MAGMA gene-based associations of all genes for ADHD and putamen 
volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 786 61 67020 7.3574 9.37E-14
5792 1 43891708 44189343 521 60 67020 7.1283 5.08E-13
9682 1 44015797 44271189 533 43 67020 6.7655 6.64E-12
23334 1 43755556 44019918 338 68 67020 6.7526 7.26E-12
81888 1 43816674 44019938 272 57 67020 6.4666 5.01E-11
4208 5 87914058 88299922 558 85 67020 6.4559 5.38E-11
1848 12 89641837 89846296 419 96 67020 6.385 8.57E-11
64834 1 43729068 43933745 266 53 67020 6.0917 5.58E-10
991 1 43724626 43928874 269 53 67020 6.0624 6.71E-10
80031 15 47376403 48166420 1966 166 67020 5.9544 1.31E-09
112950 1 43749579 43955483 247 67 67020 5.8549 2.39E-09
4352 1 43703475 43920135 297 53 67020 5.8423 2.57E-09
9048 1 44298992 44502912 365 60 67020 5.5363 1.54E-08
9670 1 44312478 44533694 417 82 67020 5.3978 3.37E-08
7075 1 43666566 43888781 372 91 67020 5.3776 3.78E-08
1630 18 49766542 51162273 4557 227 67020 5.2921 6.05E-08
22986 10 1.06E+08 1.07E+08 2208 143 67020 5.1791 1.11E-07
55857 20 21006624 21327260 521 55 67020 5.1203 1.53E-07
1802 1 44335653 44539043 396 72 67020 5.074 1.95E-07
149466 1 43647554 43851334 394 88 67020 4.9879 3.05E-07
533 1 44340118 44543972 408 77 67020 4.9292 4.13E-07
8874 13 1.12E+08 1.12E+08 1317 176 67020 4.8806 5.29E-07
93986 7 1.14E+08 1.14E+08 1141 150 67020 4.8668 5.67E-07
389549 7 1.22E+08 1.22E+08 421 74 67020 4.8493 6.2E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA (de Leeuw et al., 2015) analysis. Entrez-ID (GENE), Chromosome 
(CHR), Start (START) and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective 
number of SNPs included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based 
p-values for ADHD GWAS-MA (tab 1), ENIGMA putamen GWAS-MA (tab 2), and the weighted ADHD+putamen 
GWAS-MA (tab 3) are shown. Genes were considered gene-wide significant, if they reached the Bonferroni 
correction threshold adjusted for the total number of genes (N=18,306; P<2.731x10-6; genes marked in bold).
The complete Supplementary Table 9 is available upon request.
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Supplementary Table 10: Results of MAGMA gene-based associations of all genes for ADHD and ICV.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 828 74 55374 7.5192 2.755E-14
5792 1 43891708 44189343 536 65 55374 7.3208 1.2327E-13
23334 1 43755556 44019918 345 73 55374 7.0027 1.2552E-12
81888 1 43816674 44019938 277 61 55374 6.8669 3.2804E-12
9682 1 44015797 44271189 551 43 55374 6.836 4.0725E-12
1848 12 89641837 89846296 436 98 55374 6.482 4.5262E-11
991 1 43724626 43928874 279 62 55374 6.2968 1.5191E-10
64834 1 43729068 43933745 275 59 55374 6.2813 1.6783E-10
112950 1 43749579 43955483 254 48 55374 6.2262 2.389E-10
4208 5 87914058 88299922 590 86 55374 6.0806 5.9876E-10
4352 1 43703475 43920135 305 54 55374 5.8981 1.8383E-09
80031 15 47376403 48166420 2021 167 55374 5.7919 3.4794E-09
7075 1 43666566 43888781 388 96 55374 5.5932 1.1146E-08
22986 10 106300859 107124993 2283 141 55374 5.526 1.6383E-08
9670 1 44312478 44533694 446 90 55374 5.377 3.7875E-08
1006 16 61581169 62170939 1336 100 55374 5.3291 4.9347E-08
9048 1 44298992 44502912 392 64 55374 5.3135 5.3775E-08
1802 1 44335653 44539043 419 82 55374 5.1964 1.016E-07
149466 1 43647554 43851334 408 90 55374 5.0717 1.9719E-07
4126 4 103452643 103782151 601 70 55374 5.046 2.2558E-07
533 1 44340118 44543972 432 87 55374 5.0317 2.4309E-07
93986 7 113626365 114433827 1182 163 55374 4.9611 3.5042E-07
8704 1 44344874 44556843 453 106 55374 4.9178 4.3771E-07
128218 1 43635665 43839673 453 95 55374 4.8618 5.8163E-07
389549 7 121841373 122051173 467 91 55374 4.8556 6.0003E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA (de Leeuw et al., 2015) analysis. Entrez-ID (GENE), Chromosome 
(CHR), Start (START) and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective 
number of SNPs included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based 
p-values for ADHD GWAS-MA (tab 1), ENIGMA+CHARGE ICV GWAS-MA (tab 2), and the weighted ADHD+ICV 
GWAS-MA (tab 3) are shown. Genes were considered gene-wide significant, if they reached the Bonferroni 
correction threshold adjusted for the total number of genes (N=18,306; P<2.731x10 -6; genes marked in bold).
The complete Supplementary Table 10 is available upon request.
Supplementary Table 11: Comparison of genome-wide significant MAGMA gene-based results for ADHD 
and ICV.
Gene Name EntrezID PADHD PICV PADHD+ICV
SEMA6D 80031 3.48x10-09 0.002926 1.84x10-12
MEF2C 4208 5.99x10-10 0.001512 2.49x10-10
PTPRF 5792 1.23x10-13 0.55807 7.37x10-09
SZT2 23334 1.26x10-12 0.81234 1.41x10-08
KIZ 55857 6.47x10-07 0.015378 1.48x10-08
DUSP6 1848 4.53x10-11 0.73979 4.73x10-08
HYI 81888 3.28x10-12 0.74378 8.07x10-08
KDM4A 9682 4.07x10-12 0.348 8.10x10-08
CDC20 991 1.52x10-10 0.7465 1.73x10-07
ELOVL1 64834 1.68x10-10 0.74685 1.96x10-07
MPL 4352 1.84x10-09 0.62443 4.45x10-07
MED8 112950 2.39x10-10 0.73188 7.98x10-07
TIE1 7075 1.11x10-08 0.72988 1.42x10-06
ST3GAL3 6487 2.76x10-14 0.068167 1.50x10-06
RUNX1T1 862 1.28x10-06 0.43967 2.05x10-06
FOXP2 93986 3.50x10-07 0.51984 2.67x10-06
Genome-wide significant gene-based results of MAGMA (de Leeuw et al., 2015) for the 16 genes overlapping 
between the ADHD and ADHD+ICV data sets. Three genes showed stronger association (smaller cross-trait 
p-value and nominally significant p-value (P<0.05) in ICV data set, marked in bold) in the cross-trait meta-
analysis compared to the separate analyses of ADHD and ICV.
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Supplementary Table 12: Comparison of genome-wide significant MAGMA gene-based results for ADHD 
and amygdala volume.
Gene name EntrezID P ADHD P amygdala P ADHD+amygdala
ST3GAL3 6487 2.76E-14 0.25993 2.42E-13
PTPRF 5792 1.23E-13 0.23627 3.68E-13
SZT2 23334 1.26E-12 0.85979 1.79E-12
KDM4A 9682 4.07E-12 0.094323 1.09E-11
HYI 81888 3.28E-12 0.83715 1.24E-11
DUSP6 1848 4.53E-11 0.54697 2.54E-11
MEF2C 4208 5.99E-10 0.61052 1.43E-10
ELOVL1 64834 1.68E-10 0.83649 1.68E-10
CDC20 991 1.52E-10 0.83847 1.92E-10
MPL 4352 1.84E-09 0.82465 5.30E-10
MED8 112950 2.39E-10 0.82975 9.47E-10
SEMA6D 80031 3.48E-09 0.59009 4.69E-09
SORCS3 22986 1.64E-08 0.26674 5.55E-09
TIE1 7075 1.11E-08 0.65502 1.39E-08
ARTN 9048 5.38E-08 0.72927 2.33E-08
IPO13 9670 3.79E-08 0.87871 4.50E-08
CDH8 1006 4.93E-08 0.17713 1.05E-07
FEZF1 389549 6.00E-07 0.017209 1.35E-07
C1ORF210 149466 1.97E-07 0.59275 1.44E-07
FOXP2 93986 3.50E-07 0.75094 2.31E-07
DPH2 1802 1.02E-07 0.89686 2.35E-07
MANBA 4126 2.26E-07 0.26696 2.54E-07
ATP6V0B 533 2.43E-07 0.91025 4.52E-07
TMEM125 128218 5.82E-07 0.48427 6.64E-07
B4GALT2 8704 4.38E-07 0.89299 7.37E-07
KIZ 55857 6.47E-07 0.2255 7.65E-07
POC1B 282809 1.09E-06 0.75771 9.53E-07
ADD1 118 1.24E-06 0.83043 1.07E-06
RUNX1T1 862 1.28E-06 0.041461 1.41E-06
Genome-wide significant gene-based results of MAGMA (de Leeuw et al., 2015) for the 29 genes overlapping 
between the ADHD and ADHD+amygdala data sets. One gene showed stronger association (smaller cross-
trait p-value and nominally significant p-value (P<0.05) in amygdala data set, marked in bold) in the cross-
trait meta-analysis compared to the separate analyses of ADHD and amygdala.
Supplementary Table 13: Comparison of genome-wide significant MAGMA gene-based results for ADHD 
and nucleus accumbens volume.
Gene name EntrezID P ADHD P accumbens P ADHD+accumbens
ST3GAL3 6487 2.755E-14 0.94551 5.5663E-13
PTPRF 5792 1.2327E-13 0.94222 7.5999E-13
SZT2 23334 1.2552E-12 0.87531 3.945E-12
DUSP6 1848 4.5262E-11 0.43645 1.4698E-11
KDM4A 9682 4.0725E-12 0.96018 1.7656E-11
HYI 81888 3.2804E-12 0.86699 2.7053E-11
MEF2C 4208 5.9876E-10 0.63371 1.6309E-10
ELOVL1 64834 1.6783E-10 0.8459 3.5548E-10
CDC20 991 1.5191E-10 0.83473 4.1098E-10
MPL 4352 1.8383E-09 0.74892 1.306E-09
SEMA6D 80031 3.4794E-09 0.26938 1.6221E-09
MED8 112950 2.389E-10 0.90161 1.7026E-09
TIE1 7075 1.1146E-08 0.36207 1.7039E-08
SORCS3 22986 1.6383E-08 0.22952 2.2168E-08
FOXP2 93986 3.5042E-07 0.39951 4.1417E-08
CDH8 1006 4.9347E-08 0.74346 4.5358E-08
ARTN 9048 5.3775E-08 0.76902 4.7319E-08
IPO13 9670 3.7875E-08 0.6043 7.4177E-08
FEZF1 389549 6.0003E-07 0.66124 9.5065E-08
C1ORF210 149466 1.9719E-07 0.27701 1.8071E-07
DPH2 1802 1.016E-07 0.60244 3.1423E-07
TMEM125 128218 5.8163E-07 0.17473 6.1746E-07
ATP6V0B 533 2.4309E-07 0.56608 6.2568E-07
MANBA 4126 2.2558E-07 0.89609 6.4895E-07
ADD1 118 1.2405E-06 0.30503 9.2319E-07
B4GALT2 8704 4.3771E-07 0.52686 1.0343E-06
KIZ 55857 6.4723E-07 0.91178 1.1743E-06
POC1B 282809 1.0927E-06 0.2469 1.4311E-06
LRFN2 57497 2.5802E-06 0.10434 1.8371E-06
CEND1 51286 2.4283E-06 0.85151 2.1283E-06
Genome-wide significant gene-based results of MAGMA (de Leeuw et al., 2015) for the 30 genes overlapping 
between the ADHD and ADHD+nucleus accumbens data sets. No gene showed stronger association (smaller 
cross-trait p-value and nominally significant p-value (P<0.05) in nucleus accumbens data set) in the cross-
trait meta-analysis compared to the separate analyses of ADHD and nucleus accumbens.
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Supplementary Table 14: Comparison of genome-wide significant MAGMA gene-based results for ADHD 
and caudate nucleus volume.
Gene name EntrezID P ADHD P caudate P ADHD+acaudate
ST3GAL3 6487 2.755E-14 0.88846 1.84E-12
PTPRF 5792 1.2327E-13 0.88716 3.3722E-12
SZT2 23334 1.2552E-12 0.93397 1.3417E-11
DUSP6 1848 4.5262E-11 0.42831 2.599E-11
MEF2C 4208 5.9876E-10 0.067713 4.1061E-11
KDM4A 9682 4.0725E-12 0.64592 4.1825E-11
HYI 81888 3.2804E-12 0.94235 8.2796E-11
ELOVL1 64834 1.6783E-10 0.85376 1.2399E-09
CDC20 991 1.5191E-10 0.85221 1.5244E-09
MED8 112950 2.389E-10 0.85312 3.7897E-09
MPL 4352 1.8383E-09 0.85695 7.2054E-09
CDH8 1006 4.9347E-08 0.47936 3.2218E-08
FEZF1 389549 6.0003E-07 0.10085 3.9442E-08
TIE1 7075 1.1146E-08 0.65191 9.637E-08
SORCS3 22986 1.6383E-08 0.80094 9.6541E-08
FOXP2 93986 3.5042E-07 0.47231 1.2157E-07
ARTN 9048 5.3775E-08 0.98566 1.9172E-07
ADD1 118 1.2405E-06 0.0162 4.586E-07
IPO13 9670 3.7875E-08 0.96342 4.721E-07
SEMA6D 80031 3.4794E-09 0.22968 7.0042E-07
C1ORF210 149466 1.9719E-07 0.5263 8.9503E-07
RUNX1T1 862 0.000001283 0.43918 1.0648E-06
POC1B 282809 1.0927E-06 0.45431 1.2555E-06
DPH2 1802 1.016E-07 0.93774 0.000002359
TMEM125 128218 5.8163E-07 0.33768 0.000002393
Genome-wide significant gene-based results of MAGMA (de Leeuw et al., 2015) for the 25 genes overlapping 
between the ADHD and ADHD+caudate nucleus data sets. One gene showed stronger association (smaller 
cross-trait p-value and nominally significant p-value (P<0.05) in caudate nucleus data set, marked in bold) 
in the cross-trait meta-analysis compared to the separate analyses of ADHD and caudate nucleus.
Supplementary Table 15: Comparison of genome-wide significant MAGMA gene-based results for ADHD 
and hippocampus volume.
Gene name EntrezID P ADHD P hippocampus P ADHD+hippocampus
ST3GAL3 6487 2.76E-14 0.61499 2.49E-13
PTPRF 5792 1.23E-13 0.49516 3.85E-13
KDM4A 9682 4.07E-12 0.43352 3.85E-12
SZT2 23334 1.26E-12 0.70324 2.86E-11
HYI 81888 3.28E-12 0.59579 1.05E-10
MANBA 4126 2.26E-07 0.000875 1.00E-09
CDC20 991 1.52E-10 0.87975 5.25E-09
ELOVL1 64834 1.68E-10 0.88041 5.74E-09
SORCS3 22986 1.64E-08 0.41568 6.88E-09
MED8 112950 2.39E-10 0.84623 1.84E-08
IPO13 9670 3.79E-08 0.58968 1.98E-08
MPL 4352 1.84E-09 0.9076 2.76E-08
ARTN 9048 5.38E-08 0.66681 5.47E-08
DUSP6 1848 4.53E-11 0.43039 6.12E-08
TIE1 7075 1.11E-08 0.87312 1.31E-07
DPH2 1802 1.02E-07 0.34401 1.45E-07
SEMA6D 80031 3.48E-09 0.98523 1.84E-07
LRFN2 57497 2.58E-06 0.078658 1.95E-07
CDH8 1006 4.93E-08 0.40683 2.36E-07
ATP6V0B 533 2.43E-07 0.22951 3.45E-07
B4GALT2 8704 4.38E-07 0.32276 6.51E-07
C1ORF210 149466 1.97E-07 0.8807 9.91E-07
MEF2C 4208 5.99E-10 0.007951 1.14E-06
KIZ 55857 6.47E-07 0.5552 1.44E-06
Genome-wide significant gene-based results of MAGMA (de Leeuw et al., 2015) for the 24 genes overlapping 
between the ADHD and ADHD+hippocampus data sets. One gene showed stronger association (smaller 
cross-trait p-value and nominally significant p-value (P<0.05) in caudate nucleus data set, marked in bold) 
in the cross-trait meta-analysis compared to the separate analyses of ADHD and caudate nucleus.
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Supplementary Table 16: Comparison of genome-wide significant MAGMA gene-based results for ADHD 
and putamen volume.
Gene name EntrezID P ADHD P putamen P ADHD+putamen
ST3GAL3 6487 2.76E-14 0.36927 9.37E-14
PTPRF 5792 1.23E-13 0.59089 5.08E-13
KDM4A 9682 4.07E-12 0.32362 6.64E-12
SZT2 23334 1.26E-12 0.91611 7.26E-12
HYI 81888 3.28E-12 0.92929 5.01E-11
MEF2C 4208 5.99E-10 0.49053 5.38E-11
DUSP6 1848 4.53E-11 0.72256 8.57E-11
ELOVL1 64834 1.68E-10 0.8585 5.58E-10
CDC20 991 1.52E-10 0.85348 6.71E-10
SEMA6D 80031 3.48E-09 0.11999 1.31E-09
MED8 112950 2.39E-10 0.9054 2.39E-09
MPL 4352 1.84E-09 0.79741 2.57E-09
ARTN 9048 5.38E-08 0.52654 1.54E-08
IPO13 9670 3.79E-08 0.57582 3.37E-08
TIE1 7075 1.11E-08 0.73736 3.78E-08
SORCS3 22986 1.64E-08 0.57283 1.11E-07
KIZ 55857 6.47E-07 0.14818 1.53E-07
DPH2 1802 1.02E-07 0.62207 1.95E-07
C1ORF210 149466 1.97E-07 0.60083 3.05E-07
ATP6V0B 533 2.43E-07 0.64662 4.13E-07
FOXP2 93986 3.50E-07 0.61062 5.67E-07
FEZF1 389549 6.00E-07 0.72766 6.20E-07
B4GALT2 8704 4.38E-07 0.65805 6.86E-07
RUNX1T1 862 1.28E-06 0.62215 9.28E-07
TMEM125 128218 5.82E-07 0.56387 1.24E-06
CEND1 51286 2.43E-06 0.24057 2.65E-06
Genome-wide significant gene-based results of MAGMA (de Leeuw et al., 2015) for the 26 genes overlapping 
between the ADHD and ADHD+putamen data sets. No gene showed stronger association (smaller cross-
trait p-value and nominally significant p-value (P<0.05) in putamen data set) in the cross-trait meta-analysis 
compared to the separate analyses of ADHD and putamen.
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Supplementary Table 19: Single tissue eQTL results for index SNPs of relevant genome-wide significant 
loci in the ADHD+brain volume meta-analyses.
Index SNP
rs281320 rs281323 rs12653396 rs8756 rs2195243
Tissue (N) Gene SEMA6D SEMA6D CTC-498M16.4 HMGA2 CCDC53
Cells - Transformed 
fibroblasts (300)
P 1.7x10-20 7.4 x10-24 --- 9.8x10-6 4.8 x10-3
NES 0.52 0.55 --- -0.134 -0.132
Amygdala (88)
P 0.8 0.9 4.5x10-7 --- 0.8
NES -0.0215 -0.0162 -0.543 --- 0.0248
Caudate (144)
P 0.6 0.5 1.8x10-4 --- 0.2
NES -0.0371 -0.0397 -0.339 --- 0.127
Hippocampus (111)
P 0.5 0.5 7.4x10-9 --- 0.3
NES 0.0507 0.0509 -0.605 --- 0.0951
Nucleus accumbens 
(130)
P 0.2 0.1 8.6x10-9 --- 0.1
NES 0.0892 0.108 -0.466 --- 0.169
Putamen (111)
P 0.6 0.3 5.6x10-6 --- 0.9
NES 0.0339 0.0817 -0.406 --- 0.0188
Cortex (136)
P 0.1 0.1 3.2x10-6 --- 1
NES 0.133 0.141 -0.451 --- 0.00248
Frontal Cortex (118)
P 0.6 0.2 4.4x10-7 --- 0.7
NES 0.0417 0.109 -0.524 --- -0.0396
Blood (5,311) P --- --- 6.53x10-7 * --- ---
Z-score --- --- -4.97 --- ---
All six index SNPs from the weighted ADHD+brain volume meta-analyses with a P<8.33x10-9 and the two 
significant variants from the reciprocal lookup of genome-wide significant associations were included in 
the eQTL analysis. All SNPs with available data in the GTEx portal (GTEx Consortium, 2013) and the blood 
eQTL browser (Westra et al., 2013) are shown above. Only variant rs12653396 was present in both the GTEx 
portal and blood eQTL browser. N=sample size. NES=normalized effect size. *cis-eQTL for MEF2C.
Supplementary Table 20: Results of MAGMA gene-set analyses results for the neurite outgrowth gene-set.
GWAS-MA NGENES BETA BETA_STD SE COMP_P SELF_P
ADHD+Intracranial volume 45 0.367 0.0182 0.136 0.00338 1.55x10-6
ADHD 45 0.148 0.0073 0.145 0.15391 5.53x10-9
Intracranial volume 45 -0.0785 -0.00389 0.14 0.71179 0.40748
Competitive (COMP_P) and self-contained (SELF_P) results of the gene-set analysis of the neurite outgrowth 
gene-set performed using MAGMA (de Leeuw et al., 2015). The number of genes (N GENES), raw and semi-
standardized (STD) regression coefficients, and corresponding standard error (SE) are reported. Significant 
results after Bonferroni correction are shown in bold.
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Supplementary Table 21: Results of MAGMA gene-based associations of neurite outgrowth genes.
GENE_
NAME
CHR START STOP NSNPS ZSTAT PADHD+ICV PADHD PICV
CREB5 7 28238940 28965511 1822 3.2619 0.000553 0.0005475 0.074382
MMP24 20 33714539 33964804 453 2.5709 0.005071 0.0034001 0.77984
TLL2 10 98024363 98373683 898 2.4879 0.006425 0.033235 0.43003
NEDD4L 18 55611580 56168772 1607 2.3373 0.009711 0.0062839 0.86232
DNM1 9 130865634 131117528 389 2.293 0.010923 0.0014409 0.58186
ASTN2 9 119087504 120277317 3253 2.1668 0.015126 0.0001023 0.093386
NRXN1 2 50045643 51359674 3836 2.1233 0.016864 0.13173 0.33824
SUPT3H 6 44694467 45445788 2144 2.0192 0.021735 0.17377 0.066473
BMPR1B 4 95579128 96179601 1564 2.0112 0.022152 0.024176 0.82239
CSMD2 1 33879609 34731443 1845 1.77 0.038365 0.00806 0.16337
ADAMTS17 15 100411643 100982183 2451 1.4316 0.076131 0.059053 0.85152
ZNF423 16 49424515 49991830 1425 1.4178 0.078126 0.2668 0.20731
GPC6 13 93779078 95160274 3351 1.1491 0.12527 0.56497 0.016549
MYT1L 2 1692885 2435147 1924 1.1262 0.13004 0.022068 0.57042
MBOAT1 6 19999915 20312695 770 1.1239 0.13054 0.036503 0.58052
PPM1H 12 62937762 63428665 1293 1.1171 0.13197 0.24579 0.0385
EMP2 16 10522279 10774539 854 1.078 0.14052 0.10888 0.20062
MAP1B 5 71303118 71605397 630 1.0463 0.14772 0.056063 0.39159
UNC5B 10 72872292 73162635 776 0.8627 0.19415 0.27714 0.57631
NOS1 12 117545921 117899607 869 0.80518 0.21036 0.30687 0.11535
CDH13 16 82560399 83930215 7024 0.80402 0.21069 0.093966 0.91052
NUCB1 19 49303307 49526540 498 0.71 0.23885 0.071321 0.36184
SLCO3A1 15 92296938 92815665 1440 0.65899 0.25495 0.22741 0.35818
CDH23 10 73056691 73675704 1730 0.63549 0.26255 0.18278 0.98778
NXPH1 7 8373585 8892593 1664 0.53694 0.29565 0.0776 0.66363
KCNIP4 4 20630234 22050424 4489 0.40482 0.34281 0.41226 0.71094
MAN2A2 15 91347420 91565815 588 0.37292 0.3546 0.29083 0.15025
HKDC1 10 70880059 71127315 687 0.30449 0.38038 0.7865 0.25629
CTNNA2 2 79640060 80975993 3424 0.23372 0.4076 0.06039 0.44387
FAM190A 4 90948684 92623370 4371 0.14582 0.44203 0.053733 0.37609
FLNC 7 128370436 128599328 468 0.075226 0.47002 0.37628 0.79661
HK1 10 70929740 71261638 1025 0.061092 0.47564 0.51193 0.52288
KCP 7 128416919 128650773 446 -0.12722 0.55062 0.6579 0.79675
SPOCK3 4 167554535 168255741 1629 -0.14745 0.55861 0.51736 0.60259
DYNC2H1 11 102880160 103450591 2201 -0.31828 0.62487 0.78806 0.70885
FHIT 3 59635036 61337133 6164 -0.36753 0.64339 0.12672 0.8485
Suppplementary Table 21: Continued.
GENE_
NAME
CHR START STOP NSNPS ZSTAT PADHD+ICV PADHD PICV
NCKAP5 2 133329361 134499118 2564 -0.37607 0.64657 0.17621 0.88675
DUSP1 5 172095093 172298203 605 -0.46873 0.68037 0.30004 0.72951
ATP2C2 16 84302129 84597793 1667 -0.48023 0.68447 0.85789 0.75574
MOBP 3 39409064 39670988 815 -0.67089 0.74885 0.83675 0.88765
ITGA11 15 68491128 68824502 751 -0.68035 0.75186 0.52294 0.37697
MEIS1 2 66562257 66899891 728 -0.96337 0.83232 0.77393 0.25917
RORA 15 60680483 61621502 2214 -1.0152 0.84501 0.81967 0.94611
UGT1A9 2 234480544 234781951 949 -1.2084 0.88654 0.30306 0.37333
LRP1B 2 140888996 142989270 7745 -1.3082 0.90461 0.91812 0.1159
MAGMA (de Leeuw et al., 2015) gene-based analysis of previously reported neurite outgrowth candidate 
genes (Poelmans et al., 2011). Chromosome (CHR), Start (START) and end (STOP) position of the genes, 
number of SNPs in the genes (N SNPs), test statistics (ZSTAT), and gene-based p-values for 1) the weighted 
ADHD+ICV GWAS-MA (PADHD+ICV), 2) ADHD GWAS-MA (PADHD), and 3) ENIGMA+CHARGE ICV GWAS-MA (PICV) 
are shown. For the results of the weighted ADHD+ICV GWAS-MA, genes were considered gene-wide 
significant, if they reached the Bonferroni correction threshold adjusted for the number of genes within 
the total gene-set (N=45; P<0.00111; genes marked in bold).
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Supplementary Table 22. Results for the 19 most strongly associated SNPs from the weighted ADHD+ICV 
GWAS-MA. Results for the naïve (non-weighted) GWAS-MA are shown in Zscorenaive MA and Pnaive MA.
SNP CHR BP ZscorePGC ZscoreICV Zscorenaive MA Zscoreweighted MA Pnaive MA Pweighted MA
rs281320 15 47769424 -5.54867 -3.33 -6.46553 -6.4677 1.01x10-10 9.95x10-11
rs8039398 15 47730870 -5.48151 -3.07 -6.26643 -6.27022 3.69x10-10 3.61x10-10
rs1656604 15 47794252 -5.36599 -3.243 -6.26511 -6.26704 3.73x10-10 3.68x10-10
rs281324 15 47754018 -5.5595 -2.817 -6.19239 -6.19846 5.93x10-10 5.70x10-10
rs281323 15 47754027 5.477548 2.796 6.112398 6.118231 9.81x10-10 9.46 x10-10
rs1610098 15 47806012 -5.13664 -3.297 -6.10329 -6.10369 1.04x10-9 1.04x10-9
rs1612378 15 47813991 -4.94219 -3.269 -5.9255 -5.92516 3.11x10-9 3.12x10-9
rs1656622 15 47813909 -4.94219 -3.2 -5.88754 -5.88772 3.92x10-9 3.92x10-9
rs1347469 15 47814528 -4.93526 -3.147 -5.8526 -5.85314 4.84x10-9 4.82x10-9
rs13332522 16 5829204 4.616228 3.508 5.784743 5.781012 7.26x10-9 7.43x10-9
rs4597332 16 5829191 -4.61653 -3.499 -5.78004 -5.77638 7.47x10-9 7.63x10-9
rs4513101 16 5829196 4.602781 3.505 5.771863 5.768088 7.84x10-9 8.02x10-9
rs1656623 15 47815484 4.820448 3.153 5.760016 5.75995 8.41x10-9 8.41x10-9
rs1618196 15 47797832 -4.90586 -2.985 -5.73893 -5.74055 9.53x10-9 9.44x10-9
rs7198618 16 5829440 4.52717 3.519 5.71642 5.71217 1.09x10-8 1.12x10-8
rs1656618 15 47810363 4.746723 3.133 5.687446 5.687169 1.29x10-8 1.29x10-8
rs12596294 16 72587093 5.572012 1.849 5.673685 5.686953 1.40x10-8 1.29x10-8
rs11861310 16 5835841 4.595736 3.348 5.679619 5.676988 1.35x10-8 1.37x10-8
rs212178 16 72578131 -5.76998 -1.515 -5.65614 -5.67288 1.55x10-8 1.40x10-8
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Extended data sheet (EDS) for results of posthoc analyses for 
pallidum and thalamus
Linkage disequilibrium score regression
EDS_Table 1. SNP heritability analyses for MRI brain volumes and genetic correlation with ADHD.
Brain region N Heritability SE Genetic correlation 
with ADHD
SE Z P
Pallidum 11,640 0.1557 0.0478 -0.04864 0.08893 -0.547 0.5844
Thalamus 11,694 0.095 0.0442 0.06506 0.1132 0.5747 0.5655
Heritability and genetic correlation were estimated by using free intercepts.
SNP effect concordance analysis
EDS_Table 2. Results of pleiotropy and concordance test of SNP Effect Concordance Analysis. Brain volume 
GWAS-MA was conditioned on ADHD GWAS-MA.
Brain volume P pleiotropy CI pleiotropy P concordance CI concordance Direction of SNP effects
Pallidum 0.000999 5.12 x10-5-0.00564 1 0.996-1 /
Thalamus 0.00799 0.00406-0.0157 0.17 0.148-0.194 concordant
P-values and confidence intervals (CI) were obtained based on 1,000 permutations.
EDS_Figure 1: Global evidence of pleiotropy (a) and concordance (b) between ADHD GWAS and pallidum 
volume. P1 in the plot is the ADHD GWAS and P2 is the pallidum volume GWAS.
EDS_Figure 2: Global evidence of pleiotropy (a) and concordance (b) between ADHD GWAS and thalamus 
volume. P1 in the plot is the ADHD GWAS and P2 is the thalamus volume GWAS.
Sign tests
EDS_Table 3. Sign test results in brain volume cohorts.
P threshold Brain region N opposite direction Proportion P
< 5x10-8
Pallidum 3 0.3 0.945
Thalamus 3 0.3 0.945
< 1x10-6
Pallidum 16 0.46 0.75
Thalamus 14 0.4 0.912
< 1x10-5
Pallidum 52 0.53 0.307
Thalamus 43 0.44 0.906
Test of whether the proportion of index SNPs with estimated effects in the opposite direction as the ADHD 
GWAS-MA is greater than expected by chance. The expected proportion under the null hypothesis is 0.5. 
At threshold P<5x10-8 4 index SNPs were not available in the brain volume GWAS-MA data, so were 9 at 
threshold P<5x10-6 and 34 at threshold P<5x10-5.
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Weighted SNP meta-analyses
EDS_Figure 3: Common genetic variants associated with ADHD, pallidum volume and ADHD+pallidum 
volume. Shown here are Manhattan plots, in which every point represents a single genetic variant plotted 
according to its genomics position (x-axis) and its –log10(P) for association with the respective trait (y-axis). 
The solid bright red line represents the study-wide genome-wide significance of P<8.33x10-9, and the dashed 
dark red line represents the genome-wide significance of P<5x10-8. (a) PGC+iPSYCH ADHD GWAS-MA. (b) 
ENIGMA pallidum volume GWAS-MA. (c) ADHD+pallidum volume weighted GWAS-MA. (d) ADHD+pallidum 
volume naive GWAS-MA.
EDS_Figure 4: Common genetic variants associated with ADHD, thalamus volume and ADHD+thalamus 
volume. Shown here are Manhattan plots, in which every point represents a single genetic variant plotted 
according to its genomics position (x-axis) and its –log10(P) for association with the respective trait (y-axis). 
The solid bright red line represents the study-wide genome-wide significance of P<8.33x10-9, and the dashed 
dark red line represents the genome-wide significance of P<5x10-8. (a) PGC+iPSYCH ADHD GWAS-MA. (b) 
ENIGMA thalamus volume GWAS-MA. (c) ADHD+thalamus volume weighted GWAS-MA. (d) ADHD+thalamus 
volume naive GWAS-MA.
Gene-wide GWAS-MAs
EDS_Table 4: Results of MAGMA gene-based associations of all genes for ADHD and pallidum volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 786 61 67014 7.3409 1.0612E-13
5792 1 43891708 44189343 521 60 67014 6.9833 1.4416E-12
23334 1 43755556 44019918 338 68 67014 6.7242 8.8282E-12
9682 1 44015797 44271189 533 43 67014 6.6261 1.7231E-11
1848 12 89641837 89846296 419 96 67014 6.5208 3.4966E-11
81888 1 43816674 44019938 272 57 67014 6.4185 6.8823E-11
4208 5 87914058 88299922 558 85 67014 6.4174 6.9333E-11
64834 1 43729068 43933745 266 53 67014 6.08 6.0103E-10
991 1 43724626 43928874 269 53 67014 6.0502 7.2337E-10
112950 1 43749579 43955483 247 67 67014 5.8561 2.3695E-09
4352 1 43703475 43920135 297 53 67014 5.7949 3.4171E-09
9048 1 44298992 44502912 365 60 67014 5.6449 8.2649E-09
80031 15 47376403 48166420 1966 166 67014 5.6188 9.6122E-09
9670 1 44312478 44533694 417 82 67014 5.5001 1.8984E-08
7075 1 43666566 43888781 372 91 67014 5.3069 5.5743E-08
22986 10 106300859 107124993 2208 143 67014 5.1518 1.2902E-07
389549 7 121841373 122051173 421 74 67014 5.1474 1.3207E-07
1802 1 44335653 44539043 396 72 67014 5.1283 1.4617E-07
533 1 44340118 44543972 408 77 67014 5.0018 2.8403E-07
149466 1 43647554 43851334 394 88 67014 4.9149 4.4418E-07
8704 1 44344874 44556843 428 94 67014 4.9063 4.6405E-07
93986 7 113626365 114433827 1141 150 67014 4.7381 1.0787E-06
282809 12 89713495 90020039 636 69 67014 4.6634 1.555E-06
151648 3 20102085 20327724 850 71 67014 4.6304 1.8244E-06
1006 16 61581169 62170939 1289 89 67014 4.6265 1.8597E-06
… … … … … … … … …
Genome-wide gene-based results of MAGMA analysis. Entrez-ID (GENE), Chromosome (CHR), Start (START) 
and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective number of SNPs 
included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based p-values for ADHD 
GWAS-MA (tab 1), ENIGMA pallidum GWAS-MA (tab 2), and the weighted ADHD+pallidum GWAS-MA (tab 
3) are shown. Genes were considered gene-wide significant, if they reached the Bonferroni correction 
threshold adjusted for the total number of genes (N=18,306; P<2.731x10-6; genes marked in bold).
The complete EDS_Table 4 is available upon request.
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EDS_Table 5: Results of MAGMA gene-based associations of all genes for ADHD and thalamus volume.
GENE CHR START STOP NSNPS NPARAM N ZSTAT P
6487 1 44073204 44496837 786 61 67068 7.2671 1.84E-13
5792 1 43891708 44189343 521 60 67068 7.2529 2.04E-13
23334 1 43755556 44019918 338 68 67068 6.9625 1.67E-12
9682 1 44015797 44271189 533 43 67068 6.8068 4.99E-12
81888 1 43816674 44019938 272 57 67068 6.7098 9.74E-12
4208 5 87914058 88299922 558 85 67068 6.2764 1.73E-10
64834 1 43729068 43933745 266 53 67068 6.264 1.88E-10
991 1 43724626 43928874 269 53 67068 6.2428 2.15E-10
1848 12 89641837 89846296 419 96 67068 6.1181 4.73E-10
4352 1 43703475 43920135 297 53 67068 6.0989 5.34E-10
112950 1 43749579 43955483 247 67 67068 5.993 1.03E-09
80031 15 47376403 48166420 1966 166 67068 5.8007 3.30E-09
7075 1 43666566 43888781 372 91 67068 5.5799 1.20E-08
93986 7 1.14E+08 1.14E+08 1141 150 67068 5.5281 1.62E-08
22986 10 1.06E+08 1.07E+08 2208 143 67068 5.4915 1.99E-08
9048 1 44298992 44502912 365 60 67068 5.3491 4.42E-08
9670 1 44312478 44533694 417 82 67068 5.215 9.19E-08
149466 1 43647554 43851334 394 88 67068 5.1402 1.37E-07
1006 16 61581169 62170939 1289 89 67068 4.9275 4.17E-07
84966 1 18334240 18804977 1328 274 67068 4.895 4.92E-07
1802 1 44335653 44539043 396 72 67068 4.8937 4.95E-07
128218 1 43635665 43839673 436 84 67068 4.8762 5.41E-07
729852 7 7580342 8018854 1472 323 67068 4.8762 5.41E-07
389549 7 1.22E+08 1.22E+08 421 74 67068 4.8214 7.13E-07
533 1 44340118 44543972 408 77 67068 4.7676 9.32E-07
… … … … … … … … …
Genome-wide gene-based results of MAGMA analysis. Entrez-ID (GENE), Chromosome (CHR), Start (START) 
and end (STOP) position of the genes, number of SNPs in the genes (N SNPs), effective number of SNPs 
included (NPARAM), the total sample size (N), test statistics (ZSTAT), and gene-based p-values for ADHD 
GWAS-MA (tab 1), ENIGMA thalamus GWAS-MA (tab 2), and the weighted ADHD+ thalamus GWAS-MA 
(tab 3) are shown. Genes were considered gene-wide significant, if they reached the Bonferroni correction 
threshold adjusted for the total number of genes (N=18,306; P<2.731x10-6; genes marked in bold).
The complete EDS_Table 5 is available upon request.
EDS_Table 6: Comparison of genome-wide significant MAGMA gene-based results for ADHD and pallidum.
Gene Name EntrezID PADHD Ppallidum PADHD+pallidum
ST3GAL3 6487 5.57E-13 0.33343 1.06E-13
PTPRF 5792 7.6E-13 0.52848 1.44E-12
SZT2 23334 3.95E-12 0.79288 8.83E-12
KDM4A 9682 1.77E-11 0.40584 1.72E-11
DUSP6 1848 1.47E-11 0.58627 3.5E-11
HYI 81888 2.71E-11 0.7758 6.88E-11
MEF2C 4208 1.63E-10 0.2715 6.93E-11
ELOVL1 64834 3.55E-10 0.74887 6.01E-10
CDC20 991 4.11E-10 0.72683 7.23E-10
MED8 112950 1.7E-09 0.84361 2.37E-09
MPL 4352 1.31E-09 0.61228 3.42E-09
ARTN 9048 4.73E-08 0.29146 8.26E-09
SEMA6D 80031 1.62E-09 0.78929 9.61E-09
IPO13 9670 7.42E-08 0.19523 1.9E-08
TIE1 7075 1.7E-08 0.42991 5.57E-08
SORCS3 22986 2.22E-08 0.66127 1.29E-07
FEZF1 389549 9.51E-08 0.59552 1.32E-07
DPH2 1802 3.14E-07 0.20882 1.46E-07
ATP6V0B 533 6.26E-07 0.23988 2.84E-07
C1ORF210 149466 1.81E-07 0.29154 4.44E-07
B4GALT2 8704 1.03E-06 0.24352 4.64E-07
FOXP2 93986 4.14E-08 0.73244 1.08E-06
POC1B 282809 1.43E-06 0.72788 1.56E-06
CDH8 1006 4.54E-08 0.9676 1.86E-06
TMEM125 128218 6.17E-07 0.2747 1.89E-06
TALDO1 6888 2.54E-06 0.41757 2.16E-06
Genome-wide significant gene-based results of MAGMA for the 26 genes overlapping between the ADHD 
and ADHD+pallidum data sets. No gene showed stronger association (smaller cross-trait p-value and 
nominally significant p-value (P<0.05) in pallidum data set) in the cross-trait meta-analysis compared to 
the separate analyses of ADHD and pallidum.
10
472 473
Genetic markers of ADHD-related variations in intracranial volumeChapter 10
EDS_Table 7: Comparison of genome-wide significant MAGMA gene-based results for ADHD and thalamus.
Gene Name EntrezID PADHD Pthalamus PADHD+thalamus
ST3GAL3 6487 2.76E-14 0.68469 1.84E-13
PTPRF 5792 1.23E-13 0.44022 2.04E-13
SZT2 23334 1.26E-12 0.46816 1.67E-12
KDM4A 9682 4.07E-12 0.38912 4.99E-12
HYI 81888 3.28E-12 0.37782 9.74E-12
MEF2C 4208 5.99E-10 0.41413 1.73E-10
ELOVL1 64834 1.68E-10 0.53903 1.88E-10
CDC20 991 1.52E-10 0.55619 2.15E-10
DUSP6 1848 4.53E-11 0.48078 4.73E-10
MPL 4352 1.84E-09 0.50396 5.34E-10
MED8 112950 2.39E-10 0.53891 1.03E-09
SEMA6D 80031 3.48E-09 0.57583 3.3E-09
TIE1 7075 1.11E-08 0.62267 1.2E-08
FOXP2 93986 3.5E-07 0.027619 1.62E-08
SORCS3 22986 1.64E-08 0.48316 1.99E-08
ARTN 9048 5.38E-08 0.89288 4.42E-08
IPO13 9670 3.79E-08 0.88159 9.19E-08
C1ORF210 149466 1.97E-07 0.79855 1.37E-07
CDH8 1006 4.93E-08 0.60852 4.17E-07
DPH2 1802 1.02E-07 0.91256 4.95E-07
TMEM125 128218 5.82E-07 0.79847 5.41E-07
FEZF1 389549 6E-07 0.76437 7.13E-07
ATP6V0B 533 2.43E-07 0.91095 9.32E-07
B4GALT2 8704 4.38E-07 0.9218 1.45E-06
ADD1 118 1.24E-06 0.69817 1.88E-06
KIZ 55857 6.47E-07 0.70382 2E-06
Genome-wide significant gene-based results of MAGMA for the 26 genes overlapping between the ADHD 
and ADHD+thalamus data sets. One gene showed stronger association (smaller cross-trait p-value and 
nominally significant p-value (P<0.05, marked in bold) in thalamus data set) in the cross-trait meta-analysis 
compared to the separate analyses of ADHD and thalamus.
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The work presented in this thesis focuses on identifying the genetic underpinnings of 
the highly heritable disorder ADHD and gaining insight into its underlying biological 
mechanisms by using different molecular genetics methodologies, brain imaging genetics 
approaches, and animal model systems. In this final chapter, the results from this thesis are 
summarized and discussed in the context of the existing literature.
Summary of approaches and results
Approaches for gene identification
Genetic factors play an important role in many neuropsychiatric disorders. Understanding 
which genetic variants are relevant for a particular disorder can yield insight into the 
pathophysiology and potentially (in the long run) lead to novel treatment options. GWA 
studies in ten-thousands of individuals have identified some genetic risk variants for ADHD, 
but the amount of variance in disease susceptibility that is explained by these variants is 
relatively small. The remaining, unexplained variance has been named ‘missing heritability’ 
and we aimed to uncover part of it in Part 1 of this thesis (chapter 2 to 6) by applying various 
approaches for the identification of ADHD risk variants.
We began with a candidate gene meta-analysis study in which we investigated the 
association of the ADHD-associated variable number tandem repeat (VNTR) polymorphism 
upstream of the DRD5 gene with adult ADHD (chapter 2). We compiled data from six sites of 
the International Multicentre persistent ADHD CollaboraTion (IMpACT) and used the largest 
case-control sample investigated so far. We tested the association of the common DRD5 
alleles with categorically defined ADHD and with inattentive and hyperactive-impulsive 
symptom counts. Our findings provide evidence that, in contrast with earlier reports on 
childhood ADHD, none of the common DRD5 alleles are associated with ADHD risk or ADHD 
symptom counts in adults.
Following the testing of a single candidate gene, we applied a hypothesis-generating 
approach and investigated common genetic variants (i.e., SNPs) on a genome-wide scale. 
Hypothesizing that genetic continuity exists between clinical ADHD and ADHD symptoms in 
the general population, in chapter 3, we report results of a genome-wide association meta-
analysis of self-reported adult ADHD symptoms in adult population-based and case-only 
cohorts. The top-hit of the genome-wide meta-analysis was located within the STXBP5-AS1 
gene. This association was also observed in a meta-analysis of childhood ADHD symptom 
scores in eight population-based pediatric cohorts, validating the finding. In human HEK293 
cells, expression of STXBP5-AS1 enhanced the expression of a reporter-construct of STXBP5, 
known to be involved in SNARE complex formation. In mouse strains, Stxbp5-AS1 transcript 
levels in the prefrontal cortex correlated with motor impulsivity. The results imply that the 
long non-coding RNA STXBP5-AS1 is involved in ADHD symptom scores and point to vesicle 
transport as a biological mechanism involved in ADHD-related impulsivity levels.
It has been suggested that neurodevelopmental disorders, including ID, autism spectrum 
disorders (ASDs), ADHD, schizophrenia, and bipolar disorder, are seen as representing the 
diverse range of outcomes that follow from disrupted or deviant brain development (Owen 
and O’Donovan, 2017). This model is also known as the neurodevelopmental continuum 
and was based on emerging evidence for shared genetic and environmental risk factors, 
also predicting overlapping pathogenic mechanisms (reviewed in (Owen and O’Donovan, 
2017)). Testing the concept of a neurodevelopmental continuum, we set out to investigate 
whether genes known to carry rare mutations in ID also contribute to ADHD risk through 
common variants. By this, we aimed to identify novel ADHD genes (chapter 4). A set of 
396 ID genes was significantly associated with ADHD risk in two independent samples, 
and genetic variants in three genes, MEF2C, TRAPPC9, and ST3GAL3, were identified as 
consistent top-association findings across two different statistical methods. We then set 
out to functionally validate the newly identified ADHD candidate genes. In Drosophila 
melanogaster, two of the genes were conserved. Knockdown of dMEF2 in monoaminergic 
neurons and knockdown of dTRAPPC9 in circadian neurons showed increased locomotor 
activity and reduced sleep, implicating different biological pathways in ADHD etiology. The 
results of this study confirmed the genetic overlap of ADHD and ID, where genes, known to 
carry mutations in ID, confer ADHD risk through common variants. Utilizing this overlap, we 
identified, validated, and functionally characterized several novel ADHD genes.
An alternative to the use of large case-control cohorts or population-based samples for 
ADHD risk gene identification can be family-based approaches. In chapter 5, we used an 
innovative multi-step strategy to identify and validate a novel ADHD risk gene, combining 
the strength of a family study with the power provided by large-scale GWAS. In a single 
family, severely affected by ADHD and comorbid disorders, we applied microarray analysis to 
detect structural genetic variants co-segregating with ADHD. We identified a copy number 
gain in 8p23.3 containing three protein-coding genes (ZNF596, FBXO25, and TDRP). The 
identified novel ADHD candidate genes were tested - individually and as a set - for evidence 
of association with ADHD and other relevant psychiatric disorders based on common 
genetic variants. To functionally validate the identified ADHD risk genes, we characterized 
the effects of gene overexpression in Drosophila melanogaster using locomotor activity as 
functional read-out. Compared to the genetic background control, overexpression of the 
FBXO25 orthologue lead to increased locomotor activity. Our findings suggest that FBXO25 
is a novel risk gene for ADHD.
In large pedigrees with multiple affected individuals, it had been hypothesized that rare 
(penetrant) mutations are likely to segregate with the phenotype of interest. Therefore, in 
chapter 6, we hypothesized that an innovative approach combining linkage analysis and 
whole-exome sequencing (WES) in multi-generation pedigrees containing multiple affected 
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individuals with exome-chip analysis in a large, independent cohort can point towards novel 
ADHD-related genes. From prioritized linkage regions, 24 genes harboring WES-identified 
rare variants were selected. Those genes were taken forward and were jointly analyzed 
in gene-set analyses using data of the independent exome-chip cohort of patients with 
persistent ADHD and healthy controls. Gene-wide analysis for the AAED1 gene reached 
significance, and a single variant within the AAED1 gene segregated with ADHD in one of 
the families. We concluded that the analysis strategy followed here is a fruitful approach 
for identifying novel ADHD candidate genes. Additionally, this study suggests that both 
rare and more frequent variants in multiple genes act together in contributing to ADHD 
risk even in individual multi-case families with an apparent dominant inheritance pattern.
Mapping mechanisms from gene to disorder
In the first part of this thesis we asked the question which molecular genetics mechanisms 
are underlying ADHD etiology. We identified individual genetic risk factors for ADHD and 
additionally, we obtained novel insights into the global genetic architecture of ADHD. The 
second part of the thesis focuses on different approaches that can help to map the biological 
mechanisms from gene to the disorder. Neurobiological parameters, such as brain structure, 
connectivity, and function, were used in humans and animal models to link genetic variation 
to ADHD symptomatology.
Our systematic review in chapter 7 summarized the imaging genetics literature on 
three comorbid disorders (ID, ASD, and ADHD), focusing on studies of the effect of disease-
linked genetic variants on brain structure and function. We aimed at identifying core brain 
mechanisms affected by disease-linked genetic factors, which are related to the individual 
disorders as well as to their clinical overlap. For ADHD and ASD, we selected replicated 
candidate genes implicated through common genetic variants. For ID, which is mainly 
caused by rare genetic variants, we included genes for relatively frequent forms of ID 
occurring comorbid with ADHD or ASD. Several findings were consistent across studies, 
implicating e.g. SLC6A4/5HTT in brain activation and functional connectivity related to 
emotion regulation. This review also enabled us to look at the overlap between studies in 
healthy individuals and those in patients (case-control designs). As it has been suggested 
from recent genome-wide studies investigating the genetics of brain structure as part of 
the ENIGMA Consortium, the genetic effects on brain structure are largely similar for healthy 
individuals and those with a psychiatric disorder (Hibar et al., 2015). Thus, brain imaging 
genetics studies with healthy participants can be very informative in discovering related 
brain correlates and in understanding the biological mechanisms leading to diseases of 
interest. Generally, many studies had small sample sizes, and hypothesis-based, brain region-
specific studies were common. Therefore, replication of findings across studies was limited. 
Results from available studies confirm that imaging genetics can provide insight into the link 
between genes, disease-related behavior, and the brain. However, the field is still in its early 
stages, and conclusions about mechanisms shared across disorders could not yet be drawn.
We then extended our work from the previous chapter and performed a systematic 
review of brain imaging genetics studies involving 62 ADHD candidate genes in childhood 
and adult ADHD cohorts (chapter 8). Almost exclusively, single genetic variants were 
studied, mostly focussing on dopamine-related genes. The conclusion from this review was 
that, while promising results have been reported, imaging genetics studies of ADHD are thus 
far hampered by methodological differences in study design and analysis methodology, 
as well as limited sample sizes. In this chapter, we also comprehensively discuss the need 
for complementary methods for the evaluation of the mechanisms underlying ADHD risk 
genes. We highlight the use of bioinformatic approaches that can help to integrate findings 
from different types of molecular studies. Additionally, the utilization of animal models is 
discussed, as these can provide proof of causality for genes and molecular processes found 
associated with ADHD. Moreover, we mention that psychiatric disorders can be modelled at 
the cellular level by using human induced pluripotent stem cell (hiPSC)- derived neurons. We 
conclude this chapter by emphasizing the importance of combining and integrating findings 
across levels for a better understanding of biological pathways from gene to disorder.
In chapter 9, we used an integrative approach with the aim to replicate the earlier 
reported association of GIT1 with ADHD and to investigate its role in cognitive and brain 
phenotypes. Association of GIT1 with ADHD or any related measures, such as sustained 
attention, working memory, and brain volume measures was not confirmed in much 
larger sample sizes than used in the primary study. We did find a functional genetic variant 
to be an expression quantitative trait locus (eQTL) for GIT1. Moreover, Git knockdown in 
Drosophila caused abnormal synapse and dendrite morphology, but did not affect behavior 
(i.e. locomotor activity). Our results indicate that despite GIT1’s regulation of neuronal 
morphology, alterations in gene expression do not appear to have ADHD-related behavioral 
consequences and do not appear to alter brain volume in humans.
ADHD is a common and highly heritable neurodevelopmental disorder with a complex 
pathophysiology, where genetic risk is hypothesized to be mediated by alterations in 
structure and function of diverse brain networks. In chapter 10, we tested one aspect of this 
hypothesis by investigating the genetic overlap of ADHD with subcortical brain volumes and 
intracranial volume (ICV). At the level of common variant genetic architecture, we discovered 
a significant negative genetic correlation between ADHD and ICV. Meta-analysis of individual 
variants found significant loci associated with both ADHD risk and ICV; additional loci were 
identified for ADHD and amygdala, caudate nucleus, and putamen volumes. Gene-set 
analysis in the ADHD-ICV meta-analytic data showed significant association with variation 
in neurite outgrowth-related genes. This is the first study to show subtle but significant 
global and single variant level genetic correlations derived from polygenic overlap between 
ADHD and brain volumes. The results generate new hypotheses about neurobiological 
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mechanisms involved in ADHD etiology, the rather modest overlap reinforces the need to 
consider other structural and functional brain metrics and explore the role of environmental 
factors.
Interpretation in the context of existing literature
Approaches for gene identification
The first part of this thesis describes a set of established and novel molecular genetics 
approaches that have been used in order to gain more insight into the genetic factors 
underlying ADHD etiology. ADHD is a polygenic and multifactorial disorder, i.e., both genetic 
factors as well as environmental factors are involved (Faraone et al., 2015; Thapar and Cooper, 
2016). As schematically depicted in Figure 1, the cumulative (but individually weak) effect 
of common genetic variants contribute to ADHD susceptibility in an individual. Recently, 
the SNP-based heritability of ADHD was estimated to be approximately 22% (Demontis et 
al., 2017), i.e., this is the proportion of phenotypic variance attributable to common genetic 
variants (SNPs). This is much lower than the heritability estimated from twin studies (70-80% 
(Faraone et al., 2005; Larsson et al., 2013b)), suggesting that other types of genetic variation 
(and genetic models) contribute to ADHD etiology as well. The resulting composition of the 
genetic architecture, with its set of common genetic variants, interacting between them and 
combined with potentially intermediate to large effects of rare genetic variation, is probably 
unique for each affected individual (Figure 1). The next section relates the results of the 
different chapters to the existing literature and addresses the crucial question of “What have 
we learned about the genetic architecture of ADHD?” by describing four main emerging facets.
I. The choice of study design: candidate gene studies versus genome-wide 
approaches
The search for genetic variants contributing to ADHD risk was initially based on the 
hypothesis that a common disorder, such as ADHD, will most likely be caused by common 
genetic variants. Early studies, starting well before the publication of the human genome 
sequence, focused on investigating single candidate genes for ADHD, of which most were 
related to catecholaminergic functions, such as dopamine, noradrenalin, and serotonin 
neurotransmission. Meta-analyses of candidate gene studies have been helpful in more 
robustly estimating the strength of association between such single genetic variants and 
ADHD. In this thesis, chapter 2 and chapter 9 investigated a single gene in a candidate 
gene approach. Both the investigated DRD5 (chapter 2) and GIT1 (chapter 9) gene had 
been associated with ADHD before (Won et al., 2011; Wu et al., 2012). However, the initial 
studies had a limited samples size and were therefore not reasonably powered. Moreover, 
the previous studies were either performed in a childhood ADHD sample only (DRD5, 
chapter 2) or in a population with a different ethnicity (GIT1, chapter 9). Thus, our (negative) 
association results add important information to the literature, as the study presented in 
chapter 2 is the first performing an association analysis of the DRD5 VNTR in patients with 
persistent ADHD. Additionally, we investigated the association of GIT1 and ADHD risk in a 
sample of European decent (chapter 9). Overall, these two studies show the need and the 
added value of replication studies and meta-analysis.
Although some promising candidate genes have been identified previously, none of 
the historical ADHD candidate genes are among the strongest associated genes in the 
recent PGC+iPSYCH ADHD GWAS meta-analysis (Demontis et al., 2017). Similar findings 
for schizophrenia also indicate that the most investigated candidate gene hypotheses of 
schizophrenia (with the exception of those for DRD2) are not well supported by GWASs 
(Johnson et al., 2017). In the field of genetics, candidate-based single gene analyses have 
largely fallen out of favor owing to concerns about low power, false positives, low replication 
rates (Ioannidis et al., 2011; Koenen et al., 2013), and insufficient biological knowledge to 
correctly identify plausible candidate genes. Given the increasingly low cost of whole-
genome array data, genome-wide hypothesis-generating analyses in sufficiently powered 
cohorts are becoming available for many complex traits. As single variant association 
analyses of ADHD diagnostic status have shown considerable pitfalls (Neale et al., 2010; 
Thapar et al., 2013), this thesis describes various more suitable methods to investigate 
genetic associations in ADHD. The studies presented in chapter 5 and 6 combined analysis 
strategies to identify both common and rare variants associated with ADHD risk. Whenever 
applicable, we aimed to maximize statistical power by applying gene-based or gene-set 
association analyses (chapter 3-6, 9, and 10). This methodological approach allows the 
investigation of a combined effect of common genetic variants. Genome-wide, hypothesis-
generating approaches were applied in the studies described in chapter 3 and 10.
II. Aspects of neurodevelopmental continua in ADHD
A continuum – phenotypic and genetic – from population traits to clinical disorder
ADHD is characterized by age-inappropriate, sustained symptoms of inattention and 
hyperactivity/impulsivity (American Psychiatric Association, 2013). Earlier studies showed 
that polygenic risk for ADHD is associated with ADHD symptoms in the population (Martin 
et al., 2014) (albeit with a negligible proportion of variance explained), confirming the 
conclusion from twin studies that genes contributing to ADHD risk also regulate the 
expression of non-clinical levels of ADHD symptoms. This suggestion that etiological 
influences on ADHD symptoms are distributed throughout the population, is consistent 
with a liability model (Caspi et al., 2008). The concept of the phenotypic continuum and 
the liability model are shown in Figure 1. The liability-threshold model posits that the 
phenotypic outcome can be determined quantitatively by the combined effects of genetic 
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load and environmental factors. If cumulative predisposition exceeds a certain threshold 
value, individuals manifest with the clinical disorder, such as ADHD.
 
Figure 1. The model of ADHD liability. The liability-threshold model, assuming a Gaussian distribution of a 
continuous liability in the general population, posits phenotypic outcome can be determined quantitatively 
by the combined effects of genetic load and environmental factors. If cumulative predisposition exceeds 
a certain threshold value, individuals manifest with the clinical syndrome (continuum). Weak effects of 
common genetic variants (black arrows), intermediate and potentially larger effects of rare variation in some 
individuals (blue and red arrows, respectively), and any environmental effects (lower bar) affect liability. 
Each line of arrows represents an affected individual. The figure was adapted from (Chaste et al., 2017).
In line with those findings, we tested the association of the common DRD5 alleles with 
categorically defined ADHD and with inattentive and hyperactive-impulsive symptom 
counts in chapter 2. It is of interest to assess which symptom domain the genetic variants 
are associated with. However, this study was performed on a small scale, since only a 
single gene was investigated. The characteristic domains of inattention and hyperactivity/
impulsivity are separate domains of ADHD’s psychopathology, with a genetic correlation of 
around 0.6 (Larsson et al., 2013a). This reflects a substantial genetic overlap but also implies 
that domain-specific genetic influences exist (Bidwell et al., 2017), supporting a dimensional 
approach to genetic studies of ADHD.
A critical question in study design is, which study population to use? The study of patients 
may be obvious, but is the effect of ‘disease/disorder genes’ really restricted to patients? 
In addition to the work discussed above, recent findings show that most of the (identified) 
risk variants are common in the general population, with minor allele frequencies between 
1-50% (Gormley et al., 2016; Schizophrenia Working Group of the Psychiatric Genomics et 
al., 2014). Is it therefore possible that common risk variants only cause the disorder in a 
subset of carriers, e.g., because they exert an effect only in combination with specific other 
risk factors? This is not the most likely situation, and an alternative explanation can be that 
patients with a clinical diagnosis of ADHD are at the extreme end of a continuous spectrum, 
with non-diseased carriers of the risk variants showing less severe phenotypes. Such a 
continuity of ADHD (disorder and symptoms) can also be seen on the genetic level (genetic 
continuum). Genetic risk scores for clinical ADHD were associated with ADHD symptom levels 
in the general population (Groen-Blokhuis et al., 2014; Martin et al., 2014) and symptom 
trajectories (Riglin et al., 2016), suggesting a genetic overlap between clinical ADHD (state) 
and increasing symptoms (trait). Additional evidence for this is provided by a recent study 
that investigated the genetic correlation between a clinical (mainly childhood) ADHD sample 
and ADHD symptoms in the general population (again mainly childhood cohorts) (Demontis 
et al., 2017; Middeldorp et al., 2016). The genetic correlation between both phenotypes was 
very high (rg=0.943, SE=0.204), suggesting a strong genetic overlap between the disorder 
and the trait (Demontis et al., 2017).
Most of the studies in this thesis used clinical populations and a case-control design, 
but in the study in chapter 3 we used the opportunities provided by studying (mainly) 
general population cohorts. Inattention and hyperactivity/impulsivity symptoms can 
be reliably assessed in population-based cohorts based on rating scales (Larsson et al., 
2013a). This opens the opportunity to collect large population-based samples to identify 
disorder-relevant genetic variants. In chapter 3 we used the power of population studies of 
ADHD symptoms in adults by applying a genome-wide hypothesis-generating approach. 
The results of our study show that self-reported adult ADHD symptoms measured in the 
general population have a genetic component, and that performing population-based 
GWAS meta-analysis of adult ADHD symptoms can provide novel insights into the genetic 
underpinnings of ADHD symptoms. However, we did not find any genome-wide significant 
association, potentially indicating that the size of our population-based samples was 
still not large enough. Moreover, we had to include the combination of three different 
phenotyping instruments (i.e., ADHD symptoms rating scales), which may have increased 
the heterogeneity and therefore may have lowered the overall power. To our surprise, we 
did not observe significant genetic correlation with clinical ADHD, which may be due to 
the limitations described above. Future studies will prove if simply expanding sample size 
is indeed a winning strategy for driving discovery of adult ADHD symptoms in the general 
population. Generally, the numbers needed will depend on the phenotype’s heritability and 
polygenicity and the effect sizes of the contributing SNPs (Holland et al., 2016).
The concept of the genetic continuum is not only limited to ADHD symptoms, but can 
also be expanded to other ADHD-related traits. Also trans-diagnostic effects have been 
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observed. In the case of schizophrenia, the most compelling evidence began to emerge 
about ten years ago, particularly from genomic studies that implicated large and rare CNVs 
in conferring risk to schizophrenia and showed that the same variants also confer risk to 
intellectual disability, autism spectrum disorders, and ADHD (Kirov et al., 2014; Rutter et al., 
2006). This model is based on emerging evidence for sharing of genetic and environmental 
risk factors and predicts that there are also likely to be overlapping pathogenic mechanisms 
(Owen and O’Donovan, 2017). For ADHD, studies showed that the genetic contribution 
(of common genetic variants) to ADHD overlaps with that of other psychiatric (and non-
psychiatric) disorders (Anttila et al., 2017; Demontis et al., 2017). In line with this idea, the 
cross-phenotype effects can be investigated in other ADHD-related traits, e.g. brain volume 
measures, as was studied in chapter 10. There, we showed that genetic overlap between 
genes for ADHD risk and ICV is significant, but overall the genetic correlation with brain 
volume measures is limited.
A mutational continuum in neurodevelopmental disorders
Another concept emerging from this thesis is that of a mutational continuum: this concept 
suggests that genetic mechanisms operate across a range of disorders (Owen, 2012; Owen 
and O’Donovan, 2017), i.e., the same genes are involved in different (neurodevelopmental) 
disorders, where the severity of genetic defects may determine the specific disorder 
expressed by a patient (Figure 2). In this mutational continuum, neurodevelopmental 
disorders, including e.g. intellectual disability, autism spectrum disorder, schizophrenia, 
and ADHD, are seen as representing the diverse range of outcomes that follow from 
disrupted or deviant brain development. These findings of shared genetic risk and shared 
pathogenic mechanisms among neurodevelopmental disorders also support the view that 
these disorders lie on a gradient of severity, implying that they overlap to some extent 
quantitatively as well as qualitatively (Figure 2) (Owen and O’Donovan, 2017). Since many 
of the individual genetic association are shared across multiple psychiatric disorders, this 
points to extensive biological pleiotropy (O’Donovan and Owen, 2016). Findings from 
chapter 4 add to the concept of the mutational continuum, as it demonstrates the genetic 
continuity of ADHD and ID, where genes, known to carry mutations in ID, contribute to 
ADHD risk through common variants. There are also examples for the mutational continuum 
in other (types of) phenotypes. For example, deletions in the gene AKT3 cause microcephaly 
syndromes (Boland et al., 2007), and AKT3 duplications cause macrocephaly (Wang et al., 
2013). This gene is part of brain growth pathways, which were recently found to also be 
strongly linked to ICV in the general population (Adams et al., 2016b; Reijnders et al., 2017). 
Moreover, heterogeneity and incomplete penetrance suggest that the classical distinction 
between Mendelian and complex diseases is not always absolute and that a continuum may 
exist between purely Mendelian diseases and most complex diseases. Additionally, a more 
recent study showed that genes harboring both causal variants for Mendelian disorders 
and risk factors for complex disease traits, tend to present higher functional relevance 
in protein networks and show higher expression levels than genes associated only with 
complex disorders (Spataro et al., 2017).
Figure 2. The mutational continuum in neurodevelopmental disorders. The relative impact of genetic 
variants is shown, ranging from damaging point mutations and CNVs to common variants. Damaging variants 
are less frequent in the population compared to common genetic variants which are less penetrant. If the 
cognitive impairment is high, e.g. in ID, rare damaging mutations with a general effect on neurodevelopment 
are thought to be causal. In the case of ADHD, the cognitive impairment is less severe and the genetic 
contribution to the disorder is mainly coming from common genetic variants with smaller effects. The 
mutational continuum suggests that genetic mechanisms operate across a range of disorders, i.e., the same 
genes are involved in different (neurodevelopmental) disorders. In some instances, an increasing severity 
of genetic effects is observed (e.g., genes affected by rare genetic variation in ID patients also contribute 
to multifactorial ADHD risk through common genetic variation, chapter 4).
III. The role of rare variants in ADHD
Most genetics research in ADHD focused on common genetic variants, mainly motivated by 
the common disorder – common variant theory. Based on the results of GWASs, we know 
that the amount of variance in disease susceptibility explained by these common genetic 
variants is small. It was expected that rare genetic variants have stronger effects on ADHD 
risk (see introduction Figure 1), and that, therefore, genetic studies focusing on the less 
frequent spectrum of genetic variation could help unravel part of the so-called ‘missing 
heritability’. For several other psychiatric disorders, it is known that rare variants have a 
role in the disorder’s etiology. In the case of schizophrenia, not only large, rare structural 
genetic variants (CNVs), but also rare single nucleotide variants (SNVs) contribute to disease 
risk, as increased frequencies of de novo point mutations have been observed in samples 
of individuals with schizophrenia in comparison to control individuals (Fromer et al., 2014). 
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WES studies have been successful in identifying rare risk alleles for neurodevelopmental/
psychiatric disorders, such as autism spectrum disorders (Iossifov et al., 2014) and 
schizophrenia (Purcell et al., 2014).
Different designs can be used for studies aiming at identifying rare variants linked to 
complex disorders. Most comparable to genomic studies of common genetic variants is 
the approach to collect large case-control data sets. For ADHD, a small number of studies 
followed this strategy yet. Initial WES work revealed an enrichment of rare variants in a gene-
set of previously defined candidate genes for ADHD (Demontis et al., 2016). Additionally, a 
more hypothesis-generating approach was followed by performing a genome-wide analysis 
based on exome-chip data (Zayats et al., 2016). However, both studies are of limited sample 
size (nWES=205 and nexome-chip=9,365), and larger samples are needed for robust case-control 
WES studies (e.g., as for schizophrenia (Purcell et al., 2014)) to clarify the range of effect sizes 
of these rare variants. Alternative approaches come from integrative bioinformatic analyses. 
A recent study ranked genes, found in rare CNVs associated with ADHD, according to prior 
biological knowledge obtained from both human and cross-species databases. By this, novel 
ADHD candidate genes were prioritized (Harich et al., submitted).
In a second approach, large pedigrees with multiple affected individuals have been 
subjected to genetics research, as it had been hypothesized that rare (and penetrant) 
mutations would segregate with the phenotype of interest. In two chapters of this thesis 
(chapter 5 and chapter 6), we hypothesized that families with multiple affected family 
members are enriched in rare genetic risk factors for ADHD and thus we would be able 
to limit genetic heterogeneity, since rare variants with potentially higher penetrance 
may cause the disorders in these ADHD families. Therefore, we employed the extended 
pedigree-based approach, in which one screens for segregation of rare variants with disease 
across multiple affected individuals. Importantly, the results from both chapters imply that 
- despite the apparent dominant segregation pattern - ADHD is not a monogenic disorder 
in the pedigrees investigated. The observed (imperfect) segregation pattern is similar to 
findings in previous linkage studies of ADHD (Lesch et al., 2008; Zhou et al., 2008) and other 
neurodevelopmental disorders (Chapman et al., 2015). While rare variants were observed 
in the individual families, common genetic variants in the same genes are associated with 
ADHD in larger case-control cohorts. Thus, for all families presented in chapter 5 and 
chapter 6, we may have to assume a more complex combination of rare and common 
variants contributing to the ADHD phenotype. WES and WGS studies in multiplex autism 
families (Shi et al., 2013; Toma et al., 2014) and familial bipolar disorder (Goes et al., 2016) 
provide some evidence for rare, inherited variants segregating with the disorder. However, 
for ADHD, Mendelian (monogenic) forms may not exist (in the absence of comorbid ID), even 
not in familial ADHD pedigrees. Interestingly, families ascertained for having two or more 
children with autism spectrum disorders and simplex families showed distinct patterns of 
genetic risk: the rate of large, rare de novo CNVs is lower in multiplex families, and there is 
an increased burden of large, rare inherited CNVs (Leppa et al., 2016).
A third approach, which has successfully been applied in other neurodevelopmental 
disorders, especially in autism spectrum disorders (Hashimoto et al., 2016; Iossifov et al., 2014; 
O’Roak et al., 2011; O’Roak et al., 2012), is a trio-approach with sporadic patients and their 
parents. In this approach, it is assumed that the occurrence of the disorder in the patient 
is due to de novo mutations. However, in ADHD this approach may seem less promising, 
since the disorder does not reduce reproductive fitness as it does e.g., in autism spectrum 
disorders. Therefore, sporadic ADHD cases are less frequent, and familial aggregation of 
ADHD is more frequently observed (Chen et al., 2017a). On the other hand, recent evidence 
from the Swedish population registries suggests that ADHD risk is strongly increased in 
the offspring of older fathers (<45 years) (D’Onofrio et al., 2014), which may be linked to 
an age-dependent increase in mutation rate in the paternal germline (Kong et al., 2012). 
Moreover, it had been suggested that the cognitive profile of families with only one affected 
child differs from that of families with multiple affected children (Oerlemans et al., 2015a; 
Oerlemans et al., 2015b). This may indicate that the trio-design could be promising in ADHD 
after all. Indeed, an initial study suggests that WES of sporadic ADHD can identify novel and 
potentially pathogenic de novo variants (Kim et al., 2017a).
Overall, rare variants contribute to the genetic architecture of ADHD, however, the exact 
contribution and impact of such rare variants on ADHD etiology still has to be estimated. 
Similarly, the role of rare variants in the onset and persistence of ADHD awaits further 
studies. Many of the individual genetic associations for other types of genetic variation, 
such as CNVs and SNPs, are shared across multiple neurodevelopmental disorders in a way 
that points to extensive biological pleiotropy. Thus, the specificity of rare SNVs for ADHD 
should also be assessed.
IV. Changes in the genetic contribution across the lifespan
Although the majority of children with ADHD will not continue to meet the full set of 
criteria for ADHD as adults, the persistence of either functional impairment (Faraone et 
al., 2006) or subthreshold impairing symptoms into adulthood is high (Biederman et al., 
2000). Results of prospective longitudinal studies suggest that approximately two-thirds of 
youth with ADHD retain impairing symptoms of the disorder in adulthood (Faraone et al., 
2006). However, genetic and environmental links between ADHD in childhood and the adult 
manifestation of the disorder is poorly understood, mainly because of a lack of longitudinal 
studies. A Swedish longitudinal twin study showed that one-fourth of the heritability in 
adulthood was shared with childhood manifestations of attention problems, indicating 
the presence of stable genetic risk factors that influence ADHD symptoms over time; the 
study also revealed evidence of new genetic factors that emerged during the transition 
from child through adolescent to young adult development (Chang et al., 2013), suggesting 
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that ADHD is a developmentally complex phenotype characterized by both stable and 
shifting genetic influences across the lifespan (Biederman et al., 2010; Faraone et al., 2006). 
This means that only part of the factors that contribute to ADHD onset also contribute to 
persistence of ADHD. Since most studies used twin data to assess the proportional impact 
of genes and the environment on interindividual differences in the developmental course of 
ADHD symptom domains (Kuntsi et al., 2005; Pingault et al., 2015; Rietveld et al., 2004), 
the contribution of individual genetic factors has not yet been studied. The results of our 
candidate gene association study in chapter 2 contribute evidence that the risk alleles 
contributing to ADHD symptoms partly differ by age. While evidence for an association of 
DRD5 VNTR alleles with ADHD in children had been strengthened by meta-analysis (Wu et 
al., 2012), we did not find a similar effect in a meta-analysis of persistent ADHD in adults. 
Differential association of genetic variants with ADHD observed in childhood and adulthood 
has also been reported for the dopamine transporter gene (DAT1/SLC6A3) (Franke et al., 
2010). A potential underlying mechanism for the DAT1 gene has been suggested by positron 
emission tomography (PET) studies of the Volkow group showing that genotypes are linked 
to different developmental trajectories of DAT availability (Volkow et al., 1996) (see also 
(Shumay et al., 2011)).
On a genome-wide scale, a high genetic correlation between clinical ADHD in children 
and persistent ADHD in adults has recently been observed based on common genetic 
variants (~81%; (Ribases et al., 2017)). However, the results need to be interpreted cautiously, 
since methodological explanations for this phenomenon cannot yet be ruled out. This 
finding could also indicate that the difference between childhood and persistent ADHD 
is coming from rare (or other structural) genetic variants. Moreover, the findings could be 
related to epigenetic effects, and/or gene-gene and gene-environment interactions.
Mapping mechanisms from gene to disorder
With the recent advances in genomics by both GWASs (i.e. larger and more powerful studies 
yielding many significant associations, and providing robust candidate genes for follow-up 
studies) and next-generation sequencing (WGS and WES allow evaluation of the genome in 
much greater depth than before), more and more genetic variants are being identified that 
potentially contribute to ADHD etiology. This implies that the field of psychiatric genetics 
is now shifting focus from “simply” gene-finding to the characterization of the underlying 
biological mechanisms. So the critical question, that the following section is about to answer, 
is “How to turn information into knowledge?” and to stress potential strategies to study the 
relevance of genetic variants. For this, multi-level research approaches are indispensible as 
they can shed light on multiple levels of complexity and can help to identify the mechanisms 
underlying the effects of ADHD genes on behavior and disease (Figure 3).
Figure 3. This schematic representation of pathways from gene to disease at different levels of complexity in 
psychiatric genetics. The figure shows the convergence of the effects of multiple genetic and environmental 
factors in disease symptoms. It has been modified from a previous publication (Figure 1, (Franke et al., 
2009)). Polygenicity (schematically depicted by gene A to I (top line)) is suggested to be involved in causing 
disease symptoms. Groups of genes converge on different biochemical pathways and biological processes 
contributing to disease. These can be studied at various biological levels, e.g. biochemical processes and cell 
function can be assessed by biological assays in cell or animal models, by measuring e.g. neuron morphology 
or synaptic functioning. Bioinformatic pathway and network analyses can help to integrate data from various 
sources and to identify molecular networks or cellular processes in which ADHD-related genes are enriched. 
Neuroimaging methods (structural and functional) can be applied to assess relevant phenotypes at the level 
of brain morphology (‘Morphology brain region A-C’). ‘Function of brain units’, can be e.g. investigated by 
functional MRI or through performance measurements on neuropsychological tests. Aberrations at this 
level can result in altered behavior and disease-related behavioral traits, that subsequently lead to disease 
symptoms. Environmental influences can impact all levels, and need more attention in future studies. The 
figure was adapted from (Klein et al., 2017).
V. Bioinformatics approaches integrate findings of molecular studies
The step from a GWAS-associated locus to identifying the casual variation underlying the 
association can be challenging. In this, bioinformatics approaches can be helpful as they 
can follow-up on genetic discoveries and serve to integrate findings from different types of 
molecular studies. Bioinformatics is a broad field of research, and although it is not the focus 
of this thesis, results from bioinformatic approaches impacted on multiple chapters in this 
thesis. Bioinformatic analyses can help in the clarification of the actual effects of risk variants 
on gene expression and regulation; as disease risk variants are often found in non-protein 
coding sequences, their molecular consequences are difficult to evaluate (Civelek and Lusis, 
2014; Paul et al., 2014). Moreover, bioinformatics can help to unravel the molecular networks 
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and cellular processes that an ADHD risk gene is involved in; genetic factors associated 
with ADHD are distributed across the genome, but they have been found to be enriched 
within functional processes. Identification of these clustered functional networks can help to 
understand the biological processes underlying ADHD etiology. For example, an early study 
from our lab showed that ADHD GWASs association signals converged on the biological 
process of directed neurite outgrowth (Poelmans et al., 2011). This result has been taken 
forward in the study described in chapter 10. More recent enrichment analyses revealed 
that ADHD GWAS association signals were most enriched in biological functions related to 
nervous system development, neuron projection morphogenesis, cell-cell communication, 
glutamatergic synapse/receptor signalling, and multicellular organismal development (Hawi 
et al., 2015; Mooney et al., 2016; Yang et al., 2013).
VI. Modeling disease in animal models
In order to fully understand the role of ADHD risk genes in brain structure, cognition, and 
behavior, it is essential to manipulate genes and to monitor effects of such manipulation on 
molecular and cellular processes, as well as on the behavioral level. Of course, the animal 
models presented in this thesis should not be viewed as an attempt to model human ADHD 
in its entire complexity. However, the investigation of specific aspects of disorders has 
strongly advanced out understanding of disorder’s pathologies (Gatto and Broadie, 2011). 
Generally, molecular and cellular processes are well conserved between species. Moreover, 
specific ADHD-related behavioral traits have been shown to be suited for being modeled 
in animal models, since these are relatively basic processes, that are common in most 
species, such as locomotion. Animal models were used in this thesis in multiple chapters. 
In chapter 3, mouse strains featuring different levels of impulsivity were investigated. Stxbp-
AS1 transcript levels in the prefrontal cortex strongly correlated with motor impulsivity levels 
as measured in a reaction time task in different mouse strains. This validation provided 
additional evidence that STXBP5-AS1 is involved in ADHD-related impulsivity levels. A more 
unconventional animal model for ADHD used in our studies was the fruit fly (Drosophila 
melanogaster) (van der Voet et al., 2016; van der Voet et al., 2014). This model has several 
advantages over classical (murine) models, such as being relatively inexpensive, having a 
wide range of genomic tools available that allow spatial and temporal manipulation, and 
being highly suitable for fast studies of (candidate) genes. Drosophila melanogaster seems to 
be a suitable model for ADHD research, as it has been shown that flies exhibited increased 
locomotor activity, when expression of ADHD candidate genes was altered, and ADHD 
medication was able to reverse the behavioral phenotype (van der Voet et al., 2016). Among 
the behaviors that can be reliably assessed in Drosophila are locomotor activity and sleep, 
which are known to vary in a well-regulated day/night rhythm. Drosophila melanogaster 
was used in chapter 4 and 5 to investigate the effects of altered expression levels of the 
newly identified ADHD candidate genes. Most importantly, the results of chapter 4 and 5 
show increased locomotor activity and reduced sleep in the mutant fly lines. This provided 
evidence that specific and isolated manipulation of the genes resulting in altered expression 
can lead to ADHD-related phenotypes. Interestingly, for all three genes investigated, the 
hyperactivity was seen primarily during the dark period (night). For both the TRAPPC9 gene 
(chapter 4) and the FBXO25 gene (chapter 5) these are the first reports providing evidence 
for those gene having a role in the nervous system. A similar pattern has been observed 
in a previous study of our group, which showed that manipulation of ADHD-associated 
genes in Drosophila yields an ADHD-relevant, specific, and readily recognizable locomotor 
phenotype that is indicative of dysregulated signaling in a dopaminergic circuit (van der 
Voet et al., 2016). Importantly, in chapter 4 we dissected the role of two neuronal substrates 
can help to reveal the neurotransmitter signaling pathways that contribute to ADHD. We 
investigated both the dopaminergic and circadian components, since both circuits have 
a well-established role in ADHD (Baird et al., 2012; Gowrishankar et al., 2014). Studying 
neuronal subtypes is important to reveal phenotypes that might otherwise be masked: 
earlier studies have identified two opposing circuits within the part of Drosophila brain 
that regulates learning, memory, activity, and sleep (Sitaraman et al., 2015). Our results 
reveal an increased night activity signature of the knockdown of dMEF2 that indicated 
the importance of a dopaminergic signaling dysregulation in ADHD-relevant behavior. 
Additionally, knockdown of dTRAPPC9 in the circadian rhythm circuit showed ADHD-related 
behavior with nightly increased activity and reduced sleep. This means that manipulation 
of ADHD-associated genes can affect locomotion in a cell type specific manner. However, 
future research is needed to understand the underlying molecular mechanisms and identify 
proteins regulated by the newly identified ADHD candidate genes, probably even in distinct 
neuronal populations. This will allow to better understand the etiology of the aberrant 
behaviour caused by variation in these genes and potentially also allows individualization 
of treatment at a later stage.
The second purpose of using Drosophila melanogaster as a model system in this thesis 
was to functionally characterize novel ADHD genes. Gene function is studied in detail 
on multiple levels to determine its relevance for the disorder. This was done in chapter 
9, in which the effects of Git knockdown on behavior (locomotor activity) and neuronal 
connectivity on a cellular level (dendritic branching, axon guidance, synapse development) 
are described. Our observations support an important role for Git in synaptic and dendritic 
organization, as neuronal Git RNAi knockdown interferes with synaptic terminal branching 
and dendrite formation in Drosophila. Despite altered neuronal morphology, Git knockdown 
did not result in increased locomotor that has been observed for other Drosophila models of 
ADHD-associated genes (van der Voet et al., 2016). However, this may not be unexpected, as 
our results clearly show that the GIT1 locus is not associated with ADHD risk, ADHD symptom 
counts, neuropsychological performance, or brain volume and white matter integrity 
variation in large human data sets. Although we demonstrated that genetic variation in the 
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GIT1 locus is not associated with ADHD in humans, we cannot rule out any other effects of 
the GIT1 locus on different behavioral characteristics. The observed effect of Git1 deficiency 
in mice on fear learning and adaptation to new environments (Won et al., 2011), may be 
interesting starting points for future studies in humans. Interestingly, a more recent study 
proposed that rare variants in GIT1, along with other genetic and environmental factors, 
cause dysregulation of PAK3 leading to synaptic deficits in schizophrenia (Kim et al., 2017b).
VII. What is the value of brain imaging genetics?
A possibility for combining neuroimaging and genetics is by exploring the effects of known 
disease genes on the brain. While association studies (e.g., GWAS) have identified genetic 
variants for ADHD, there is still a long way to go from genetic association to understanding 
the pathophysiological mechanism underlying its effect on ADHD risk. As shown in Figure 
3, while genetic risk variants have in common that they confer risk for a particular disorder, 
the pathophysiological mechanisms by which they do so are not necessarily the same. 
Brain imaging genetics can shed light on which specific pathways are actually involved. 
Imaging genetics studies have been pursued with two main aims: First, such studies were 
suggested as a short-cut for the identification of ADHD candidate genes via the use of brain 
phenotypes (Bigos and Weinberger, 2010; Durston, 2010; Meyer-Lindenberg and Weinberger, 
2006). As those brain phenotypes are thought to lie in-between a genetic factor and the 
clinical phenotype, it has been argued that effect size for effects of genes on those brain 
phenotypes may be larger than those for effects on behavior (Gottesman and Gould, 2003). 
However, for structural brain phenotypes, (i.e., brain volumes) this assumption has been 
refuted by recent large-scale studies (Franke et al., 2016). Overall, the success of this strategy 
(mainly candidate genes investigated) has been limited, as reviewed in chapter 7 and 8.
The second aim for using brain imaging genetics studies is to better understand the 
pathways leading from gene to disorder (via the brain and behavior). Most studies reviewed 
in chapter 7 and 8 have used the design for this purpose. A nice example from literature 
for the successes achievable through this approach is the functional genetic variation in 
the SLC6A4/5HTT gene, for which converging evidence from different studies suggest that 
it is linked to emotion regulation through effects on brain activation in the amygdala and 
the wider ‘threat circuit’. Studies of healthy participants and of different clinical cohorts 
have shown that those individuals carrying the risk factor for emotional dysregulation 
show increased activation in tasks related to emotion processing and learning (reviewed 
in chapter 7). Despite such promising results, our reviews of the existing literature in 
chapters 7 and 8 show that existing work is severely flawed. Briefly, the main drawbacks 
are the small samples sizes of the individual studies (studies are underpowered), the fact 
that mostly only single genetic candidate variants/genes were investigated (hypothesis-
driven studies), and that mainly region-of-interest analysis were performed (instead of brain-
wide studies). Overall, only a very limited number of replication studies could be identified, 
since most studies used different analysis strategies. For example, conflicting results with 
regard to the effects of schizophrenia risk variants on structural brain changes in the general 
population have been reported (Papiol et al., 2014; Van der Auwera et al., 2015). Obviously, 
alternative analysis approaches are highly needed. In chapter 10 of this thesis, we revisited 
brain imaging genetics studies by performing a highly powered, genome-wide study. We 
investigated, whether the genetic contributions to ADHD risk and (subcortical) brain volume 
overlap. This was achieved by genome-wide analyses at two levels: first, at the level of the 
global genetic architecture, and, second, at the single variant level. On both levels, we found 
significant - though modest - genetic covariation between ADHD risk and brain volumes. 
Interestingly, genetic correlation between ADHD and ICV shows apparent specificity to this 
disorder, as it was not found in studies of other psychiatric disorders, e.g. schizophrenia 
(Adams et al., 2016b; Franke et al., 2016), major depressive disorder (Wigmore et al., 2016), or 
autism (Adams et al., 2016b). Overall, the degree of genetic overlap between ADHD and ICV 
was statistically modest. This may seem to be inconsistent with the general hypothesis that 
ADHD is a (or psychiatric disorders in general are) genetic-based brain disorder(s). However, 
several possible explanations for this modest amount of shared effects exist: All studies 
investigated brain structure at a gross anatomical measure and such atlas-based brain 
segmentations might be too coarse to identify subtler volumetric differences. Additionally, 
there is a limited link between structure and function at the level of MRI-derived volumes, 
so other neuroimaging phenotypes (structural and functional connectivity measures) could 
be more informative. With increasing availability of large consortia and/or biobank data sets, 
more hypothesis-generating studies will be performed.
Although the model of intermediate brain phenotypes can be helpful to provide a deeper 
understanding of the pathways from genes to the disorder, some caution is needed. Once 
stepped away from a clinical diagnosis, the results could become less (disorder-) specific. This 
means that the importance of shared neural substrates across psychopathologies need to be 
considered (Goodkind et al., 2015), as well as the high level of comorbidities in ADHD patients 
(e.g., anxiety disorders, autism spectrum disorders, major depressive disorder). For example, 
a reduction of (subcortical) brain volumes is not unique to an ADHD diagnosis, but is also 
seen in depression and bipolar disorder (Hibar et al., 2016; Schmaal et al., 2016). In addition, 
there is also evidence for substantial sharing of genetic risks across different psychiatric 
disorders. This extends to the level of characteristic traits throughout the population, with 
which some clinical disorders also share genetic risks (reviewed in (Martin et al., 2017)). The 
extent to which the shared genetic risk variants contribute to the shared neural substrates 
that are observed across psychiatric disorders, still needs to be determined.
Based on the results of the different studies reported in this thesis, it can be concluded 
that complementary methods are needed (1) to identify ADHD candidate genes (i.e., by a 
deliberate use of candidate gene studies and hypothesis-generating approaches and by 
looking at both common and rare variants) and (2) to validate the (functional) involvement 
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of such genes in ADHD (i.e., by combining statistical genetics approaches, bioinformatics, 
animal models, and brain imaging genetics). Moreover, replication studies and thorough 
validation of novel candidate genes are essential. Additionally, this thesis provides evidence 
for rare genetic variants playing a role in ADHD etiology, however their exact impact is still 
unknown.
Strengths and limitations
Approaches for gene identification
A main strength of this thesis is the integration of findings of many different samples, 
cohorts, and data sets. Whenever possible, information from large-scale international 
consortia (i.e. association summary statistics) was combined with data from well-
phenotyped local and international cohorts (cohorts are summarized in Table 1 in the 
thesis introduction). Although the maximization of sample size is always important for 
genetic association studies, smaller cohorts can be of importance as well, as they may 
be phenotyped more precisely (less measurement error and thus more homogeneous), 
and a broader phenotypic spectrum may be investigated. Essentially, this means that the 
trade-off between maximizing power by increasing sample size (thus potentially increasing 
heterogeneity) and more in-depth phenotyping in smaller (potentially less heterogeneous, 
but also more expensive per individual) cohorts needs to be considered.
A second strength is that the different chapters (which) of this thesis report a wide range 
of approaches for genetic association studies approaches. These reach from hypothesis-
based analyses at candidate SNP level to hypothesis-generating genome-wide analyses to 
uncover different aspects of ADHD’s genetic architecture. Whenever possible, we aimed 
at meta-analyzing data sets to maximize statistical power (chapter 2 and 3) or we used 
the largest data sets that were publicly available (GWAS meta-analysis summary statistics). 
Increase in statistical power was also achieved by aggregating association signals in a 
single statistical test instead of performing single variant association analyses only, as it 
was done by gene-based or gene-set association analyses (chapter 3, 4, 5, 6, 9, 10). We also 
covered a broad spectrum of genetic variants. In chapters 3, 5, and 6, we investigated rare 
variants, other chapters focused on common genetic variants. In chapter 5, we specifically 
investigated the role of structural genetic variations (CNVs), in the other chapters single 
nucleotide variants (SNVs) were examined. A limitation of using association statistics data 
from large international consortia is that those often do not incorporate information 
on confounding factors, such as medication use or the presence of comorbid disorders. 
Additionally, all those data came from cross-sectional studies. However, longitudinal studies 
are essential if ADHD across the lifespan, including detailed information on remission and 
persistence, should be investigated. Moreover, most cohorts collected data only on a single 
type of genetic variation for all individuals. However, it is known that each individual carries 
a combination of different types of genetic variants that jointly may cause ADHD.
Mapping mechanisms from gene to disorder
Chapter 7 and 8 contribute to the literature by providing a comprehensive literature 
review of brain imaging genetics studies for ADHD and additional neurodevelopmental 
disorders with high comorbidity (ASD and specific forms of ID). Given the inconsistency of 
the research findings, it is challenging for researchers to integrate findings and to provide 
robust conclusions based on existing studies. However, we uncovered important gaps in the 
current literature and pointed the reader to common pitfalls in imaging genetics studies. We 
formulated important directions for future brain imaging genetics studies. Integration of 
interdisciplinary research findings and the use of complementary approaches are essential to 
better map the molecular mechanisms involved in ADHD etiology. Chapter 9 describes the 
results of such an attempt for a single gene, GIT1. There, we functionally characterized gene 
effects in Drosophila, by investigating both the morphology of neurons and ADHD-related 
behavioral phenotypes. Additionally, this chapter integrated results of genetic association 
analyses, brain imaging genetics, and mRNA expression analysis. We also addressed one 
of the limitations of imaging genetics studies by performing a genome-wide analysis (in 
chapter 10). With increasing availability of summary statistics derived from GWAS meta-
analyses on brain imaging phenotypes, brain-wide approaches will contribute to improving 
the brain imaging genetics research field further. Future studies should also investigate 
interactions of the environment with genetic factors contributing to development of ADHD, 
as adverse prenatal and postnatal environmental exposures have been linked to both ADHD 
and general brain growth and development (Faraone et al., 2015).
(Clinical) implications
The underlying molecular and neurobiological mechanisms of ADHD are still not completely 
understood, and although pharmacological treatment options exist, these are limited 
especially in treating executive function deficits or disordered emotional regulation 
(Warikoo and Faraone, 2013). The drugs used to treat ADHD, only reduce symptoms, they 
are not curative. Additionally, not every patient with ADHD responds well to the existing 
treatment options. There is thus a need to better understand the underlying mechanisms 
leading to ADHD to enable the development of better medication. While this thesis describes 
fundamental research, it may contribute to the search for such novel treatment options (as 
well as potential diagnostic innovations and prevention) by increasing knowledge on ADHD 
etiology.
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In the field of ADHD as well as in the whole of psychiatry, it is challenging to translate 
genome-wide association findings into diagnostic tools and new therapeutics for psychiatry 
(Breen et al., 2016). Currently, the genetic findings (and neuroimaging markers as well) 
are not suitable to diagnose psychiatric disorders, due to the overall limited amount of 
explained variance and the (resulting) lack of sensitivity and specificity. Examples from 
neurodegenerative disease show that the added predictive value of these genetic variants 
is low (Chouraki et al., 2016; Verhaaren et al., 2013). The challenges for the development of 
novel therapeutics for psychiatric disorders result from the paucity of novel, valid targets. 
This results from etiological heterogeneity, the complex and polygenic nature of genetic 
risk, and the definition of psychiatric disorders on the basis of the range and duration of 
symptoms (which can be subjective, self-reported, or observational) (Breen et al., 2016). 
Integration of genetic data downstream of genome-wide approaches may be used for 
target selection, but also for matching targets to indications; e.g., by allowing more accurate 
identification of high-risk individuals (Breen et al., 2016). Indeed, the evidence from genomics 
for a tractable biology underlying psychiatric disorders is promising, and the high degree 
of genetic pleiotropy suggests that therapeutic approaches may even be successful across 
current diagnostic boundaries (O’Donovan and Owen, 2016).
Although not directly a result of this thesis, it is important that clinicians increasingly 
take a developmental life-course approach ensuring that patients are effectively managed 
across the transition from childhood to and through adulthood. Developmental change 
over time should be expected and anticipated. Increased understanding of the factors 
contributing to the persistence of ADHD is essential in ultimately providing a better care 
for ADHD across the lifespan.
Important knowledge about ADHD etiology (e.g., obtained by interdisciplinary research) 
should efficiently be disseminated to the society in order to reduce the stigma of mental 
disorders. A central aspect therein is the concept of the genetic continuum, as it is discussed 
above. Given the fact that ADHD can be seen as an extreme of a continuum, treatment 
options or support may also be offered to individuals with subthreshold symptoms.
Challenges for the future
For genetic discoveries, the most obvious approach is to increase the sample size for discovery 
studies. This has been successful for other complex traits (Gormley et al., 2016; Okbay et 
al., 2016; Schizophrenia Working Group of the Psychiatric Genomics et al., 2014), and there 
is little doubt that this will also improve the power of genetic studies in ADHD and brain 
imaging phenotypes. Given the small effect sizes of common genetic variants, large study 
samples are needed. To be able to obtain these large data sets, (international) collaborations 
have been created, such as IMpACT (Franke and Reif, 2013), the PGC (Schizophrenia Working 
Group of the Psychiatric Genomics et al., 2014), and iPSYCH (Pedersen et al., 2017), ENIGMA 
(Thompson et al., 2014), the Human Connectome Project (Van Essen et al., 2013), and the 
UK Biobank (Sudlow et al., 2015).
A second aspect is to maximize the information that can be extracted from already 
collected data (within data sets). For example, existing DNA material can be genome-wide 
genotyped or sequenced in order to increase density of genetic information. In current 
ADHD genetics research, basically two parallel research approaches have been considered: 
First, large consortia that localize the main differences between cases and controls. Secondly, 
deeply phenotyped (smaller but reasonably sized) data-collections at single sites. Such 
single site data sets are useful to work out the underlying mechanisms involved in different 
aspects of ADHD (e.g., quantitative behavior, brain, neuropsychology); these data will 
(potentially) be more homogeneous than a combined set of data sets. This may especially be 
important if different studies measure the same phenotypes, but use different instruments 
to assess these (e.g., adult ADHD symptoms as described in chapter 3). Additionally, large 
biobanks have been initiated in the past years (Elliott and Peakman, 2008; The German 
National Cohort, 2014), and the first batches of their data have already become available 
for analyses (Davies et al., 2016; Gale et al., 2016; Hagenaars et al., 2016; Lane et al., 2016; 
Lyall et al., 2016; Wain et al., 2015). Such growing resources in electronic health records and 
population/based registries linked to genomic data can now be used to investigate the 
pleiotropic effects of psychiatric risk variants across the phenome (Smoller, 2017). Biobanks 
are likely to receive a prominent role in genetic discoveries in the coming years.
An additional approach to boost statistical analyses for genetic discoveries is by using 
more powerful statistical techniques. This relates to the analysis of genetic variability as well as 
to the type/complexity of the phenotype that is being analyzed. Examples come from recent 
novel meta-analytical techniques that allow for combining results from multiple studies in 
a way that yields the same results as pooled analysis, but does not require the raw data to 
be shared, which allows for an increased sample size (Adams et al., 2016a). In addition, most 
studies focus on univariate linear regression models for analyzing associations between 
genetic variants and imaging markers or disease status. Here, there is room for improvement 
through more sophisticated (multivariate) methods including machine learning algorithms, 
e.g., deep learning, or support vector machines (Burges, 1998; LeCun et al., 2015). Future 
work will also likely focus on the integration of information from various sources of genetic 
variation at the level of the individual subject. In genetics, successful discovery for psychiatric 
disorders will increasingly depend on the ability to integrate genetic information from de 
novo and inherited, rare and common forms of variation in the genome. Accurate estimation 
of the genetic load across such variability will subsequently enhance our understanding 
of ADHD.
11
500 501
Summary and general discussionChapter 11
Additionally, statistical power can be improved in alternative ways, e.g., by reducing 
the measurement error in both genetics and imaging. For example, the haplotype reference 
consortium has pooled together 65,000 human haplotypes to create a reference panel to 
which genotypes with minor allele frequencies as low as 0.1% can still be reliably imputed 
(the Haplotype Reference, 2016). Furthermore, the use of common analysis protocols 
across collaborating sites can help to reduce between site heterogeneity, e.g. in behavioral 
phenotyping and in neuroimaging. Recent advances in DNA sequencing and reductions 
in the associated costs also pave the way for obtaining whole genome sequences (Davies, 
2015). This may enable the identification of causal variants instead of tagging variants, in 
such instances in which the association signal is diluted and the linkage disquilibrium is 
not high enough. Similarly, imaging markers contain noise that is due to the equipment 
or subsequent image processing. Additionally, ultra-high field strength MRI scanners can 
provide more detail of the brain (Tallantyre et al., 2008; Tallantyre et al., 2010) and may be 
of great importance for future brain imaging genetics studies. Generally, imaging genetics 
studies should consider more consistent study designs. Confounding factors such as age, 
gender, symptom dimensions, comorbid disorders, and the genetic makeup should carefully 
be controlled for.
Most brain imaging genetics studies in ADHD up to now are cross-sectional studies. 
However, longitudinal studies are warranted to study developmental trajectories of brain 
changes in ADHD, as differences across the lifespan have been found in neuroimaging 
(Hoogman et al., 2017) and genetic results (Thissen et al., 2015), and provide a chance to 
study the potential role of such effects on persistence and remittance of ADHD. Especially 
longitudinal population-based cohorts with genomic data can help to discover trajectories 
of ADHD risk and gene-environment interplay (Riglin et al., 2016). Therefore it is critical 
that participants in biobanks and large-scale cohorts can be recalled, e.g., for further 
deep phenotyping. Another note on the choice of study design is about hypothesis-driven 
versus hypothesis-generating approaches. Hypothesis-generating approaches can provide 
new leads to follow. For example, genome-wide whole-brain analyses in ADHD, being 
hypothesis-generating on both genetic and neuroimaging data points, can generate 
new hypotheses (Stein et al., 2010). Although hypothesis-driven approaches have some 
limitations, investigation of candidate genes and candidate brain areas will remain useful 
in future research by providing insights into the underlying mechanisms in ADHD. However, 
candidates for these approaches should be selected downstream of the hypothesis-
generating approaches in future studies.
The selection of imaging markers will have an important impact on future research in 
a more general sense. The structural measures that are frequently used so far are fairly 
gross measures and probably oversimplify the complexity of the structural volumes. 
Genes themselves might affect specific regions of the brain, and the use of an aggregate 
brain measure can make such localized effects difficult to find. Emerging imaging markers 
that can be relevant for neuropsychiatric disorders, and specifically for ADHD, include 
(among others) the white matter microstructure. Future studies can extend the scope of 
imaging genetics to other clinically relevant and heritable imaging markers, including 
the microstructural integrity of white matter as measured by diffusion tensor imaging 
and functional connectivity assessed by functional MRI (Jahanshad et al., 2013; Meyer-
Lindenberg, 2012). However, work by global collaborations is currently still hampered by 
the large heterogeneity of such data between different sites. One attempt to reduce such 
heterogeneity is the use of shared protocols for data acquisition and analyses.
Furthermore, cross-investigations with other sources of biological data (e.g., transcriptomics, 
proteomics, metabolomics, microbiomics) can amplify the synergistic value of imaging 
genetics. These data represent yet another dimension that can be added on top of imaging 
and genetics, and may therefore also require novel methods to be developed for facilitating 
such studies. Sophisticated integration of all types of ‘omics’ data will be helpful in turning 
the information about ADHD’s genetic architecture into knowledge about its biological 
signature. Next to such interdisciplinary approaches, studies will also focus on proving 
causality. To dissect the functional effects of risk variants and to prove causality, mechanistic 
studies including cell or animal models are used. Statistical genetics approaches, such as 
mendelian randomization, also aim to contribute to our understanding of causal relationship 
between risk variants and risk for the disorder. Until now, such mendelian randomization 
approaches are mainly limited by lack of robust association findings, but this will probably 
be explored in more detail in the near future.
At least for psychiatric disorders, a substantial fraction of heritability is likely explained 
by interactions between genes and familial environment. This is seen in current estimates 
of SNP heritability, which are well below the heritability computed by twin studies. A 
further complication is that the environment likely contributes to pleiotropy. For psychiatric 
disorders we know of many shared environmental risks (e.g., anoxic episodes, exposures 
to toxins, low birth weight), each of which have small effects on disease risk (Faraone, 
2017). Moreover, ADHD’s association with reduced brain volumes may partly be driven by 
environmental effects, either independently or in interaction with genetic factors. Adverse 
prenatal and postnatal environmental exposures have been linked to both ADHD and 
general brain growth and development (Faraone et al., 2015). Consistently, monozygotic 
twins discordant for ADHD were found to have significant epigenetic differences among 
genes highly expressed in the developing cerebellum, striatum, and thalamus, in addition 
to genes functionally related to neurodevelopment and neurotransmitter regulation (Chen 
et al., 2017b). Therefore, future work will need to investigate environmental influences, e.g., 
by epigenetics studies, given the potential importance of DNA methylation variation in 
genes related to neurodevelopmental processes that play a key role in the maturation and 
stability of cortical circuits (Walton et al., 2017).
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Key findings of this thesis
• None of the common DRD5 alleles is associated with ADHD risk or ADHD symptom counts 
in adults (chapter 2).
• Common genetic variants within the STXBP5-AS1 gene are associated with self-reported 
adult ADHD symptoms (chapter 3).
• Genes, known to carry rare mutations in ID, contribute to ADHD risk through common 
variants (chapter 4).
• In Drosophila, knockdown of TRAPPC9 and MEF2C contributes to ADHD-related behavior 
through different pathways (chapter 4).
• Common genetic variants in FBXO25 gene are associated with ADHD, and overexpression 
of the FBXO25 orthologue in the fruit fly leads to increased locomotion (chapter 5).
• Combining linkage analysis and whole-exome sequencing in multi-generation pedigrees 
is a fruitful approach for identifying novel ADHD candidate genes (chapter 6).
• ADHD imaging genetics studies can provide insight into the link between genes, disease-
related behavior, and the brain (chapter 7 and 8).
• In ADHD imaging genetics studies, single genetic variants were studied, mostly focussing 
on dopamine-related genes. While promising results have been reported, ADHD imaging 
genetics studies are hampered by methodological differences in study design and analysis 
methodology, as well as by limited sample sizes (chapter 7 and 8).
• Imaging genetics research is still in its early stages, and conclusions about shared 
mechanisms of neurodevelopmental disorders cannot yet be drawn (chapter 7).
• Future studies should invest into complementary approaches at multiple levels of 
biological complexity. By combining and integrating findings across levels, we may get 
a better understanding of biological pathways from gene to disease (chapter 8).
• Common genetic variants in GIT1 are not associated with ADHD, and despite GIT1’s 
regulation of neuronal morphology, alterations in gene expression do not appear to have 
ADHD-related behavioral consequences (chapter 9).
• ADHD and intracranial volume are significantly negatively correlated. Individual loci of 
interest point to an involvement of neurite outgrowth-related genes (chapter 10).
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Nederlandse samenvatting
Attention-Deficit/Hyperactivity Disorder (ADHD), ook wel aandachtstekort-hyperactivi-
teitstoornis genoemd, is een veelvoorkomende ontwikkelingstoornis. Het wordt geken-
merkt door aandachtsproblemen, overmatige activiteit of moeite met het controleren van 
gedrag dat niet geschikt is voor iemands leeftijd. De symptomen verschijnen meestal voor-
dat een persoon twaalf jaar oud is en voor een psychiatrische diagnose moeten de sympto-
men langer dan zes maanden aanwezig zijn en problemen veroorzaken in ten minste twee 
instellingen (zoals school, thuis of recreatieve activiteiten). Bij kinderen kunnen aandachts-
problemen leiden tot slechte schoolprestaties. Ondanks dat het een van de meest voorko-
mende en gediagnosticeerde psychische stoornissen is bij kinderen en adolescenten, is de 
exacte oorzaak in de meeste gevallen vrijwel onbekend. We weten uit eerder onderzoek dat 
genetische factoren een rol spelen. Daarnaast zijn er op groepsniveau verschillen gevonden 
in de bouw en het functioneren van de hersenen tussen mensen met en zonder ADHD.
Het doel van de studies beschreven in dit proefschrift was om genetische mechanismen 
te identificeren die betrokken zijn bij deze hoogst erfelijke aandoening ADHD en inzicht 
te krijgen in de onderliggende biologische mechanismen. Deel 1 van dit proefschrift 
(hoofdstuk 2 t/m 6) richt zich op de identificatie van genetische mechanismen die 
betrokken zijn bij ADHD. Hiervoor werd gebruik gemaakt van verschillende methoden uit 
de moleculaire en statistische genetica. In deel 2 van dit proefschrift (hoofdstuk 7 t/m 10) 
ligt de nadruk op het combineren van hersenmaten en genetica om verbanden te leggen 
tussen genetische risicofactoren en veranderingen in de hersenen. Hieronder wordt kort 
beschreven wat er in de individuele hoofdstukken werd onderzocht en gevonden.
Hoofdstuk 2 beschrijft een kandidaat gen studie, waarin de associatie van een 
polymorfisme van het DRD5 gen met ADHD bij volwassenen werd onderzocht. Hiervoor 
werd een tot nu toe grootste meta-analyse uitgevoerd en werd de associatie van de 
DRD5-allelen met categorisch gedefinieerde ADHD en met onoplettende en hyperactief-
impulsieve symptomen getest. In tegenstelling tot eerdere rapporten over ADHD bij 
kinderen, is geen van de DRD5-allelen geassocieerd met ADHD of met ADHD symptomen 
bij volwassenen.
In hoofdstuk 3 hebben we een hypothesegenererende benadering toegepast en 
genetische varianten op genoomwijde schaal onderzocht. In dit hoofdstuk worden 
de resultaten gerapporteerd van een genoomwijde associatie meta-analyse van 
zelfgerapporteerde ADHD symptomen bij volwassenen. Genetische varianten binnen 
het STXBP5-AS1 gen vertoonden de sterkste associatie, die werd gevalideerd in een meta-
analyse van ADHD symptoomscores uit de kindertijd. Met behulp van een in vitro celassay 
werd aangetoond dat expressie van STXBP5-AS1 de expressie van STXBP5 verhoogde. Van 
STXBP5 is bekend dat het betrokken is bij de SNARE complexvorming, een belangrijk 
proces bij het transport van neurotransmitters in zenuwcellen. Bovendien correleerde 
de expressie van Stxbp5-AS1 in de prefrontale cortex met motorische impulsiviteit in 
verschillende muizenlijnen. Deze resultaten suggereren dat het STXBP5-AS1 gen betrokken 
is bij het ontstaan van ADHD symptomen en wijzen op een rol van vesikeltransport 
van neurotransmitters als een biologisch mechanisme voor ADHD-gerelateerde 
impulsiviteitniveaus.
In hoofdstuk 4 hebben we onderzocht of genen, waarvan bekend is dat als ze zeldzame 
mutaties dragen verstandelijke beperkingen veroorzaken, ook via vaker voorkomende 
genetische varianten bijdragen aan een verhoogt risico op ADHD. Hiermee wilden we 
nieuwe risicogenen voor ADHD identificeren. Een set van 396 genen, die eerder geassocieerd 
waren met verstandelijke beperkingen, was significant geassocieerd met ADHD in twee 
onafhankelijke cohorten. Genetische varianten in drie genen, MEF2C, TRAPPC9 en ST3GAL3, 
werden geïdentificeerd als consistente topassociatie bevindingen. Vervolgens werden de 
nieuw geïdentificeerde ADHD kandidaat-genen functioneel gevalideerd met behulp van 
de fruitvlieg Drosophila melanogaster. Deze studie bevestigde de genetische overlapping 
van ADHD en verstandelijke beperkingen en we hebben verschillende nieuwe risicogenen 
voor ADHD geïdentificeerd, gevalideerd en functioneel gekarakteriseerd.
In hoofdstuk 5 werd een stapsgewijze strategie gebruikt om een  nieuw ADHD 
risicogen te identificeren en te valideren, waarbij de kracht van een familieonderzoek werd 
gecombineerd met de kracht van een grootschalige genoomwijde associatie studie. In een 
enkele familie, ernstig aangedaan door ADHD en comorbide psychiatrische stoornissen, 
ontdekten we een structurele genetische variant, die drie eiwitcoderende genen (ZNF596, 
FBXO25 en TDRP) bevat, en deze segregeerde met ADHD in de familie. Deze geïdentificeerde 
nieuwe ADHD kandidaat-genen werden getest - individueel en gecombineerd - op tekenen 
van associatie met ADHD en andere relevante psychiatrische stoornissen. Vergeleken met 
de genetische achtergrondcontrole leidde verhoogde expressie van de FBXO25-ortholoog 
in Drosophila melanogaster tot verhoogde locomotorische activiteit. Deze studie wijst op 
een rol voor het FBXO25 gen bij het ontstaan van ADHD.
In hoofdstuk 6 wordt een innovatieve aanpak beschreven die linkage-analyse en 
whole-exome sequencing (WES) combineert in ADHD families met meerdere generaties. 
In totaal werden 24 genen geselecteerd die door WES-geïdentificeerde zeldzame genetische 
varianten bevatten. Die genen werden gezamenlijk geanalyseerd in gen-set analyses met 
behulp van gegevens van een grootschalig onafhankelijk exome-chip cohort van patiënten 
met persisterende vorm van ADHD en controles. Gen-wijde analyse voor het AAED1-gen 
bereikte significantie en een enkele variant binnen AAED1 segregeerde met ADHD in de 
familie.
In hoofdstuk 7 werd het effect van genetische risicofactoren op de structuur en de 
functie van de hersenen onderzocht. We gingen uit van bekende genetische risicofactoren 
voor een groep van aandoeningen die regelmatig samen voorkomen: ADHD, autisme 
spectrum stoornis, en bepaalde vormen van verstandelijke beperkingen. We onderzochten 
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per aandoening welke mechanismen in het brein worden beïnvloed door de genetische 
risicofactoren en probeerden mechanismen te vinden die geassocieerd zijn met de klinische 
overlap tussen de aandoeningen. We vonden dat genetische variatie in het serotonine 
transporter gen (SLC6A4/5HTT) consistent geassocieerd is met verhoogde activiteit van 
de amygdala en gerelateerde hersengebieden, in combinatie met een verminderde 
connectiviteit tussen deze gebieden, allemaal gerelateerd aan emotieregulatie. Op basis 
van de onderzochte literatuur, konden we specifieke aanbevelingen voor toekomstig 
onderzoek geven. Er is een grote noodzaak voor grotere studies, die hypothesevrij naar 
alle hersengebieden kijken, en die meer genen onderzoeken. Daarnaast is het nodig om te 
onderzoeken of veranderingen in de hersenen de effecten van genetische risicofactoren op 
het klinische fenotype kunnen verklaren. Naast het geven van een uitgebreid overzicht van 
de literatuur toonde dit onderzoek aan dat het combineren van genetica en hersenmaten 
nuttig is om meer te weten te komen over verbanden tussen genen, hersenen, en gedrag. 
Toch is het werkveld nog in een vroeg stadium en kunnen er nog geen definitieve conclusies 
getrokken worden over de overlap tussen de verschillende onderzochte aandoeningen.
In hoofdstuk 8 hebben we ons werk uit het vorige hoofdstuk uitgebreid en een 
systematische literatuuronderzoek uitgevoerd, waarin we het effect van specifieke 
genetische risicofactoren van 62 ADHD kandidaat-genen op de structuur en functie 
van de hersenen onderzochten. Vrijwel uitsluitend werden individuele genetische 
varianten bestudeerd, voornamelijk van dopamine-gerelateerde genen. De conclusie 
van dit literatuuronderzoek was dat, hoewel veelbelovende resultaten zijn gemeld, 
‘brain imaging genetics’ onderzoeken naar ADHD tot nu toe worden belemmerd door 
methodologische verschillen in onderzoeksopzet en analysemethodologie, evenals 
beperkte steekproefgroottes. In dit hoofdstuk bespreken we ook uitgebreid de behoefte 
aan complementaire methoden voor de evaluatie van de mechanismen die ten grondslag 
liggen aan ADHD risicogenen. Verder werd het belang van het combineren en integreren 
van bevindingen op verschillende niveaus benadrukt om daardoor een beter begrip over 
de biologische mechanismen van gen tot stoornis te verkrijgen.
In hoofdstuk 9 wordt een integrale benadering beschreven die gericht was op het 
repliceren van een eerder gerapporteerde associatie van het GIT1 gen met ADHD en op 
het onderzoeken van de rol ervan in cognitieve en hersenfenotypen. Associatie van GIT1 
met ADHD of gerelateerde fenotypes, zoals aanhoudende aandacht, werkgeheugen en 
hersenvolumematen werden niet bevestigd in veel grotere steekproefomvang dan in 
het primaire onderzoek. Wel werd aangetoond dat een functionele genetische variant 
de expressie van GIT1 beïnvloed. Bovendien veroorzaakte Git knockdown in Drosophila 
abnormale synaps- en dendrietmorfologie, maar had geen invloed op het gedrag (dat 
wil zeggen de locomotorische activiteit). Onze resultaten geven aan dat, ondanks GIT1’s 
regulatie van de neuronale morfologie, veranderingen in genexpressie geen effect op 
ADHD-gerelateerd gedrag lijken te hebben en het hersenvolume bij mensen niet lijken 
te veranderen.
In hoofdstuk 10 werd de genetische overlap van ADHD met subcorticale hersenvolumes 
en intracranieel volume (ICV) onderzocht. In overeenstemming met de fenotypische 
observatie werd een significante negatieve genetische correlatie tussen ADHD en 
ICV ontdekt, wat betekent dat een verhoogd risico op ADHD gecorreleerd is met een 
verminderde ICV. Meta-analyse van individuele varianten toonde aan dat significante 
genomische loci waren geassocieerd met zowel ADHD-risico als ICV; extra loci werden 
geïdentificeerd voor ADHD- en amygdala-, caudate nucleus- en putamenvolumes. Deze 
bevindingen, samen met resultaten van exploratieve gen-wijde en gen-set analyses 
suggereren dat hierbij genen een rol spelen die betrokken zijn bij de uitgroei van neuriten.
Door gebruik te maken van uiteenlopende analysemethoden, geven de studies 
beschreven in dit proefschrift nieuwe inzichten in de genetische architectuur en individuele 
genetische risicofactoren die bijdragen aan ADHD. Bovendien helpen deze studies om het 
biologische mechanisme van gen tot stoornis beter te schetsen door gebruik te maken van 
diermodellen en het combineren van genetische informatie met hersenmechanismen die 
betrokken zijn bij ADHD.
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